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Abbreviations 
 
 
3-NBA  3-nitro-benzyl alcohol (matric for 
FAB-MS) 
Å Ångström (10-10 m) 
Ar aryl 
B(ArF)4 tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 
BINAP 2,2’-bis-(diphenylphosphino)-
1,1’-bi-naphthalene 
BOX bisoxazoline 
br broad (NMR) 
c concentration 
cat.  catalyst 
COD 1,5-cyclooctadien 
Conv.  conversion 
COSY correlation spectroscopy (NMR) 
Cy cyclohexyl 
δ chemical shift 
DCM dichloromethane 
de diastereomeric excess 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
ee enantiomeric excess 
EI electron impact ionization (MS) 
eq equivalent 
ESI electronspray ionization 
EtOAc ethyl acetate 
FAB fast atom bombardment 
FTIR fourier transform infrared 
GC gas chromatography 
HMBC heteronuclear multiple-bond 
correlation (NMR) 
HMQC heteronuclear multiple quantum 
coherence 
HPLC high performance liquid 
chromatography 
Hx hexane 
Hz Hertz 
J coupling constant 
M molar (mol/L) 
m.p. melting point 
MS mass spectroscopy 
2-Naph 2-naphthalin 
n.d. not determined 
NMR nuclear magnetic resonance 
NOESY nuclear overhause effect 
spectroscopy 
Pe pentane 
Ph phenyl 
PHOX phoshinooxazoline 
ppm parts per million 
Py pyridine 
rac. racemic 
Rf retention factor 
rt room temperature 
tert tertiary 
THF tetrahydrofuran 
TLC thin-layer chromatography 
TOCSY total correlated spectroscopy 
Tol toluene 
tr retention time 
w weak 
υ~  wave number (IR) 
 used to illustrate relative 
stereochemistry 
 used to illustrate absolute 
stereochemistry 
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 3
1 Introduction 
 
1.1 Racemic Versus Enantiopure Drugs 
 
For a long time the decision whether a drug should be developed as a racemate or as an 
enantiopure compound was left to the institution producing the drug. The situation changed 
when it was realized that there is often a significant difference between the enantiomers of 
chiral drugs regarding their pharmacodynamic and pharmacokinetic properties. In addition 
recent advances in stereoselective synthesis and analysis of chiral molecules helped to make 
the decision in favour of enantioselective synthesis of chemical entities. At present no 
regulatory institution has an absolute requirement for the development of enantiopure drugs 
but if a racemate is presented for marketing then its use must be justified. Arguments like the 
individual isomers are stereochemically unstable and readily racemize in vitro and/or in vivo 
or the use of a racemate produces a superior therapeutic effect than either individual 
enantiomer could for instance support the submission of a racemates. However, the trend 
towards the development of enantiopure drugs is clearly visible and therefore further 
development of stereoselective synthesis is highly desirable. This will be demonstrated by the 
following examples. 
 
1.2 Different Pharmacokinetic Properties of Enantiomers 
 
Since drug absorbtion, distribution, metabolism and excretion involve an interaction between 
the enantiomers of a drug and a chiral biological macromolecule it is hardly surprising that 
enantioselectivity is observed during these processes. 
 
Absorbtion 
 
The most important mechanism of drug absorbtion is passive diffusion through biological 
membranes. During this process there is generally little enantiomeric differentiation because it 
is dominated by the lipid and aqueous solubilities which are the same for both enantiomers. 
One way of drug absorbtion which discriminates between enantiomers is the active transport 
process. L-dopa for instance (Figure 1), which is used in the treatment of Parkinson’s disease, 
is rapidly absorbed from the gut by an active transport process, whereas D-dopa is slowly but 
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also completely absorbed by passive diffusion.1 Large rate differences between passive and 
active transportation may result in a considerable difference of bioavailability.2 
 
 
 
 
 
Figure 1. 
 
 
Distribution 
 
The majority of drugs undergo reversible binding to plasma proteins. Stereoselectivity can be 
observed in plasma protein binding to human serum albumin (HSA) and α1-acid glycoprotein 
(AGP), the two most important plasma proteins with respect to drug binding. In general acidic 
drugs bind predominantly to HSA, whereas basic drugs bind predominantly to AGP, which is 
only present to the extent of 3% of HSA. The differences between the enantiomers in plasma 
protein binding are usually quite small. But also the low stereoselectivity in binding may have 
a significant effect on the amount of unbound drug in the plasma which is available for 
activity. In the case of indacrinone (Figure 2), which is used in the treatment of hypertension 
and congestive heart failure, the free fractions are 0.9% and 0.3% for the (R)- and (S)-
enantiomer respectively.3 
 
 
 
 
 
 
Figure 2. 
 
 
Metabolism 
 
Drug metabolism frequently shows stereoselectivity and involves the interaction with enzyme 
systems. Some enzymes are highly specialized whereas others like cytochrome P450 are 
multifunctional and accept a wide range of substrates. They usually show great substituent 
and stereochemical sensitivity including those systems that accept a wide range of substrates. 
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Examination of the stereochemistry of drug metabolism is of importance because individual 
enantiomers of a racemic drug may be metabolised by different routes to yield different 
products and they are frequently metabolised at different rates. 
The (S)-enantiomer of barbiturate hexobarbital (Figure 3) has an elimination half-life which is 
three times longer than that of the (R)-enantiomer as a result of metabolic clearance.4 
 
 
 
 
 
 
 
Figure 3. 
 
 
Excretion 
 
Glomerular filtration, active secretion and passive and active reabsorbtion are the four major 
processes of renal excretion. In contrast to the active excretion processes no differences 
between the enantiomers are expected for the passive processes like glomerular filtration and 
passive reabsorbtion. 
Since renal clearance of L-pindolol is faster than that of D-pindolol active renal secretion or 
renal metabolism is thought to be responsible for the differential clearance of the two 
enantiomers (Figure 4).5 
 
 
 
 
 
 
Figure 4. 
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1.3 Different Pharmacodynamic Properties of Enantiomers 
 
The most important differentiation between enantiomers occurs at the level of receptor 
interactions. This leads to different pharmacodynamic properties of the enantiomers. Some of 
the possible situations are discussed below. 
 
Only one enantiomer shows pharmacological activity 
 
α-Methyldopa (Figure 5) is used against hypertension. The activity arises exclusively from 
the (S)-enantiomer6 and it is therefore marketed as a single enantiomer. 
 
 
 
 
 
Figure 5. 
 
 
Both enantiomers have similar activities 
 
The enantiomers of the antihistamine promethazine (Figure 6) have similar pharmacological 
properties.7 
 
 
 
 
 
 
Figure 6. 
 
 
The enantiomers have opposite effects 
 
Dextropropoxyphene, exhibiting the (1S,2R)-configuration, is a useful painkiller whereas its 
enantiomer levopropoxyphene is an antitussive agent (Figure 7). Appropriately not only the 
molecules are mirror images but also their trade names DARVON®(dextropropoxyphene) and 
NOVRAD®(levopropoxyphene).8 
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Figure 7. 
 
 
One enantiomer antagonises the side effects of the other 
 
Indacrinone (Figure 2) is an interesting example to show how the different modes of action of 
enantiomers can be used to create a more favourable profile of action of a drug by changing 
the ratio of the enantiomers. The (R)-enantiomer is a more potent natriuretic agent whereas 
the (S)-enantiomer is a more potent uricosuric agent. Following administration of the 
racemate to man the plasma half-life of the (S)-enantiomer is much shorter than that of the 
(R)-enantiomer (2-5 h, compared to the (R), 10-12 h). Hence its uricosuric activity is too short 
to prevent the undesirable rise in uric acid concentration. Alteration of the enantiomeric 
composition of the drug from the 1:1 ratio by increasing the proportion of the (S)-enantiomer 
resulted in a mixture (S : R : 4 : 1) which was isouricemic.9 In other words one enantiomer is 
used to prevent the side effects caused by the other enantiomer. 
 
 
Both enantiomers show activity but the adverse effects are predominantly associated with one 
enantiomer 
 
Ketamine (Figure 8) is a general anaesthetic agent with painkilling properties. The drug 
exhibits stereoselective actions in both main-effect and the most important side-effects. The 
most unwanted side effects originate from the less potent enantiomer for the main-effects, the 
(R)-enantiomer.10 
 
 
 
 
 
 
Figure 8.
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2 Biological Activity of Pyrrolidines and Resulting Objectives 
 
2.1 Biological Active Pyrrolidines 
 
Worldwide about 170 million individuals are afflicted with chronic hepatitis C11, a viral 
disease that is caused by a hepatotropic virus called Hepatitis C virus (HCV). The infection 
can cause liver inflammation and might progress to cirrhosis or also liver cancer. The latter 
two are the major causes of morbidity and mortality. 
The treatment of the disease with a combination of PEG-interferon-α and ribavirin is not 
always successful and shows severe side effects.12 Therefore the identification of more 
effective treatments is essential. 
Only recently it was reported that acyl pyrrolidines inhibit the Hepatits C NS5B polymerase 
whereas only one enantiomer showed a significant biological activity (Figure 9).13 
 
 
 
 
 
 
 
 
 
 
Figure 9. 
 
Optimization of the substitution −pattern further increased the compounds’ potency.14 The 
synthesis of such an optimized pyrrolidine moiety 11 is illustrated in Scheme 1.15 Subsequent 
to the formation of the imine 3 2 equivalents of lithium bromide were used to promote the 
1,3-dipolar cycloaddition reaction between the imine 3 and methyl acrylate 4 under basic 
conditions in THF. The racemic endo pyrrolidine species 5 was resolved into its enantiomers 
by diastereomeric salt formation using the chiral acid, R-BINAP phosphate 6. The resulting 
salt was treated with triethylamine to obtain the chiral pyrrolidine 7 with a yield of 82% and 
an enantioselectivity of >95%. Further transformations led to the desired pyrrolidine moiety 
11 with an overall yield of >25% in a 7 step sequence. 
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Scheme 1. 
 
The [3+2] cycloaddition of the Scheme above might alternatively be performed by an 
asymmetric metal-catalyzed 1,3-dipolar cycloaddition reaction. This could then lead directly 
to the enantioenriched compound without the time consuming resolution step by 
diastereomeric salt formation. 
Chiral pyrrolidines are present in many other biologically active compounds.16 Therefore, the 
development of enantioselective catalysts for [3+2] cycloaddition leading to this ring system 
is highly desirable. 
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2.2 Objectives 
 
The aim of the thesis was to develop chiral catalysts for enantioselective inter- and 
intramolecular [3+2] cycloaddition reactions between azomethine ylides precursors 12, 15 
and electron-deficient dipolarophiles 13 (Scheme 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. 
 
In initial metal- and ligand screenings Ag(I)-phosphinooxazoline (PHOX) complexes turned 
out to be the most promising chiral catalysts. Subsequently, the structure of the PHOX ligand 
17 (Figure 10) was optimized by systematic variation of the various substituents. The most 
successful ligand structures were later used to examine the scope of the reaction. 
 
 
 
 
 
 
 
Figure 10. 
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In connection with the optimization studies we also became interested in applying (S)-valine 
methyl ester derived C5-substituted PHOX ligands 23 to Ir(I)-catalyzed asymmetric 
hydrogenations of unfunctionalized and functionalized olefins 18 and imines 20. The aim was 
to compare them with the successful but expensive (S)-tert-leucine-derived PHOX ligand 23 
(Scheme 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. 
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3 [3+2] Cycloadditions 
 
3.1 General Aspects 
 
The [3+2] cycloaddition of a 1,3-dipole to a dipolarophile involves 4π-electrons from the 
dipole and 2π-electrons from the dipolarophile. The 4π-electron component is of such nature 
that the stabilized all octet structure can only be represented by zwitterionic forms in which 
the positive charge is located on the central heteroatomic atom and the negative charge is 
distributed over the two terminal atoms (Figure 11). There exist two principal types of 
dipoles. The bent allyl type 1,3-dipoles have their four π-electrons in three parallel atomic 
pz-orbitals perpendicular to the plane of the dipole. Dipoles of the propargyl-allenyl type, 
which have a triple bond in one canonical form, contain an additional π-orbital orthogonal to 
the allyl-anion type molecular orbital and have a linear structure. 
 
 
Allyl type:          
 
 
 
 
Propargyl-allenyl type:  
 
 
 
 
Figure 11. 
 
A considerable number of 1,3-dipoles containing various combinations of carbon and hetero-
atoms is theoretically possible. Restricting the permutations to second row elements Huisgen 
has classified eighteen possibilities of which six are from the propargyl-allenyl type and 
twelve are from the allyl type (Table 1).17 
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Table 1. 
Allyl type1 
Nitrogen in the middle Oxygen in the middle 
C N O
 
Nitrones C O C
 
Cabonyl Ylides 
C N N
 
Azomethine Imines C O N
 
Carbonyl Imines 
C N C
 
Azomethine Ylides C O O
 
Carbonyl Oxides 
N N N
 
Azimines N O N
 
Nitrosimines 
N N O
 
Azoxy Compounds N O O  
Nitrosoxides 
O N O
 
Nitro Compounds O O O  
Ozone 
Propargyl-allenyl type 
Nitrillium Betaines Diazonium Betaines 
C N O  
Nitrile Oxide N N C
 
Diazoalkanes 
C N N
 
Nitrile Imines N N N
 
Azides 
C N C
 
Nitrile Ylides N N O  
Nitrous Oxide 
1 For facility reasons the bent allyl type 1,3-dipoles are illustrated in a linear from. 
 
The reaction between a 1,3-dipole and a dipolarophile leads to a five-membered heterocycle 
and proceeds usually via a concerted mechanism. It is thermally allowed with the description 
[π4s + π2s] according to the Woodward-Hoffmann rules.18 This means that the three 
pz-orbitals of the 1,3-dipole and the two pz-orbitals of the alkene both combine suprafacially 
(Figure 12). 
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Figure 12. 
 
Depending on the structure of the dipole and the dipolarophile, up to four stereogenic centers 
can be formed by a 1,3-dipolar cycloaddition reaction in a single step. Three types of 
selectivities must be considered (Figure 13) - regioselectivity, diastereoselectivity and 
enantioselectivity which will be discussed on the following pages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. 
 
3.2 Reactivity and Regioselectivity of [3+2] Cycloadditions 
 
Relative activity and regioselectivity of 1,3-dipolar cycloadditon reactions can be explained 
by means of the FMO-theory. It states that only interactions of filled orbitals with unfilled 
ones lead to an important energy-lowering effect of the transition-state when two molecules 
approach each other, particularly the interaction of the HOMO with the LUMO being 
decisive. 
[3+2] Cycloadditions 
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Salem19 derived a second-order perturbation expression for the energy gained and lost when 
the orbitals of one reactant overlap with those of another one in a cycloaddition reaction. 
 
)/()(2)/()()(
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ab absbra
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βεβ  
 
 
qa, qb :   Electron populations in the atomic orbitals a and b. 
β :   Resonance integral. 
S :   Overlap integral. 
Qk, Ql : Total charges on atom k and l. 
ε :  Local dielectric constant. 
Rkl:  Distance between the atoms k and l. 
cra: Coefficient of atomic orbital a in molecular orbital r; r refers to the molecular 
orbitals on one molecule and s refers to those on the other one. 
Er: Energy of molecular orbital r. 
 
The first term is the closed-shell repulsion term and represents the interaction of the filled 
orbitals of one molecule with the filled orbitals of the other one. Overall it has an antibonding 
effect and presents a good deal of the enthalpy of activation for many reactions. 
The second term is the Coulombic repulsion or attraction. This term is obviously important 
when ions or polar molecules are reacting together. 
The third term represents the interaction of all filled orbitals with all the unfilled orbitals of 
correct symmetry. The denominator of this expression indicates that, the closer in energy the 
orbitals, the more they will interact, while the numerator indicates that, if the orbitals are of 
the same symmetry and overlap effectively, the interaction will be large. The largest 
contribution to this term is obtained from the HOMO/LUMO interaction. 
Most perturbation treatments of cycloaddition reactivity have focused on the last term of the 
second-order perturbation expression and have considered only interactions between frontier 
orbitals on the 1,3-dipole and the dipolarophile. This frontier orbital approximation is 
remarkably successful in rationalizing reactivity and regioselectivity phenomena, in spite of 
the fact that interactions of extrafrontier orbitals, closed-shell repulsion, and coulombic terms 
also contribute to energy changes. 
first term second term third term 
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The application of the perturbation theory to the 1,3-dipolar cycloaddition reaction is only 
possible if the 1,3-dipoles and dipolarophiles frontier orbital energies and coefficients are 
approximately known. Calculations on specific addends of all types by a variety of methods 
have been reported,20 but simple generalizations often suffice for predictive purposes. In the 
following the qualitative substituent effect on alkene coefficients and energies will be 
described (Figure 14). 
Electron-withdrawing substituents lower the HOMO energy slightly but have a much larger 
effect on the LUMO energy. The coefficient on the unsubstituted atom is larger than on the 
substituted atom in both HOMO and LUMO, with the difference in coefficient magnitudes 
much larger in the LUMO. 
Electron-donating groups increase the LUMO energy slightly but have a much larger effect 
on the HOMO energy. The unsubstituted HOMO coefficient is larger than the substituted 
HOMO coefficient. The LUMO coefficients are opposite in magnitude, but the difference in 
coefficient magnitudes is smaller. 
Conjugating substituents raise the HOMO energy and lower the LUMO energy, and the 
coefficients are larger at the unsubstituted centers in both molecular orbitals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. 
 
Due to the limited experimental data which are available to determine the effect of dipole 
substituents on frontier orbital energies and coefficients, only very qualitative assumptions 
can be done. All 1,3-dipoles have in common a three atomic orbital π system containing four 
electrons analoguous to an allyl anion (Figure 15). It can be assumed that the effect of various 
types of substituents on dipole frontier orbital energies and coefficients will be qualitatively 
similar to the effect of these substituents on dipolarophile frontier orbital energies and 
[3+2] Cycloadditions 
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coefficients. Figure 15 shows the average orbital coefficients of the most common 
1,3-dipoles. The effect of a substituent on dipole energies and coefficients is expected to be a 
function of the magnitude of the coefficient at the site of attachment on the parent dipole 
(Figure 15).21 Therefore the substituent effect for the HOMO of the dipole should be in the 
order anionic terminus > neutral terminus >> central atom. The corresponding order for the 
LUMO is neutral terminus ∼ central atom > anionic terminus.20b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. 
 
From these generalizations the regioselectivity of most 1,3-dipolar cycloadditions can be 
rationalized from Figure 16 assuming that the larger orbital coefficient of one molecule is 
interacting with the larger orbital coefficient of the other molecule. Control of regioselectivity 
by the dipole HOMO will lead to five-membered heterocycles with the substituent close to the 
neutral terminus X for monosubstituted, conjugated, and electron-deficient dipolarophiles and 
to products with the substituent near the anionic terminus Z for electron rich dipolarophiles. 
Control of regioselectivity by the dipole LUMO will lead to products with the substituent near 
the anionic atom Z for all monosubstituted dipolarophiles. 
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Figure 16. 
 
It will be necessary to identify if a HOMOdipole – LUMOdipolarophile or a LUMOdipole – 
HOMOdipolarophile interaction is taking place in order to rationalize or predict product 
regiochemistry. Sustmann has classified the 1,3-dipolar cycloaddition reaction into three 
types22, on the basis of the relative FMO energies between the dipole and the dipolarophile 
indicating which FMO interaction will be favoured (Figure 17). In type I 1,3-dipolar 
cycloaddition reactions the dominant FMO interaction is that of the dipole HOMO with the 
dipolarophile LUMO (HOMO-controlled), in type II both FMO interactions are possible 
(HOMO,LUMO-controlled) and in type III the dipole LUMO interacts with the dipolarophile 
HOMO (LUMO-controlled). HOMO-controlled reactions will be accelerated by substituents 
which raise the dipole HOMO energy or lower the dipolarophile LUMO energy but on the 
other hand these substituents decelerate LUMO-controlled reactions. Conversely, substituents 
which lower the dipole LUMO energy or raise the dipolarophile HOMO energy will 
accelerate LUMO-controlled reactions and decelerate HOMO-controlled reactions. HOMO, 
LUMO-controlled reactions will be accelerated by an increase of either frontier orbital 
interactions. 
 
 
 
 
 
 
 
 
 
Figure 17. 
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Considering azomethine ylides, which are the 1,3-dipoles of main interest in this work, it has 
to be emphasized that the unsubstituted 1,3-dipole has C2v symmetry, thus regioselectivity is 
not an issue in this case. Unsymmetrically substituted azomethine ylides can form 
regioisomers with unsymmetrical dipolarophiles, but the regiochemistry will be induced by 
asymmetry in the dipole frontier orbitals caused by the substituents. Presumably the 
azomethine ylides will react readily with both electron-deficient and electron-rich 
dipolarophiles due to the narrow frontier orbital separation. 
The presence of metals, such as a lewis acid, can alter both the orbital coefficients of the 
reacting atoms and the energy of the frontier orbitals of the 1,3-dipole or the alkene. Thus 
lewis acids may have an influence not only on the reactivity but also on the selectivity of the 
1,3-dipolar cycloaddition reaction, since regio-, diastereo-, and enantioselectivity can be 
controlled by the presence of a metal-ligand complex. 
Kanemasa et al.29c calculated the energy level of the HOMO and the corresponding orbital 
coefficients of the lithium enolate illustrated in Figure 18. The high-lying HOMO23 of this 
1,3-dipole implies that the 1,3-dipolar cycladdition reaction between a metal-stabilized 
azomethine ylide and an electron-deficient dipolarophile proceeds by a HOMO-controlled 
interaction which is confirmed by experimental data. 
 
 
 
 
 
 
Figure 18. 
 
The perturbation treatment satisfactorily predicts both the regioselectivity of 1,3-dipolar 
cycloadditions and the relative reactivities of each individual dipole with a series of 
dipolarophiles, but it usually fails in the comparison of relative reactivities of widely different 
1,3-dipoles. The reasons for these difficulties can be partially found in the crudeness of the 
frontier orbital energy estimates, as well as the neglect of electrostatic interactions, 
closed-shell repulsions, and steric effects.24,27 An additional factor which must be taken into 
account is the stability of products and reactants. 
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3.3 Mechanism of [3+2] Cycloadditions 
 
3.3.1 Concerted versus Stepwise Mechanism 
 
The vivid debate of Huisgen25 and Firestone26 in the 1970’s about the mechanism of the 
1,3-dipolar cycloaddition reaction (Figure 19) will be shortly summarized. 
Huisgen was proposing a concerted mechanism, which implies stereospecificity with respect 
to the olefin and the allyl anion configuration. On the other hand Firestone was arguing for a 
stepwise diradical mechanism, whereas this two step pathway is equally compatible with a 
stereospecific or nonstereospecific reaction course. The former mechanism emerged as the 
only mechanism that satisfactorily explains all the experimental observation in particular the 
stereospecificity that characterizes these reactions. It is now generally accepted that in general 
the reaction follows a concerted pathway.27 
 
 
 
 
 
 
 
 
 
 
Figure 19. 
 
Huisgen et al.28 found later 1,3-dipolar cycloadditions which did not follow a stereospecific 
course. This was explained by bond-rotations of a postulated zwitterionic intermediate in the 
course of a two-step non-concerted [3+2] cycloaddition, but not by a diradical mechanism 
(Scheme 4). 
 
 
 
 
 
 
[3+2] Cycloadditions 
 26
= R2 S
CH2
NC
MeO2C CN
CO2Me R2C
S
CO2Me
CN
MeO2C
NC
R2HC
S
CO2Me
CN
NC
MeO2C
R2C
S
NC CN
MeO2C CO2Me
R2C
S
MeO2C CN
NC CO2Me
57                  :                   43
S
CH2 CH3CN
R1 N CO2Me R1 N
O
OLi
R1 N
O
OLi
CO2Me
NR1
O
O
O
O Li
R1 N CO2Me
CO2Me
NR
1
MeO2C
O
OLi
N
H
R1
MeO2C
O
O
LiBr, NEt3 Et3NHBr
NR1
O
O
O
O Li
A B1 B2
C
D1 D2
E
FG
+Et3NHBr
-LiBr, -NEt3
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. 
 
3.3.2 Mechanistic Aspects of [3+2] Cycloadditions of Metal-Stabilized Azomethine 
Ylides 
 
Kanemasa29 as well as Cossío30 proposed on the basis of computional and experimental 
studies independently a mechanism for [3+2] cycloadditions between metal stabilized 
azomethine ylides and electron-deficient dipolarophiles (Scheme 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. 
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According to the mechanistic cycle (Scheme 5) the stabilized lithium azomethines ylide B is 
built in the first step which exist exclusively in the conformation where the lithium is not only 
coordinated to the nitrogen but also to the carbonyl oxygen of the ester. Electron density and 
NBO (natural bond orbital) calculations state that the structure is closer to that of an enolate 
B2 than to that of an azomethine ylide B1. However, bond formation at the β-carbon of the 
methyl acrylate C proceeds at the α-carbon of intermediate B. Protonation of intermediate D 
would lead to Michael adduct E whose formation competes with the intramolecular 
cyclization producing the lithiated cycloadduct F which upon protonation leads to the desired 
pyrrolidine moiety G and regeneration of the catalyst. 
 
Figure 20 shows the qualitative reaction pathway calculated by Kanemasa et al.13c by the 
MNDO- and PM3-methods for the Michael additions between the lithium Z-enolates of 
N-alkylidene-glycinates and methyl crotonate (α to χ) and the subsequent cyclization leading 
to the 1,3-dipolar cycloaddition products (χ to ε). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1 R = CHPh  
   2 R = Bornylidene =  
 
Figure 20. 
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The reaction pathway which results by employing substrate 1 indicates that the cyclized 
product ε1 is thermodynamically more stable than the Michael-adduct χ1 and the energy 
barrier for the cyclization step is lower than that for the Michael-addition step. For that reason 
the reaction of 1 with methyl crotonate leads to the preferred formation of the 1,3-dipolar 
cycloadduct ε1 what was also found experimentally. 
By contrast, sterically demanding substituents like boronylidene lead to an alternative 
pathway indicating that the energy barrier for the cycloaddition step is larger than the one for 
the formation of the Michael-adduct χ2. In addition, the cycloadduct ε2 has nearly the same 
stability like the Michael-adduct χ2. Therefore the Michael-adduct χ2 is formed preferentially 
what is likewise found experimentally. 
On the basis of these computional data, it can be revealed that the reaction of sterically less 
hindered substrates like 1 with methyl crotonate lead only to the 1,3-dipolar cycloadduct ε1, 
whereas sterically hindered substrates like 2 preferentially lead to the Michael adduct χ2. 
To get a complete picture of the thermodynamic stability not only the enthalpic contribution 
but also the entropic contributions have to be considered. PM3 calculations showed that the 
entropy change favours the cycloadducts but the contributions to thermodynamic stability 
were that small (max. 1 kcal/mol) that the above conclusions do not have to be changed. 
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3.4 Diastereoselectivity of [3+2] Cycloadditions 
 
In the reaction between a disubstituted 1,3-dipole and a disubstituted dipolarophile up to four 
new chiral centers can theoretically be formed and up to eight different diastereomers may be 
obtained. The formation of the different diastereomers will be explained by focusing on the 
reaction between a metal stabilized azomethine ylide A and dimethyl maleate as outlined in 
Figure 21. As formerly mentioned, the metal stabilized azomethine ylide (B1, B2) exists 
exclusively in the conformer in which the metal interacts with both the nitrogen and the 
oxygen atom.30 Thus, only the conformational change from B1 to B2 is possible, whereas B1 
seems to be the reacting intermediate according to experimental data. Taking this into account 
the number of possible diastereomers is reduced to four (C, C’, D, D’). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. 
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The number of possible diastereomeric products is reduced to diastereomers C and D by the 
fact that the relative orientation of the substituents at the dipolarophile usually correlates with 
that in the cycloadduct such that cis-disubstituted alkenyl dipolarophiles lead to 
3,4-cis-disubstituted pyrrolidine products and trans-disubstituted alkenyl dipolarophiles lead 
to 3,4-trans-disubstituted pyrrolidine products. This result is expected on the basis that the 
rotation around the former alkene-bond of the dipolarophile is slower than the cyclization step 
according to the mechanism discussed before. Finally, diastereomer C and D are formed by 
the endo respectively exo orientation of the substituents on the dipolarophile to the newly 
formed ring. Depending upon the substituents on the dipolarophile, the endo transition state 
may be stabilized by small secondary π-orbital interactions. 
 
3.5 Enantioselectivity of [3+2] Cycloadditions 
 
There exist several methods for inducing asymmetry in [3+2] cycloadditions. They comprise 
the application of chiral 1,3-dipoles31, chiral dipolarophiles32, chiral auxiliaries attached to the 
1,3-dipole33 or the dipolarophile34, enzymes35, organocatalysts36 and chiral metal-complexes. 
The use of the latter will be discussed in the following chapter. 
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4 Metals and Ligands Employed for [3+2] Cycloadditions of Azomethine Ylides 
 
4.1 Metals Used to Promote [3+2] Cycloaddition Reactions 
 
A wide range of metals salts have been employed to promote the [3+2] cycloaddition of 
azomethine ylides with dipolarophiles (Figure 22), including Li(I)37, Mg(II)38, Ti(IV)39, 
Sn(IV)40, Mn(II)41, Co(II) 39a,41, Ni(II)42, Cu(I), Cu(II), Zn(II), Ag(I) and samarium43 and a 
range of rare earth44 triflates, but only Cu(I)42,45-, Cu(II)46-, Zn(II)46b,47- and Ag(I)48-
complexes have been used in the catalytic asymmetric variant. 
 
 
 
 
 
 
Figure 22. 
 
4.2 Chiral Ligands Used for Cu(I)-Catalyzed [3+2] Cycloadditions 
 
The employment of ferrocene based P,N-, P,S- and P,P-ligands 25, 26, 27, 24 and 28 led to 
date to the most successful induction of asymmetry to Cu(I)-catalyzed 1,3-dipolar 
cycloaddition reactions between azomethine ylides and electron-deficient dipolarophiles 
(Figure 23). P,N-ligands 25, 26 and 27 were used by the research groups of Zhang45b, Hou45d 
and Carretero45a, whereas the latter45c also employed P,S-ligands like 24. Perchlorate was the 
counterion of choice and the addition of 10 to 18 mol% of an organic base supported the 
formation of the metal stabilized azomethine ylide. The employment of 3 to 10 mol% of the 
catalyst, reaction temperatures of -20 °C to 0 °C and aprotic solvents usually led after reaction 
times of 6 to 24 h to the formation of the pyrrolidine moieties with good enantioselectivities. 
Figure 23 shows a selection of the most selective pyrrolidine formations for each ligand type. 
Hou claimed that the diastereoselectivity of the reaction is determined by the electronic 
properties of the substituents at the phosphorous atom. While electron-rich substituents favor 
the exo product, formation of the endo product is observed with electron-deficient 
substituents. This is illustrated in Figure 23 by the results generated by Zhang and Hou. 
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Grigg42 successfully employed the Josiphos-ligand 28 to the Cu(I)-catalyzed [3+2] cyclo-
addition. In contrast to the other research groups iodide was used as a counterion but no 
detailed reaction conditions were described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. 
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4.3 Chiral Ligands Used for Cu(II)-Catalyzed [3+2] Cycloadditions 
 
The research group of Komatsu46a achieved enantiocontrol in Cu(II)-catalyzed 1,3-dipolar 
cycloadditions between azomethine ylides and electron-deficient dipolarophiles by using the 
(R)-BINAP- 29 and the (R)-SEGPHOS- ligand 30 (Figure 24). Triflate was the counterion of 
choice and 4 mol% of triethylamine was used to support the formation of the metal stabilized 
azomethine ylide. The employment of 2 mol% of catalyst, a reaction temperature of -40 °C 
and dichloromethane as a solvent led after a reaction time of 24 h to the formation of the 
desired five-membered heterocycles. Figure 24 shows a selection of the most selective 
heterocyclic ring-formations for the two ligand-types. Jørgensen46b and his co-workers 
applied a Cu(II)-complex derived from CuOTf2 and the (S)-tBu-BOX-ligand 31 to 
[3+2] cycloadditions of azomethine ylides. The desired endo products where isolated with 
high yields but as a racemate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. 
 
4.4 Chiral Ligands Used for Zn(II)-Catalyzed [3+2] Cycloadditions 
 
The research groups of Jørgensen46b and Dogan47 applied complexes obtained from zinc 
triflate and the (S)-tBu-BOX- 31 respectively a ferrocenyl-substituted aziridino alcohol ligand 
32 to the 1,3-dipolar cycloaddition reaction between azomethine ylides and electron-deficient 
dipolarophiles (Figure 25).  
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Figure 25. 
 
The performance of the reaction using 10 mol% of the catalyst in combination with 10 mol% 
of triethylamine in aprotic polar solvents at -20 °C led after a reaction time of 6 to 12 h to the 
exclusive formation of the endo products with high enantioselectvities as shown from the 
selected examples in Figure 25. 
 
4.5 Chiral Ligands Used for Ag(I)-Catalyzed [3+2] Cycloadditions 
 
The employment of ferrocene based P,P- and P,N-ligands 33 and 34 by the research groups of 
Zhang48a and Zhou48d as well as the use of the P,N-ligands QUINAP 36 and PINAP 35 by 
Schreiber48b respectively Carreira48c led to successful induction of asymmetry to the 
Ag(I)-catalyzed 1,3-dipolar cycloaddition between azomethine ylides and electron-deficient 
dipolarophiles (Figures 26 and 27). Acetate was the counterion of choice and 10 mol% of 
Hünig base was used to support the azomethine ylide formation. Zhou did not use base 
claiming that the addition of extra base is not necessary for the acetate probably facilitates the 
deprotonation of the iminoester to generate the metal stabilized azomethine ylide. The 
employment of 3 mol% of catalyst, reaction temperatures from -45 °C to 0 °C and aprotic 
solvents led after reaction times of 3 to 96 h to the formation of the cycloaddition products 
with high selectivities as shown in Figures 26 and 27. 
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Figure 26. 
 
Schreiber et al. additionally investigated the 1,3-dipolar cycloaddition reaction between 
acyclic electron deficient dipolarophiles and iminoesters derived from amino esters other than 
glycinate or alaninate. Albeit 10 mol% of the catalyst were used the resulting pyrrolidines 
with a quaternary center at the 2-position were isolated with good selectivities (Figure 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. 
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5 Initial Metal and Ligand Screening for the [3+2] Cycloaddition of 
Azomethine Ylides 
 
5.1 Metal Screening 
 
The initial screening of metal salts (Cu(OAc)2, AgOAc, AgSbF6, ZnCl2, MgCl2, Sn(SO3CF3)2, 
AuCl3) for the 1,3-dipolar cycloaddition reaction between (E)-methyl 2-(naphthalene-2-
ylmethyleneamino)acetate 37 and methyl acrylate 4 (Scheme 6) performed by Mark Enzler in 
his diploma thesis49 was supplemented with further metal salts including CuCl, 
(Cu(SO3CF3))2⋅C6H5CH3, CoCl2, CoOAc, NiCl2, Pd(OAc)2, AuCl and SmI2. Apart from the 
Cu(I) salts none of the other metal salts catalyzed the reaction satisfyingly. 
 
 
 
 
 
Scheme 6. 
 
As a result of both screenings only Ag(I) and Cu(I) salts were applied to the asymmetric 
variant of this reaction.  
 
5.2 Ligand Screening for the Ag(I)-Catalyzed [3+2] Cycloaddition 
 
In addition to the ligands Mark Enzler screened during his diploma thesis1 further ligands 
were applied to the reaction outlined in Scheme 7. They were chosen from the Pfaltzs’ group 
ligand library with the intention to cover the widest possible range of ligand classes, 
comprising various P,N-, P,P-, N,N- and monodentate P-ligands. The reaction was performed 
following a general procedure using the in-situ preparation of the catalyst. 31P-NMR studies 
concerning the complexation of AgOAc with the PHOX ligand 39 showed that a 
complexation time of at least 4 h is required.49 Due to the fact that different ligand types had 
to be complexed with AgOAc, the complexation time was increased to 12 h to avoid a 
background reaction with uncomplexed AgOAc. After preparation of the catalyst a solution of 
the imine50 was added, followed by the base and the dipolarophile. Prior to the ligand 
screening the reaction conditions were optimized in terms of solvent, reaction temperature 
and base. 
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5.2.1 Optimization of the Reaction Conditions 
 
Influence of the base on reactivity and selectivity 
 
 
 
 
 
 
 
 
 
 
Scheme 7. 
 
The results illustrated in Table 2 demonstrate that the addition of base affected neither the 
reactivity nor the selectivity of the reaction (Scheme 7). The basicity of the acetate seems to 
be sufficient to deprotonate the imine 37 for forming the metal stabilized azomethine ylide 
(see chapter 4.5). This result was also confirmed by Zhou and co-workers.48d 
 
Table 7. 
Entry L* Et3N (mol%) t (h) Yield (%)a 38a : 38bb ee (%)c (38a) 
1 39 10 5 95 >40 : 1 22 (+) 
2 39 0 5 92 >40 : 1 22 (+) 
a After column chromatography. 
b Determined by 1H NMR. 
c Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligand 39 (3.3 mol%), methyl acrylate (4) (1.2 eq), 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), Et3N 
(x mol%), toluene, rt. 
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Influence of the reaction temperature on reactivity and selectivity 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8. 
 
The decrease of the reaction temperature from room temperature to 0 °C did not have an 
effect on reactivity but on selectivity, which was slightly improved (Table 3, compare entries 
1 and 2). Further lowering of the temperature using toluene as solvent was impossible because 
the substrates precipitated at a temperature of about -6 °C. Therefore the solvent was changed 
to chlorobenzene or to tetrahydrofuran, to carry out the reaction at -40 °C (Table 3, entry 4 
and 5). Neither chlorobenzene nor tetrahydrofuran had a beneficial effect on selectivity and 
reactivity. Thus subsequent reactions were conducted at 0 °C. 
 
Table 3. 
Entry L* Solvent T (°C) t (h) Conversion (%)a 38a : 38ba ee (%)b (38a)
1 39 Toluene rt 4 > 95 >40 : 1 22 (+) 
2 39 Toluene 0 4 > 95 >40 : 1 29 (+) 
3 40 Toluene 0 8 93c >40 : 1 45 (+) 
4 40 Chlorobenzene -40 28 40c 11 : 1 30 (+) 
5 41 Toluene 0 7 89 >40 : 1 49 (+) 
6 41 Tetrahydrofuran -40 16 90 >40 : 1 37 (+) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
c Yield after column chromatography. 
Reaction conditions: AgOAc (3 mol%), ligands 39-41 (3.3 mol%), methyl acrylate (4) (1.2 eq), (E)-methyl 
2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), solvent, T. 
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Influence of solvents on reactivity and selectivity 
 
 
 
 
 
 
 
 
 
 
 
Scheme 9. 
 
The results illustrated in Table 4 for the reaction in Scheme 9 showed that the application of 
apolar solvents like benzene and toluene had a beneficial effect on reactivity and selectivity 
compared to the use of aprotic polar solvents (Table 4, compare entries 6 and 7 with entries 
1-5). Only tetrahydrofuran could compete with the apolar solvents, but just in terms of 
reactivity. Therefore toluene was the solvent of choice for the following reactions. 
 
Table 4. 
Entry L* Solvent t (h) Conversion (%)a 38a : 38ba ee (%)b (38a) 
1c 39 Dichloromethane 7 82 10 : 1 13 (+)  
2c 39 1,2-Dichloroethane 12 7 9 : 1 18 (+) 
3c 39 Acetonitrile 4 68 11 : 1 13 (+) 
4d 39 Dioxane 24 38 n.d. 5 (+) 
5 39 Tetrahydrofuran 6 > 95 >40 : 1 21 (+) 
6 39 Benzene 6 > 95 >40 : 1 25 (+) 
7 39 Toluene 5 > 95 >40 : 1 29 (+) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
c 10 mol% of Et3N were used. 
d Reaction temperature 15 °C. 
Reaction conditions: AgOAc (3 mol%), ligands 39 (3.3 mol%), methyl acrylate (4) (1.2 eq), (E)-methyl 
2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), solvent, 0 °C. 
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5.2.2 Application of Different P,N-Ligands to the Ag(I)-Catalyzed [3+2] Cycloaddition 
 
Various P,N-ligands were applied to the [3+2] cycloaddition outlined in Scheme 10, including 
PHOX ligands 39-41, phosphate- and bis(N-tosylamino)phosphine-oxazoline ligands 42, 43, a 
phosphine-imidazoline ligand 44 and phosphinite-oxazoline ligands 45-47. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10. 
 
With exception of the phosphite and the bis(N-tosylamino)phosphine-oxazoline ligands 42 and 
43 all ligand types induced acceptable reactivity and endo:exo selectivity (Table 5). Promising 
enantioselectivities were obtained with the phosphite-ligand 42, the phosphinite-oxazoline 
ligand 46 and the PHOX ligands 39-41 (Table 5, entries 2, 3, 5 and 7). The 
bis(N-tosylamino)phosphine-oxazoline ligand 43 decomposed during complexation and, 
therefore, no conversion was observed (Table 5, entry 8). 
The results generated by the three PHOX ligands allowed a first interpretation of the influence 
of different substituents at the ligand on asymmetric induction. The introduction of substituents 
at the C5 position of the oxazoline moiety seemed to have a beneficial effect on 
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enantioselectivity (Table 5, compare entries 1 and 4). Also the introduction of sterically more 
demanding substituents at the phosphorous atom led to an enhancement of the enantiomeric 
excess (Table 5, compare entries 1 and 2). 
 
Table 5. 
Entry L* t (h) Conversion (%)a 38a : 38ba ee (%)b (38a) 
1 39 5 95 >40 : 1 29 (+) 
2 40 8 93 >40 : 1 45 (+) 
3 41 7 86 >40 : 1 49 (+) 
4 45 6 >95 >40 : 1 3 (+) 
5 46 7 >95 >40 : 1 29 (+) 
6 47 5 81 >40 : 1 17 (+) 
7 42 14 29 n.d. 41 (−) 
8 43 20 - - - 
9 44 5 67 33 : 1 rac. 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligands 39-47 (3.3 mol%), methyl acrylate (4) (1.2 eq), 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), 
toluene, 0 °C. 
 
In addition some pyridine derived phosphine- and phosphinite ligands 48 and 49 as well as 
phosphine imine ligands 50 and 51 (Figure 28) were applied to the reaction of Scheme 10. 
 
 
 
 
 
 
Figure 28. 
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The application of these ligands led to silver complexes with medium to good reactivity 
forming the desired pyrrolidine products 38a and 38b with excellent endo:exo selectivities but 
poor enantioselectivities (Table 6). 
 
Table 6. 
Entry L* t (h) Conversion (%)a 38a : 38ba ee (%)b (38a) 
1 48 6.5 95 >40 : 1 rac. 
2 49 8 58 40 : 1 rac. 
3 50 5 71 >40 : 1 20 (+) 
4 51 6 80 >40 : 1 rac. 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligands 48-51(3.3 mol%), methyl acrylate (4) (1.2 eq), 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), 
toluene, 0 °C. 
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5.2.3 Application of Different P,P-Ligands to the Ag(I)-Catalyzed [3+2] Cycloaddition 
 
Several P,P-ligands were employed in the [3+2] cycloaddition reaction of Scheme 11. These 
comprise a TADDOL-phosphite ligand 52, the Josiphos ligands 53-55, two dimeric TADDOL 
derived phosphonite ligands 56 and 58 linked by phenoxathiin or dibenzofuran and a dimeric 
bis(N-tosylamino)phosphine ligand 57 linked by phenoxathiin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 11.  
 
Silver complexes of these ligands usually showed low reactivity and low asymmetric 
induction with exception of the TADDOL derived phosphonite ligand 58 (Table 7). Using this 
ligand the pyrrolidines 38a and 38b were formed with moderate endo:exo selectivity but 
promising enantioselectivity of 59%. As already observed for the bis(N-tosyl-
amino)phosphine-oxazoline ligand 43 also the dimeric bis(N-tosylamino)phosphine ligand 57 
decomposed during complexation and, therefore, no product could be isolated (Table 7, 
entry 6). 
 
 
 
 
Initial Metal and Ligand Screening for the [3+2] Cycloaddition of Azomethine Ylides 
 49
N
OO
N
tBu tBu
31
Table 7. 
Entry L* t (h) Conversion (%)a 38a : 38ba ee (%)b (38a) 
1 52 12 57 >40 : 1 3 (+) 
2 53 12 35 2 : 1 rac. 
3 54 12 24 1 : 2 20 (−) 
4 55 12 16 2 : 1 10 (−) 
5 56 8 15 >40 : 1 rac. 
6 57 24 - - - 
7 58 7 34 24 : 1 59 (−) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligands 52-58 (3.3 mol%), methyl acrylate (4) 
(1.2 eq), (E)-methyl 2-(naphthalene-2-ylmethyleneamino) acetate 
(37) (1.0 eq), toluene, 0 °C. 
 
 
5.2.4 Application of an N,N-Ligand to the Ag(I)-Catalyzed [3+2] Cycloaddition 
 
The application of the BOX ligand 31 (Figure 29) to the reaction of Scheme 11 following the 
general procedure did not lead to any formation of product. 
 
 
 
 
 
Figure 29. 
Initial Metal and Ligand Screening for the [3+2] Cycloaddition of Azomethine Ylides 
 50
2-Naph N CO2Me
MeO2C [L*Ag(OAc)] 
Toluene, 0 °C
N
H
2-Naph
MeO2C
CO2Me
37 4 38a (endo)
N
H
2-Naph
MeO2C
CO2Me
38b (exo)
+
L* =
O
P
O
R
O
O
O
P
O
Ph Ph
Ph Ph
R
N
O O
59 R = NMe2 
60 R = OCH2tBu
61 R =
62 R = NMe2 
63 R = OCH2tBu
5.2.5 Application of Different Monodentate P-Ligands to the Ag(I)-Catalyzed [3+2] 
Cycloaddition 
 
Monodentate BINOL and TADDOL derived phosphoramidite 59, 61 and 62 and phosphite 
ligands 60 and 63 were applied to the reaction in Scheme 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12. 
 
Each reaction was carried out using either one or two equivalents of ligand with respect to 
AgOAc. The corresponding complexes showed different 31P-NMR shifts in the two cases. 
This is probably due to the fact that a monomeric or a dimeric complex is formed. However, 
the metal/ligand ratio did not have an effect on the reactivity of the complexes or its 
asymmetric induction.  
The silver complex of the BINOL derived phosphite ligand 60 was not reactive at all (Table 
8, entry 2) whereas the analogous phosphoramidite ligands 59 and 61 led to complexes with 
good reactivity (Table 8, entries 1 and 3). An enantioselectivity of 70% was obtained when 
this ligand type contained a chiral amine building block (61). 
The catalysts of both TADDOL derived ligands 62 and 63 showed good reactivity and 
endo:exo selectivity whereas only the phosphoramidite ligand 62 could induce good 
enantioselectivtiy (Table 8, entry 4 and 5). 
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Table 8. 
Entry L* t (h) Conversion (%)a 38a : 38ba ee (%)b (38a) 
1 59 5.5 >95 >40 : 1 3 (+) 
2 60 72.0 - - - 
3 61 5.5 86 >40 : 1 70 (+) 
4 62 6.0 >95 >40 : 1 61 (−) 
5 63 9.0 >95 >40 : 1 12 (+) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligands 59-63 (3.3 mol%), methyl acrylate (4) (1.2 eq), 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), 
toluene, 0 °C. 
 
 
5.2.6 Conclusion 
 
The results of the ligand screening focused the interest on P,N- and on monodentate 
P-ligands. 
Based on the results obtained with monodentate P-ligands, the variation of the structure of 
TADDOL derived phosphoramidites appeared most promising. Unfortunately, the synthesis 
of this ligand type derived from sterically more demanding amines is not trivial and the yields 
are usually low as demonstrated by Alexakis et al.51 
Therefore the efforts were directed to P,N-ligands. The first results generated by the three 
PHOX ligands 39-41 already indicated a strong influence of its substitution pattern on 
asymmetric induction. Motivated by these results and the fact that this ligand type is highly 
variable and easily accessible, it was chosen to be optimized for the [3+2] cycloaddition 
reaction between azomethine ylides and electron-deficient dipolarophiles. 
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5.3 Ligand Screening for the Cu(I)-Catalyzed [3+2] Cycloaddition 
 
Several Cu(I) sources were tested in the asymmetric [3+2] cycloaddition including CuOAc, 
CuOtBu and Cu(CH3CN)4PF6. Since the initially used CuOAc required a laborious 
complexation method52 to obtain the desired catalyst, CuOtBu53 was synthesized and used as 
catalyst precursor. This metal salt is soluble in organic solvents including apolar solvents like 
cyclohexane and benzene and allowed complexation with the PHOX ligand under the same 
conditions used for Ag(I) complexes. Commercially available Cu(CH3CN)4PF6 could be used 
in the same way as CuOtBu with the difference that Et3N had to be added to the reaction 
mixture to assure the formation of the azomethine ylide.45a,45c 
The ligand screening comprised a limited number of P,N-, P,P- and N,N-ligands and was 
performed following the general procedure used for the Ag(I)-catalyzed 1,3-dipolar 
cycloaddition reaction. 
 
5.3.1 Application of Different P,N-Ligands to the Cu(I)-Catalyzed [3+2] Cycloaddition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 13. 
 
Cu(I)-PHOX complexes showed good activities in the reaction illustrated in Scheme 13 and 
formed the products with up to 76% enantiomeric excess but with low endo:exo selectivity 
(Table 9). Decreasing the temperature from room temperature to 0 °C improved the ee-values 
and the endo:exo selectivity slightly whereas the conversion dropped (Table 9, compare 
entries 1 and 2). Increasing the steric bulk at the C4 position of the oxazoline moiety or the 
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introduction of two phenyl groups at the C5 position favoured the generation of the 
exo product and lowered the enantiomeric excess of the endo product dramatically while the 
ee-value of the exo product raised (Table 9, compare entry 2 with entries 3 and 4). The use of 
CuOtBu and cyclohexane/benzene instead of CuOAc and toluene led to a higher 
endo selectivity and slightly higher enantioselectivity for the endo product (Table 9, compare 
entries 1 and 5). The application of pure benzene instead of the cyclohexane/benzene mixture 
led to a decrease of the endo:exo selectivity. Complexation of Cu(CH3CN)4PF6 with the 
PHOX ligand 64 led to a highly reactive catalyst which afforded preferentially the 
exo product whereas the enantioselectivities were rather low. 
 
Table 9. 
ee (%)b (38a) 
Entry Metal salt L* Cat. (mol%) 
T 
(°C) Solvent 
t 
(h) 
Conv.a 
(%) 38a : 38b
a 
ee (%)b (38b) 
70 (−) 
1 CuOAc 39 5 rt toluene 12 85 1.5 : 1.0 
23d 
76 (−) 
2 CuOAc 39 5 0 toluene 12 71 2.5 : 1.0 
24d 
3 (+) 
3 CuOAc 63 5 0 toluene 12 80 1.0 : 1.9 
43d 
28 (+) 
4 CuOAc 41 5 0 toluene 12 70 1.0 : 3.5 
62d 
74 (−) 
5 CuOtBu 39 3 rt 
cyclohexane
/benzene 
(4:1) 
4 84 5.4 : 1.0 
23d 
10 (+) 
6 CuOtBu 63 3 rt benzene 3.5 65 1.5 : 1.0 
39d 
4 (+) 
7 CuOtBu 63 3 rt 
cyclohexane
/benzene 
(4:1) 
4 61 4.9 : 1.0 
34d 
56 (+) 
8c Cu(CH3CN)4PF6 64 5 0 toluene 5 90 1 : 3 
30d 
rac. 
9 CuOtBu 65 3 0 
cyclohexane
/benzene 
(2:1) 
5 >95 4 : 1 
10d 
10 (−) 
10 CuOtBu 66 3 0 
cyclohexane
/benzene 
(2:1) 
7 >95 38 : 1 
n.d. 
a Determined by 1H NMR spectroscopy. 
b Determined by chiral HPLC. 
c Addition of 10 mol% Et3N to the reaction solution. 
d Optical rotation not determined. 
Reaction conditions: Metal salt (x mol%), ligands 39, 41, 63-66 (x.x mol%), methyl acrylate (4) (1.2 eq), 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), solvent, T. 
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The Cu(I) complexes of the pyridine derived phosphine- 65 and phosphinite-ligands 66 
showed excellent reactivity but formed the products with low enantioselectivites. The use of 
the phosphinite ligand 66 led to the highest endo selectivity in the course of this screening. 
 
5.3.2 Application of Different P,P-Ligands to the Cu(I)-Catalyzed [3+2] Cycloaddition 
 
 
 
 
 
 
 
 
 
 
Scheme 14. 
 
The Cu(I)-catalyzed [3+2] cycloaddition using the two dimeric TADDOL derived 
phosphonite ligands 56 and 58 linked by phenoxathiin or dibenzofuran proceeded with 
extremely low yield even after a reaction time of 24 h (Table 10). Interestingly the ligand with 
the phenoxathiin linker gave the endo product with a medium enantioselectivity of 60% 
whereas the ligand with the dibenzofuran linker gave the exo product with an 
enantioselectivity of 59%. 
 
Table 10. 
ee (%)b (38a) 
Entry L* t (h) Conversion (%)a  38a : 38ba 
ee (%)b (38b) 
14 (−) 
1 56 24 <5 n.d. 
59c 
60 (−) 
2 58 24 <10 n.d. 
n.d. 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
c Optical rotation not determined. 
Reaction conditions: AgOAc (3 mol%), ligands 56 and 58 (3.3 mol%), methyl acrylate (4) 
(1.2 eq), (E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) 
(1.0 eq), toluene, 0 °C. 
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5.3.3 Application of an N,N-Ligand to the Cu(I)-Catalyzed [3+2] Cycloaddition 
 
The Cu(I)-BOX complex derived from CuOAc and ligand 67 showed no reactivity in the 
[3+2] cycloaddition reaction illustrated in Scheme 14. 
 
 
 
 
 
 
Figure 30. 
 
5.3.4 Conclusion 
 
With regard to the results generated during the narrow ligand screening for the 
Cu(I)-catalyzed [3+2] cycloaddition, the PHOX ligand represents the most promising ligand 
type. Cu(I) catalysts derived from this ligand type were usually quite active and produced the 
cycloaddition products with moderate to good enantioselectivities. On the other hand the low 
endo:exo selectivity and the lack of conclusive models explaining the influence of the 
substituents at the ligand on asymmetric induction demand further ligand screening. 
In addition further Cu(I) sources should be tested to make the complexation and the reaction 
more practicable. 
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5.4 Au(I)-Catalyzed [3+2] Cycloaddition 
 
After the successful application of Cu(I) and Ag(I) complexes to the [3+2] cycloaddition 
reaction between (E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) and methyl 
acrylate (4) the focus was laid on Au(I), the remaining d10-transition metal representative of 
this group. The initial metal screening demonstrated that the use of 10 mol% of AuCl in 
combination with 0.5 equivalents of triethylamine did not lead to the formation of pyrrolidine 
38 (Scheme 15, method A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 15. 
 
Despite these results a Au(I)-PHOX complex similar to the effective PHOX-Ag(I) acetate or 
PHOX-Cu(I) tert-butoxide was generated. As neither AuOAc nor AuOtBu are commercially 
available the desired complex was prepared by initial formation of the corresponding 
PHOX-Au(I) chloride complex and subsequent anion exchange with sodium tert-butoxide to 
create 69. A suspension of AuCl and the PHOX ligand 39 in toluene was stirred for 4 h. 
31P-NMR studies of the resulting solution showed that the desired complex must have been 
formed since the signal of the free ligand disappeared (-8.5 ppm (CDCl3)) whereas a new 
signal appeared at 30.6 ppm. After addition of sodium tert-butoxide, the reaction solution was 
stirred for an additional 12 h and analyzed by 31P-NMR spectroscopy. As the obtained signal 
did not shift significantly from the signal of the starting material (∆δ = 0.4 ppm) no statement 
can be made if the anion exchange took place. A complexation trial using sodium 
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tert-butoxide with the PHOX ligand 39 excluded the formation of a sodium PHOX complex, 
as proved by 31P-NMR studies of the reaction solution which showed only the signal of the 
free ligand. 
The application of the PHOX-Au(I) chloride complex 68 to the [3+2] cycloaddition shown in 
Scheme 15 (Method B) did not lead to the formation of the desired product 38. Even after a 
reaction time of 24 h and the addition of 0.8 equivalents of base, which should assure the 
formation of the azomethine ylide, none of the pyrrolidine product 38 could be isolated. On 
the other hand excellent reactivity was obtained if the reaction was performed in a filtered 
solution of a PHOX-Au(I) complex, prepared from the PHOX-Au(I) chloride complex 68 by 
treatment with sodium tert-butoxide at 0 °C (Scheme 15, method C). The desired 
five-membered heterocycle 38 was obtained with a endo:exo selectivity of 7:1 and an 
enantioselectivity of 16%. 
A control experiment demonstrated that the 1,3-dipolar cycloaddition reaction is also 
catalyzed by 10 mol% of sodium tert-butoxide suspended in toluene. After a reaction time of 
12 h almost full conversion was obtained. However, filtration of a suspension of sodium 
tert-butoxide in toluene prior to the addition of the substrates did not show catalytic activity, 
excluding the possibility of a background reaction caused by the alkali salt. 
 
5.4.1 Application of Different PHOX-Ligands to the Au(I)-Catalyzed [3+2] 
Cycloaddition 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 16. 
 
The Au(I)-PHOX complexes derived from ligands 39, 41 and 63 and AgOAc showed good 
reactivity towards the [3+2] cycloaddition illustrated in Scheme 16. The pyrrolidines 38a and 
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38b were isolated with an acceptable endo:exo selectivity of 7:1 but low enantioselectivities 
(Table 11). 
 
Table 11. 
Entry L* Conversion (%)a 38a : 38ba ee (%)b (38a) 
1 39 80 7 : 1 16 (−) 
2 63 87 7 : 1 19 (−) 
3 41 91 7 : 1 7 (−) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
Reaction conditions: AuCl (5 mol%), ligands 39, 41 and 63 (5.5 mol%), 
NaOtBu (0.3 eq), methyl acrylate (4) (1.2 eq), (E)-methyl 
2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), 
toluene, rt, 10 h. 
 
5.4.2 Conclusion 
 
The experiments with Au(I)-PHOX complexes demonstrate that the Au(I) species presumably 
catalyzes the reaction shown in Scheme 16 if it is complexed with a PHOX ligand and 
disposes of the adequate counterion. However, low asymmetric induction, the small choice of 
different commercially available Au(I) salts, the high prize of the AuCl and the impractical 
complexation method speak against further investigations of this catalytic system. 
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5.5 Final Conclusion 
 
Although one of the Cu(I)-PHOX catalysts tested led to the formation of the desired 
cycloaddition product with higher enantiomeric excess than analogous Ag(I) and Au(I) 
complexes (Table 9, entry 2 and Table 3, entry 2) the attention was directed to the 
Ag(I)-PHOX system. Firstly, because only the results obtained with Ag(I)-PHOX complexes 
indicated a strong influence of the ligand substitution pattern on asymmetric induction. This 
suggested the possibility of substantial improvement of the enantioselectivity by optimizing 
the substitution pattern of the ligand. Secondly, high endo selectivity was observed in 
comparison to the Cu(I) and Au(I) system. Thirdly, the practical realization of the 
Ag(I)-catalyzed 1,3-dipolar cycloaddition reaction is easier than in the Cu(I) or Au(I) series. 
It was decided to optimize the substitution pattern of the PHOX ligand at the phosphorous 
atom and the C5 position of the oxazoline moiety, as these structural elements seemed to have 
the highest influence on asymmetric induction (Table 5, entries 1-3). 
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6 Phosphinooxazolines 
 
6.1 General Aspects 
 
The research groups of Pfaltz54, Helmchen54 and Williams55 independently developed the so 
called PHOX-ligand 39 which contains a “soft“ π-accepting phosphorous atom and a “hard“ 
σ-donating nitrogen atom. The electronic properties of this nonsymmetrical ligand type 
having two coordinating electronically different heteroatoms can aid the control of the 
stereochemical outcome of a catalyzed reaction. This was demonstrated by the 
palladium-catalyzed allylic alkylation. In this reaction the nucleophile preferentially attacks 
the allylic carbon atom trans to the phosphorus atom due to strong electronic differentiation 
of the allylic termini caused by the ligand (Figure 31, A).54 
 
 
 
 
 
 
 
Figure 31. 
 
The PHOX ligand possesses a highly modular structure allowing variations at the oxazoline 
ring, the backbone and the phosphine moiety. This property often enables the creation of a 
ligand tailored to the requirements of its application. Heck-reactions56, Diels-Alder reactions57 
and hydrogenations58 are only some examples of reactions to which PHOX ligands were 
applied to. 
 
6.2 Synthesis of C5-Disubstituted Phosphinooxazoline Ligands 
 
A preliminary ligand screening for the Ag(I)-catalyzed [3+2] cycloaddition reaction showed 
promising results by applying C5-disubstituted PHOX ligands (Table 5, entry 3) to this 
reaction. On the basis of these initial experiments a small library of this ligand type was 
synthesized (Figure 32). 
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Figure 32. 
 
The synthesis of PHOX ligands is usually achieved by the formation of an aryl-oxazoline 82 
and subsequent preparation of the corresponding phosphorous derivative 83 by substitution. 
There exist several methods for preparing oxazoline rings59 and the chiral variants are usually 
synthesized from the chiral pool of natural amino acids. The most common methods involve 
four one step procedures60 and a two step procedure61 (Scheme 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 17. 
 
Phosphinooxazolines 
 65
84
Cl H3N
O
OMe
PhCOCl, Et3N
Dioxane, 12 h, 82%
TsCl, Et3N
CH2Cl2, reflux, 24 h, no conv.
Burgess-reagent
THF, reflux, 12 h, 68%
2-NaphMgBr,
THF, 0 °C → rt, 4.5 h, 60%
H2N
OH
2-Naph
2-Naph
O
HN
O
OMe
PhCOCl, Et3N
CH2Cl2, 12 h,  97%
2-NaphMgBr,
THF, 0 °C → rt, 12 h, 90%
N
O 2-Naph
2-Naph
O
HN
OH
2-Naph
2-Naph
CH3SO3H 
CH2Cl2, reflux, 12 h,  82%
86 85
87
88
A B
C D E
The first step of the synthesis of chiral C5-disubstituted oxazolines requires the formation of 
the amide 87. This can be achieved by following either pathway A or B which differ only in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 18. 
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the sequence of the steps. While pathway A converts L-valin methyl ester 84 to the 
corresponding tertiary alcohol 86 by the appropriate Grignard reagent and subsequently 
forms the amide 87, in pathway B the reactions are performed in the opposite order. Reaction 
sequence B is more convenient since the isolation and handling of amide 85 is easier in 
contrast to the alternative amino alcohol 86. In addition, the remarkable difference between 
the overall yields of 49% and 87% for pathway A and B, respectively, also favours the latter 
synthetic sequence. 
Subsequent formation of the oxazoline 88 by use of tosylchloride62 failed presumably due to 
the difficulty in transforming a sterically hindered tertiary alcohol into the sulfonate (Scheme 
18, method C). The application of the Burgess reagent63 led to the desired product 88 
(Scheme 18, method D) but the most efficient ring closing reaction was achieved by 
intramolecular condensation using methanesulfonic acid64 under azeotropic removal of water 
(Scheme 18, method E). This was confirmed by the cyclization reaction of the amides bearing 
two phenyl- or cyclohexyl groups at the tertiary alcohol carbon. The phenyl substituted 
oxazoline was formed with a yield of 65% using the Burgess reagent but with a yield of 82% 
if methanesulfonic acid was used. In the case of the cyclohexyl substituted oxazoline no 
product could be isolated by employing method D whereas a yield of 61% was obtained 
following method E. 
The efficient synthesis of 2-phenyloxazoline 88 following pathway B and method E resulted 
in an overall yield of 72% and did not require further optimization.65 Based on this synthetic 
sequence methyl-65, ethyl-, propyl-65, phenyl-, and ortho-tolyl-substituents were introduced to 
amide 85 or 89 with yields ranging from 60% to 79% (Scheme 19). The preparation of 
tertiary alcohols by the use of sterically more demanding Grignard reagents like cyclohexyl- 
or isopropylmagnesiumbromide65 was only possible in the presence of cerium chloride 
(Scheme 19, pathway B’).66 The products were isolated with yields of 52% respectively 68%. 
Imamoto67 stated that cerium chloride activates the carbonyl group by coordination whereas 
Colon68 claimed that transmetalation generates a more nucleophilic species. In the absence of 
an activating reagent only the corresponding ketone could be isolated. 3,5-dimethylphenyl-, 
3,5-dimethoxyphenyl- and 3,5-di-tert-butoxyphenyl-substituents were also introduced by the 
“activation process“ expecting higher yields than if the reaction would have been done in the 
conventional way. Cyclization of the tertiary alcohols 90-96 to the 2-phenyloxazolines 97-103 
proceeded with yields ranging from 61% to 85%. 
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Scheme 19. 
 
The final PHOX ligands 41, 64, and 70-79 were obtained by either ortho-lithiation of the 
corresponding 2-phenyloxazolines 88 and 98-101 with sec-butyllithium/TMEDA in pentane 
and subsequent treatment with chlorodiarylphosphines60b(method F, Scheme 20) or 
nucleophilic substitution by the treatment of the 2-(2-fluorophenyl)oxazolines 97, 102 and 
103 with a diarylphosphide61(method G, Scheme 20). 
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The 2-phenyloxazolines 88 and 98-101 were easily transformed to 2-(2-
phosphinoaryl)oxazolines 41, 64 and 72-77 by the appropriate commercially available 
chlorodiarylphosphines using method F (Scheme 20). However, the purification of the crude 
product by column chromatography was usually quite demanding since unreacted 
phenyloxazolines, phosphino-oxazolines and side-products have very similar Rf values. 
The introduction of the phosphino group by the reaction of the oxazolines 97, 102 and 103 
with lithium diarylphosphide was very clean, allowing easy purification of the crude product. 
However, the use of method G required the preparation of the phosphane moiety69 which is 
not commercially available. 
A selective introduction of the phosphane group is not possible by pathway F if the 
2-phenyloxazoline bears two 3,5-dimethoxyphenyl groups at the C5 position of the oxazoline 
moiety. The ortho- and especially the para-position of the 3,5-dimethoxyphenyl group are 
prone to lithiation and subsequent reaction with the electrophilic phosphorous reagent. 
Presumably also a simple electrophilic aromatic substitution can take place at the formerly 
mentioned positions. On this account the introduction of the phosphane moiety was realized 
by pathway G. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 20. 
 
The C5-disubstituted PHOX ligands 41, 64 and 70-79 can be efficiently synthesized 
following pathway B, method E and method F or G. The yield over the four step synthetic 
pathway reaches from 16% to 55% as illustrated in Scheme 20. 
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6.3 Synthesis of Phosphinooxazoline Ligands Bearing Two Chirality Centers at the 
Oxazoline Unit 
 
The (4S,5R)- 111 and (4S,5S)-PHOX 114 ligands, prepared by the synthetic pathway 
illustrated in Scheme 21, were designed to examine the influence of a second stereocenter at 
the oxazoline unit on asymmetric induction in comparison to the analogous C5-disubstituted 
PHOX ligand 64. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 21. 
 
Boc-protection70 of L-valine 104 and subsequent reaction with O,N-dimethylhydroxylamine 
led to the formation of the Weinreb amide71 106. The N-methoxy-N-methylamide 106 has the 
beneficial property to react cleanly with phenylmagnesium bromide to ketone 107 without 
producing a tertiary alcohol even if 2.5 equivalents of the Grignard reagent were used. The 
reduction of the aminoketone 107 with sodium borohydride led to formation of the 
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boc-protected amino alcohol 108 with a syn:anti ratio of 98:2. This result was in accordance 
to the data reported by Zhou et al.72 With regard to the following reaction steps, which could 
further shift the diastereomeric ratio, it was planned to separate the diastereomers at the latest 
possible step before the introduction of the phosphorous group, namely at the stage of the 
2-phenyloxazolines 110 and 113. Deprotection of the amino group was achieved with a 4M 
HCl-solution in dioxane whereas reagents like trifluoroacetic acid or a 1% HF-solution failed 
to react. 
Conversion of the amino alcohol 109 with ethyl iminobenzoate yielded the (4S,5R)-4-
isopropyl-2,5-diphenyl-4,5-dihydrooxazole 110.60a Although the reaction proceeded with 
retention of configuration, the product could be isolated with a diastereoselectivity of only 
92%. Separation of the diastereomers by semipreparative HPLC provided the pure compound 
110. 
The C5-diastereomeric (4S,5S)-4-isopropyl-2,5-diphenyl-4,5-dihydrooxazole 113 was 
obtained by a two step procedure. Upon formation of the amide 112 the cyclization to the 
oxazoline 113 was achieved with methanesulfonic acid.64a The reaction took place under 
inversion of the configuration. The product could be isolated with a diastereoselectivity of 
96% and was likewise purified by semipreparative HPLC. 
The final PHOX ligands 111 and 114 were obtained by ortho-lithiation of the 
2-phenyloxazolines 110 and 113 with sec-butyllithium/TMEDA in pentane and subsequent 
treatment with chloro-di-ortho-tolylphosphines.60b 
The synthesis of the (4S,5R)-4-isopropyl-2,5-diphenyl-4,5-dihydrooxazole 111 and the 
C5-diastereomeric (4S,5S)-4-isopropyl-2,5-diphenyl-4,5-dihydrooxazole 114 is 
straightforward and provides the products with overall yields of 13% over 7 steps (111) and 
19% over 8 steps (114), respectively. The replacement of the disadvantageous HPLC 
separation of the diastereomers 110 and 113 by crystallization would improve the synthetic 
ease of the pathway. Upon this optimization it would represent a versatile method to 
synthesize PHOX ligands with a second stereocenter at the oxazoline unit. 
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7 Optimization of the Ligand Structure for Ag(I)-Catalyzed [3+2] Cyclo-
additions  
 
7.1 Introduction 
 
Preliminary results of the ligand screening for the Ag(I)-catalyzed [3+2] cycloaddition 
reaction showed especially for the PHOX ligand a strong influence of its substitution pattern 
on asymmetric induction. Thus, it was intended to investigate this issue in greater detail. For 
this purpose the influence of different substituents at the phosphorous atom, the phenyl 
backbone and the oxazoline moiety on stereoselectivity of the reaction were examined (Figure 
33). The ligands used for these investigations were derived from the Pfaltzs’ group ligand 
library or were synthesized as previously described (Chapter 6). 
 
 
 
 
 
 
 
Figure 33. 
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7.2 Influence of Different Substituents at the Phosphorous Atom of the PHOX Ligand 
 
PHOX ligands 39-41, 64, 73-75, 115-118 with different substituents at the phosphorous atom 
were applied to the reaction illustrated in Scheme 22. The results in Table 12 display a 
remarkable influence of these groups on the stereoselectivity of this reaction and the reactivity 
of the catalysts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22. 
 
The introduction of sterically more demanding and electron-rich 2-methoxyphenyl groups 
(117) at the phosphorous atom of the ligand was not advantageous, as it led to a lower 
reaction rate, endo:exo selectivity and enantioselectivity than if the reaction was performed 
with the reference PHOX ligand 39 (Scheme 22 and Table 12, entry 5). Pentafluorophenyl 
and 2-trifluoromethylphenyl substituents prevented complexation with AgOAc (Table 12, 
entries 3 and 4) and a silver mirror could be observed on the reaction flask after a reaction 
time of 12 h. 
The replacement of the phenyl groups of 39 by sterically more demanding ortho-tolyl 
substituents improved the enantioselectivity regardless if the ligand was carrying substituents 
at the C5 position of the oxazoline ring or not (Table 12, compare entries 1, 7 and 10 with 2, 8 
and 11). On the other hand the endo:exo selectivity and the regioselectivity decreased whereas 
the activity of the catalyst stayed the same. Exchange of the ortho-tolyl groups by 
3,5-dimethylphenyl-substituents improved the reactivity, regioselectivity and 
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endo:exo selectivity (Table 12, compare entries 11 and 12) but the enantioselectivity was 
lower than with the ortho-tolyl substituted PHOX ligand 74. 
The aliphatic cyclohexyl groups had a comparable effect on enantioselectivity to ortho-tolyl 
groups but a disadvantageous effect on endo:exo selectivity, regioselectivity and reactivity of 
the catalyst (Table 12, compare entries 7, 8 and 9). 
 
Table 12. 
Entry L* t (h) Yield (%)a 38a : 38bb 38a : 38cb ee (%)c (38a) 
1 39 5 95 >40 : 1 >40 : 1 29 (+) 
2 40 8 93 >40 : 1 >40 : 1 45 (+) 
3 115 12 - - - - 
4 116 12 - - - - 
5 117 8 24d 9 : 1 >40 : 1 10 (+) 
7 41 7 86 >40 : 1 >40 : 1 49 (+) 
8 64 7 90 40 : 1 35 : 1 65 (+) 
9 118 7 80 24 : 1 30 : 1 62 (+) 
10 73 7 78 >40 : 1 >40 : 1 17 (+) 
11 74 6 81 26 : 1 15 : 1 60 (+) 
12 75 6 87 >40 : 1 39 : 1 49 (+) 
a After column chromatography. 
b Determined by 1H NMR. 
c Determined by chiral HPLC. 
d Conversion: Determined by 1H NMR. 
Reaction conditions: AgOAc (3 mol%), ligands 39-41, 64, 73-75, 115-118 (3.3 mol%), methyl acrylate (4) 
(1.2 eq), (E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), 
toluene, 0 °C. 
 
It was clear that ortho-tolyl substitutents had the most beneficial effect on the reaction. The 
enantioselectivity reached the highest value of this serie and was accompanied by an 
acceptable loss of reactivity, endo:exo selectivity and regioselectivity in comparison to the 
reference ligand 39. 
 
Optimization of the Ligand Structure for Ag(I)-Catalyzed [3+2] Cycloadditions 
 76
2-Naph N CO2Me
MeO2C
N
H
2-Naph
MeO2C
CO2Me
37 4 38a (endo)
N
H
2-Naph
MeO2C
CO2Me
38b (exo)
N
O
(Ph)2P
  39 R = H
119 R = OH
120 R = OTBDMS
L* =
[L*Ag(OAc)]
Toluene, 0 °C
R
7.3 Influence of Different Substituents at the Phenyl Backbone of the PHOX Ligand 
 
The influence of different substituents at the phenyl backbone of the PHOX ligand on the 
reaction of Scheme 23 was briefly investigated. Structural variation was limited to the 
introduction of a hydroxy- and a silyloxy-group at the para position of the phenyl backbone 
(Scheme 23, structures 119 and 120). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 23. 
 
The results in Table 13 show that electron donating groups at the phenyl backbone slow down 
the reaction similar to the situation previously discussed for 2-methoxyphenyl substituents at 
the phosphorous atom. In addition, ligands 119 and 120 induced lower enantioselectivities 
than the unsubstituted ligand 39. 
 
Table 13. 
Entry L* t (h) Conversion (%)a 38a : 38aa ee (%)b (38a) 
1 39 5 >95 >40 : 1 29 (+) 
2 119 24 traces n.d. 12 (+) 
3 120 8 65 >40 : 1 20 (+) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligand 39, 119, 120 (3.3 mol%), methyl acrylate (4) 
(1.2 eq), (E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) 
(1.0 eq), toluene, 0 °C. 
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7.4 Influence of Different Substituents at the C4 Position of the Oxazoline Ring 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24. 
 
PHOX ligands carrying an isopropyl substituent at the C4 position of the oxazoline ring 39, 
40 and 123 were compared with the corresponding ligands bearing a tert-butyl- 63, a 
cyclohexyl- 124 or a phenyl-substituent 122 at this position. Furthermore the L-serine derived 
PHOX ligand 121 was applied to the reaction illustrated in Scheme 24. 
 
Table 14. 
Entry L* t (h) Conversion (%)a 38a : 38ba ee (%)b (38a) 
1 39 5 >95 >40 : 1 29 (+) 
2 63 6 >95 >40 : 1 27 (+) 
3 121 7 >95 >40 : 1 48 (−) 
4 40 8 >95 >40 : 1 45 (+) 
5 122 7 >95 >40 : 1 15 (+) 
6 123 8 49 >40 : 1 62 (+) 
7 124 7 81 >40 : 1 23 (−) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligands 39, 40, 121-124 (3.3 mol%), methyl acrylate 
(4) (1.2 eq), (E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) 
(1.0 eq), toluene, 0 °C. 
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The tert-butyl group had almost no effect on the enantioselectivity of the reaction (Table 14, 
compare entries 1 and 2) whereas the cyclohexyl and the phenyl substituted ligands 124 and 
122 reduced the enantioselectivity strongly (Table 14, compare entries 4 with 5 and 6 with 7). 
The sterically demanding L-serine-derived ligand 121 had a positive influence on the 
asymmetric induction with regard to the reference ligand 39 (Table 14, compare entries 1 and 
3). A comparable positive effect on asymmetric induction was obtained if the phenyl group at 
the phosphorous atom was replaced by an ortho-tolyl group (Table 14, compare entries 1 with 
3 and 1 with 4). 
 
7.5 Influence of Different Substituents at the C5 Position of the Oxazoline Ring 
 
PHOX ligands bearing various aliphatic or aryl substituents at the C5 position of the 
oxazoline ring were applied to the [3+2] cycloaddition reaction outlined in Scheme 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 25. 
 
In general the enantioselectivity is positively influenced by substituents at the C5 position of 
the oxazoline ring whereas the reactivity decreases. For ligands bearing ortho-tolyl 
substituents at the phosphorous atom, the increase of the steric bulk at the C5 position of the 
oxazoline moiety usually led to a decrease of the endo:exo selectivity and the formation of the 
opposite regioisomer 38c. 
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The results obtained with ligands possessing aliphathic substituents at the C5 position of the 
oxazoline ring did not follow a clear trend. Cyclohexyl, methyl and n-propyl groups had a 
more positive effect on the enantioselectivity than if the ligand incorporated isopropyl 
substituents (Table 15, compare entries 2 and 3 with 4 and 8). Ligand 125 stood out since it 
gave the product with low endo:exo selectivity whereas comparable ligands 39, 41, 73, 126 
and 127 also bearing phenyl substitutents at the phosphorous atom typically induced almost 
perfect endo selectivity. 
 
Table 15. 
Entry L* t (h) Yield (%)a 38a : 38bb 38a : 38cb ee (%)c (38a) 
1 39 5 95 >40 : 1 >40 : 1 29 (+) 
2 125 8 57 >24 : 1 n.d. 43 (+) 
3 126 7 86 >40 : 1 >40 : 1 32 (+) 
4 127 7 88 >40 : 1 >40 : 1 53 (+) 
5 41 7 86 >40 : 1 >40 : 1 49 (+) 
6 73 7 78d >40 : 1 >40 : 1 17 (+) 
7 40 8 93 >40 : 1 >40 : 1 45 (+) 
8 123 8 49 24 : 1 24 : 1 62 (+) 
9 72 9 40 9 : 1 9 : 1 62 (+) 
10 64 7 90 40 : 1 >40 : 1 65 (+) 
11 74 6 81 26 : 1 15 : 1 60 (+) 
12 76 6 56 12 : 1 12 : 1 67 (+) 
13 77 6.5 73 14 : 1 14 : 1 81 (+) 
14 78 6 91 18 : 1 16 : 1 74 (+) 
15 79 7 80 >40 : 1 >40 : 1 84 (+) 
a After column chromatography. 
b Determined by 1H NMR. 
c Determined by chiral HPLC. 
d Conversion: Determined by 1H NMR. 
Reaction conditions: AgOAc (3 mol%), ligands of Scheme 25 (3.3 mol%), methyl acrylate (4) (1.2 eq), 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), toluene, 0 °C. 
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Aryl substituents tend to have a more positive effect on asymmetric induction than their 
aliphatic counterparts. Since phenyl groups had a promising effect on the enantioselectivity of 
the reaction, this substitution pattern was somewhat varied. The introduction of an ortho-tolyl 
substituent at the C5 position of the oxazoline ring increased the enantioselectivity while the 
regio- and the endo:exo selectivity as well as the yield dropped (Table 15, compare entry 10 
with 12). The 3,5-dimethylphenyl-substituted ligand 77 formed a quite active Ag(I) complex 
which induced even higher enantioselectivity and a comparatively improved endo:exo- and 
regioselectivity (Table 15, compare entry 12 with 13). The Ag(I) complex of ligand 78 
incorporating 3,5-dimethoxyphenyl substituents was even more reactive and formed the 
product with higher endo- and regioselectivity but with lower enantiomeric excess (Table 15, 
compare entry 13 with 14). Introduction of 3,5-di-tert-butylphenyl groups at the C5 position 
of the oxazoline ring led to the most efficient PHOX ligand 79 to date. The cycloaddition 
product 38a was formed with an enantioselectivity of 84%, high endo:exo selectivity and a 
yield of 80% after a reaction time of 7 hours. 
 
7.5.1 Influence of an Additional Chirality Center at the C5 Position of the PHOX 
Ligand 
 
The PHOX ligands 111 and 114 were synthesized to investigate the influence of a second 
stereocenter on the asymmetric induction of the reaction illustrated in Scheme 26. 
Additionally the steric influence of the substituents cis respectively trans to the isopropyl 
group at the oxazoline ring on the outcome of the reaction was examined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 26. 
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A comparison of the results generated by the C5-disubstituted ligand 64 and the ligands 
bearing a second stereocenter at the oxazoline ring 111 and 114 showed that the additional 
stereocenter did not have a beneficial effect on enantioselectivity (Table 16, compare entries 1 
with 2 and 3). 
 
Table 16. 
Entry L* t (h) Yield (%)a 38a : 38bb 38a : 38cb ee (%)c (38a) 
1 64 7.0 90 40 : 1 >40 : 1 65 (+) 
2 111 4.5 85 >40 : 1 >40 : 1 52 (+) 
3 114 4.5 84 30 : 1 26 : 1 45 (+) 
a After column chromatography. 
b Determined by 1H NMR. 
c Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligand 64, 111, 114 (3.3 mol%), methyl acrylate (4) (1.2 eq), 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) (1.0 eq), toluene, 0 °C. 
 
7.6 Conclusion 
 
Studies of the influence of different substitution patterns at the PHOX ligand on the reaction 
rate and asymmetric induction of the [3+2] cycloaddition demonstrated several trends. 
Sterically more demanding alkyl-substituted aryl groups at the phosphorous atom of the 
ligand had the most beneficial effect on the reaction. The application of ligands with an 
unsubstituted phenyl backbone led in contrast to the substituted phenyl analog to superior 
results. An L-serine-derived and functionalized PHOX ligand gave higher enantioselectivity 
than its isopropyl-substituted analog. Despite this fact the focus was laid on the L-valine 
derived PHOX ligand since C5-substituted ligands are easily accessible from this amino acid. 
Studies concerning the substituents at the C5 position demonstrated that meta substituted 
phenyl groups had a very positive effect on reaction rate and asymmetric induction. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
 
Scope of the Asymmetric Ag(I)-Catalyzed Intermolecular [3+2] 
Cycloaddition 
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8 Scope of the Asymmetric Ag(I)-Catalyzed Intermolecular [3+2] Cycloaddition 
 
In the course of the optimization of the PHOX ligands’ substitution pattern differently 
substituted azomethine ylides and dipolarophiles were applied to the [3+2] cycloaddition. The 
variations should provide an indication of the limitation of the reaction. 
 
8.1 Application of Differently Substituted Azomethine Ylides 
 
The substituents introduced to the imine system illustrated in Scheme 27 allowed the 
investigation of different features in comparison to the reference imine 37. Imines 128-131 
should demonstrate the effect of electron withdrawing and electron donating substituents on 
the outcome of the reaction. The influence of sterically more demanding 1,3-dipoles was 
examined by replacing the methyl ester (37) with a tertiary butyl ester (134), the incorporation 
of a substituent alpha to the imine (133) or the formation of a ketimine (132). The substitution 
of the ester group of substrates 37 and 131 by a pyridine (135) or a phenyl (136) group was 
chosen to study the importance of the coordination of this group to the silver ion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 27. 
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Table 17. 
Entry L* 1,3-Dipole t (h) Yield (%)a endo : exob ee (%)(endo)c ee (%)(exo)c 
1d 77 128 6 69 9 : 1 65 (+) n.d. 
2 39 129 8 >95e 30 : 1 30 (+) n.d. 
3 64 129 7 82 7 : 1 50 (+) n.d. 
4 77 129 7 87 4 : 1 57 (+) n.d. 
5 77 130 12 43 n.d. 85f n.d. 
6 39 37 5 95 >40 : 1 29 (+) n.d. 
7 40 37 8 93 >40 : 1 45 (+) n.d. 
8 64 37 7 90 40 : 1 65 (+) n.d. 
9 77 37 6.5 73 14 : 1 81 (+) n.d. 
10 39 131 7 91e >40 : 1 17 (+) n.d. 
11 40 131 7 85e >40 : 1 17 (+) n.d. 
12 64 131 7 60 >40 : 1 47 (+) n.d. 
13i - 132 12 - - - - 
14i - 133 12 - - - - 
15 40 134 6.5 92e >40 : 1 20 (+) n.d. 
16 64 134 6 68 13 : 1 41 (+) n.d. 
17 39 135 9 >95e 3 : 1 41f 16f,g 
18 40 135 5.5 80e 1 : 1 7f,h 8f 
19 41 135 4 96e 3 : 1 73f 25f 
20 64 135 7 88e 1 : 2 52f 74f 
21 39 136 7 - - - - 
a After column chromatography. b Determined by 1H NMR. c Determined by chiral HPLC. d 5 mol% of 
the catalyst was used. e Conversion: Determined by 1H NMR. f Optical rotation not determined. g The 
opposite enantiomer was detected by chiral HPLC, with respect to the enantioselectivity found for the 
exo products under entry 18-20. h The opposite enantiomer was detected by chiral HPLC, with respect to 
the enantioselectivity found for the endo products under entry 17, 19 and 20. 
i Reaction conditions: AgOAc (3 mol%), Et3N (1.1 eq), methyl acrylate (4) (2.4 eq), 1,3-dipoles 132, 
133 (1.0 eq), CH3CN, rt. 
Reaction conditions: AgOAc (3 mol%), ligands 39-41, 64, 77 (3.3 mol%), methyl acrylate (4) 
(1.2 eq), 1,3-dipoles 37, 128-131, 134-136 (1.0 eq), toluene, 0 °C. 
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Electron-withdrawing substituents at the imine 128 and 129 did not affect the reactivity of the 
system in comparison to the reference imine 37 (Table 17, compare entries 1, 4 and 9), but the 
corresponding pyrrolidine products were formed with lower endo- and enantioselectivity. 
Imines 130 and 131 bearing electron-donating groups usually reacted slower with the 
dipolarophile, with no effect on the endo:exo selectivity of the reaction (Table 17, compare 
entries 5 with 9 and 8 with 12). Depending on the particular substituent, higher or lower 
enantioselectivities were obtained in comparison to the reference imine 37. 
Starting from ketimine 132 and methyl acrylate (4) no reaction was observed applying 
10 mol% of AgOAc (Table 17, entry 13). Although formation of the Michael-adduct might be 
expected, only starting material was recovered after 12 h reaction time.29,30 Later Carretero et 
al. performed the reaction between the identical ketimine 132 and N-phenylmaleimide in the 
presence of 3 mol% of a Cu(I)-Fesulphos catalyst and isolated the desired product with good 
yields and enantioselectivity.45c 
The incorporation of an isopropyl group at the α-position of the imine (133) was unfavourable 
(Table 17, entry 14). The reaction with methyl acrylate (4) did not proceed following the 
Lewis acid protocol (Table 17, footnote f). Schreiber et al. likewise applied the sterically less 
hindered iminoesters derived from leucine, phenylalanine and tryptophan to the [3+2] 
cycloaddition with tert-butyl acrylate. The corresponding pyrrolidine bearing a quaternary 
center at the C2 position could be isolated with moderate to excellent yields and good 
enantioselectivities.48b 
Increasing the steric bulk at the ester group of imine 37 by implementing a tert-butyl ester 
group in compound 134 decreased reactivity as well as selectivity (Table 17, compare entry 8 
with 16). 
The replacement of the ester group in imine 131 by a phenyl group led to a completely 
inactive 1,3-dipole 136 (Table 17, entry 21). This indicates that the coordination of the 
carbonyl oxygen of the ester group to the silver is crucial for the activation of the azomethine 
ylide since the phenyl group can not coordinate to the metal ion. The introduction of a 
pyridine moiety linked over the C2 atom should provide the possibility of coordination thus 
leading to an activated 1,3-dipole, and indeed conversion to the desired pyrrolidine product 
144 was quite high (Table 17, entries 17-20). The 1,3-dipolar cycloaddition reaction using 
substrate 135 showed a somewhat unusual influence of the ligand substitution pattern on 
asymmetric induction. The exchange of the phenyl groups at the phosphorous atom by 
ortho-tolyl groups slowed down the reaction, increased the enantiomeric excess of the 
exo products and lowered the endo selectivity as well as the enantioselectivity of the 
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endo products (Table 17, compare entries 17 with 18 and 19 with 20). The decrease of the 
enantioselectivity of the endo product corresponds to an effect which is opposite to previous 
findings. However, the implementation of phenyl substituents at the C5 position of the 
oxazoline moiety had the expected effect on the outcome of the reaction (Table 17, compare 
entries 17 with 19 and 18 with 20). The pyrrolidine products were formed with higher 
enantiomeric excesses but slightly lower endo:exo selectivities and lower conversions. 
 
8.2 Application of Differently Substituted Dipolarophiles 
 
In order to study how steric and electronic factors influence the reaction the dipolarophiles 4, 
146-148 illustrated in Scheme 28 were used as reactants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 28. 
 
The influence of different steric demands of the dipolarophile on the outcome of the 
cycloaddition (Scheme 28) could be easily examined by applying methyl acrylate 4 and 
tert-butyl acrylate 146 to the reaction since their electronic properties are similar. The larger 
steric bulk of the tertiary ester had a disadvantageous effect on asymmetric induction as well 
as on reaction rate (Table 18, compare entries 1 with 3 and 2 with 4). The use of the 
oxazolidinone dipolarophile 148 resulted in a similar effect (Table 18, compare entries 7 and 
8). 
Dimethyl maleate (147) representing the most electron poor dipolarophile of Scheme 28 was 
expected to react fastest with the azomethine ylide. Surprisingly, the formation of the 
corresponding pyrrolidine 150 was slower than if methyl acrylate (4) was used as the 
dipolarophile (Table 18, compare entries 1 with 5 and 2 with 6). However, the negative 
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influence on asymmetric induction and reaction rate was not as strong as observed with 
tert-butyl acrylate 146 (Table 18, compare entries 3 with 5 and 4 with 6). 
 
Table 18. 
Entry L* Dipolarophile t (h) Yield (%)a endo : exob ee (%)(endo)c 
1 41 4 7 86 >40 : 1 49 (+) 
2 64 4 7 90 40 : 1 65 (+) 
3 41 146 12 84d 8 : 1 9 (+) 
4 64 146 9 60 3 : 1 43 (+) 
5 41 147 12 83 35 : 1 39 (+) 
6 64 147 7 73 7 : 1 60 (+) 
7 40 4 8 93 >40 : 1 45e 
8 40 148 6 65d n.d. 14e 
a After column chromatography. 
b Determined by 1H NMR. 
c Determined by chiral HPLC. 
d Conversion: Determined by 1H NMR. 
e Optical rotation not determined. 
Reaction conditions: AgOAc (3 mol%), ligands 40, 41, 64 (3.3 mol%), dipolarophiles 4, 
146-148 (1.2 eq), (E)-methyl 2-(naphthalene-2-ylmethyleneamino)- 
acetate (37) (1.0 eq), toluene, 0 °C. 
 
Carretero and co-workers investigated the 1,3-dipolar cycloaddition of azomethine ylides with 
aryl vinyl sulfones.45c The desired pyrrolidine products were formed with complete 
exo selectivity and enantioselectivities of up to 85% by employing a Cu(I)-Taniaphos catalyst 
system. Brief studies using AgOAc instead of Cu(CH3CN)4ClO4 in combination with various 
Fesulphos, Walphos and Taniaphos ligands showed that the silver catalyst system led to lower 
asymmetric induction. Interested by these results it was intended to apply phenyl vinyl 
sulfone 152 to our catalyst system. 
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Scheme 29. 
 
The conversion of phenyl vinyl sulfone 152 with the electron poor as well as the electron rich 
phenyl imines 128 and 130 was realized with a catalyst derived from AgOAc and the PHOX 
ligand 77. The results generated by these reactions were compared with the one of the 
corresponding reaction using methyl acrylate (4) instead of phenyl vinyl sulfone 152.  
The higher electron deficiency of the CC-double bond of the α,β-unsaturated sulfone 152 (Table 
19, compare entries 1 and 2) presumably accelerated the cycloaddition with the electron-poor 
phenyl imine 128 since compound 153 was isolated with a higher yield than cycloproduct 137. 
While the use of the vinyl ester 4 led to the preferential formation of the endo product with an 
enantioselectivity of 65%, the reaction with phenyl vinyl sulfone 152 preferentially led to the 
exo product with an enantiomeric excess of 88%. The latter result is superior to that of 
Carretero and co-workers obtained with their catalyst system (82% ee) for this reaction. 
Reduction of the catalyst loading from 5 to 3 mol% lowered the reaction rate and the 
enantioselectivity slightly, but the results were still superior to those of Carreteros’ study (Table 
19, compare entries 2 and 3). 
Initial studies with the electron rich phenyl imine 130 showed that the cycloaddition with 
phenyl vinyl sulfone 152 is much faster than with the unsaturated ester 4 (Table 19, compare 
entries 4 with 5). In contrast to methyl acrylate (4), phenyl vinyl sulfone 152 reacted 
preferentially to the exo product but both products were formed with similar 
enantioselectivities. Carretero et al. isolated the pyrrolidine 154 with slightly higher 
enantiomeric excess (84% ee) but they used a higher catalyst loading (5 mol%). 
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Table 19. 
Entry 1,3-Dipole Dipolarophile t (h) Yield (%)a endo : exob ee (%)c (endo) 
1d 128 4 6 69 9 : 1 65 (+) 
2d 128 152 6 90 1 : 10 88 (+) 
3 128 152 6 80 1 : 10 86 (+) 
4 130 4 12 43 n.d. 85e 
5 130 152 6 83 1 : 14 82 (+) 
a After column chromatography. 
b Determined by 1H NMR. 
c Determined by chiral HPLC. 
d 5 mol% of catalyst were used. 
e Optical rotation not determined. 
Reaction conditions: AgOAc (3 mol%), ligand 77 (3.3 mol%), dipolarophile 4, 152 (1.2 eq), 
1,3-dipoles 128, 130 (1.0 eq), toluene, 0 °C. 
 
 
8.3 Conclusion 
 
The differently substituted azomethine ylides and dipolarophiles, which were applied to the 
[3+2] cycloaddition, provided an indication of the limits of the reaction. 
Sterically more demanding 1,3-dipoles either could not be converted to the desired products 
or slowed down the reaction and the corresponding products were formed with lower 
endo:exo selelctivity and enantioselectivity. Variations of the substituents in the β-position of 
the imine demonstrated that, in addition to the coordination of the silver ion to the imine 
nitrogen, coordination to a second atom is also necessary to create an active 1,3-dipole. In the 
absence of such a second coordination site no reaction could be observed. Electron-deficient 
phenyl substituents at the imine did not affect the reaction rate but the substrates were 
transformed to pyrrolidines with lower selectivity. The electron-rich analogs reacted more 
slowly, but depending on their substituents they were converted to five-membered 
heterocycles with high enantioselectivities. 
Dipolarophiles containing sterically more demanding groups were less reactive and gave 
lower selectivity. Phenyl vinyl sulfones, in contrast to vinyl esters, preferentially formed the 
exo products with high yields and enantioselectivity. 
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9 Asymmetric Ag(I)-Catalyzed Intramolecular [3+2] Cycloadditions of 
Azomethine Ylides 
 
9.1 Introduction 
 
In the course of the investigations of intermolecular [3+2] cycloadditions the idea arose to 
apply the Ag(I)-PHOX system to the intramolecular variant of this reaction. This project was 
started by Florentine Wahl73 in her diploma thesis. 
The substrate of the intramolecular cycloaddition incorporates both the dipole and the 
dipolarophile what makes the reaction entropically more favourable. The dipolarophile can be 
connected to either the nitrogen or to one of the two carbon atoms of the azomethine ylide 
(Figure 34, Type A and Type B). Attachment to the carbon atom is more common and could 
basically lead to two regioisomeric products (Figure 34, Type A). Conformational constraints 
usually limit effective orbital overlap to such an extent that one regioisomer is much preferred 
over the other. Experimental data support this conclusion since almost all examples in which 
the dipolarophile is connected to a carbon atom of the azomethine ylide give the fused 
bicyclic amine product.74 Cyclization of a substrate in which the dipolarophile is connected to 
the nitrogen atom gives necessarily a bridged bicyclic product (Figure 34, Type B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. 
 
It was planned to investigate substrates of Type A. Their structure was designed to be as close 
as possible to the 1,3-dipole and the dipolarophile of the intermolecular cycloaddition, 
resulting in structure A (Scheme 30). 
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Scheme 30. 
 
 
 
 
Asymmetric Ag(I)-Catalyzed Intramolecular [3+2] Cycloadditions of Azomethine Ylides 
 97
Grigg and co-workers were the first to cyclize these kind of substrates.75 Initial studies 
showed that a 1,2-prototropic shift (Scheme 30) could be promoted on heating imines derived 
from aromatic aldehydes and α-amino esters or 2-picolylamine.76 The derived azomethine 
ylide is preferentially formed in its W-shaped form. The concept of 1,2-prototropy was 
subsequently applied to the intramolecular cycloaddition of imine 155 (Scheme 30, Method 
A). Upon heating of this substrate in xylene, the tricyclic compounds 156a and 156b were 
isolated with a ratio of 1.2 : 1. The major product had the trans fused ring junction and 
resulted from the energetically more favoured endo transition state. The fraction of the 
thermodynamically more favoured exo product incorporating the cis fused ring junction 
usually increases if secondary orbital interactions are less important, if sterical reasons gain 
importance or the reaction conditions are severe enough to permit equilibration. 
Later Grigg and his co-workers induced the intramolecular cycloaddition reaction of imine 
155 with metal salts like AgOAc (Scheme 30, method B).77 Similar to the azomethine ylides 
formed by prototropy also the N-metalated azomethine ylides predominantly exist in the 
W-shaped form.30 The cycloaddition of substrate 155 proceeded at ambient temperature and 
the product was generated with complete endo selectivity.75d 
The often high regio- and stereoselectivity of the reaction, the enhanced reactivity and the 
ability to generate complex bicyclic or polycyclic ring systems in only a few steps makes the 
intramolecular [3+2] cycloaddition an interesting reaction. The development of an 
asymmetric version of this reaction was therefore strived for. 
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9.2  Substrate Synthesis 
 
Substrate 159 was prepared according to the reaction pathway illustrated in Scheme 31 by 
formation of the ether species 15878 and its subsequent conversion with glycine methyl ester 
to the imine 159.50 It was used without further purification in the subsequent cycloaddition 
reaction, since the crude product contained only 6 mol% of the starting aldehyde 158 as an 
impurity and none of the common purification methods could reduce the amount of 
compound 158. 
 
 
 
 
 
 
 
 
Scheme 31. 
 
Surprisingly, substantial amounts of a macrocyclic species 160 (>30 mol% by 1H NMR) 
(Scheme 32) were observed as a side product when aldehyde 158 reacted with glycine methyl 
ester and anhydrous magnesium sulfate in dichloromethane at ambient temperature to form 
the imine 159. The structure of this macrocyclic compound 160 resulted from dimerization of 
imine 159 by a double cycloaddition (Scheme 32) and was unambiguously determined by 
X-ray analysis. Dimerization could be easily suppressed by performing the reaction at 0 °C in 
a diluted reaction solution.  
 
 
 
 
 
 
 
 
 
Scheme 32. 
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9.3 Influence of Solvent and Reaction Temperature 
 
The silver(I) catalyst derived from the standard PHOX ligand 63 and AgOAc was successfully 
applied to the intramolecular cyclization reaction illustrated in Scheme 33. The initial reaction 
was performed in toluene at 0 °C and led to full conversion after a reaction time of 6 h. The 
formation of a single diastereomer with low enantioselectivity was observed (Table 20, entry 1). 
In the following the influence of solvents and reaction temperatures on the reaction was 
investigated. 
 
 
 
 
 
 
 
 
 
 
Scheme 33. 
 
The results in Table 20 demonstrate that the intramolecular [3+2] cycloaddition (Scheme 33) 
proceeded with full conversion and generated the tricyclic product 161 as a single diastereomer, 
irrespective in which solvent the reaction was performed. The employment of acetonitrile or 
dichloromethane led to a substantial decrease of the enantioselectivity whereas all other 
solvents did not influence asymmetric induction significantly. Since the substrates precipitated 
in toluene at temperatures below 0 °C, the influence of lower reaction temperatures was 
investigated using THF as a solvent. The increase of enantiomeric excess was however 
negligible. 
The results of the solvent screening did not ask for a change of the reaction conditions already 
applied to the intermolecular cycloaddition reaction and therefore all subsequent reactions were 
performed at 0 °C in toluene. 
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N CO2Me
O CO2Me
[L*Ag(OAc)]
Toluene, 0 °C
O
HN
CO2Me
CO2Me
H
H
L* =
(R1)2P N
O
R3
R2
R2
  63 R1 = Ph, R2 = H, R3 = tBu   
  39 R1 = Ph, R2 = H, R3 = iPr   
126 R1 = Ph, R2 = iPr, R3 = iPr  
124 R1 = Ph, R2 = Me, R3 = Cy
127 R1 = Ph, R2 = Cy, R3 = iPr  
  41 R1 = Ph, R2 =Ph, R3 = iPr  
118 R1 = Cy, R2 = Ph, R3 = iPr
  40 R1 = oTol, R2 = H, R3 = iPr   
123 R1 = oTol, R2 = Me, R3 = iPr   
  72 R1 = oTol, R2 = Cy, R3 = iPr  
  64 R1 = oTol, R2 = Ph, R3 = iPr
  77 R1 = oTol, R2 = 3,5-dimethylphenyl, R3 = iPr  
  78 R1 = oTol, R2 = 3,5-dimethoxyphenyl, R3 = iPr
159 161 (endo)
Table 20. 
Entry Solvent T (°C) Conversion (%)a endo : exoa ee (%)b (161) 
1 Toluene 0 >95 >40 : 1 18 (+) 
2 THF 0 >95 >40 : 1 17 (+) 
3 THF -40 >95 >40 : 1 20 (+) 
4 
Cyclohexane/ 
Benzenec 
0 >95 >40 : 1 21 (+) 
5 Acetonitrile 0 >95 >40 : 1 6 (+) 
6 Dichloromethane 0 >95 >40 : 1 11 (+) 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
c ratio: 3 : 2. 
Reaction conditions: AgOAc (3 mol%), ligand 63 (3.3 mol%), substrate 159 (1.0 eq), solvent, 
6 h, T. 
 
9.4 Ligand Screening for the Ag(I)-Catalyzed Intramolecular [3+2] Cycloaddition 
 
A ligand screening comprising several differently substituted PHOX ligands was performed for 
the reaction illustrated in Scheme 34. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 34. 
Asymmetric Ag(I)-Catalyzed Intramolecular [3+2] Cycloadditions of Azomethine Ylides 
 101
pTsCl, NEt3
CH2Cl2, reflux, 20 h, 83%
O
HN
CO2Me
CO2Me
H
H
161 (endo) (96% ee)
O
N
CO2Me
CO2Me
H
H
pTs
162 (endo) (97% ee)
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When imine 159 was treated with Ag(I)-PHOX complexes full conversion was obtained after a 
reaction time of 6 h and the tricyclic product 161 was formed as a single diastereomer; no traces 
of other diastereomers could be detected in the 1H and 13C NMR spectra. The 
enantioselectivities induced by the different ligands illustrated in Scheme 34 showed the same 
trends as in the intermolecular cycloaddition. The isopropyl substituent at the C4 position of the 
oxazoline ring had a more positive effect on enantioselectivity than tertiary butyl respectively 
cyclohexyl groups (Table 21, compare entries 1A, 1B and 1D). Furthermore the introduction of 
ortho-tolyl instead of phenyl groups at the phosphorous atom (Table 21, compare entries 1B 
and 1H) as well as the incorporation of substituted phenyl groups at the C5 position of the 
oxazoline (Table 21, compare entries 1H with 1M) improved the asymmetric induction. The 
highest enantioselectivity was achieved with ligand 77 (Table 21, entry 1M). While the 
screening experiments were carried out using 3 mol% of PHOX complex, the catalyst loading 
could be reduced to 1 mol% without loss of enantioselectivity or yield. Studies of the reaction 
time indicated that full conversion was achieved after 1.5 h using 3 mol% of the catalyst. 
 
Table 21. 
Ligand 
Product 
63 
A 
39 
B 
126 
C 
124 
D 
127 
E 
41 
F 
118 
G 
40 
H 
123 
I 
72 
K 
64 
L 
77 
M 
78 
N 
161 ee (%)a 1 18 
(+) 
26 
(+) 
54 
(+) 
18 
(+) 
82 
(+) 
65 
(+) 
67 
(+) 
66 
(+) 
75 
(+) 
88 
(+) 
96 
(+) 
98 
(+) 
96 
(+) 
a Determined by chiral HPLC. 
Reaction conditions: AgOAc (3 mol%), ligands illustrated in Scheme 34 (3.3 mol%), substrate 159 (1.0 eq), 
toluene, 0 °C, 6 h. 
 
9.5 Absolute Configuration of a Tricyclic Product 
 
Tosylation of the tricyclic product 161 was performed to determine its absolute configuration. 
The reaction product 162 could be isolated with good yield and an enantiomeric excess of 
97%. 
 
 
 
 
 
 
Scheme 35. 
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N R2
O CO2Me
[L*Ag(OAc)]
Toluene, 0 °C, 6 h
O
HN
R2
CO2Me
H
H
L* =
(oTol)2P N
O R
R
159 R1 = H, R2 = CO2Me
163 R1 = H, R2 = CO2tBu
164 R1 = Me, R2 = CO2Me
155 R1 = H, R2 = Py
161 R1 = H, R2 = CO2Me
165 R1 = H, R2 = CO2tBu
166 R1 = Me, R2 = CO2Me
156 R1 = H, R2 = Py
64 R = Ph
77 R = 3,5-dimethylphenyl
R1
R1
(endo)
Recrystallization of the tosylated compound 162 from ethylacetate/pentane gave crystals 
suitable for single crystal X-ray structure determination. The analysis revealed a (2S, 3R, 3aR, 
9bR)-configuration for 162 and therefore also for 161 (Figure 35). 
 
 
 
 
 
 
 
 
 
Figure 35. 
 
9.6 Scope of the Ag(I)-Catalyzed Intramolecular [3+2] Cycloaddition 
 
The most successful ligands 64 and 77 of the preliminary ligand screening were applied to three 
other substrates (Scheme 36). The variation of the substrate concerned the α-position of the 
imine. The methyl ester of imine 159 was replaced by a sterically more demanding tertiary 
butyl ester (163) and by a pyridine moiety (155). Additionally, a sterically more demanding 
alanine derived substrate 164 was synthesized. In contrast to the glycine derivatives 159 and 
163, imines 164 and 155 did not show any tendency to dimerize at room temperature and were 
therefore synthesized without cooling the reaction mixture (compare chapter 9.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 36. 
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The replacement of the methyl ester of imine 159 by a tertiary butyl ester in 163 increased the 
asymmetric induction. The tricyclic product 165 was isolated with slightly lower yield but 
higher enantioselectivity (Table 22, entries 1 and 2). Substrate 155, with a pyridine ring instead 
of an ester group, reacted with lower enantioselectivity but comparable yield (Table 22, entries 
1 and 4). The cyclization product of the alanine-derived substrate 164 was isolated with the 
comparatively lowest yield but high enantioselectivity (Table 22, entry 3). 
The ligands applied to the cycloaddition illustrated in Scheme 36 differed only in their 
substituents at the C5 position of the oxazoline ring. The 3,5-dimethylphenyl substituted ligand 
77 gave the tricyclic product with higher enantioselectivity but lower yield than its phenyl 
substituted counterpart 64. 
 
Table 22. 
Entry Product Yield (%)a ee (%)b 
1 161 68 (74)c 98 (+) (96 (+))c 
2 165 62 (66)c 99 (+) (99 (+))c 
3 166 60 (61)c 96 (+) (96 (+))c 
4 156 67 (70)c 85 (−) (83 (−))c 
a After column chromatography. 
b Determined by chiral HPLC. 
c The free standing values were generated by using ligand 77, the values 
in brackets were generated by using ligand 64. 
Reaction conditions: AgOAc (3 mol%), ligands 77, 64 (3.3 mol%), 
substrates 155, 159, 163, 164 (1.0 eq), toluene, 
0 °C. 
 
Application of the conditions used for the preparation of the non-glycine derived imines 159 
and 163 to the synthesis of substrate 169 failed, since the tricyclic product 170b was isolated 
as the major product (Scheme 37). X-ray analysis of compound 170b indicated that it 
possesses the cis-fused ring junction of the thermodynamically more stable exo product 
(Figure 36).79 Its formation occurs presumably via the exo transition state of the W-shaped 
1,3-dipole which is probably generated by prototropy.75a The replacement of MgSO4 by 
molecular sieves increased the fraction of the imine 169 only slightly excluding the possibility 
that 1,3-dipole generation could have proceeded via the N-metalated azomethine ylide route 
by complexation of the magnesium to the imine 169.38 However, decreased reaction 
temperature suppressed the formation of the tricyclic product 170b almost completely and 
imine 169 was isolated as the major product. According to 1H NMR studies the crude product 
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N
O
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63 R1 = Ph, R2 = tBu, R3 = H 
64 R1 = oTol, R2 = iPr, R3 = Ph
R3
R3
mixture contained after a reaction time of 80 h 67 mol% of imine 169, 25 mol% of the 
aldehyde 167 and 8 mol% of the cycloproduct 170b. 
 
 
 
 
 
 
 
 
 
 
Scheme 37. 
 
 
 
 
 
 
 
 
 
 
Figure 36. 
 
For reasons already discussed for substrate 159 the crude product was applied without further 
purification to the cycloaddition reaction catalyzed by Ag(I)-PHOX complexes derived from 
ligands 63 and 64 and AgOAc (Scheme 38). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 38. 
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1H NMR spectra of the crude products generated by cycloaddition of substrate 169 showed 
that the reaction was not diastereoselective in contrast to the analogous reactions with 
substrates 155, 159, 163, and 164. The cycloaddition which proceeded under the influence of 
ligand 63 gave the tricyclic products 170a and 170b with a ratio of 1 : 1.3 whereas the 
employment of ligand 64 gave an endo:exo ratio of 1.5 : 1. The enantioselectivity of the 
exo product 170b was not determined because it was already present in the starting material 
and can additionally be formed by an uncatalyzed background reaction. Full conversion was 
obtained after a reaction time of 6 h and the endo product 170a was generated with high 
enantioselectivity (Table 23). Surprisingly, the application of ligand 63 resulted in formation 
of the tricyclic product 170a with high enantioselectivity in constrast to the reaction with 
substrate 159 which gave low enantioselectivity with this ligand (compare Table 23, entry 1, 
with Table 21, ligand 63). 
 
Table 23. 
Entry Ligand Conversion (%)a ee (%)b 
1 63 >95 80c 
2 64 >95 90c 
a Determined by 1H NMR. 
b Determined by chiral HPLC. 
c Absolute configuration not determined. 
Reaction conditions: AgOAc (3 mol%), ligands 63, 64 
(3.3 mol%), substrate 169 (1.0 eq), toluene, 
0 °C, 6 h. 
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9.7 Aliphatic Substrates for the Intramolecular [3+2] Cycloaddition 
 
In order to extend the scope of the intramolecular [3+2] cycloaddition to aliphatic substrates, 
imine 175 was synthesized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 39. 
 
Imine 175 was prepared following the reaction sequence illustrated in Scheme 39. Addition of 
p-toluenesulfonic acid to the ozonolysis reaction medium led to the formation of an acetal-
alkoxy hydroperoxide. Prior to reduction of the alkoxy hydroperoxide with dimethylsulfide to 
the acetal-aldehyde 172, the acid had to be neutralized with NaHCO3 to avoid bisacetal 
formation.80 Subsequent Wittig reaction selectively gave the unsaturated ester 173 with trans 
stereochemistry.81 Hydrolysis of the acetal with a 2M HCl-solution yielded the aldehyde 
174.82 The usual reaction procedure for imine formation had to be slightly modified. The 
addition of the aldehyde 174 in dichloromethane to a suspension of the amino ester 
hydrochloride, triethylamine and MgSO4 in dichloromethane, which was already stirred for 
one hour, led even after a reaction time of two days only to a conversion of 50%. For that 
reason the amino ester hydrochloride was extracted first with a concentrated aqueous 
ammonia solution to obtain the free amine. The aldehyde 174 was subsequently added to a 
concentrated solution of the free amine and MgSO4 in dichloromethane. After a reaction time 
of 2 days 1H NMR studies showed that the aldehyde 174 was only present to an extent of 
8 mol%. 
Attempts to cyclize imine 175 to the bicyclic product 176 were not successful, neither by 
application of AgOAc nor by employment of Ag(I)-PHOX-complexes. After a reaction time 
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of 12 h the crude product was purified by column chromatography but none of the isolated 
compounds corresponded to the desired product 176. 
 
9.8 Conclusion 
 
Although Ag(I)-PHOX complexes gave only moderate to good asymmetric induction in 
intermolecular [3+2] cycloadditions, they are efficient catalysts for intramolecular [3+2] 
cycloadditions of azomethine ylides with aryl backbones, giving access to tricylic products 
with almost complete diastereocontrol and enantiomeric excesses of up to 99%. 
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10 Structural Elucidation of a Ag(I)-PHOX Complex 
 
In order to gain insight into the coordination mode of the silver metal ion to PHOX ligands, 
attempts to grow crystals suitable for X-ray analysis were pursued. Single crystals of complex 
216 were obtained from a solution of toluene/pentane. Its solid-state structure is shown in 
Figure 37 with some relevant structural parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selected bond length [Å] and angles [°]: 
 
Ag1-P1:  2.3530(11)    Ag1-P1:  2.3659(6) 
Ag1-O2:  2.166(3)    Ag1-O1:  2.183(2) 
Ag1⋅⋅N1:  2.640(3)    Ag1-N1:  2.478(2) 
P1-Ag1-O2:  158.27(8)    P1-Ag1-O2:  174.70(7) 
 
Figure 37. X-ray structures of complexes 216 and 217 (POV-Ray83 view, datasets for the preparation of the 
pictures were generated with ORTEP84). Hydrogen atoms have been omitted for clarity reasons. 
 
The silver metal ion of complex 216 adopts a distorted linear twofold coordination, which 
represents a common geometry of silver complexes. The tendency of this metal type to 
twofold linear coordination can be explained by hybridization of the 2zd4 - and s-orbitals 
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generating an sd-hybrid-orbital in which the electron density is shifted from the lobes of the 
2zd -orbital to the lobe of the xy-plane. Thus, coordination along the z-axis is favored. This is 
realized by a second hybridization of the sd-hybrid-orbital with a pz-orbital forming the 
hybrid orbitals suitable for covalent bond formation. The metal center of complex 216 is 
bound to the soft phosphorous atom of the PHOX ligand on the one hand and to an oxygen 
atom of the acetate on the other hand. The Ag1-O2 bond length is slightly shorter than the one 
found in other related complexes.85 Coordination of the silver ion to the second oxygen atom 
O3 (Ag1-O3 2.641(3)) is not assumed since the van der Waals radius86 of the oxygen and the 
ionic radius87 of metal ion do not indicate an interaction. Nonetheless, the linear geometry is 
largely distorted, as indicated by the P1Ag1O2 angle of 158.27(8)°; a peculiarity that could be 
indicative for an allylic coordination mode of the acetate. Finally, the large distance between 
the Ag1 and N1 and the dihedral angle of 48.7° found between N1-C21-C20 and C15-P1-Ag1 
exclude the existence of a chemical bond. 
These findings stand in sharp contrast to the structural properties of the most closely related 
silver complex 217 found in the Cambridge Crystallographic Data Center (CCDC) whose 
solid structure is illustrated in Figure 37.88 The silver metal center of this complex adopts a 
less common trigonal T-shaped geometry defined by the atoms Ag1, P1, N1 and O1. The 
angle defined by P1, Ag1, and O1 is almost linear (174.70(7)°). Interestingly, the Ag1-P1 
bond length of both complexes is similar as well as the torsion angle defined by the atoms C2, 
C1, P1, Ag1, 46.77°, and C20, C15, P1, Ag1, 43.6°, for 217 and 216, respectively. 
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11 Ir(I)-Complexes of C5-Substituted PHOX Ligands as Catalysts for the Asym-
metric Hydrogenation of Olefins and Imines 
 
11.1 Introduction 
 
Ir(I)-PHOX complexes are efficient catalysts for enantioselective hydrogenations of 
unfunctionalized olefins and imines.89 They do not require a coordination group next to the 
double bond for efficient asymmetric induction, which distinguishes them from chiral 
rhodium and ruthenium catalysts.90 
Initially, these complexes were applied to the asymmetric hydrogenation of imines.89d Up to 
89% enantiomeric excess and high turn over numbers (TON) could be achieved with 
N-phenylimine 177 derived from phenyl methyl ketone (Scheme 40). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 40. 
 
Since the coordination sphere of Ir-PHOX complexes resembles that of the Crabtree’s catalyst 
179 (Scheme 41) which efficiently catalyzes the hydrogenation of unfunctionalized tri- and 
tetrasubstituted olefins,91 Pfaltz and co-workers used these complexes also in carbon-carbon 
double bond hydrogenation of this kind. First studies with the catalyst 182 using substrate 180 
showed promising results (Scheme 41). With 4 mol% of catalyst at 50 bar hydrogen pressure 
the desired product 181 was obtained with an enantioselectivity of 75% and a conversion of 
78%.89c Systematic variation of the PHOX ligand substitution pattern successively improved 
the enantioselectivity (Table 24). Thus catalyst 185 incorporating two ortho-tolyl groups at 
the phosphorous atom and a tertiary butyl group at the C4 position of the oxazoline ring gave 
the product 181 with an enantioselectivity of 97%. The moderate conversion could be 
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MeO
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MeO
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XCat.:
182 Ar = Ph, R = iPr, X = PF6
183 Ar = Ph, R = tBu, X = PF6
184 Ar = oTol, R = iPr, X = PF6
185 Ar = oTol, R = tBu, X = PF6
186 Ar = oTol, R = tBu, X = B(ArF)4
180 181
Crabtree catalyst:
N PCy3
Ir
PF6
179
improved by replacing the PF6- anion with B(ArF)4- (Table 24, compare entries 4 and 5). 
Catalysts with this counter ion did not suffer from deactivation before the reaction was 
finished and were less sensitive against moisture.89c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 24. 
Entry Cat. (mol%) Conversion (%) ee (%) (181) 
1 182 (4) 78 75 (R) 
2 183 (4) 98 90 (R) 
3 184 (4) >99 91 (R) 
4 185 (4) 57 97 (R) 
5 186 (0.3) >99 98 (R) 
 
Scheme 41. 
 
Further investigations showed that the Ir(I)-complex derived from ligand 187 is suitable for 
the asymmetric hydrogenation of various aryl substituted olefins forming the products with 
good enantioselectivity.89a However, the precursor of this ligand, tert-leucine, is expensive. 
Therefore, it was of interest to test, whether the C5-substituted PHOX ligands 188 derived 
from inexpensive (S)-valine could be used as substitutes of ligand 187. The steric bulk caused 
by the groups at C5 should direct the methyl groups of the C4 isopropyl substituent towards 
the coordination center producing a similar effect to a tert-butyl group (Figure 38).  
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Figure 38. 
 
This assumption was at least confirmed by the solid state structures of the Ir(I)-complexes of 
ligand 187 and one representative of the C5-substituted PHOX ligands 188 (Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selected bond length [Å] and angles [°]: 
 
Ir1-P1:  2.292(1)     Ir1-P1:  2.3047(9) 
Ir1-N1:  2.102(3)     Ir1-N1:  2.095(3) 
P1-Ir1-N1: 85.15(3)     P1-Ir1-N1: 87.54(8) 
N1-C3-O1-C2: -7.82      N1-C18-O1-C5: -9.95 
 
Figure 39. X-ray structures of complexes 21889e and 219 (POV-Ray83 view, datasets for the preparation of the 
pictures were generated with ORTEP84). Hydrogen atoms have been omitted for clarity reasons. 
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187 R1 = tBu, R2 = R3 = H, R4 = oTol
  40 R1 = iPr, R2 = R3 = H, R4 = oTol
  70 R1 = iPr, R2 = R3 = Et, R4 = Ph
  71 R1 = iPr, R2 = R3 = Et, R4 = oTol
  72 R1 = iPr, R2 = R3 = Cy, R4 = oTol
  41 R1 = iPr, R2 = R3 = R4 = Ph
  64 R1 = iPr, R2 = R3 = Ph, R4 = oTol
114 R1 = iPr, R2 = H, R3 = Ph, R4 = oTol
111 R1 = iPr, R2 = Ph, R3 = H, R4 = oTol
  74 R1 = iPr, R2 = R3 = 2-Naph, R4 = oTol
  76 R1 = iPr, R2 = R3 = R4 = oTol
  77 R1 = iPr, R2 = R3 = 3,5-dimethylphenyl, R4 = oTol
186 R1 = tBu, R2 = R3 = H, R4 = oTol
189 R1 = iPr, R2 = R3 = H, R4 = oTol
190 R1 = iPr, R2 = R3 = Et, R4 = Ph
191 R1 = iPr, R2 = R3 = Et, R4 = oTol
192 R1 = iPr, R2 = R3 = Cy, R4 = oTol
193 R1 = iPr, R2 = R3 = R4 = Ph
194 R1 = iPr, R2 = R3 = Ph, R4 = oTol
195 R1 = iPr, R2 = H, R3 = Ph, R4 = oTol
196 R1 = iPr, R2 = Ph, R3 = H, R4 = oTol
197 R1 = iPr, R2 = R3 = 2-Naph, R4 = oTol
198 R1 = iPr, R2 = R3 = R4 = oTol
199 R1 = iPr, R2 = R3 = 3,5-dimethylphenyl, R4 = oTol
11.2 Application of Ir(I)-Complexes Derived from C5-Substituted PHOX Ligands to 
Asymmetric Hydrogenation 
 
Several PHOX ligands bearing substituents at the C5 position of the oxazoline moiety which 
were initially prepared for the [3+2] cycloaddition reaction (Chapter 6) were transformed to 
the corresponding iridium catalysts. The desired oxygen and moisture stable complexes were 
obtained by refluxing [Ir(COD)Cl]2 and the ligand in dichloromethane and subsequent 
exchange of the chloride ion by Na(B(ArF)4) (Scheme 42).89c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 42. 
 
These complexes were applied to the asymmetric hydrogenation of trisubstituted and 
tetrasubstituted olefins as well as imines. The hydrogenations were usually performed in 
dichloromethane at room temperature and a hydrogen pressure of 50 bar using 1 mol% of 
catalyst. 
 
Hydrogenation of trisubstituted olefins 
 
Initially the Ir(I)-PHOX complexes illustrated in Scheme 42 were tested in the hydrogenation 
of six trisubstituted olefins 200-205 (Scheme 43). 
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Scheme 43. 
 
The results in Table 25 demonstrate that the Ir(I)-catalyst 186 derived from the tert-leucine-
derived PHOX ligand 187 induces higher enantioselectivity in the hydrogenation of the 
substrates 200-205 than its analog 189 bearing an isopropyl group instead of a tert-butyl 
group (Table 25, compare columns A with B). Introduction of substituents at the C5 position 
of the oxazoline moiety in catalyst 189 showed various trends. 
The application of this ligand type to the hydrogenation of (E)-1,2-diphenyl-1-propene (200) 
or the allylic alcohol 204 led to the formation of products 206 and 210 with enantiomeric 
excesses comparable to those obtained with the reference catalyst 189 (Table 25, rows 1 and 
5). Replacement of the ortho-tolyl groups at the phosphorous atom by phenyl substituents led 
to lower asymmetric induction in the formation of product 206 (Table 25, compare 1F with 
1G, and 1C with 1D). Ortho-tolyl substituents at the C5 position of the oxazoline moiety also 
gave relatively low enantiomeric excess (Table 25, entry 1L). 
A more pronounced effect of the C5 substituents on enantioselectivity was observed for the 
hydrogenation of (Z)-2-(4-methoxyphenyl)-2-butene (202) or the acrylic ester 205 (Table 25, 
rows 3 and 6). In comparison to the reference catalyst 189 the hydrogenation products of 208 
were formed with higher enantioselectivity except for catalysts bearing phenyl groups instead 
of ortho-tolyl groups at the phosphorous atom or only one substituent at the C5 position 
(Table 25, entries 3C, 3F and 3H). In the case of the acrylic ester 205, catalyst 190 containing 
ethyl substituents at the C5 position and phenyl substituents at the phosphorous atom afforded 
superior enantioselectivity than the tert-leucine-derived catalyst 186 (Table 25, compare 
entries 6A and 6C). Surprisingly, its analog 193 bearing phenyl substituents at the C5 position 
gave almost racemic product (Table 25, entry 6F). 
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Hydrogenation of 6-methoxy-1-methyl-3,4-dihydronaphthalene (203) and (E)-2-(4-
methoxyphenyl)-2-butene (201) proceeded with substantial higher asymmetric induction 
using some of the complexes bearing C5 substituents instead of the reference catalyst 189 
(Table 25, rows 2 and 4). In some cases, the enantiomeric excesses were even higher than 
those induced by the tert-leucine derived ligand 186 (Table 25, compare entries 2A with 2M 
and 4A with 4E). In case of the cyclic substrate 203, it was found to be crucial that the 
catalyst incorporates ortho-tolyl substituents at the phosphorous atom and aliphatic groups at 
the C5 position of the oxazoline ring to reach high enantiomeric excesses.  
 
Table 25. 
Catalyst 
Compound 
186 
A 
189 
B 
190 
C 
191 
D 
192 
E 
193 
F 
194 
G 
195 
H 
196 
I 
197 
K 
198 
L 
199 
M 
206a (R) ee (%)b 1 98 94 89 93 92 69 94 94 96 93 43 93 
207a (R) ee (%)b 2 73d 55 78 64 85 76 85 48 55 86 28 90 
208a (S) ee (%)b 3 58d 24 17 28 46 22 40 14 40 49 39 51 
209a (S) ee (%)b 4 75d 47 30 63 78 12 53 46 65 51 52 55 
210a (−) ee (%)b 5 95d 93 89 92 88 91 92 92 93 92 87 94 
211a (R) ee (%)b 6 84 82 86 84 71 5 79 84 81 69 18c 75 
a Product was obtained with full conversion. 
b Determined by chiral HPLC. 
c Conversion: 40%. 
d Values are not in accordance to those published in reference 89f. 
Reaction conditions: Substrates 200-205 (1 eq), catalysts illustrated in Scheme 42 (1 mol%), 50 bar H2, 
dichloromethane, rt, 2 h. 
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Hydrogenation of a tetrasubstituted olefin 
 
The tetrasubstituted olefine 212 is a more challenging substrate for asymmetric hydrogenation 
than the trisubstituted alkenes 200-205. It is known that less bulky ligands as 
diphenylphosphino-isopropyloxazoline 39 are more suitable for the reaction of Scheme 44 
than sterically more demanding analogs like the bis(ortho-tolyl)phosphino-tert-butyloxazoline 
ligand 187 (Table 26, compare entries 1A and 1B). 
 
 
 
 
 
 
 
 
 
Scheme 44. 
 
This trend was also observed for ligands listed in Scheme 44 (Table 26). Since the 
C5-substituted ligands are sterically more demanding than the diphenylphosphino-
isopropyloxazoline ligand 39, low enantiomeric excess and conversion were obtained in the 
reaction shown in Scheme 44 (Table 26, row 1). 
 
Table 26. 
Ligand 
Compound 
187 
A 
39 
B 
72 
C 
64 
D 
114 
E 
111 
F 
74 
G 
76 
H 
77 
I 
213  (−) ee (%)a 
(conversion)b 
1 
3c 
(37) 
60c 
(>99) 
18d 
(12) 
34 
(85) 
12 
(>99) 
19d 
(91) 
28 
(95) 
23 
(53) 
19 
(79) 
a Determined by chiral HPLC. 
b Conversion determined by GC. 
c 2 mol% of catalyst were used. 
d Opposite enantiomer was formed. 
Reaction conditions: Substrate 212 (1 eq), catalysts illustrated in Scheme 44 (1 mol%), 50 bar H2, 
dichloromethane, rt, 2 h. 
 
Ir(I)-Complexes of C5-Substituted PHOX Ligands as Catalysts for the Asymmetric Hydrogenation of Olefins and 
Imines 
 122
Ph
N [Ir(L*)(COD)][B(ArF)4], 50 bar H2 
CH2Cl2, rt, 4 h
177 178
L* = 40, 41, 64, 70-72, 74, 76, 77, 111, 114, 187
Ph
Ph
HN
Ph
Hydrogenation of an imine 
 
The Ir(I)-catalysts listed in Scheme 42 were also applied to the asymmetric hydrogenation of 
imine 177 (Scheme 45). 
 
 
 
 
 
 
 
Scheme 45. 
 
In contrast to the hydrogenation of the trisubstituted olefins, the bis(ortho-tolyl)phosphino-
isopropyloxazoline ligand 40 induced higher enantioselectivity in the reduction of substrate 
177 than the analogous tert-butyl-substituted ligand 187 (Table 27, compare entries 1A and 
1B). A slight negative effect on asymmetric induction was generally observed if substituents 
were introduced at the C5 position of the oxazoline ring of ligand 40. However, ligand 77 did 
not follow this trend since its use led to the formation of the desired product 178 with the 
highest enantioselectivity in this series (Table 27, entry 1M). 
 
Table 27. 
Ligand 
Compound 
187 
A 
40 
B 
70 
C 
71 
D 
72 
E 
41 
F 
64 
G 
114 
H 
111 
I 
74 
K 
76 
L 
77 
M 
178a (R) ee (%)b 1 77 83 76 71 65 76 76 76 70 83 83 87 
a Product was obtained with full conversion. 
b Determined by chiral HPLC. 
Reaction conditions: Substrate 177 (1 eq), catalysts illustrated in Scheme 42 (1 mol%), 50 bar H2, 
dichloromethane, rt, 4 h. 
 
 
Ir(I)-Complexes of C5-Substituted PHOX Ligands as Catalysts for the Asymmetric Hydrogenation of Olefins and 
Imines 
 123
11.3 Conclusion 
 
For each of the test substrates listed in Schemes 43 and 45 at least one representative of the 
C5-disubstituted bis(aryl)phosphino-isopropyloxazoline ligands was found that induced 
higher enantioselectivity than its unsubstituted analog 40. This can be explained by the steric 
bulk at the C5 position of the oxazoline ring which directs the methyl groups of the isopropyl 
substituent at the C4 position to the coordination center creating a “tertiary butyl substitute“, 
as previously mentioned. Thus, C5-disubstituted isopropyloxazoline ligands, derived from 
inexpensive (R)- or (S)-valine, are an attractive alternative to the more expensive 
tert-leucine-derived PHOX ligands. 
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12 Asymmetric Metal-Catalyzed [3+2] Cycloadditions of Azomethine Ylides 
(Synopsis) 
 
Cycloadditions of azomethine ylides with olefins provide a short, attractive route to pyrrolidine units with the 
potential to control the relative and absolute configuration by means of a chiral catalyst. Grigg and co-workers 
have pioneered the use of chiral transition metal complexes to induce enantioselective cycloadditions of this 
type. However, stoichiometric amounts of metal complexes were employed in this work.39a,41 
 
Paying regard to Griggs investigations it was intended to develop a system which gives asymmetric induction 
using catalytic amounts of chiral transition metal complexes. A first screening of different transition metal 
sources showed promising results for Cu(I) and Ag(I) species. The application of their complexes with several 
members of different ligand classes to the 1,3-dipolar cycloaddition reaction directed the interest towards 
phosphinooxazoline (PHOX) ligands. The catalysts derived from the two different metals and PHOX ligand 39 
induced enantioselectivity in both cases (Scheme 46, Table 28). Subsequent investigations demonstrated that 
also the use of the analogous Au(I) catalyst led to the formation of enantioenriched pyrrolidines. 
 
 
 
 
 
 
 
 
Table 28. 
Entrya Metal X Cat. 
(mol%) 
t  
(h) 
Conv. 
(%)b 
38a : 38bb ee (38a) 
(%)c 
1 Cu(I) OAc 5 12 85 1.5 : 1 70 (−) 
2 Ag(I) OAc 3 4 >95 >40.0 : 1 22 (+) 
3 Au(I) OtBu 5 10 80 7.0 : 1 16 (−) 
a Imine (37) : dipolarophile (4) = 1 : 1.2. b Determined by 1H NMR. c Determined by chiral HPLC. 
 
 
Although the Cu(I)-PHOX catalyst generated the five-membered heterocycle 38a with higher enantiomeric 
excess than the other two catalysts (Table 28, compare entries 1 with 2 and 3) the focus was directed to the 
Ag(I) system. Firstly, because a further screening with differently substituted PHOX ligands indicated only for 
the Ag(I) system the chance of substantial improvement of the enantioselectivity. Secondly, much higher 
endo:exo selectivity could be observed than for the other two systems. Optimization of the substitution pattern of 
the PHOX ligand (Figure 40) showed that particularly the variation of the substituents at the phosphorous atom 
and the C5 position of the oxazoline moiety had a positive effect on asymmetric induction. 
 
 
 
 
 
 
 
Figure 40. 
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Scheme 47 shows the most selective PHOX ligand (79) found to date which resulted in formation of the 
pyrrolidine product 38a with 84% enantiomeric excess. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 47. 
 
Although Ag(I)-PHOX complexes gave only moderate to good asymmetric induction in intermolecular 
[3+2] cycloadditions, they demonstrated to be efficient catalysts for intramolecular [3+2] cycloadditions of 
azomethine ylides, giving access to tricylic products with almost complete diastereocontrol and enantiomeric 
excesses of up to 99% (Scheme 48, Table 29, entry 2).48e 
 
 
 
 
 
 
 
 
 
 
 
 
      Table 29. 
 
 
 
 
 
 
 
 a After column chromatography. b Determined by chiral HPLC. 
Scheme 48. 
 
Additionally the C5-substituted PHOX ligands, originally synthesized for the [3+2] cycloaddition reaction, were 
applied to the Ir(I)-catalyzed asymmetric hydrogenation of an imine as well as tri- and tetrasubstituted olefins. 
They induced similar or superior enantioselectivity than the best PHOX ligand (bis(ortho-tolyl)phosphino-tert-
butyloxazoline). This confirmed the preliminary assumption that the steric bulk caused by the substituents at the 
C5 position of the oxazoline ring might direct the methyl groups of the isopropyl substituent at the C4 position to 
the coordination center creating a “tertiary butyl substitute“. Thus, this ligand type represents a less expensive 
substitute of the tert-leucine-derived PHOX ligand. 
 
Entry Product Yield (%)a ee (endo) (%)b 
1 161 68 98 (+) 
2 165 62 99 (+) 
3 166 60 96 (+) 
4 156 67 85 (−) 
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13 Experimental Part 
 
13.1 Analytical Methods 
 
NMR-Spectrometry: NMR spectra were recorded on Bruker Advance 400 (400 MHz) and 
Bruker Advance DRX 500 (500 MHz) NMR spectrometers, equipped with BBO broadband 
probeheads. The chemical shift δ is given in ppm. References were 7.26 ppm (1H NMR) and 
77.16 ppm (13C NMR) for CHCl3, 5.32 ppm (1H NMR) and 54.0 ppm (13C NMR) for CH2Cl2, 
2.09 ppm (1H NMR) and 20.40 ppm (13C NMR) for toluene and 2.50 ppm (1H NMR) and 
39.51 ppm (13C NMR) for DMSO.92 85% phosphoric acid (0 ppm) was taken as an external 
standard in a capillary for 31P NMR. For spectra that were measured on the 500 MHz NMR 
spectrometer, the shifts were corrected (−0.209 ppm for CD2Cl2, 0.640 ppm for toluene-D8). 
For spectra that were measured on the 400 MHz NMR spectrometer, the shifts were corrected 
(−3.592 ppm for CD2Cl2, −3.626 ppm for CDCl3). CFCl3 was taken as an external standard in 
a capillary for 19F NMR. For spectra that were measured on the 400 MHz NMR spectrometer, 
the shifts were corrected (−0.851 ppm for CD2Cl2, −0.884 ppm for CDCl3). The assignment of 
1H- and 13C-signals was made by 2D-NMR, namely COSY, HMQC, HMBC, TOCSY and 
difference NOESY-spectrometry. 13C and 31P, until otherwise noted, were recorded 
1H-decoupled. Multiplets were assigned with s (singlet), d (doublet), t (triplet), ds (doublet of 
septet), m (multiplet). The relative configuration of the pyrrolidine compounds was 
determined by NOESY experiments. 
 
Mass Spectrometry (MS): Mass spectra were recorded by Dr. H. Nadig. Electron ionization 
(EI) was measured on VG70-250, fast atom bombardment (FAB) was measured on MAR 
312, Electron spray ionization (ESI) was measured on Finnigan MAT LCQ by A. Teichert. 
FAB was performed with 3-nitrobenzyl alcohol as matrix. The signals are given in mass-to-
charge ratio (m/z). The fragment and intensities of the signals are given in brackets. 
 
Infrared Spectrometry (IR): Infrared spectra were measured on a Perkin Elmer 1600 series 
FTIR spectrometer. Solid samples were prepared as KBr wafers, liquid samples were 
prepared between NaCl plates. For air and moisture sensitive compounds KBr was thoroughly 
dried under high vacuum and samples were prepared in the glove box. Absorption bands are 
given in wave numbers υ~  [cm-1]. The peak intensity is assigned with s (strong), m (medium) 
and w (weak).^ 
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Melting Point (m.p.): The melting point was measured in a Büchi 535 melting point 
apparatus. The values are not corrected. 
Optical Rotation ( 20][ Dα ): α-values were measured in a Perkin Elmer Polarimeter 341 in a 
cuvette (l = 1 dm) at 20 °C at 589 nm (sodium lamp). Concentration c is given in g/100 mL. 
 
Thin Layer Chromatography (TLC): TLC plates were obtained from Macherey-Nagel 
(Polygram® SIL G/UV254, 0.2 mm silica with fluorescence indicator, 40 × 80 mm). 
 
Gas Chromatography (GC): The gas chromatographs in use were Carlo Erba HRGC Mega2 
Series 800 (HRGC Mega 2). Achiral separations were performed with Macherey-Nagel 
Restek Rtx-1701 (30 m × 0.25 mm × 0.25 µm). For chiral separations β-cyclodextrine 
columns (30 m × 0.25 mm × 0.25 µm) were used. 
 
High Performance Liquid Chromatography (HPLC): For HPLC analysis Shimadzu 
systems with SCL-10A System Controller, CTO-10AC column oven, LC10-AD pump 
system, DGU-14A degasser, and SPD-M10A Diode Array- or UV-vis detector were used. 
Chiral columns Chiracel OD-H, OB-H, OJ, AS, AD-H and Chiralpak AD from Daicel 
Chemical Industries Ltd. were used. 
 
Elemental Analysis (EA): Elemental analyses were carried out by Mr. W. Kirsch at the 
Department of Chemistry at the University of Basel, on Leco CHN-900 (C-, H-, N-detection) 
and Leco RO-478 (O-detection) analysers. The data are indicated in mass percent. 
 
13.2 Working Techniques 
 
Sensitive Compounds: Syntheses of air- and moisture-sensitive compounds were carried out 
under inert atmosphere in a glove box (MBRAUN labmaser 130, N2) or using standard 
Schlenk techniques (Ar). 
 
Solvents: Dichloromethane, diethyl ether, pentane, tetrahydrofuran, and toluene were dried 
and degassed by reflux over an adequate drying agent under nitrogen.93 Other solvents were 
purchased dry at Fluka or Aldrich in septum sealed bottles, kept under inert atmosphere and 
over molecular sieves. If necessary, solvents were degassed by three freeze-pump-thaw 
cycles. Deuterated solvents were degassed and stored over activated molecular sieves (4Å). 
 
Column Chromatography: Silica gel was obtained from CU Chemie Uetikon (C-560 D, 
0.040-0.063 mm) or Merck (silica gel 60, 0.040-0.063 mm). Generally, the flash column 
chromatography according to Still94 was performed. 
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13.3 Synthesis of PHOX Ligands 
 
13.3.1 Synthesis of C5-Disubstituted PHOX Ligands 
 
(S)-methyl 2-benzamido-3-methylbutanoate (85) 
 
 
 
 
General Procedure I: 
To a solution of L-valine methyl ester hydrochloride (3.10 g, 18.3 mmol) and triethylamine 
(7.60 mL, 54.6 mmol) in dichloromethane (25.0 mL) a solution of the benzoylchloride 
(2.10 mL, 18.3 mmol) in dichloromethane (15.0 mL) was added within 55 min. at 0 °C. The 
resulting suspension was stirred at rt over night. The solvent was removed under reduced 
pressure, the residue was dissolved in ethyl acetate and filtered over silica gel, which was 
washed with ethyl acetate. The solvent was removed under reduced pressure and the obtained 
colorless solid (4.20 g, 97%) was pure enough to be used in the following step. 
 
C13H17NO3 (235.28). 
Rf = 0.34 (EtOAc : Hx  1 : 3). 
m.p. 110-112 °C. 
20][ Dα  = +40.6° (c = 0.870, CHCl3). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.99 (d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 1.01 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 2.28 (ds, J(H,H)= 6.8 Hz, J(H,H)= 4.8 Hz, 1H, CH(CH3)2), 
3.78 (s, 3H, CH3), 4.79 (dd, J(H,H) = 8.7 Hz, J(H,H) = 4.9 Hz, 1H, NHCH), 6.62 (d, J(H,H) 
= 8.4 Hz, 1H, NH), 7.42-7.47 (m, 2H, Ph-H), 7.50-7.54 (m, 1H, Ph-H), 7.80-7.82 (m, 2H, Ph-
H). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 18.1 (CH(CH3)2), 19.1 (CH(CH3)2), 31.8 
(CH(CH3)2), 52.4 (OCH3), 57.5 (NCH), 127.2 (2C, Ph-H), 128.8 (2C, Ph-H), 131.9 (Ph-H). 
134.3 (Ph-C), 167.4 (CONH), 172.8 (CO2CH3). 
MS (FAB) m/z (rel int %): 236 (M + H, 81), 176 (23), 105 (100), 77 (20). 
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IR (KBr) : υ~  [cm-1] = 3347s, 3074w, 2967w, 2872w, 1739s, 1641s, 1603m, 1581m, 1522s, 
1490s, 1460m, 1431m, 1392w, 1361m, 1328m, 1297m, 1204s, 1152s, 1067w, 994m, 928w, 
892w, 803w, 750m, 734m, 714m, 693m. 
EA % found (calcd): C: 66.41 (66.36), H: 7.25 (7.28), N: 5.95 (5.95). 
 
(S)-methyl 2-(2-fluorobenzamido)-3-methylbutanoate (89) 
 
 
 
 
Product 89 was prepared according to general procedure I (page 133) from L-valine methyl 
ester hydrochlorid (1.67 g, 10.0 mmol), triethylamine (4.18 mL, 30.0 mmol) and 
2-fluorobenzoyl chloride (1.18 mL, 10.0 mmol) in dichloromethane (20.0 mL). The obtained 
colorless solid (2.20 g, 93%) was pure enough to be used in the following step. 
 
C13H16NO3F (253.27). 
Rf = 0.43 (EtOAc : Hx  1 : 3). 
m.p. 59-60 °C. 
20][ Dα  = +32.9° (c = 0.500, CHCl3). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 1.00 (d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 1.03 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 2.30 (ds, J(H,H)= 6.8 Hz, J(H,H)= 4.7 Hz, 1H, CH(CH3)2), 
3.77 (s, 3H, CH3), 4.79 (dd, J(H,H) = 8.7 Hz, J(H,H) = 4.9 Hz, 1H, NHCH), 7.11-7.27 (m, 
3H, Ph-H and NH), 7.48-7.53 (m, 1H, Ph-H), 7.89-8.19 (m, 1H, Ph-H). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 18.3 (CH(CH3)2), 19.4 (CH(CH3)2), 31.7 
(CH(CH3)2), 52.6 (OCH3), 58.1 (NCH), 116.6 (d, J(C,F) = 24.6 Hz, Ph-H), 121.2 (d, J(C,F) = 
11.3 Hz, Ph-H), 125.2 (d, J(C,F) = 3.1 Hz, Ph-H), 132.5 (d, J(C,F) = 1.9 Hz, Ph-H), 133.9 (d, 
J(C,F) = 9.2 Hz, Ph-C), 159.4 (d, J(C,F) = 246.2 Hz, Ph-F), 163.5 (d, J(C,F) = 3.2 Hz, 
CONH), 172.6 (CO2CH3). 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -114.5 (m). 
MS (FAB) m/z (rel int %): 254 (M + H, 100), 194 (41), 123 (62). 
IR (KBr) : υ~  [cm-1] = 3350s, 2966w, 2879w, 1739s, 1645s, 1631m, 1614m, 1484s, 1455m, 
1429m, 1362m, 1315m, 1262m, 1240s, 1219m, 1204m, 1159s, 1149m, 1097w, 996m, 893w, 
843w, 805w, 766m. 
EA % found (calcd): C: 61.84 (61.65), H: 6.29 (6.37), N: 5.54 (5.53). 
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L-valine methyl ester hydrochloride (3.07g, 18.0 mmol) was added portionwise over 20 min 
to a 2M Grignard solution (55.0 mL, 110 mmol) in THF at 0 °C. The reaction mixture was 
stirred for 4 h at rt before it was quenched by a 2M HCl-solution at 0 °C. The mixture was 
basified by the addition of aqueous ammonia. The organic layer was separated and the 
aqueous layer was extracted with ethyl acetate (3 x 10 mL). The organic extracts were 
combined, dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
amino alcohol was purified by column chromatography (DCM : MeOH  20 : 1, Rf = 0.56) 
over silica gel to afford a colorless solid (2.00 g, 31%). 
 
C25H25NO (355.47). 
m.p. 199-201 °C. 
20][ Dα  = -281.5° (c = 0.505, CH2Cl2). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.94 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 0.98 
(d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 1.29 (br s, 2H, NH2), 1.78 (ds, J(H,H) = 6.9 Hz, J(H,H) 
= 2.0 Hz, 1H, CH(CH3)2), 4.17 (d, J(H,H) = 2.3 Hz, 1H, H2NCH), 4.81 (br s, 1H, OH), 7.39-
7.51 (m, 4H, Naph-H), 7.55 (dd, J(H,H) = 8.6 Hz, J(H,H) = 1.77 Hz, 1H, Naph-H), 7.72-7.79 
(m, 5H, Naph-H), 7.85-7.90 (m, 2H, Naph-H), 8.16 (d, J(H,H) = 12.1 Hz, 2H, Naph-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 15.8 (CH(CH3)2), 22.6 (CH(CH3)2), 28.2 
(CH(CH3)2), 59.4 (H2NCH), 79.9 (C(Naph)2OH), 123.6 (Naph-H), 123.9 (Naph-H), 124.3 
(Naph-H), 125.5 (Naph-H), 125.7 (Naph-H), 125.9 (Naph-H), 126.0 (Naph-H), 126.1 
(Naph-H), 127.4 (2C, Naph-H), 127.5 (Naph-H), 128.1 (Naph-H), 128.2 (2C, Naph-H), 
132.1 (Naph-C), 132.3 (Naph-C), 133.2 (Naph-C), 133.3 (Naph-C), 142.4 (Naph-C), 145.5 
(Naph-C). 
MS (FAB) m/z (rel int %): 356 (M + H, 9), 338 (18), 127 (11), 72 (100), 55 (13); 
IR (KBr) : υ~  [cm-1] = 3407s, 3338s, 3060m, 2952s, 2926s, 2875m, 1627m, 1597s, 1505s, 
1466m, 1435m, 1394m, 1376s, 1293m, 1272m, 1248m, 1164m, 1121s, 1015m, 982m, 905m, 
861s, 814s, 754s. 
 
 
Experimental Part 
 136
O
HN
OH
F
(S)-N-(4-Ethyl-4-hydroxy-2-methylhexan-3-yl)-2-fluorobenzamide (90) 
 
 
 
 
General Procedure II: 
A 3M Grignard solution (5.60 mL, 16.8 mmol) in THF was added drop wise to a solution of 
(S)-methyl 2-(2-fluorobenzamido)-3-methylbutanoate (700 mg, 2.80 mmol) in THF (15.0 mL) 
at 0 °C. After full addition of the Grignard reagent the reaction mixture was stirred over night 
at rt. The resulting suspension was quenched with a saturated NH4Cl-solution (10 mL) and 
water (10 mL). The water phase was extracted with CH2Cl2 (3 x 10 mL), the combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was purified by column chromatography (Hx : EtOAc  4 : 1, Rf = 0.29) 
over silica gel to afford a colorless solid (590 mg, 75%). 
 
C16H24FNO2 (281.37). 
m.p. 80–81 °C. 
20][ Dα  = -4.0° (c = 0.620, CHCl3). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.86 (t, J(H,H) = 7.6 Hz, 3H, CH2CH3), 0.92 (t, 
J(H,H) = 7.6 Hz, 3H, CH2CH3), 0.99 (d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 1.01 (d, J(H,H) = 
7.1 Hz, 3H, CH(CH3)2), 1.43 (br s, 1H, OH), 1.45-1.72 (m, 4H, CH2CH3), 2.20 (ds, J(H,H) = 
6.8 Hz, J(H,H) = 2.3 Hz, 1H, CH(CH3)2), 4.18 (dd, J(H,H) = 9.8 Hz, J(H,H) = 2.6 Hz, 1H, 
NHCH), 7.05-7.15 (m, 2H, Ph-H, NH), 7.26 (dt, J(H,H) = 7.6 Hz, J(H,H) = 1.0 Hz, 1H, Ph-
H), 7.43-7.47 (m, 1H, Ph-H), 8.08 (dt, J(H,H) = 7.8 Hz, J(H,H) = 1.7 Hz, 1H, Ph-H). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 7.9 (CH2CH3), 8.2 (CH2CH3), 17.2 
(CH(CH3)2), 22.4 (CH(CH3)2), 28.0 (CH2CH3), 28.2 (CH(CH3)2), 28.9 (CH2CH3), 57.3 
(NCH), 77.9 (COH), 116.2 (d, J(C,F) = 24.9 Hz, Ph-H), 121.7 (d, J(C,F) = 11.9 Hz, Ph-C), 
124.9 (d, J(C,F) = 3.5 Hz, Ph-H), 132.3 (d, J(C,F) = 2.3 Hz, Ph-H), 133.1 (d, J(C,F) = 9.2 
Hz, Ph-H), 160.7 (d, J(C,F) = 247.3 Hz, Ph-F), 163.9 (d, J(C,F) = 3.5 Hz, C=O). 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -115.9 (m). 
MS (FAB) m/z (rel int %): 282 (M + H, 58), 264 (100), 194 (25), 140 (31), 123 (91), 87 (11), 
83 (12), 69 (26). 
IR (KBr) : υ~  [cm-1] = 3465s, 3088w, 2963m, 2885w, 1654s, 1614w, 1530s, 1477m, 1450w, 
1374w, 1315m, 1244w, 1204m, 1138m, 1095w, 1035w, 932w, 884w, 818w, 788w, 757m. 
Experimental Part 
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EA % found (calcd): C: 68.27 (68.30), H: 8.60 (8.60), N: 5.00 (4.98). 
 
(S)-N-(1-hydroxy-3-methyl-1,1-diphenylbutan-2-yl)benzamide (91) 
 
 
 
 
Product 91 was prepared according to general procedure II (page 136) from (S)-methyl 2-
benzamido-3-methylbutanoate (3.50 g, 14.9 mmol), 3M Grignard solution (18.3 mL, 
55.0 mmol) in THF and THF as a solvent (20.0 mL). After column chromatography (Hx : 
EtOAc  4 : 1, Rf = 0.29) on silica compound 91 (4.23 g, 79%) was isolated as a colorless 
solid. 
 
C24H25NO2 (359.47). 
m.p. 233-235 °C. 
20][ Dα  = -118.5° (c = 0.375, CHCl3). 
1H NMR (400.1 MHz, DMSO, 300 K): δ = 0.75 (d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 0.98 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.81 (ds, J(H,H) = 6.8 Hz, J(H,H) = 2.0 Hz, 1H, 
CH(CH3)2), 5.14 (dd, J(H,H) = 9.8 Hz, J(H,H) = 1.8 Hz, 1H, NHCH), 5.86 (s, 1H, OH), 7.07 
(t, J(H,H) = 7.3 Hz, 1H, Ph-H), 7.15 (t, J(H,H) = 7.3 Hz, 1H, Ph-H), 7.21 (t, J(H,H) = 7.5 Hz, 
2H, Ph-H), 7.30 (t, J(H,H) = 7.5 Hz, 2H, Ph-H), 7.41-7.51 (m, 3H, Ph-H), 7.54-7.57 (m, 4H, 
Ph-H), 7.61-7.63 (m, 2H, Ph-H), 7.79 (d, J(H,H) = 9.8 Hz, 1H, NH). 
13C{1H} NMR (100.6 MHz, DMSO, 300 K): δ = 18.4 (CH(CH3)2), 23.2 (CH(CH3)2), 28.6 
(CH(CH3)2), 58.2 (NHCH), 80.9 (COH), 125.0 (2C, Ph-H), 125.4 (2C, Ph-H), 126.1 (Ph-H), 
126.3 (Ph-H), 127.0 (2C, Ph-H), 127.8 (2C, Ph-H), 128.1 (2C, Ph-H), 128.3 (2C, Ph-H), 
131.1 (Ph-H), 135.2 (Ph-C), 146.2 (Ph-C), 147.8 (Ph-C), 167.1 (CO). 
MS (FAB) m/z (rel int %): 360 (M + H, 4), 342 (23), 176 (19), 105 (100), 77 (16). 
IR (KBr) : υ~  [cm-1] = 3417s, 3062w, 3024w, 2960w, 1630s, 1521s, 1489m, 1449m, 1366m, 
1324m, 1162m, 1061m, 898w, 749m, 700s. 
EA % found (calcd): C: 79.84 (80.19), H: 7.25 (7.01), N: 4.04 (3.90). 
 
Experimental Part 
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(S)-N-(1-hydroxy-3-methyl-1,1-di(naphthalen-2-yl)butan-2-yl)benzamide (87) 
 
 
 
 
 
Product 87 was prepared according to general procedure II (page 136) from (S)-methyl 2-
benzamido-3-methylbutanoate (0.97 g, 4.1 mmol), 3M Grignard solution (8.00 mL, 24.1 
mmol) in THF and THF as a solvent (22.0 mL). After column chromatography (Hx : EtOAc  
3 : 1, Rf = 0.71) on silica compound 87 (1.69 g, 90%) was isolated as a colorless solid. 
 
C32H29NO2 (459.58). 
m.p. 230-232 °C. 
20][ Dα  = -150.0° (c = 0.555, CH2Cl2). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.98 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.10 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 2.07 (ds, J(H,H) = 6.8 Hz, J(H,H) = 2.3 Hz, 1H, 
CH(CH3)2), 3.85 (br s, 1H, OH), 5.49 (dd, J(H,H) = 10.0 Hz, J(H,H) = 2.3 Hz, 1H, NHCH), 
7.06 (d, J(H,H) = 9.8 Hz, 1H, NH), 7.09-7.13 (m, 2H, Ar-H), 7.27-7.30 (m, 1H, Ar-H), 7.37-
7.42 (m, 2H, Ar-H), 7.44-7.53 (m, 4H, Ar-H), 7.60-7.70 (m, 4H, Ar-H), 7.80-7.83 (m, 3H, 
Ar-H), 7.91 (d, J(H,H) = 7.6 Hz, 1H, Ar-H), 8.28-8.29 (m, 2H, Ar-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 17.8 (CH(CH3)2), 22.8 (CH(CH3)2), 29.6 
(CH(CH3)2), 58.3 (HNCH), 82.8 (COH), 123.7 (Ar-H), 124.2 (Ar-H), 124.3 (Ar-H), 124.3 
(Ar-H), 126.1 (Ar-H), 126.2 (2C, Ar-H), 126.4 (Ar-H), 126.7 (2C, Ar-H), 127.3 (Ar-H), 
127.5 (Ar-H), 128.2 (Ar-H), 128.2 (Ar-H), 128.3 (Ar-H), 128.3 (2C, Ar-H), 128.5 (Ar-H), 
131.2 (Ar-H), 132.3 (Ar-C), 132.4 (Ar-C), 133.2 (Ar-C), 133.3 (Ar-C), 135.0 (Ar-C), 143.0 
(Ar-C), 143.5 (Ar-C), 168.2 (CO). 
MS (FAB) m/z (rel int %): 460 (M + H, 1), 442 (22), 177 (23), 127 (10), 105 (100), 77 (17). 
IR (KBr) : υ~  [cm-1] = 3417sbr, 3056m, 2959m, 2872w, 1629s, 1601m, 1578m, 1522sbr, 
1487s, 1357m, 1315m, 1271m, 1244w, 1204w, 1154m, 1122m, 1076w, 1019w, 967w, 903w, 
860w, 817m, 783.4m, 758s, 691m, 477m. 
EA % found (calcd): C: 83.31 (83.63), H: 6.65 (6.36), N: 2.72 (3.05). 
 
Experimental Part 
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(S)-N-(1-hydroxy-3-methyl-1,1-di-o-tolylbutan-2-yl)benzamide (92) 
 
 
 
 
Product 92 was prepared according to general procedure II (page 136) from (S)-methyl 2-
benzamido-3-methylbutanoate (700 mg, 3.00 mmol), 3M Grignard solution (3.30 mL, 
10.0 mmol) in THF and THF as a solvent (17.0 mL). After column chromatography (Hx : 
EtOAc  5 : 1, Rf = 0.29) on silica compound 92 (0.70 g, 60%) was isolated as a colorless 
solid. 
 
C26H29NO2 (387.51). 
m.p. 184-186 °C. 
20][ Dα  = -210.7° (c = 0.870, CDCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.91 (d, J(H,H) = 6.2 Hz, 3H, CH(CH3)2), 0.99 
(d, J(H,H) = 6.2 Hz, 3H, CH(CH3)2), 1.59 (br s, 1H, CH(CH3)2), 1.98 (s, 6H, Ph-CH3), 2.90 
(br s, 1H, OH), 5.33 (br s, 1H, NHCH), 7.02-7.29 (m, 6H, Ar-H), 7.36-7.39 (m, 2H, Ar-H), 
7.45-7.48 (m, 1H, Ar-H), 7.68 (br s, 2H, Ar-H), 7.89 (m, 1H, Ar-H), 8.17 (br s, 1H, Ar-H). 
(NH not visible). 
13C{1H} NMR (125.8 MHz, CDCl3, 300 K): δ = 17.0 (CH3), 21.8 (CH3), 21.9 (CH3), 23.1 
(CH3), 30.4 (CH(CH3)2), 55.8 (NHCH), 83.0 (COH), 125.2 (Ar-H), 125.7 (Ar-H), 126.9 (2C, 
Ar-H), 127.5 (Ar-H), 127.8 (Ar-H), 128.0 (Ar-H), 128.1 (Ar-H), 128.6 (2C, Ar-H), 131.4 
(Ar-H), 132.3 (Ar-C), 132.4 (Ar-H), 133.5 (Ar-H), 135.3 (Ar-C), 136.1 (Ar-C), 142.2 (Ar-
C), 142.3 (Ar-C), 167.6 (C=O). 
MS (FAB) m/z (rel int %): 388 (M + H, 6), 370 (40), 211 (10), 176 (23), 119 (12), 105 (100). 
IR (KBr) : υ~  [cm-1] = 3428s, 3341s, 3061w, 2959s, 2872w, 1632s, 1575m, 1524s, 1484s, 
1459s, 1363m, 1314s, 1165w, 1125m, 1050m, 904w, 745s, 694m, 619w, 571w. 
EA % found (calcd): C: 80.70 (80.59), H: 7.52 (7.54), N: 3.58 (3.61). 
 
(S)-N-(1,1-dicyclohexyl-1-hydroxy-3-methylbutan-2-yl)benzamide (93) 
 
 
 
 
Experimental Part 
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General Procedure III: 
CeCl3·7H2O (11.2 g, 30.0 mmol) was heated at 140 °C under high vacuum over night. After 
cooling the colorless powder to 0 °C it was suspended in THF (80.0 mL) and stirred for 
30 min before a 2M Grignard solution (15.0 mL, 30.0 mmol) in THF was added drop wise. 
After the reaction mixture was stirred for 2 h at 0 °C, (S)-methyl 2-benzamido-3-
methylbutanoate (1.20 g, 5.00 mmol) was added and the mixture was stirred over night at rt. 
The mixture was carefully quenched by a 1M HCl-solution and the pH-value was adjusted to 
about 3. The organic layer was separated, the aqueous phase was extracted with ethyl acetate 
(2 x 30 mL) and the combined organic layers were dried over Na2SO4. The solvent was 
removed under reduced pressure and the crude product was purified by column 
chromatography (Hx : EtOAc  5 : 1, Rf = 0.29) on silica to give a colorless solid (0.97 g, 
52%). 
 
C24H37NO2 (371.56). 
m.p. 206-207 °C. 
20][ Dα  = +17.8° (c = 0.630, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.96 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.00 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.05-1.15 (m, 4H, Cy-H), 1.19-1.35 (m, 6H, Cy-H), 
1.57-1.88 (m, 13H, Cy-H and OH), 2.20 (ds, J(H,H) = 6.8 Hz, J(H,H) = 1.8 Hz, 1H, 
CH(CH3)2), 4.36 (dd, J(H,H) = 9.8 Hz, J(H,H) = 1.5 Hz, 1H, NHCH), 6.59 (br d, J(H,H) = 
9.8 Hz, 1H, NH), 7.43-7.53 (m, 3H, Ph-H), 7.76-7.78 (m, 2H, Ph-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 17.9 (CH(CH3)2), 23.0 (CH(CH3)2), 27.3 
(Cy(CH2)), 27.4 (Cy(CH2)), 28.0 (Cy(CH2)), 28.0 (Cy(CH2)), 28.1 (Cy(CH2)), 28.5 (Cy(CH2)), 28.6 
(Cy(CH2)), 29.6 (CH(CH3)2), 29.7 (Cy(CH2)), 29.8 (Cy(CH2)), 30.2(Cy(CH2)), 46.1(Cy(CH)), 
47.8(Cy(CH)), 55.6 (NCH), 80.6 (COH), 127.3 (2C, Ph-H), 129.1 (2C, Ph-H), 131.6 (Ph-H), 
136.2 (Ph-C), 167.2 (CONH). 
MS (FAB) m/z (rel int %): 372 (M + H, 11), 354 (20), 176 (29), 105 (100), 83 (13), 77 (17), 
55 (20), 41 (14). 
IR (KBr) : υ~  [cm-1] = 3548w, 3427m, 3072w, 2931s, 2853m, 1648s, 1603m, 1578w, 1508s, 
1484m, 1450w, 1318w, 1195s, 1039w, 967w, 894w, 718m, 692m. 
EA % found (calcd): C: 77.25 (77.58), H: 9.98 (10.04), N: 3.78 (3.77). 
 
Experimental Part 
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(S)-N-(1,1-bis(3,5-dimethylphenyl)-1-hydroxy-3-methylbutan-2-yl)benzamide (94) 
 
 
 
 
Product 94 was prepared according to general procedure III (page 140) from CeCl3·7H2O 
(19.0 g, 51.0 mmol), 2M Grignard solution (25.5 mL, 51.0 mmol) in THF, (S)-methyl 2-
benzamido-3-methylbutanoate (2.00 g, 8.50 mmol), and THF as a solvent (140 mL). After 
column chromatography (DCM, Rf = 0.44) on silica compound 94 (2.8 g, 80%) was isolated 
as a colorless solid. 
 
C28H33NO2 (415.57). 
m.p. 203-205 °C. 
20][ Dα  = -78.0° (c = 0.750, CDCl3). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.97 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 0.98 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.91 (ds, J(H,H) = 6.8 Hz, J(H,H) = 2.0 Hz, 1H, 
CH(CH3)2), 2.21 (s, 6H, Ar-CH3), 2.31 (s, 6H, Ar-CH3), 5.10 (dd, J(H,H) = 9.8 Hz, J(H,H) = 
2.0 Hz, 1H, NCH), 6.62 (d, J(H,H) = 9.6 Hz, 1H, NH), 6.76 (br s, 1H, Ar-H), 6.86 (br s, 1H, 
Ar-H), 7.11-7.13 (m, 4H, Ar-H), 7.31-7.35 (m, 2H, Ar-H), 7.40-7.44 (m, 1H, Ar-H), 7.54-
7.58 (m, 2H, Ar-H). (OH not visible). 
13C{1H} NMR (125.8 MHz, CDCl3, 300 K): δ = 18.1 (CH(CH3)2), 21.6 (2C, Ar-CH3), 21.7 
(2C, Ar-CH3), 23.2 (CH(CH3)2), 29.4 (CH(CH3)2), 58.3 (NHCH), 82.6 (COH), 123.2 (2C, 
Ar-H), 123.3 (2C, Ar-H), 126.9 (2C, Ar-H), 128.5 (2C, Ar-H), 128.7 (Ar-H), 128.8 (Ar-H), 
131.2 (Ar-H), 135.7 (Ar-C), 137.9 (2C, Ar-C), 138.0 (2C, Ar-C), 145.6 (Ar-C), 146.2 (Ar-
C), 168.0 (C=O). 
MS (FAB) m/z (rel int %): 416 (M + H, 4), 398 (42), 239 (12), 177 (23), 133 (23), 105 (100), 
77 (12), 55 (14), 43 (13). 
IR (KBr) : υ~  [cm-1] = 3425s, 3304m, 3058w, 2958m, 2919m, 2870w, 1628s, 1546m, 1484m, 
1367m, 1320m, 1277m, 1152m, 1032w, 851m, 744w. 
EA % found (calcd): C: 80.55 (80.93), H: 8.30 (8.00), N: 3.28 (3.37). 
 
Experimental Part 
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(S)-N-(1,1-bis(3,5-dimethoxyphenyl)-1-hydroxy-3-methylbutan-2-yl)-2-fluorobenzamide 
(95) 
 
 
 
Product 95 was prepared according to general procedure III (page 140) from CeCl3·7H2O 
(7.70 g, 20.7 mmol), 2M Grignard solution (10.4 mL, 20.7 mmol) in THF, (S)-methyl 2-(2-
fluorobenzamido)-3-methylbutanoate (875 mg, 3.45 mmol), and THF as a solvent (60.0 mL). 
After column chromatography (Hx : EtOAc 4 : 1, Rf = 0.09) on silica compound 95 (1.27 g, 
74%) was isolated as a colorless solid. 
 
C28H32FNO6 (497.56). 
m.p. 199-200 °C. 
20][ Dα  = -107.0° (c = 0.820, CHCl3). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.95 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 0.97 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.89 (ds, J(H,H) = 6.8 Hz, J(H,H) = 2.0 Hz, 1H, 
CH(CH3)2), 2.70 (br s, 1H, OH), 3.72 (s, 6H, OCH3), 3.76 (s, 6H, OCH3), 5.16 (td, J(H,H) = 
9.8 Hz, J(H,H) = 2.6 Hz, 1H, NHCH), 6.25 (t, J(H,H) = 2.3 Hz, 1H, Ar-H), 6.31 (t, J(H,H) = 
2.3 Hz, 1H, Ar-H), 6.65 (d, J(H,H) = 2.3 Hz, 2H, Ar-H), 6.73 (d, J(H,H) = 2.3 Hz, 2H, Ar-
H), 7.04 (ddd, J(H,F) = 11.9 Hz, J(H,H) = 8.1 Hz, J(H,H) = 1.0 Hz, 1H, Ar-H), 7.18 (dt, 
J(H,H) = 8.0 Hz, J(H,H) = 1.0 Hz, 1H, Ar-H), 7.22 (d, J(H,H) = 9.8 Hz, 1H, NH), 7.37–7.43 
(m, 1H, Ar-H), 7.93 (dt, J(H,H) = 7.9 Hz, J(H,H) = 1.8 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CDCl3, 300 K): δ = 17.6 (CH(CH3)2), 22.9 (CH(CH3)2), 29.4 
(CH(CH3)2), 55.5 (2C, OCH3), 55.5 (2C, OCH3), 60.5 (NHCH), 82.4 (COH), 98.5 (Ar-H), 
99.8 (Ar-H), 103.7 (2C, Ar-H), 103.9 (2C, Ar-H), 116.2 (d, J(C,F) = 24.5 Hz, Ar-H), 121.7 
(d, J(C,F) = 11.5 Hz, Ar-C), 124.8 (d, J(C,F) = 3.1 Hz, Ar-H), 131.9 (d, J(C,F) = 1.9 Hz, Ar-
H), 133.1 (d, J(C,F) = 9.2 Hz, Ar-H), 148.1 (Ar-C), 148.9 (Ar-C), 160.6 (d, J(C,F) = 247.7 
Hz, Ar-F), 160.9 (2C, Ar-OMe), 160.9 (2C, Ar-OMe), 163.5 (d, J(C,F) = 3.1 Hz, C=O). 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = - 115.8 (m). 
MS (FAB) m/z (rel int %): 480 (M + H, 64), 341 (13), 177 (100), 162 (37), 123 (63), 69 (10), 
57 (13), 55 (16), 43 (14), 41 (13). 
IR (KBr) : υ~  [cm-1] = 3444m, 3083w, 2959m, 2837w, 1643s, 1601s, 1529s, 1460s, 1427s, 
1311s, 1204s, 1155s, 1061s, 926w, 835m, 752m. 
EA % found (calcd): C: 67.50 (67.59), H: 6.40 (6.48), N: 2.90 (2.82). 
Experimental Part 
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3,5-di-tert-butylphenyl
3,5-di-tert-butylphenylF
(S)-N-(1,1-bis(3,5-di-tert-butylphenyl)-1-hydroxy-3-methylbutan-2-yl)-2-
fluorobenzamide (96) 
 
 
 
 
Product 96 was prepared according to general procedure III (page 140) from CeCl3·7H2O 
(6.90 g, 18.6 mmol), 2M Grignard solution (9.30 mL, 18.6 mmol) in THF, (S)-methyl 2-(2-
fluorobenzamido)-3-methylbutanoate (784 mg, 3.10 mmol), and THF as a solvent (55.0 mL). 
After column chromatography (Hx : EtOAc  8 : 1, Rf = 0.27) on silica compound 96 (1.72 g, 
92%) was isolated as a colorless solid. 
 
C40H56FNO2 (601.88). 
m.p. 79-81 °C. 
20][ Dα  = -10.4° (c = 0.585, CHCl3). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.90 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 0.99 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.21 (s, 18H, 2 x C(CH3)3), 1.29 (s, 18H, 2 x C(CH3)3), 
1.97 (ds, J(H,H) = 6.8 Hz, J(H,H) = 2.0 Hz, 1H, CH(CH3)2), 2.24 (br s, 1H, OH), 5.25 (td, 
J(H,H) = 9.8 Hz, J(H,H) = 2.3 Hz, 1H, NHCH), 7.01-7.12 (m, 2H, Ar-H and NH), 7.15-7.18 
(m, 2H, Ar-H), 7.25 (t, J(H,H) = 1.8 Hz, 1H, Ar-H), 7.33 (d, J(H,H) = 1.8 Hz, 2H, Ar-H), 
7.35 (d, J(H,H) = 1.8 Hz, 2H, Ar-H), 7.36-7.41 (m, 1H, Ar-H), 7.86 (dt, J(H,H) = 7.8 Hz, 
J(H,H) = 1.8 Hz, 1H, Ar-H). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): 17.9 (CH(CH3)2), 23.2 (CH(CH3)2), 29.3 
(CH(CH3)2), 31.5 (6C, C(CH3)3), 31.6 (6C, C(CH3)3), 35.0 (2C, C(CH3)3), 35.1 (2C, 
C(CH3)3), 59.0 (NHCH), 83.1 (C-OH), 116.0 (d, J(C,F) = 24.5 Hz, Ar-H), 120.1 (2C, Ar-H), 
120.1 (2C, Ar-H), 120.5 (Ar-H), 120.6 (Ar-H), 121.9 (d, J(C,F) = 11.9 Hz, Ar-C), 124.6 (d, 
J(C,F) = 3.1 Hz, Ar-H), 132.0 (d, J(C,F) = 2.3 Hz, Ar-H), 132.8 (d, J(C,F) = 9.2 Hz, Ar-H), 
144.7 (Ar-C), 145.2 (Ar-C), 150.4 (2C, Ar-C(CH3)3), 150.5 (2C, Ar-C(CH3)3), 160.6 (d, 
J(C,F) = 247.6 Hz, Ar-F), 163.2 (d, J(C,F) = 3.1 Hz, C=O). 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -115.7. 
MS (FAB) m/z (rel int %): 584 (M - OH, 5), 195 (10), 123 (44), 57 (100), 41 (25), 39 (11). 
IR (KBr) : υ~  [cm-1] = 3454m, 3078w, 2961s, 2871s, 1705m, 1657s, 1597m, 1530s, 1478s, 
1364s, 1313m, 1250s, 1203m, 1095w, 1141w, 879m, 818w, 756m. 
EA % found (calcd): C: 79.45 (79.82), H: 9.47 (9.38), N 2.27 (2.33)  
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(S)-5,5-Diethyl-2-(2-fluorophenyl)-4-isopropyl-4,5-dihydrooxazole (97) 
 
 
 
 
General Procedure IV: 
A solution of (S)-N-(4-ethyl-4-hydroxy-2-methylhexan-3-yl)-2-fluorobenzamide (1.00 g, 
3.60 mmol) and methanesulfonic acid (717 µL, 11.1 mmol) in dichloromethane (65.0 mL) 
was heated to reflux for 12 h using a Soxhlet kind extractor filled with CaH2 (4.60 g) to 
remove the water. The reaction mixture was then quenched with a saturated NaHCO3-solution 
(55 mL) and the aqueous phase was extracted with dichloromethane (2 x 35 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was removed under reduced 
pressure. The residue was purified by column chromatography (Hx : EtOAc  6 : 1, Rf = 0.37) 
on silica to afford product 97 (0.8 g, 85%) as a colorless solid. 
 
C16H22FNO (263.35). 
20][ Dα  = -65.0° (c = 0.270, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.95 (t, J(H,H) = 7.6 Hz, 3H, CH2CH3), 1.01 (t, 
J(H,H) = 7.4 Hz, 3H, CH2CH3), 1.04 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.06 (d, J(H,H) = 
6.6 Hz, 3H, CH(CH3)2), 1.60-1.74 (m, 2H, CH2), 1.84-1.92 (m, 2H, CH2), 1.94 (ds, J(H,H) = 
6.8 Hz, J(H,H) = 6.7 Hz, 1H, CH(CH3)2), 3.65 (d, J(H,H) = 7.0 Hz, 1H, NCH), 7.12 (ddd, 
J(H,F) = 10.8 Hz, J(H,H) = 8.3 Hz, J(H,H) = 1.2 Hz, 1H, Ph-H), 7.19 (dt, J(H,H) = 7.6 Hz, 
J(H,H) = 1.2 Hz, 1H, Ph-H), 7.41-7.46 (m, 1H, Ph-H), 7.86 (dt, J(H,H) = 7.6 Hz, J(H,H) = 
1.2 Hz, 1H, Ph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 8.1 (CH3), 8.9 (CH3), 20.6 (CH(CH3)2), 
22.1 (CH(CH3)2), 25.6 (CH2), 29.0 (CH(CH3)2), 30.2 (CH2), 77.8 (NCH), 91.1 (OC), 117.0 
(d, J(C,F) = 21.9 Hz, Ph-H), 117.8 (d, J(C,F) = 11.1 Hz, Ph-C), 124.4 (d, J(C,F) = 4.8 Hz, 
Ph-H), 131.6 (d, J(C,F) = 2.3 Hz, Ph-H), 132.8 (d, J(C,F) = 8.8 Hz, Ph-H), 158.9 (d, J(C,F) = 
4.6 Hz, C=N), 161.6 (d, J(C,F) = 256.3 Hz, Ph-F). 
19F{1H} NMR (376.5 MHz, CD2Cl2, 300 K): δ = -112.7 (m). 
MS (FAB) m/z (rel int %): 264 (M + H, 100), 220 (16), 140 (18), 83 (14), 69 (35), 57 (40). 
IR (NaCl) : υ~  [cm-1] = 3078w, 2968s, 2880m, 2868m, 1649s, 1614w, 1582w, 1495m, 1459s, 
1342m, 1276m, 1228m, 1112w, 1061m, 1034m, 929m, 765m, 669w. 
EA % found (calcd): C: 72.91 (72.97), H: 8.46 (8.42), N: 5.43 (5.32). 
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(S)-4-isopropyl-2,5,5-triphenyl-4,5-dihydrooxazole (98) 
 
 
 
 
Product 98 was prepared according to general procedure IV (page 144) from (S)-N-(1-
hydroxy-3-methyl-1,1-diphenylbutan-2-yl)benzamide (4.00 g, 11.1 mmol), methanesulfonic 
acid (2.20 mL, 34.4 mmol), CaH2 (10.0 g) and dichloromethane as a solvent (240 mL). After 
column chromatography (Hx : EtOAc  8 : 1, Rf = 0.5 ) on silica compound 98 (3.10 g, 82%) 
was isolated as a colorless solid.  
 
C24H23NO (341.45). 
m.p. 93-95 °C. 
20][ Dα  = -354.6° (c = 0.945, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.58 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 1.04 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.89 (ds, J(H,H) = 6.6 Hz, J(H,H) = 4.5 Hz, 1H, 
CH(CH3)2), 4.79 (d, J(H,H) = 4.2 Hz, 1H, NCH), 7.23–7.40 (m, 8H, Ph-H), 7.45-7.55 (m, 
3H, Ph-H), 7.59-7.61 (m, 2H, Ph-H), 8.11 (m, 2H, Ph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 17.1 (CH(CH3)2), 22.2 (CH(CH3)2), 31.0 
(CH(CH3)2), 80.5 (NCH), 93.0 (OCPh2), 126.5 (2C, Ph-H), 127.4 (2C, Ph-H), 127.7 (Ph-H), 
128.3 (Ph-H), 128.3 (2C, Ph-H), 128.7 (Ph-C), 128.8 (2C, Ph-H), 128.9 (2C, Ph-H), 128.9 
(2C, Ph-H), 131.9 (Ph-H), 141.6 (Ph-C), 146.5 (Ph-C), 161.6 (C=N). 
MS (FAB) m/z (rel int %): 342 (M + H, 49), 159 (44), 144 (16), 105 (100), 77 (21). 
IR (KBr) : υ~  [cm-1] = 3426m, 3057m, 2952m, 2865m, 1662s, 1582w, 1494m, 1448m, 1330s, 
1286m, 1177w, 1104s, 1070w, 1026m, 950s, 896w, 765m, 695s. 
EA % found (calcd): C: 84.41 (84.42), H: 6.84 (6.79), N: 4.10 (4.10). 
 
(S)-4-isopropyl-5,5-di(naphthalen-2-yl)-2-phenyl-4,5-dihydrooxazole (88) 
 
 
 
 
Product 88 was prepared according to general procedure IV (page 144) from (S)-N-(1-
hydroxy-3-methyl-1,1-diphenylbutan-2-yl)benzamide (1.50 g, 3.30 mmol), methanesulfonic 
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acid (0.66 mL, 10.2 mmol), CaH2 (4.00 g) and dichloromethane as a solvent (66.0 mL). After 
column chromatography (Hx : EtOAc  6 : 1, Rf = 0.5 ) on silica compound 88 (1.20 g, 82%) 
was isolated as a colorless solid. 
 
C32H27NO (441.56). 
m.p. 76-79 °C. 
20][ Dα  = -499.0° (c = 0.530, CH2Cl2). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.62 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 1.11 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.95 (ds, J(H,H) = 6.6 Hz, J(H,H) = 4.3 Hz, 1H, 
CH(CH3)2), 5.09 (d, J(H,H) = 4.3 Hz, 1H, NCH), 7.45-7.54 (m, 8H, Ar-H), 7.69 (dd, J(H,H) 
= 8.7 Hz, J(H,H) = 2.0 Hz, 1H, Ar-H), 7.78 (d, J(H,H) = 8.6 Hz, 1H, Ar-H), 7.80-7.83 (m, 
4H, Ar-H), 7.88-7.91 (m, 1H, Ar-H), 7.99-8.00 (m, 1H, Ar-H), 8.13-8.18 (m, 3H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 17.1 (CH(CH3)2), 22.3 (CH(CH3)2), 31.1 
(CH(CH3)2), 79.6 (NCH), 93.4 (C(Naph)2), 125.0 (Ar-H), 125.0 (Ar-H), 125.8 (Ar-H), 125.9 
(Ar-H), 126.0 (Ar-H), 126.8 (Ar-H), 126.8 (Ar-H), 126.9 (Ar-H), 126.9 (Ar-H), 127.9 (Ar-
H), 127.9 (Ar-H), 128.0 (Ar-H), 128.7 (Ar-H), 128.8 (Ar-H), 128.8 (Ar-H), 128.8 (Ar-C), 
128.9 (Ar-H), 129.0 (2C, Ar-H), 131.9 (Ar-H), 133.0 (Ar-C), 133.4 (2C, Ar-C), 133.4 (Ar-
C), 138.9 (Ar-C), 143.2 (Ar-C), 161.8 (C=N). 
MS (FAB) m/z (rel int %): 442 (M + H, 51), 321 (5), 267 (8), 159 (84), 144 (38), 127 (10), 
105 (100), 77 (19). 
IR (KBr) : υ~  [cm-1] = 3462wbr, 3057m, 2957m, 2870m, 1654s, 1600w, 1579w, 1506m, 
1450m, 1340s, 1272m, 1175m, 1118m, 1062m, 1024m, 968m, 938m, 904m, 858m, 813s, 
772m, 746s, 693s. 
EA % found (calcd): C: 86.81 (87.04), H: 6.43 (6.16), N: 3.09 (3.17). 
 
(S)-4-isopropyl-2-phenyl-5,5-dio-tolyl-4,5-dihydrooxazole (99) 
 
 
 
 
Product 99 was prepared according to general procedure IV (page 144) from (S)-N-(1-
hydroxy-3-methyl-1,1-di-o-tolylbutan-2-yl)benzamide (3.20 g, 8.26 mmol), methanesulfonic 
acid (1.66 mL, 25.6 mmol), CaH2 (10.0 g) and dichloromethane as a solvent (180 mL). After 
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column chromatography (Hx : EtOAc  8 : 1, Rf = 0.4) on silica compound 99 (2.20 g, 71%) 
was isolated as a colorless solid. 
 
C26H27NO (369.5). 
m.p. 39-42 °C. 
20][ Dα  = -601.8° (c = 0.940, CDCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.59 (d, J(H,H)= 6.6 Hz, 3H, CH(CH3)2), 1.11 (d, 
J(H,H)= 6.8 Hz, 3H, CH(CH3)2), 1.42 (ds, J(H,H)= 6.8 Hz, J(H,H)= 2.5 Hz, 1H, CH(CH3)2), 
1.83 (s, 3H, oTol-CH3), 2.05 (s, 3H, oTol-CH3), 5.22 (d, J(H,H)= 2.5 Hz, 1H, NCH), 7.06-
7.08 (m, 2H, Ar-H), 7.15-7.24 (m, 4H, Ar-H), 7.39-7.42 (m, 2H, Ar-H), 7.45-7.49 (m, 1H, 
Ar-H), 7.70-7.72 (m, 1H, Ar-H), 7.92 (bs, 1H, Ar-H), 7.97-7.99 (m, 2H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 16.5 (CH3), 22.0 (CH3), 22.7 (CH3), 23.1 
(CH3), 30.4 (CH(CH3)2), 74.8 (NHCH), 94.7 (C(oTol)2), 125.4 (Ar-H), 125.6 (Ar-H), 127.1 
(Ar-H), 128.0 (Ar-H), 128.6 (Ar-H), 128.7 (2C, Ar-H), 128.8 (Ar-H), 128.9 (2C, Ar-H), 
128.9 (Ar-C), 131.8 (Ar-H), 131.9 (Ar-H), 133.6 (Ar-H), 135.2 (Ar-C), 139.0 (Ar-C), 139.5 
(Ar-C), 140.6 (Ar-C), 161.6 (C=O). 
MS (FAB) m/z (rel int %): 370 (M + H, 68), 195 (9), 159 (70), 144 (17), 119 (13), 105 (100). 
IR (KBr) : υ~  [cm-1] = 3420w, 3061w, 3021w, 2962s, 2871m, 1649s, 1578w, 1487m, 1453s, 
1382w, 1341s, 1296m, 1230w, 1172w, 1064m, 1027m, 954s, 820w, 754s, 693s. 
EA % found (calcd): C: 84.36 (84.51), H: 7.46 (7.36), N: 3.86 (3.79). 
 
(S)-5,5-dicyclohexyl-4-isopropyl-2-phenyl-4,5-dihydrooxazole (100) 
 
 
 
 
Product 100 was prepared according to general procedure IV (page 144) from (S)-N-(1,1-
dicyclohexyl-1-hydroxy-3-methylbutan-2-yl)benzamide (1.78 g, 4.80 mmol), methane-
sulfonic acid (0.98 mL, 15.1 mmol), CaH2 (3.30 g) and dichloromethane as a solvent (50.0 
mL). After column chromatography (Hx : EtOAc + 3% Et3N 50 : 1, Rf = 0.23 and Pe : 
Diethyl ether  40 : 1, Rf = 0.15) on silica compound 100 (1.04 g, 61%) was isolated as a 
colorless solid.  
 
C24H35NO (353.54). 
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m.p. 110-115 °C. 
20][ Dα  = -5.4° (c = 0.790, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 1.00-1.33 (m, 10H, Cy-H), 1.06 (d, J(H,H) = 6.6 
Hz, 3H, CH(CH3)2), 1.21 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 1.53-1.57 (m, 1H, Cy-H), 
1.62-1.82 (m, 10H, Cy-H), 1.93-2.01 (m, 1H, Cy-H), 2.07 (ds, J(H,H) = 9.4 Hz, J(H,H) = 6.6 
Hz, 1H, CH(CH3)2), 3.72 (d, J(H,H) = 9.4 Hz, 1H, NCH), 7.37-7.47 (m, 3H, Ph-H), 7.89-7.91 
(m, 2H, Ph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 22.9 (CH(CH3)2), 24.3 (CH(CH3)2), 27.0 
(Cy(CH2)), 27.1 (Cy(CH2)), 27.2 (Cy(CH2)), 27.2 (Cy(CH2)), 27.3 (Cy(CH2)), 27.3 (Cy(CH2)), 27.8 
(Cy(CH2)), 28.2 (Cy(CH2)), 28.6 (Cy(CH2)), 29.4 (CH(CH3)2), 29.5 (Cy(CH2)), 41.5 (Cy(CH)), 43.4 
(Cy(CH)), 76.4 (NCH), 94.0 (C(Cy)2), 128.5 (2C, Ph-H), 128.7 (2C, Ph-H), 129.2 (Ph-C). 
131.2 (Ph-H), 161.0 (C=N). 
MS (FAB) m/z (rel int %): 354 (67), 310 (11), 176 (27), 159 (29), 144 (10), 122 (14), 105 
(100), 95 (32), 83 (51), 77 (20), 69 (27), 55 (60), 41 (38). 
IR (KBr) : υ~  [cm-1] = 3449w, 3066w, 2927s, 2849s, 1657s, 1580w, 1451s, 1337s, 1300m, 
1263m, 1169w, 1101m, 1023w, 964m, 891w, 766m, 695s. 
EA % found (calcd): C: 81.52 (81.53), H: 9.87 (9.98), N: 3.97 (3.96). 
 
(S)-5,5-bis(3,5-dimethylphenyl)-4-isopropyl-2-phenyl-4,5-dihydrooxazole (101) 
 
 
 
 
Product 101 was prepared according to general procedure IV (page 144) from (S)-N-(1,1-
bis(3,5-dimethylphenyl)-1-hydroxy-3-methylbutan-2-yl)benzamide (1.50 g, 3.61 mmol), 
methanesulfonic acid (0.73 mL, 11.2 mmol), CaH2 (4.50 g) and dichloromethane as a solvent 
(80.0 mL). After column chromatography (Hx : EtOAc  8 : 1, Rf = 0.38) on silica compound 
101 (1.20 g, 84%) was isolated as a colorless solid. 
 
C28H31NO (397.55). 
m.p. 42-44 °C. 
20][ Dα  = -333.2° (c = 1.210, CDCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.53 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 1.06 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.90 (ds, J(H,H) = 6.8 Hz, J(H,H) = 4.0 Hz, 1H, 
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CH(CH3)2), 2.27 (s, 6H, 3,5-dimethylphenyl-CH3), 2.29 (s, 6H, 3,5-dimethylphenyl-CH3), 
4.62 (d, J(H,H) = 4.0 Hz, 1H, NCH), 6.88-6.90 (m, 2H, Ar-H), 7.01 (s, 2H, Ar-H), 7.19 (s, 
2H, Ar-H), 7.44-7.54 (m, 3H, Ar-H), 8.09-8.12 (m, 2H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 16.7 (CH(CH3)2), 21.8 (2C, 3,5-
dimethylphenyl-CH3), 21.8 (2C, 3,5-dimethylphenyl-CH3), 22.2 (CH(CH3)2), 30.8 
(CH(CH3)2), 79.7 (NCH), 93.0 (C(3,5-dimethylphenyl)2), 124.1 (2C, Ar-H), 124.9 (2C, Ar-
H), 128.8 (2C, Ar-H), 128.9 (2C, Ar-H), 128.9 (Ar-C), 129.0 (Ar-H), 129.7 (Ar-H), 131.7 
(Ar-H), 137.8 (2C, Ar-C), 138.3 (2C, Ar-C), 141.5 (Ar-C), 146.7 (Ar-C), 162.0 (C=N). 
MS (FAB) m/z (rel int %): 398 (M + H, 57), 223 (11), 159 (73), 144 (31), 133 (20), 133 (20), 
105 (100), 77 (25), 57 (13), 55 (15), 43 (15), 41 (15). 
IR (KBr) : υ~  [cm-1] = 3444w, 3033w, 2956s, 2919s, 2869m, 1655s, 1603s, 1451s, 1342s, 
1294m, 1239w, 1177m, 1107m, 1060m, 1025m, 979m, 852m. 
EA % found (calcd): C: 84.51 (84.59), H: 7.90 (7.86), N: 3.60 (3.52). 
 
(S)-5,5-Bis(3,5-dimethoxyphenyl)-2-(2-fluorophenyl)-4-isopropyl-4,5-dihydrooxazole 
(102) 
 
 
 
 
Product 102 was prepared according to general procedure IV (page 144) from (S)-N-(1,1-
bis(3,5-dimethoxyphenyl)-1-hydroxy-3-methylbutan-2-yl)-2-fluorobenzamide (0.90 g, 
1.80 mmol), methanesulfonic acid (365 µL, 5.58 mmol), CaH2 (2.50 g) and dichloromethane 
as a solvent (45.0 mL). After column chromatography (Hx : EtOAc  4 : 1, Rf = 0.21) on silica 
compound 102 (600 mg, 70%) was isolated as a colorless solid. 
  
C28H30FNO5 (479.54). 
m.p. 85-86 °C. 
20][ Dα  = -303.3° (c = 0.650, CHCl3). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.66 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 1.09 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 2.00 (ds, J(H,H) = 6.8 Hz, J(H,H)= 4.4 Hz, 1H, CH(CH3)2), 
3.75 (s, 6H, 3,5-dimethoxyphenyl-OCH3), 3.77 (s, 6H, 3,5-dimethoxyphenyl-OCH3), 4.78 (d, 
J(H,H) = 4.1 Hz, 1H, NCH), 6.35 (t, J(H,H) = 2.3 Hz, 1H, Ar-H), 6.36 (t, J(H,H) = 2.3 Hz, 
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1H, Ar-H), 6.59 (d, J(H,H) = 2.3 Hz, 2H, Ar-H), 6.76 (d, J(H,H) = 2.3 Hz, 2H, Ar-H), 7.14-
7.23 (m, 2H, Ar-H), 7.45-7.50 (m, 1H, Ar-H), 8.02 (br s, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 17.0 (CH(CH3)2), 22.2 (CH(CH3)2), 30.3 
(CH(CH3)2), 55.5 (2C, 3,5-dimethoxyphenyl-OCH3), 55.5 (2C, 3,5-dimethoxyphenyl-OCH3), 
79.6 (NCH), 93.1 (C(3,5-dimethoxyphenyl)2), 98.6 (Ar-H), 99.4 (Ar-H), 104.8 (2C, Ar-H), 
105.8 (2C, Ar-H), 116.8 (d, J(C,F) = 21.5 Hz, Ph-H), 124.2 (d, J(C,F) = 3.8 Hz, Ph-H), 131.6 
(d, J(C,F) = 2.3 Hz, Ph-H), 133.0 (d, J(C,F) = 8.8 Hz, Ph-H), 142.6 (C(3,5-
dimethoxyphenyl(ipso))2), 147.8 (C(3,5-dimethoxyphenyl(ipso))2), 160.3 (C=N), 160.2 (2C, 
3,5-dimethoxyphenyl-OCH3), 160.7 (2C, 3,5-dimethoxyphenyl-OCH3), 161.5 (d, J(C,F) = 
257.6 Hz, Ph-F). (One quaternary C-atom is not visible). 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -111.5 (m). 
MS (FAB) m/z (rel int %): 480 (M + H, 64), 341 (13), 177 (100), 162 (37), 123 (63), 69 (10), 
57 (17), 55 (16), 43 (14), 41 (13). 
IR (KBr) : υ~  [cm-1] = 3076w, 2964m, 2936m, 2873w, 2838w, 1647s, 1599s, 1459s, 1431s, 
1317s, 1206s, 1158s, 1115m, 1062s, 1023s, 990m, 972m, 859m, 821m, 747m. 
EA % found (calcd): C: 69.93 (70.13), H: 6.35 (6.31), N: 3.05 (2.92). 
 
(S)-5,5-Bis(3,5-di-tert-butylphenyl)-2-(2-fluorophenyl)-4-isopropyl-4,5-dihydrooxazole 
(103) 
 
 
 
 
Product 103 was prepared according to general procedure IV (page 144) from (S)-N-(1,1-
bis(3,5-dimethoxyphenyl)-1-hydroxy-3-methylbutan-2-yl)-2-fluorobenzamide (1.20 g, 
2.00 mmol), methanesulfonic acid (400 µL, 6.20 mmol), CaH2 (2.50 g) and dichloromethane 
as a solvent (45.0 mL). After column chromatography (Hx : EtOAc  25 : 1, Rf = 0.15) on 
silica compound 103 (978 mg, 84%) was isolated as a colorless solid. 
 
C40H54FNO (583.86). 
m.p. 139-141 °C. 
20][ Dα  = -158.6° (c = 0.635, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.61 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 0.98 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.26 (s, 18H, 2 x C(CH3)3), 1.30 (s, 18H, 2 x C(CH3)3), 
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1.91 (ds, J(H,H) = 6.6 Hz, J(H,H)= 5.1 Hz, 1H, CH(CH3)2), 4.68 (d, J(H,H) = 5.0 Hz, 1H, 
NCH), 7.19-7.27 (m, 2H, Ar-H), 7.25 (d, J(H,H) = 1.8 Hz, 2H, Ar-H), 7.29 (t, J(H,H) = 1.8 
Hz, 1H, Ar-H), 7.35 (t, J(H,H) = 1.8 Hz, 1H, Ar-H), 7.47 (d, J(H,H) = 1.8 Hz, 2H, Ar-H), 
7.49-7.53 (m, 1H, Ar-H), 8.04 (dt, J(H,H) = 7.4 Hz, J(H,H) = 2.0 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 17.5 (CH(CH3)2), 22.1 (CH(CH3)2), 31.2 
(CH(CH3)2), 31.7 (6C, C(CH3)3), 31.8 (6C, C(CH3)3), 35.3 (2C, C(CH3)3), 35.5 (2C, 
C(CH3)3), 82.0 (NCH), 94.0 (OC), 117.2 (d, J(C,F) = 21.9 Hz, Ar-H), 117.4 (d, J(C,F) = 11.1 
Hz, Ar-C), 120.5 (2C, Ar-H), 121.2 (Ar-H), 121.8 (2C, Ar-H), 122.1 (Ar-H), 124.6 (d, 
J(C,F) = 3.8 Hz, Ar-H), 131.7 (d, J(C,F) = 1.9 Hz, Ar-H), 133.3 (d, J(C,F) = 8.4 Hz, Ar-H), 
140.3 (C(3,5-di-tert-butylbenzene(ipso))2), 146.0 (C(3,5-di-tert-butylbenzene(ipso))2), 150.5 
(2C, Ar-C(CH3)3), 151.1 (2C, Ar-C(CH3)3), 159.1 (d, J(C,F) = 4.2 Hz, C=N), 161.8 (d, 
J(C,F) = 256.8 Hz, Ar-F). 
19F{1H} NMR (376.5 MHz, CD2Cl2, 300 K): δ = -112.2 (m). 
MS (FAB) m/z (rel int %): 584 (M + H, 10), 177 (30), 162 (11), 123 (31), 57 (100), 41 (24). 
IR (KBr) : υ~  [cm-1] = 3423w, 3078w, 2960s, 2870s, 1661s, 1598s, 1460s, 1342s, 1249m, 
1222m, 1117s, 1030w, 980m, 820w, 768m, 717m. 
EA % found (calcd): C: 82.24 (82.28), H: 9.16 (9.32), N: 2.55 (2.40). 
 
(S)-2-(2-(Diphenylphosphino)phenyl)-4-isopropyl-5,5-diphenyl-4,5-dihydrooxazole (41) 
 
 
 
 
General Procedure V: 
A 1.3M solution of sec-BuLi in cyclohexane (1.20 mL, 1.61 mmol) was added within 10 min 
to a solution of (S)-4-isopropyl-2,5,5-triphenyl-4,5-dihydrooxazole (500 mg, 1.46 mmol) and 
TMEDA (242 µL, 1.61 mmol) in pentane (14.0 mL) at –78 °C. The reaction mixture was 
stirred for a further 5 min at –78 °C before the cooling bath was replaced by an ice-bath. After 
10 min a solution of chlorodiphenylphosphine (420 mg, 1.90 mmol) in pentane (8.00 mL) was 
added over 10 min. After 10 min the ice-bath was removed and the solution was stirred over 
night at rt. The resulting suspension was filtered, the solvent was removed by high vacuum 
and the crude product was purified by column chromatography (Hx : EtOAc  8 : 1, Rf = 0.45) 
on silica to afford a colorless solid (613 mg, 80%). 
 
Experimental Part 
 152
(Ph)2P N
O
2-Naph
2-Naph
C36H32NOP (525.22). 
20][ Dα  = -315.0° (c = 0.150, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.41 (d, J(H,H) = 6.5 Hz, 3H, CH(CH3)2), 0.82 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.70 (ds, J(H,H) = 6.6 Hz, J(H,H)= 4.9 Hz, 1H, 
CH(CH3)2), 4.63 (d, J(H,H) = 4.9 Hz, 1H, NCH), 6.95 (ddd, J(H,H) = 7.7 Hz, J(H,H) = 3.6 
Hz, J(H,H) = 1.3 Hz, 1H, Ph-H), 7.20-7.25 (m, 9H, Ph-H), 7.26-7.36 (m, 10H, Ph-H), 7.43-
7.47 (m, 3H, Ph-H), 8.17 (ddd, J(H,H) = 7.7 Hz, J(H,H) = 3.6 Hz, J(H,H) = 1.3 Hz, 1H, Ph-
H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 17.4 (d, J(C,P) = 2.4 Hz, CH(CH3)2), 21.9 
(CH(CH3)2), 30.8 (CH(CH3)2), 81.5 (NCH), 92.8 (CO), 126.8 (2C, Ph-H), 127.5 (2C, Ph-H), 
128.1 (2C, Ph-H), 128.2 (Ph-H), 128.7 (Ph-H), 128.8-128.9 (9C, Ph-H), 130.4 (d, J(C,P) = 
2.9 Hz, Ph-H), 131.0 (Ph-H), 132.6 (d, J(C,P) = 20.6 Hz, Ph-CN), 134.4 (Ph-H), 134.5 (Ph-
H), 134.5 (Ph-H), 134.6 (Ph-H), 135.2 (Ph-H), 139.5 (d, J(C,P) = 12.0 Hz, Ph-P), 139.5 (d, 
J(C,P) = 12.0 Hz, Ph-P), 139.6 (d, J(C,P) = 27.4 Hz, Ph-P), 141.6 (C(Ph(ipso))2), 146.3 
(C(Ph(ipso))2), 160.7 (d, J(C,P) = 2.9 Hz, C=N). 
31P{1H} NMR (162.0 MHz, CDCl3, 300 K): δ = -13.4. 
MS (FAB) m/z (rel int %): 526 (M + H, 17), 304 (100), 289 (12), 55 (16), 43 (16). 
IR (KBr) : υ~  [cm-1] = 3423w, 3061w, 2954s, 2925m, 2867s, 1659s, 1584s, 1491s, 1471s, 
1446s, 1434m,1384s, 1282m, 1138m, 1099s, 1063w, 1038w, 974m, 773w, 761m. 
EA % found (calcd): C: 81.67 (82.26), H: 6.19 (6.14), N: 2.42 (2.66). 
 
(S)-2-(2-(Diphenylphosphino)phenyl)-4-isopropyl-5,5-di(naphthalen-2-yl)-4,5-
dihydrooxazole (73) 
 
 
 
 
Product 73 was prepared according to general procedure V (page 151) from (S)-4-isopropyl-
5,5-di(naphthalen-2-yl)-2-phenyl-4,5-dihydrooxazole (200 mg, 0.45 mmol), sec-BuLi in 
cyclohexane (0.39 mL, 0.50 mmol), TMEDA (75.0 µL, 1.25 mmol), 
chlorodiphenylphosphine (110 µL, 0.59 mmol) and pentane as a solvent (12.0 mL). After 
column chromatography (Hx : EtOAc  10 : 1, Rf = 0.32) on silica compound 73 (200 mg, 
71%) was isolated as a colorless solid. 
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C44H36NOP (625.71). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.48 (d, J(H,H) = 6.5 Hz, 3H, CH(CH3)2), 0.91 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.79 (ds, J(H,H) = 6.6 Hz, J(H,H) = 4.6 Hz, 1H, 
CH(CH3)2), 4.93 (d, J(H,H) = 4.6 Hz, 1H, NCH), 6.97 (dddd, J(H,H) = 7.8 Hz, J(H,H) = 3.6 
Hz, J(H,H) = 1.3 Hz, J(H,H) = 0.4 Hz, 1H, Ar-H), 7.22-7.28 (m, 7H, Ar-H), 7.28-7.32 (m, 
3H, Ar-H), 7.34 (m, 2H, Ar-H), 7.44-7.48 (m, 3H, Ar-H), 7.49-7.51 (m, 3H, Ar-H), 7.72 (d, 
J(H,H) = 8.8 Hz, 1H, Ar-H), 7.76-7.82 (m, 4H, Ar-H), 7.85-7.88 (m, 2H, Ar-H), 8.00 (d, 
J(H,H) = 2.0 Hz, 1H, Ar-H), 8.22 (dddd, J(H,H) = 7.8 Hz, J(H,H) = 3.6 Hz, J(H,H) = 1.3 Hz, 
J(H,H) = 0.4 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 17.4 (CH3), 22.1 (CH3), 30.9 (CH(CH3)3), 
80.5 (NCH), 93.4 (C(Naph)2), 125.2 (Ar-H), 126.1 (Ar-H, 2C), 126.3 (Ar-H), 126.7 (Ar-H), 
126.7 (Ar-H), 126.8 (Ar-H), 126.9 (Ar-H), 127.7 (Ar-H), 127.9 (Ar-H), 128.0 (Ar-H), 128.6 
(Ar-H), 128.7 (Ar-H), 128.8 (Ar-H), 128.8 (Ar-H, 2C), 128.9 (Ar-H, 2C), 128.9 (Ar-H), 
128.9 (Ar-H), 129.0 (Ar-H), 130.6 (d, J(C,P) = 3.4 Hz, Ar-H), 131.1 (Ar-H), 132.8 (d, J(C, 
P) = 21.2 Hz, Ar-CN), 132.9 (Ar-C), 133.3 (Ar-C), 133.4 (Ar-C), 133.4 (Ar-C), 134.5 (Ar-
H), 134.4 (Ar-H), 134.5 (Ar-H), 134.6 (Ar-H), 135.2 (Ar-H), 139.0 (C(Naph(ipso))2), 139.4 
(d, J(C,P) = 12.5 Hz, Ar-P), 139.5 (d, J(C,P) = 12.0 Hz, Ar-P), 139.6 (d, J(C,P) = 27.4 Hz, 
Ar-P), 143.0 (C(Naph(ipso))2), 161.0 (d, J(C,P) = 2.8 Hz, C=N). 
31P{1H} NMR (202.5 MHz, CD2Cl2, 295 K): δ = -7.1. 
 
(S)-2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-di(naphthalen-2-yl)-4,5-
dihydrooxazole (74) 
 
 
 
 
Product 74 was prepared according to general procedure V (page 151) from (S)-4-isopropyl-
5,5-di(naphthalen-2-yl)-2-phenyl-4,5-dihydrooxazole (500 mg, 1.13 mmol), sec-BuLi in 
cyclohexane (0.96 mL, 1.25 mmol), TMEDA (190 µL, 1.25 mmol), chlorodiortho-
tolylphosphine (366 mg, 1.47 mmol) and pentane as a solvent (20.0 mL). After column 
chromatography (Hx : EtOAc  10 : 1, Rf = 0.30) on silica compound 74 (518 mg, 70%) was 
isolated as a colorless solid. 
 
C46H40NOP (653.79).  
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m.p. 114-118 °C. 
20][ Dα  = -294.6° (c = 0.970, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.45 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 0.93 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.83 (ds, J(H,H) = 6.7 Hz, J(H,H)= 4.4 Hz, 1H, 
CH(CH3)2), 2.29 (d, J(H,H) = 1.3 Hz, 3H, oTol-CH3), 2.33 (d, J(H,H) = 1.3 Hz, 3H, oTol-
CH3), 4.97 (d, J(H,H) = 4.6 Hz, 1H, NCH), 6.70-6.77 (m, 2H, Ar-H), 6.95-7.08 (m, 3H, Ar-
H), 7.18-7.25 (m, 4H, Ar-H), 7.33-7.40 (m, 2H, Ar-H), 7.43-7.51 (m, 6H, Ar-H), 7.70-7.86 
(m, 7H, Ar-H), 8.02 (d, J(H,H) = 1.8 Hz, 1H, Ar-H), 8.19-8.21 (m, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 16.6 (d, J(C,P) = 2.9 Hz, CH(CH3)2), 20.8 
(d, J(C,P) = 5.3 Hz, oTol-CH3), 21.0 (d, J(C,P) = 5.7 Hz, oTol-CH3), 21.5 (CH(CH3)2), 30.3 
(CH(CH3)2), 80.4 (NCH), 93.6 (CO), 124.6 (Ar-H), 125.5 (Ar-H), 125.6 (d, J(C,P) = 1.0 Hz, 
Ar-H), 125.7 (Ar-H), 125.9 (Ar-H), 126.0 (Ar-H), 126.1 (Ar-H), 126.1 (Ar-H), 126.2 (Ar-
H), 126.3 (Ar-H), 127.1 (Ar-H), 127.3 (Ar-H), 127.4 (Ar-H), 128.0 (Ar-H), 128.1 (Ar-H), 
128.3 (Ar-H), 128.4 (2C, Ar-H), 128.4 (Ar-H), 129.9 (d, J(C,P) = 4.3 Hz, Ar-H), 130.0 (d, 
J(C,P) = 4.3 Hz, Ar-H), 130.3 (d, J(C,P) = 4.3 Hz, Ar-H), 130.7 (Ar-H), 132.3 (Ar-C), 132.7 
(Ar-C), 132.8 (Ar-C), 132.8 (Ar-C), 133.1 (Ar-H), 133.1 (Ar-H), 133.2 (d, J(C,P) = 21.3 Hz, 
Ar-CN), 134.9 (Ar-H), 136.7 (d, J(C,P) = 13.4 Hz, oTol-P), 136.7 (d, J(C,P) = 13.4 Hz, 
oTol-P), 137.5 (d, J(C,P) = 25.4 Hz, Ar-P), 138.4 (C(Naph(ipso))2), 142.3 (d, J(C,P) = 26.9 
Hz, oTol-CH3), 142.3 (d, J(C,P) = 26.9 Hz, oTol-CH3), 142.6 (C(Naph(ipso))2), 161.5 (d, 
J(C,P) = 2.0 Hz, C=N). 
31P{1H} NMR (202.5 MHz, CD2Cl2, 295 K): δ = -26.0. 
MS (FAB) m/z (rel int %): 654 (M + H, 13), 332 (100), 317 (30), 179 (19), 165 (10), 141 
(10), 105 (7), 91 (13), 77 (10), 57 (15), 55 (17), 43 (14). 
IR (KBr) : υ~  [cm-1] = 3433wbr, 3052m, 2956s, 2869m, 1649s, 1591m, 1503m, 1462s, 1378m, 
1333s, 1270m, 1166w, 1127m, 1093m, 1036s, 966m, 938m, 899m, 856m, 812s, 745s. 
EA % found (calcd): C: 84.15 (84.51), H: 6.32 (6.17), N: 1.90 (2.14). 
 
(S)-2-(2-(bis(3,5-dimethylphenyl)phosphino)phenyl)-4-isopropyl-5,5-di(naphthalen-2-yl)-
4,5-dihydrooxazole (75) 
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Product 75 was prepared according to general procedure V (page 151) from (S)-4-isopropyl-
5,5-di(naphthalen-2-yl)-2-phenyl-4,5-dihydrooxazole (300 mg, 0.68 mmol), sec-BuLi in 
cyclohexane (0.58 mL, 0.75 mmol), TMEDA (113 µL, 0.75 mmol), chlorobis(3,5-
dimethylphenyl)phosphine (236 mg, 0.88 mmol) and pentane as a solvent (18.0 mL). After 
column chromatography (Tol : Diethyl ether : Pe  5 : 1 : 5, Rf = 0.25) on silica compound 75 
(270 mg, 58%) was isolated as a colorless solid. 
 
C48H44NOP (681.84).  
m.p. 91-100 °C. 
20][ Dα  = -258.2° (c = 0.370, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.52 (d, J(H,H) = 6.5 Hz, 3H, CH(CH3)2), 0.93 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.81 (ds, J(H,H) = 6.8 Hz, J(H,H) = 4.6 Hz, 1H, 
CH(CH3)2), 2.17 (s, 6H, 3,5-dimethylphenyl-CH3), 2.21 (s, 6H, 3,5-dimethylphenyl-CH3), 
4.89 (d, J(H,H) = 4.5 Hz, 1H, NCH), 6.87-6.89 (m, 5H, Ar-H), 6.95 (br s, 1H, Ar-H), 7.01 
(dd, J(H,H) = 7.7 Hz, J(H,H) = 3.6 Hz, 1H, Ar-H), 7.34 (dd, J(H,H) = 8.6 Hz, J(H,H) = 1.9 
Hz, 1H, Ar-H), 7.35 (dt, J(H,H) = 7.6 Hz, J(H,H) = 1.4 Hz, 1H, Ar-H), 7.43-7.53 (m, 6H, Ar-
H), 7.71 (d, J(H,H) = 8.6 Hz, 1H, Ar-H), 7.75-7.82 (m, 4H, Ar-H), 7.86-7.88 (m, 2H, Ar-H), 
7.99 (d, J(H,H) = 1.6 Hz, 1H, Ar-H), 8.18 (ddd, J(H,H) = 7.7 Hz, J(H,H) = 3.8 Hz, J(H,H) = 
1.6 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 17.4 (d, J(C,P) = 2.9 Hz, CH(CH3)2), 21.5 
(2C, 3,5-dimethylphenyl), 21.6 (2C, 3,5-dimethylphenyl), 22.1 (CH(CH3)2), 30.8 
(CH(CH3)2), 80.2 (NCH), 93.4 (OC), 125.1 (Ar-H), 126.1 (Ar-H), 126.2 (Ar-H), 126.3 (d, 
J(C,P)= 1.4 Hz, Ar-H), 126.7 (2C, Ar-H), 126.8 (Ar-H), 126.9 (Ar-H), 127.7 (Ar-H), 127.9 
(Ar-H), 127.9 (Ar-H), 128.5 (Ar-H), 128.6 (Ar-H), 128.7 (Ar-H), 129.0 (Ar-H), 130.5 (d, 
J(C,P)= 3.4 Hz, Ar-H), 130.6 (Ar-H), 130.7 (Ar-H), 130.9 (Ar-H), 132.1 (Ar-H), 132.2 (Ar-
H), 132.3 (Ar-H), 132.3 (Ar-H), 132.9 (d, J(C,P) = 21.1 Hz, Ar-CN), 132.9 (Naph(Cq)), 133.2 
(Naph(Cq)), 133.3 (Naph(Cq)), 132.3 (Naph(Cq)), 135.2 (Ar-H), 138.2 (d, J(C,P) = 1.9 Hz, 2C, 
3,5-dimethylphenyl-CH3), 138.3 (d, J(C,P) = 1.9 Hz, 2C, 3,5-dimethylphenyl-CH3), 138.9 
(d, J(C,P) = 11.5 Hz, Ar-P), 138.9 (d, J(C,P) = 12.0 Hz, Ar-P), 139.1 (C(Naph(ipso))2), 140.1 
(d, J(C,P) = 27.4 Hz, Ar-P), 143.1 (C(Naph(ipso))2), 161.3 (d, J(C,P)= 2.9 Hz, C=N). 
31P{1H} NMR (202.5 MHz, CD2Cl2, 295 K): δ = -10.2. 
MS (FAB) m/z (rel int %): 682 (M + H, 8), 360 (100), 345 (17), 179 (20), 165 (13), 141 (11), 
136 (18), 127 (14), 115 (11), 105 (12), 91 (21), 89 (25), 77 (39), 65 (18), 63 (17), 57 (21), 55 
(20), 51 (21), 43 (21), 41 (30), 39 (34). 
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IR (KBr) : υ~  [cm-1] = 3427wbr, 3020w, 2917s, 2864m, 1652s, 1593m, 1500w, 1462s, 1333s, 
1264s, 1168w, 1093m, 1036s, 967m, 938w, 898w, 847m, 811s, 741s, 690s. 
EA % found (calcd): C: 84.77 (84.55), H: 6.76 (6.50), N: 1.77 (2.05). 
 
(S)-2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-dio-tolyl-4,5-dihydrooxazole (76) 
 
 
 
 
Product 76 was prepared according to general procedure V (page 151) from (S)-4-isopropyl-
2-phenyl-5,5-dio-tolyl-4,5-dihydrooxazole (500 mg, 1.35 mmol), sec-BuLi in cyclohexane 
(1.10 mL, 1.49 mmol), TMEDA (224 µL, 1.49 mmol), chlorodiortho-tolylphosphine (438 mg, 
1.76 mmol) and pentane as a solvent (32.0 mL). After column chromatography (Hx : EtOAc  
10 : 1, Rf = 0.37) on silica compound 76 (510 mg, 65%) was isolated as a colorless solid. 
 
C40H40NOP (581.73). 
m.p. 79-82 °C. 
20][ Dα  = -378.3° (c = 0.540, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.52 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 0.97 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.29 (ds, J(H,H) = 6.7 Hz, J(H,H) = 4.4 Hz, 1H, 
CH(CH3)2), 1.64 (br s, 3H, oTol-CH3), 1.72 (br s, 3H, oTol-CH3), 2.29 (br s, 3H, oTol-CH3), 
2.44 (br s, 3H, oTol-CH3), 5.12 (br s, 1H, NCH), 6.69 (dd, J(H,H) = 7.6 Hz, J(H,H) = 4.0 Hz, 
2H, Ar-H), 6.93 (ddd, J(H,H) = 7.0 Hz, J(H,H) = 3.5 Hz, J(H,H)= 1.1 Hz, 1H, Ar-H), 6.95-
6.99 (m, 1H, Ar-H), 6.99-7.05 (m, 3H, Ar-H), 7.11-7.18 (m, 4H, Ar-H), 7.20-7.23 (m, 3H, 
Ar-H), 7.24 (dd, J(H,H) = 7.3 Hz, J(H,H) = 1.4 Hz, 1H, Ar-H), 7.28 (dt, J(H,H) = 7.6 Hz, 
J(H,H) = 1.5 Hz, 1H, Ar-H), 7.37 (dt, J(H,H) = 7.6 Hz, J(H,H) = 1.4 Hz, 1H, Ar-H), 7.57 (br 
s, 1H, Ar-H), 7.84-7.85 (m, 1H, Ar-H), 7.89 (ddd, J(H,H) = 7.8 Hz, J(H,H)= 3.8 Hz, J(H,H)= 
1.4 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 16.5 (d, J(C,P) = 4.8 Hz, CH(CH3)2), 21.3 
(d, J(C,P) = 3.8 Hz, oTol-CH3), 21.5 (d, J(C,P) = 3.8 Hz, oTol-CH3), 21.8 (oTol-CH3), 22.4 
(oTol-CH3), 23.0 (CH(CH3)2), 30.0 (CH(CH3)2), 75.4 (NCH), 95.1 (OC), 125.2 (Ar-H), 
125.7 (Ar-H), 126.5 (Ar-H), 126.6 (Ar-H), 127.1 (Ar-H), 127.9 (Ar-H), 128.5 (Ar-H), 128.9 
(Ar-H), 128.9 (Ar-H), 129.0 (Ar-H), 129.2 (d, J(C,P) = 2.9 Hz, Ar-H), 130.5 (Ar-H), 130.5 
(Ar-H), 130.7 (d, J(C,P) = 4.8 Hz, Ar-H), 131.0 (Ar-H), 131.6 (Ar-H), 133.4 (Ar-H), 133.5 
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Cy
Cy
(Ar-H), 133.7 (Ar-H), 134.9 (oTol-CH3), 135.6 (Ar-H), 137.1-137.4 (3C, Ar-P), 139.0 
(C(oTol(ipso))2), 139.6 (C(oTol(ipso))2), 140.7 (oTol-CH3), 142.6-142.8 (2C, oTol-CH3), 161.8 
(br s, C=N). (Ar-CN is not visible). 
31P{1H} NMR (162.0 MHz, CD2Cl2, 300 K): δ = -30.3. 
MS (FAB) m/z (rel int %): 582 (M + H, 16), 332 (100), 317 (20), 179 (7), 165 (8), 105 (11), 
91 (15), 77 (7), 57 (12), 55 (13), 43 (15), 41 (13). 
IR (KBr) : υ~  [cm-1] = 3433mbr, 3054m, 2958s, 2924s, 2867m, 1646s, 1588w, 1459s, 1379w, 
1355m, 1303w, 1267w, 1229w, 1202w, 1166w, 1133m, 1091m, 1035s, 951s, 891w, 815w, 
749s, 685w. 
EA % found (calcd): C: 82.60 (82.59), H: 7.16 (6.93), N: 2.23 (2.41). 
 
(S)-5,5-dicyclohexyl-2-(2-(dio-tolylphosphino)phenyl)-4-isopropyl-4,5-dihydrooxazole 
(72) 
 
 
 
 
Product 72 was prepared according to general procedure V (page 151) from (S)-5,5-
dicyclohexyl-4-isopropyl-2-phenyl-4,5-dihydrooxazole (300 mg, 0.85 mmol), sec-BuLi in 
cyclohexane (692 µL, 0.93 mmol), TMEDA (135 µL, 0.93 mmol), chlorodiortho-
tolylphosphine (274 mg, 1.10 mmol) and pentane as a solvent (20.0 mL). After column 
chromatography (Hx : EtOAc  15 : 1, Rf = 0.48 and Tol : DCM : Hx  5 : 1 : 1 Rf = 0.39) on 
silica compound 72 (252 mg, 52%) was isolated as a colorless solid. 
 
C38H48NOP (565.77). 
m.p. 143-145 °C.  
20][ Dα  = -6.3° (c = 0.530, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.95 (d, J(H,H) = 6.5 Hz, 6H, CH(CH3)2), 0.91-
1.26 (m, 10H, CH2(Cy)), 1.44 (d, J(H,H) = 12.2 Hz, 1H, CH2(Cy) ), 1.57-1.82 (m, 11H, 
CH2(Cy)), 1.91 (br s, 1H, CH(CH3)2), 2.30 (d, J(H,P) = 1.6 Hz, 3H, Ph-CH3), 2.33 (d, J(H,P) = 
1.5 Hz, 3H, Ph-CH3), 3.61 (d, J(H,H) = 9.6 Hz, 1H, NCH), 6.69 (m, 2H, Ar-H), 6.87 (ddd, 
J(H,H) = 7.8 Hz, J(H,H) = 3.4 Hz, J(H,H) = 1.0 Hz, 1H, Ar-H), 7.00-7.06 (m, 2H, Ar-H), 
7.15-7.28 (m, 5H, Ar-H), 7.38 (td, J(H,H) = 7.6 Hz, J(H,H) = 1.3 Hz, 1H, Ar-H), 7.99 (ddd, 
J(H,H) = 7.8 Hz, J(H,H) = 3.4 Hz, J(H,H) = 1.0 Hz, 1H, Ar-H). 
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O
3,5-dimethylphenyl
3,5-dimethylphenyl
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 21.3 (d, J(C,P) = 1.6 Hz, oTol-CH3), 21.5 
(d, J(C,P) = 1.6 Hz, oTol-CH3), 22.9 (CH(CH3)2), 24.2 (CH(CH3)2), 27.0 (CH2(Cy)), 27.1 
(CH2(Cy)), 27.2 (CH2(Cy)), 27.2 (CH2(Cy)), 27.3 (CH2(Cy)), 27.3 (CH2(Cy)), 27.7 (CH2(Cy)), 28.1 
(CH2(Cy)), 28.2 (CH2(Cy)), 29.3 (CH(CH3)2), 29.6 (CH2(Cy)), 41.3 (CH(Cy)),43.3 (CH(Cy)), 76.7 
(NCH), 94.6 (C(Cy)2), 126.4 (Ar-H), 126.5 (Ar-H), 128.6 (Ar-H), 128.7 (Ar-H), 130.3 (Ar-
H), 130.3 (Ar-H), 130.4 (Ar-H), 130.4 (Ar-H), 130.7 (Ar-H), 133.6 (Ar-H), 133.8 (Ar-H), 
134.4 (d, J(C,P) = 23.5 Hz, Ar-CN), 135.2 (Ar-H), 137.5 (d, J(C,P) = 14.0 Hz, oTol-P), 
137.6 (d, J(C,P) = 25.3 Hz, Ar-P), 137.8 (d, J(C,P) = 13.4 Hz, oTol-P), 142.8 (br s, 2C, oTol-
CH3), 161.0 (C=N). 
31P{1H} NMR (162.0 MHz, CD2Cl2, 300 K): δ = -29.5. 
MS (FAB) m/z (rel int %): 566 (M + H, 36), 332 (100), 317 (16), 242 (12), 95 (23), 83 (27), 
69 (26), 57 (21), 55 (51), 43 (24), 41 (34), 39 (11). 
IR (KBr) : υ~  [cm-1] = 3447w, 3052w, 2927s, 2850s, 1629s, 1587w, 1450s, 1333m, 1265w, 
1201w, 1184w, 1060w, 957w, 892w, 747m, 716w, 686w. 
EA % found (calcd): C: 80.71 (80.67), H: 8.57 (8.55), N: 2.27 (2.48). 
 
(S)-2-(2-(Dio-tolylphosphino)phenyl)-5,5-bis(3,5-dimethylphenyl)-4-isopropyl-4,5-
dihydrooxazole (77) 
 
 
 
 
Product 77 was prepared according to general procedure V (page 151) from (S)-5,5-bis(3,5-
dimethylphenyl)-4-isopropyl-2-phenyl-4,5-dihydrooxazol (600 mg, 1.51 mmol), sec-BuLi in 
cyclohexane (1.30 mL, 1.66 mmol), TMEDA (250 µL, 1.66 mmol), chlorodiortho-
tolylphosphine (490 mg, 1.96 mmol) and pentane as a solvent (36.0 mL). After column 
chromatography (Hx : EtOAc  10 : 1, Rf = 0.45) on silica compound 77 (770 mg, 84%) was 
isolated as a colorless solid. 
 
C42H44NOP (609.78). 
m.p. 85-90 °C. 
20][ Dα  = -190.3° (c = 0.780, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 295 K): δ = 0.32 (br s, 3H, CH(CH3)2), 0.84 (br s, 3H, 
CH(CH3)2), 1.72-1.82 (m, 1H, CH(CH3)2), 2.24 (s, 6H, 2 x 3,5-dimethylphenyl-CH3), 2.28 (s, 
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6H, 2 x 3,5-dimethylphenyl-CH3), 2.30 (d, J(H,H) = 1.6 Hz, 3H, oTol-CH3), 2.33 (d, J(H,H) 
= 1.6 Hz, 3H, oTol-CH3), 4.68 (d, J(H,H) = 3.8 Hz, 1H, NCH), 6.65-6.68 (m, 1H, Ar-H), 
6.70-6.73 (m, 1H, Ar-H), 6.84 (br s, 1H, Ar-H), 6.90 (br s, 1H, Ar-H), 6.94-6.97 (m, 3H, Ar-
H), 6.99-7.06 (m, 2H, Ar-H), 7.10 (br s, 2H, Ar-H), 7.17-7.24 (m, 4H, Ar-H), 7.33 (td, 
J(H,H) = 7.6 Hz, J(H,H) = 1.5 Hz, 1H, Ar-H), 7.48 (td, J(H,H) = 7.6 Hz, J(H,H) = 1.3 Hz, 
1H, Ar-H), 8.17-8.20 (m, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 16.0 (CH(CH3)2), 20.8 (d, J(C,P) = 13.0 
Hz, Ar-CH3), 20.9 (d, J(C,P) = 13.0 Hz, Ar-CH3), 21.2 (2C, 3,5-dimethylphenyl-CH3), 21.2 
(2C, 3,5-dimethylphenyl-CH3), 21.4 (CH(CH3)2), 30.0 (CH(CH3)2), 80.2 (NCH), 92.3 (OC), 
123.7 (2C, Ar-H), 124.5 (2C, Ar-H), 125.9 (Ar-H), 125.9 (Ar-H), 128.2 (Ar-H), 128.3 (Ar-
H), 128.3 (Ar-H), 128.3 (Ar-H), 129.0 (Ar-H), 129.9 (d, J(C,P) = 8.1 Hz, Ar-H), 129.9 (d, 
J(C,P) = 8.1 Hz, Ar-H), 130.1 (d, J(C,P) = 4.3 Hz, Ar-H), 130.5 (Ar-H), 132.9 (Ar-H), 133.1 
(Ar-H), 133.2 (d, J(C,P) = 23.0 Hz, Ar-CN), 134.9 (Ar-H), 136.9 (d, J(C,P) = 12.5 Hz, oTol-
P), 137.0 (d, J(C,P) = 12.5 Hz, oTol-P), 137.0 (2C, 3,5-dimethylphenyl-CH3), 137.5 (d, 
J(C,P) = 25.9 Hz, Ar-P), 137.7 (2C, 3,5-dimethylphenyl-CH3), 141.0 (C(3,5-
dimethylphenyl(ipso))2), 142.2 (d, J(C,P) = 26.9 Hz, oTol-CH3), 142.2 (d, J(C,P) = 26.9 Hz, 
oTol-CH3), 146.1 (C(3,5-dimethylphenyl(ipso))2), 160.5 (d, J(C,P) = 2.0 Hz, C=N). 
31P{1H} NMR (162.0 MHz, CD2Cl2, 300 K): δ = -29.8. 
MS (FAB) m/z (rel int %): 610 (M + H, 14), 332 (100), 317 (20), 263 (8), 157 (10), 133 (8), 
91 (7), 57 (14), 55 (15), 43 (18), 41 (14). 
IR (KBr) : υ~  [cm-1] = 3448w, 3051w, 2955s, 2918s, 2866m, 1651m, 1601s, 1463s, 1378w, 
1337m, 1306w, 1274w, 1167w, 1134m, 1107m, 1095m, 1037s, 976m, 851m. 
EA % found (calcd): C: 82.54 (82.73), H: 7.50 (7.27), N: 2.02 (2.30). 
 
(S)-2-(2-(Diphenylphosphino)phenyl)-5,5-diethyl-4-isopropyl-4,5-dihydrooxazole (70) 
 
 
 
 
General Procedure VI: 
A 1.6M solution of n-BuLi in hexane (1.30 mL, 2.09 mmol) was added drop wise to a solution 
of diphenylphosphane (389 mg, 2.09 mmol) in THF (20.0 mL) at 0 °C. The reaction mixture 
was stirred for 30 min before it was added drop wise to a solution of (S)-5,5-Diethyl-2-(2-
fluorophenyl)-4-isopropyl-4,5-dihydrooxazole (500 mg, 1.90 mmol) in THF (20 mL) at 0 °C. 
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After 10 min the cooling bath was removed and the reaction solution was stirred over night at 
rt. The solvent was removed under reduced pressure before dichloromethane (20 mL) was 
added and the resulting solution was washed with water, dried over MgSO4 and the solvent 
was removed under reduced pressure. The crude product was purified by column 
chromatography (Hx : EtOAc  15 : 1, Rf = 0.44) on silica to afford a colorless oil 70 (555 mg, 
68%). 
 
C28H32NOP (429.53). 
20][ Dα  = -30.0° (c = 0.200, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.82 (t, J(H,H) = 7.4 Hz, 3H, CH2CH3), 0.87 (d, 
J(H,H) = 6.5 Hz, 3H, CH(CH3)2), 0.88 (t, J(H,H) = 7.5 Hz, 3H, CH2CH3), 0.89 (d, J(H,H) = 
6.5 Hz, 3H, CH(CH3)2), 1.50 (dq, J(H,H) = 14.8 Hz, J(H,H) = 7.4 Hz, 1H, CH2CH3), 1.52 
(dq, J(H,H) = 14.8 Hz, J(H,H) = 7.6 Hz, 1H, CH2CH3), 1.63 (dq, J(H,H) = 14.7 Hz, J(H,H) = 
7.4 Hz, 1H, CH2CH3), 1.68 (ds, J(H,H) = 7.8 Hz, J(H,H) = 6.5 Hz, 1H, CH(CH3)2), 1.76 (dq, 
J(H,H) = 14.8 Hz, J(H,H) = 7.6 Hz, 1H, CH2CH3), 3.40 (d, J(H,H) = 7.9 Hz, 1H, NCH), 6.86 
(ddd, J(H,H) = 7.9 Hz, J(H,H) = 4.0 Hz, J(H,H) = 1.3 Hz, 1H, Ph-H), 7.21-7.32 (m, 11H, Ph-
H), 7.36 (dt, J(H,H) = 7.4 Hz, J(H,H) = 1.5 Hz, 1H, Ph-H), 7.89 (ddd, J(H,H) = 7.6 Hz, 
J(H,H) = 3.7 Hz, J(H,H) = 1.4 Hz, 1H, Ph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 8.2 (CH2CH3), 8.7 (CH2CH3), 21.2 
(CH(CH3)2), 21.8 (CH(CH3)2), 25.5 (CH2CH3), 28.9 (CH(CH3)2), 30.0 (CH2CH3), 78.4 
(NCH), 91.1 (OC), 128.4 (Ph-H), 128.7 (Ph-H), 128.8 (Ph-H), 128.8 (2C, Ph-H), 128.8 (Ph-
H), 128.8 (Ph-H), 129.9 (d, J(C,P) =2.9 Hz, Ph-H), 130.5 (Ph-H), 133.5 (d, J(C,P) = 19.7 Hz, 
Ph-CN), 134.4 (Ph-H), 134.4 (Ph-H), 134.6 (Ph-H), 134.6 (2C, Ph-H), 139.4 (d, J(C,P) = 
26.8 Hz, Ph-P), 139.6 (d, J(C,P) = 13.4 Hz, Ph-P), 139.7 (d, J(C,P) = 13.4 Hz, Ph-P), 161.1 
(d, J(C,P) = 3.4 Hz, C=N). 
31P{1H} NMR (162.0 MHz, CDCl3, 300 K): δ = -12.4. 
MS (FAB) m/z (rel int %): 430 (M + H, 31), 304 (100), 289 (9), 317(10), 246 (50), 202 (10), 
155 (10), 137 (20), 105 (25). 
IR (NaCl) : υ~  [cm-1] = 3380wbr, 3056m, 2967s, 2876m, 1652s, 1586w, 1465s, 1435s, 1382m, 
1355s, 1302m, 1277m, 1180w, 1090s, 1046s, 928s, 746s. 
EA % found (calcd): C: 78.29 (77.50), H: 7.54 (7.51), N: 3.09 (3.26). 
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O
(S)-2-(2-(Dio-tolylphosphino)phenyl)-5,5-diethyl-4-isopropyl-4,5-dihydrooxazole (71) 
 
 
 
 
Product 71 was prepared according to general procedure VI (page 159) from (S)-5,5-
Diethyl-2-(2-fluorophenyl)-4-isopropyl-4,5-dihydrooxazole (500 mg, 1.90 mmol), 1.6M 
n-BuLi in hexane (1.30 mL, 2.09 mmol), diortho-tolylphosphane (447 mg, 2.09 mmol) and 
THF as a solvent (40.0 mL). After column chromatography (Hx : EtOAc  10 : 1, Rf = 0.53) on 
silica compound 71 (478 mg, 55%) was isolated as a colorless solid. 
 
C30H36NOP (457.58). 
m.p. 68-73 °C. 
20][ Dα  = -45.0° (c = 0.200, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.84 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 0.84 (t, 
J(H,H) = 7.4 Hz, 3H, CH2CH3), 0.85 (t, J(H,H) = 7.5 Hz, 3H, CH2CH3), 0.90 (d, J(H,H) = 6.6 
Hz, 3H, CH(CH3)2), 1.52 (dq, J(H,H) = 14.8 Hz, J(H,H) = 7.4 Hz, 1H, CH2CH3), 1.55 (dq, 
J(H,H) = 14.8 Hz, J(H,H) = 7.4 Hz, 1H, CH2CH3), 1.67-1.79 (m, 3H, CH2CH3 & CH(CH3)2), 
2.34 (d, J(H,H) = 1.8 Hz, 3H, oTol-CH3), 2.35 (d, J(H,H) = 1.8 Hz, 3H, oTol-CH3), 3.48 (d, 
J(H,H) = 7.3 Hz, 1H, NCH), 6.71-6.73 (m, 2H, Ar-H), 6.88 (dddd, J(H,H) = 7.7 Hz, J(H,H) = 
3.5 Hz, J(H,H) = 1.3 Hz, J(H,H) = 0.5 Hz, 1H, Ar-H) 7.01-7.06 (m, 2H, Ar-H), 7.17-7.24 (m, 
4H, Ar-H), 7.28 (dt, J(H,H) = 7.6 Hz, J(H,H) = 1.4 Hz, 1H, Ar-H), 7.38 (dt, J(H,H) = 7.4 Hz, 
J(H,H) = 1.3 Hz, 1H, Ar-H), 7.89 (dddd, J(H,H) = 7.7 Hz, J(H,H) = 4.0 Hz, J(H,H) = 1.7 Hz, 
J(H,H) = 0.5 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 8.2 (CH2CH3), 8.7 (CH2CH3), 20.7 
(CH(CH3)2), 21.3 (d, J(C,P) = 5.6 Hz, oTol-CH3), 21.5 (d, J(C,P) =5.8 Hz, oTol-CH3), 22.0 
(CH(CH3)2), 25.4 (CH2CH3), 29.0 (CH(CH3)2), 30.0 (CH2CH3), 78.4 (NCH), 91.2 (OC), 
126.4 (Ar-H), 126.5 (Ar-H), 128.6 (Ar-H), 128.8 (Ar-H), 128.8 (Ar-H), 130.2 (d, J(C,P) = 
3.8 Hz, Ar-H), 130.4 (d, J(C,P) = 4.8 Hz, Ar-H), 130.4 (d, J(C,P) = 4.3 Hz, Ar-H), 130.6 
(Ar-H), 133.5 (Ar-H), 133.7 (Ar-H), 134.7 (d, J(C,P) = 23.5 Hz, Ar-CN), 134.9 (Ar-H), 
137.4 (d, J(C,P) = 13.0 Hz, oTol-P), 137.5 (d, J(C,P) = 13.9 Hz, oTol-P), 137.7 (d, J(C,P) = 
24.5 Hz, Ph-P), 142.8 (d, J(C,P) = 26.9 Hz, oTol-CH3), 142.8 (d, J(C,P) = 26.9 Hz, oTol-
CH3), 161.5 (d, J(C,P) = 1.9 Hz, C=N). 
31P{1H} NMR (162.0 MHz, CDCl3, 300 K): δ = -28.9. 
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O
3,5-dimethoxyphenyl
3,5-dimethoxyphenyl
MS (FAB) m/z (rel int %): 458 (M + H, 43), 366 (11), 332 (100), 317(10), 242 (13). 
IR (KBr) : υ~  [cm-1] = 3424wbr, 3053w, 2942s, 2876m, 1649s, 1586w, 1462s, 1379m, 1333m, 
1273m, 1132w, 1088m, 1046s, 925s, 888m, 863w, 751s, 716w. 
EA % found (calcd): C: 78.66 (78.74), H: 7.88 (7.93), N: 2.86 (3.06). 
 
(S)-2-(2-(Dio-tolylphosphino)phenyl)-5,5-bis-(3,5-dimethoxyphenyl)-4-isopropyl-4,5-
dihydrooxazole (78) 
 
 
 
 
Product 78 was prepared according to general procedure VI (page 159) from (S)-5,5-bis-
(3,5-dimethoxyphenyl)-2-(2-fluorophenyl)-4-isopropyl-4,5-dihydrooxazole (200 mg, 
0.42 mmol), 1.6M n-BuLi in hexane (288 µL, 0.46 mmol), diortho-tolylphosphane (100 mg, 
0.46 mmol) and THF as a solvent (10.0 mL). After column chromatography (Hx : EtOAc  3 : 
1, Rf = 0.38) on silica compound 78 (150 mg, 53%) was isolated as a colorless solid. 
 
C42H44NO5P (673.78). 
m.p. 77-78 °C. 
20][ Dα  = -212.5° (c = 0.410, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.32 (br s, 3H, CH(CH3)2), 0.82 (br s, 3H, 
CH(CH3)2), 1.84 (br s, 1H, CH(CH3)2), 2.30 (d, J(H,H) = 1.6 Hz, oTol-CH3), 2.33 (d, J(H,H) 
= 1.8 Hz, oTol-CH3), 3.72 (s, 6H, 2 x OCH3), 3.74 (s, 6H, 2 x OCH3), 4.63 (d, J(H,H) = 4.0 
Hz, 1H, NCH), 6.32 (t, J(H,H) = 2.4 Hz, 3,5-dimethoxyphenyl-H), 6.36 (t, J(H,H) = 2.4 Hz, 
3,5-dimethoxyphenyl-H), 6.53 (d, J(H,H) = 2.4 Hz, 3,5-dimethoxyphenyl-H), 6.65 (d, J(H,H) 
= 2.2 Hz, 3,5-dimethoxyphenyl-H), 6.65-6.67 (m, 1H, Ar-H), 6.69-6.71 (m, 1H, Ar-H), 6.96 
(ddd, J(H,H) = 7.9 Hz, J(H,H) = 3.3 Hz, J(H,H) = 1.0 Hz, 1H, Ar-H), 6.97-7.04 (m, 2H, Ar-
H), 7.16-7.22 (m, 4H, Ar-H), 7.34 (td, J(H,H) = 7.6 Hz, J(H,H) = 1.4 Hz, 1H, Ar-H), 7.47 (td, 
J(H,H) = 7.6 Hz, J(H,H) = 1.5 Hz, 1H, Ar-H), 8.17 (br s, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 16.8 (CH(CH3)2), 21.3 (d, J(C,P) = 8.6 Hz, 
oTol-CH3), 21.5 (d, J(C,P) = 8.6 Hz, oTol-CH3), 22.0 (CH(CH3)2), 30.6 (CH(CH3)2), 55.8 
(2C, OCH3), 55.9 (2C, OCH3), 81.4 (NCH), 92.5 (OC), 98.6 (methoxyphenyl-H), 99.5 
(methoxyphenyl-H), 105.1 (2C, methoxyphenyl-H), 106.3 (2C, methoxyphenyl-H), 126.4 
(2C, Ar-H), 128.8 (2C, Ar-H), 128.9 (Ar-H), 130.4 (d, J(C,P) = 4.3 Hz, Ar-H), 130.5 (d, 
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O
3,5-di-tert-butylphenyl
3,5-di-tert-butylphenyl
J(C,P) = 5.3 Hz, Ar-H), 130.6 (Ar-H), 131.1 (Ar-H), 133.3 (d, J(C,P) = 19.5 Hz, Ar-CN), 
133.4 (Ar-H), 133.7 (Ar-H), 135.5 (Ar-H), 137.4 (d, J(C,P) = 13.0 Hz, oTol-P), 137.5 (d, 
J(C,P) = 12.9 Hz, oTol-P), 138.4 (d, J(C,P) = 25.4 Hz, Ph-P), 142.8 (d, J(C,P) = 25.4 Hz, 
oTol-CH3), 142.8 (d, J(C,P) = 25.4 Hz, oTol-CH3), 143.6 (C(3,5-dimethoxyphenyl(ipso))2), 
148.8 (C(3,5-dimethoxyphenyl(ipso))2), 160.6 (d, J(C,P) = 2.4 Hz, C=N), 160.8 (2C, 3,5-
dimethoxyphenyl-OCH3), 161.2 (2C, 3,5-dimethoxyphenyl-OCH3). 
31P{1H} NMR (162.0 MHz, CD2Cl2, 295 K): δ = -30.0. 
MS (FAB) m/z (rel int %): 674 (M + H, 11), 342 (24), 332 (100), 317 (19), 165 (12), 91 (14), 
89 (16), 77 (20), 65 (11), 63 (10), 51 (12), 41 (12), 39 (21). 
IR (KBr) : υ~  [cm-1] = 3424w, 3054w, 2954m, 2836w, 1654w, 1598s, 1460s, 1426s, 1333m, 
1203s, 1156s, 1062m, 977w, 928w, 837w, 748m. 
EA % found (calcd): C: 74.80 (74.87), H: 6.80 (6.58), N: 1.81 (2.08). 
 
(S)-2-(2-(Dio-tolylphosphino)phenyl)-5,5-bis-(3,5-di-tert-butylphenyl)-4-isopropyl-4,5-
dihydrooxazole (79) 
 
 
 
 
Product 79 was prepared according to general procedure VI (page 159) from (S)-5,5-bis-
(3,5-di-tert-butylphenyl)-2-(2-fluorophenyl)-4-isopropyl-4,5-dihydrooxazole (200 mg, 
0.34 mmol), 1.6M n-BuLi in hexane (236 µL, 0.38 mmol), diortho-tolylphosphane (81.0 mg, 
0.38 mmol) and THF as a solvent (10.0 mL). After column chromatography (Hx : EtOAc  
100 : 1, Rf = 0.10) on silica compound 79 (142 mg, 54%) was isolated as a colorless solid. 
 
C54H68NOP (778.10). 
m.p. 205 °C. 
20][ Dα  = -87.1° (c = 0.480, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.22 (br s, 3H, CH(CH3)2), 0.66 (br s, 3H, 
CH(CH3)2), 1.24 (s, 18H, 2 x C(CH3)3), 1.30 (s, 18H, 2 x C(CH3)3), 1.84 (br s, 1H, 
CH(CH3)2), 2.29 (d, J(H,H) = 1.8 Hz, 3H, oTol-CH3), 2.35 (d, J(H,H) = 1.8 Hz, 3H, oTol-
CH3), 4.52 (d, J(H,H) = 5.0 Hz, 1H, NCH), 6.65-6.68 (m, 1H, Ar-H), 6.70-6.73 (m, 1H, Ar-
H), 6.95-6.98 (m, 1H, Ar-H), 6.99-7.03 (m, 2H, Ar-H), 7.15-7.19 (m, 4H, Ar-H), 7.20 (d, 
J(H,H) = 1.8 Hz, 2H, Ar-H), 7.27 (t, J(H,H) = 1.8 Hz, 1H, Ar-H), 7.35 (td, J(H,H) = 6.3 Hz, 
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J(H,H) = 1.3 Hz, 1H, Ar-H), 7.27 (t, J(H,H) = 1.8 Hz, 1H, Ar-H), 7.40 (d, J(H,H) = 1.8 Hz, 
2H, Ar-H), 7.47 (td, J(H,H) = 6.3 Hz, J(H,H) = 1.3 Hz, 1H, Ar-H), 8.25 (br s, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 16.7 (CH(CH3)2), 20.8 (d, J(C,P) = 13.4 
Hz, oTol-CH3), 21.0 (d, J(C,P) = 14.4 Hz, oTol-CH3), 21.1 (CH(CH3)2), 30.5 (CH(CH3)2), 
31.1 (6C, C(CH3)3), 31.2 (6C, C(CH3)3), 34.7 (2C, C(CH3)3), 34.8 (2C, C(CH3)3), 83.1 
(NCH), 92.5 (OC), 120.1 (2C, 3,5-di-tert-butylphenyl-H), 120.5 (3,5-di-tert-butylphenyl-
H), 121.4 (3,5-di-tert-butylphenyl-H), 121.5 (2C, 3,5-di-tert-butylphenyl-H), 125.8 (Ar-H), 
125.9 (Ar-H), 128.1 (Ar-H), 128.1 (Ar-H), 128.3 (Ar-H), 129.6 (Ar-H), 129.7 (Ar-H), 129.8 
(d, J(C,P) = 4.3 Hz, Ar-H), 129.8 (d, J(C,P) = 4.3 Hz, Ar-H), 130.3 (Ar-H), 132.8 (Ar-H), 
133.1 (Ar-H), 134.8 (Ar-H), 137.0 (d, J(C,P) = 14.4 Hz, oTol-P), 137.2 (d, J(C,P) = 11.5 Hz, 
oTol-P), 137.9 (d, J(C,P) = 24.0 Hz, Ph-P), 140.1 (C(3,5-di-tert-butylphenyl(ipso))2), 142.1 (d, 
J(C,P) = 22.6 Hz, oTol-CH3), 142.1 (d, J(C,P) = 22.7 Hz, oTol-CH3), 145.4 (C(3,5-di-tert-
butylphenyl(ipso))2), 149.7 (2C, C(3,5-di-tert-butylphenyl(meta))2), 150.5 (2C, C(3,5-di-tert-
butylphenyl(meta))2), 159.8 (br s, C=N). (Ar-CN not visible). 
31P{1H} NMR (162.0 MHz, CD2Cl2, 295 K): δ = -29.3. 
MS (FAB) m/z (rel int %): 779 (M + H, 1), 332 (21), 77 (9), 57 (100), 41 (21), 39 (10). 
IR (KBr) : υ~  [cm-1] = 3425w, 3056w, 2960s, 2867m, 1653m, 1596m, 1467m, 1362w, 
1333w, 1247w, 1134w, 1092w, 1038m, 967w, 880w, 749m, 718w. 
EA % found (calcd): C: 83.33 (83.35), H: 8.90 (8.81), N: 1.57 (1.80). 
 
 
13.3.2 Synthesis of PHOX Ligands Bearing Two Chirality Centers at the Oxazoline Unit 
 
(S)-tert-butyl 1-(methoxy(methyl)amino)-3-methyl-1-oxobutan-2-ylcarbamate (106) 
 
 
 
 
A solution of (S)-2-(tert-butoxycarbonylamino)-3-methylbutanoic acid (23.5 g, 108 mmol) in 
dichloromethane (50.0 mL) was successively added to a stirred suspension of 
O,N-dimethylhydroxylamine hydrochloride (11.6 g, 119 mmol) and triethylamine (16.6 mL, 
119 mmol) in dichloromethane (200 mL). After adding a solution of 
N,N’-dicyclohexylcarbodiimide (24.6 g, 119 mL) in dichloromethane (50.0 mL) over 30 min 
the reaction mixture was stirred for 3 h. The suspension was filtered over Celite, the solvent 
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was removed under reduced pressure and the crude product was purified by column 
chromatography (Hx : EtOAC  4 : 1, KMnO4 and Ninhydrin dips, Rf = 0.25 (KMnO4)) on 
silica to afford a colorless oil (19.1 g, 68%). 
 
C12H24N2O4 (260.33). 
20][ Dα  = +11.2° (c = 0.860, CH2Cl2). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.90 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 0.95 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.43 (s, 9H, C(CH3)3), 1.98 (ds, J(H,H) = 6.8 Hz, J(H,H) = 
6.6 Hz, 1H, CH(CH3)2), 3.21 (s, 3H, NCH3), 3.76 (s, 3H, OCH3), 4.57 (br s, 1H, NHCH), 
5.13 (d, J(H,H) = 9.1 Hz, 1H, NH). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 17.6 (CH(CH3)2), 19.5 (CH(CH3)2), 28.5 
(3C, C(CH3)3), 31.5 (CH(CH3)2), 32.0 (NCH3), 55.1 (NCH), 61.7 (OCH3), 79.5 (C(CH3)3), 
156.0 (CON(Me)OMe), 173.1 (COOC(CH3)3). 
MS (FAB) m/z (rel int %): 261 (M + H, 74), 205 (100), 161 (44), 144 (12), 116 (29), 72 (41), 
62 (55), 57 (41). 
IR (NaCl): υ~  [cm-1] = 3327m, 2970s, 2936s, 2876m, 2823w, 1713s, 1657s, 1498s, 1389m, 
1367s, 1304m, 1242s, 1172s, 1117w, 1084w, 1042w, 1015m, 966w, 875w, 830w. 
EA % found (calcd): C: 55.45 (55.36), H: 9.02 (9.29), N: 10.86 (10.72). 
 
(S)-tert-butyl 3-methyl-1-oxo-1-phenylbutan-2-ylcarbamate (107) 
 
 
 
 
1M Phenylmagnesiumbromide-solution (158 mL, 134 mmol) in THF was added over 30 min. 
to a solution of the Weinreb amide 106 (12.4 g, 46.1 mmol) in THF (110 mL) at 0 °C. The 
reaction mixture was stirred over night at rt and was subsequently quenched with a 10% 
HCl-solution (115 mL) at 0 °C. The resulting solution was extracted with ethyl acetate (3 x 
280 mL), the combined organic layers were washed with water (2 x 120 mL) and brine 
(80 mL) and were dried over Na2SO4. The solvent was removed under reduced pressure and 
the crude product was purified by column chromatography (Hx : EtOAc  8 : 1, Rf = 0.30) on 
silica to afford a colorless solid (10.5 g, 82%). 
 
C16H23NO3 (277.36). 
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m.p. 38-40 °C. 
20][ Dα  = +82.8° (c = 0.950, CH2Cl2). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.74 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.03 (d, 
J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.45 (s, 9H, C(CH3)3), 2.15 (ds, J(H,H) = 6.8 Hz, J(H,H) = 
4.3 Hz, 1H, CH(CH3)2), 5.23 (dd, J(H, H) = 8.8 Hz, J(H, H) = 4.1 Hz, 1H, NHCH), 5.41 (d, 
J(H, H) = 8.6 Hz, 1H, NH), 7.48 (t, J(H, H) = 7.7 Hz, 2H, Ph-H), 7.59 (t, J(H,H) = 7.3 Hz, 
1H, Ph-H), 7.97 (d, J(H ,H) = 7.3 Hz, 2H, Ph-H). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 16.6 (CH(CH3)2), 20.2 (CH(CH3)2), 28.5 
(3C, C(CH3)3), 31.8 (CH(CH3)2), 59.7 (NHCH), 79.7 (C(CH3)3), 128.7 (2C, Ph-H), 128.9 
(2C, Ph-H), 133.7 (Ph-H), 135.6 (Ph-C), 156.1 (OCO), 199.9 (COPh). 
MS (FAB) m/z (rel int %): 278 (M + H, 22), 222 (72), 178 (51), 172 (19), 116 (36), 105 (26), 
72 (52), 57 (100), 41 (16). 
IR (KBr) : υ~  [cm-1] = 3368s, 2973m, 2954w, 2903w, 1704s, 1681s, 1595w, 1521s, 1451w, 
1390w, 1365s, 1301w, 1245m, 1217m, 1160s, 1094m, 1002w, 877m, 774w, 693m. 
EA % found (calcd): C: 69.25 (69.29), H: 8.20 (8.36), N: 4.96 (5.05). 
 
Tert-butyl (1R,2S)-1-hydroxy-3-methyl-1-phenylbutan-2-ylcarbamate (108) 
 
 
 
 
Sodium borohydride (2.70 g, 72.1 mmol) was added to a stirred solution of (S)-tert-butyl 3-
methyl-1-oxo-1-phenylbutan-2-ylcarbamate (10.0 g, 36.1 mmol) in dry methanol (450 mL) at 
–20 °C. After a stirring period of 3.5 h the reaction solution was quenched with water (90 mL) 
and the resulting mixture was concentrated under reduced pressure until a colorless solid 
precipitated. The suspension was diluted with ethyl acetate (900 mL), was successively 
washed with water and brine and was dried over Na2SO4. The solvent was removed under 
reduced pressure and the residue was purified by column chromatography (Hx : EtOAc  4 : 1, 
Rf = 0.25) on silica to afford a colorless solid (8.5 g, 84%). 
 
C16H25NO3 (279.37). 
m.p. 101-103 °C. 
20][ Dα  = -80.8° (c = 0.570, CHCl3). 
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1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.87 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.02 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.35 (s, 9H, C(CH3)), 1.70-1.79 (m, 1H, CH(CH3)2), 
3.02 (d, J(H,H) = 4.5 Hz, 1H, OH), 3.70-3.76 (m, 1H, NHCH), 4.38 (d, J(H,H) = 9.1 Hz, 1H, 
NH), 4.79 (t, J(H,H) = 4.8 Hz, 1H, CH(OH)Ph), 7.25-7.34 (m, 5H, Ph-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 18.1 (CH(CH3)2), 21.1 (CH(CH3)2), 28.6 
(3C, C(CH3)3), 28.8 (CH(CH3)2), 61.6 (NHCH), 75.7 (CH(OH)Ph), 79.7 (C(CH3)3), 127.4 
(2C, Ph-H), 128.1 (Ph-H), 128.6 (2C, Ph-H), 142.1 (Ph-C), 157.3 (CO). 
MS (FAB) m/z (rel int %): 280 (M + H, 25), 224 (25), 206 (85), 172 (23), 145 (17), 116 (49), 
91 (13), 72 (64), 57 (100), 41 (12). 
IR (KBr) : υ~  [cm-1] = 3383s, 3067w, 3033w, 2963m, 2944w, 2933w, 2894w, 1688s, 1521s, 
1458m, 1389w, 1366m, 1306m, 1253m, 1172s, 1114w, 1046m, 988m, 873w, 812w, 761w, 
702w. 
EA % found (calcd): C: 68.59 (68.79), H: 8.89 (9.02), N: 4.91 (5.01). 
 
(1R, 2S)-2-Amino-3-methyl-1-phenylbutan-1-ol hydrochloride (109) 
 
 
 
 
A 4M HCl-solution (88.4 mL, 354 mmol) in dioxane was added to tert-butyl (1R,2S)-1-
hydroxy-3-methyl-1-phenylbutan-2-ylcarbamate (7.80 g, 27.9 mmol). The reaction mixture 
was stirred for 3 h before the solvent was removed under reduced pressure. The residue was 
diluted in absolute diethyl ether whereupon the product precipitated as a colorless solid. It 
was filtered and washed with cold absolute diethyl ether and pentane to afford the pure 
product 109 (5.78 g, 96 %). 
 
C11H17NO·HCl (215.72). 
m.p. 193–195 °C (decomp.). 
20][ Dα  = -32.5° (c = 0.540, MeOH, syn:anti 98:2). 
1H NMR (400.1 MHz, (CD3)2SO, 300 K): δ = 0.89 (d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 0.92 
(d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 1.66-1.75 (m, 1H, CH(CH3)2), 3.11 (t, J(H,H) = 4.8 Hz, 
1H, CHNH), 4.98-4.99 (m, 1H, OH), 6.08 (d, J(H,H) = 4.0 Hz, 1H, CHOH), 7.28-7.32 (m, 
1H, Ph-H), 7.36-7.44 (m, 4H, Ph-H), 7.94 (br s, 3H, +NH3) 
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13C{1H} NMR (100.6 MHz, (CD3)2SO, 300 K): δ = 18.0 (CH(CH3)2), 20.5 (CH(CH3)2), 26.1 
(CH(CH3)2), 60.9 (CHNH), 71.0 (CHOH), 126.5 (2C, Ph-H), 127.5 (Ph-H), 128.2 (2C, Ph-
H), 140.7 (Ph-C). 
MS (FAB) m/z (rel int %):180 (M+-Cl, 100), 162 (M-OH, 23), 72 (M-CH(OH)Ph, 11). 
IR (KBr) : υ~  [cm-1] = 3328s, 3032s, 2964s, 1603m, 1560w, 1508m, 1451m, 1405w, 1376w, 
1203w, 1139w, 1027m, 753m, 703s. 
 
(4S,5R)-4-Isopropyl-2,5-diphenyl-4,5-dihydrooxazole (110) 
 
 
 
 
Ethyl benzimidate hydrochloride (2.00 g, 4.21 mmol) was dissolved in dichloromethane 
(50.0 mL) and was extracted with a saturated NaHCO3-solution (2 x 50 mL) and brine. The 
combined organic phases were dried over MgSO4 and the solvent was removed under reduced 
pressure to afford a colorless oil (1.60 g). 
(1R,2S)-2-amino-3-methyl-1-phenylbutan-1-ol hydrochloride (1.00 g, 4.64 mmol) was added 
to a solution of the imidate (0.63 g, 4.21 mmol) in dichloroethane (35.0 mL). The reaction 
solution was heated to reflux for 20 h before the precipitate which was formed during the 
reaction was filtered off and washed with dichloroethane. The solvent was removed under 
reduced pressure and the crude product was purified by column chromatography (Hx : EtOAc  
5 : 1, Rf = 0.50) on silica to afford a colorless solid (0.77 g, 69%) with a de-value of 92%. By 
means of semipreperative HPLC (OD, Hep : IPA  95 : 5, 0.5 mL/min, 20 °C, 220 nm and 
254 nm, 7.8 min and 13.8 min) the pure diastereomer 110 (0.50 g, 45%) could be isolated as a 
colorless solid. 
 
C18H19NO (265.35). 
m.p. 86-89 °C. 
20][ Dα  = -238.1° (c = 0.640, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.77 (d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 0.91 
(d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 1.58 (ds, J(H,H) = 6.6 Hz, J(H,H)= 6.6 Hz, 1H, 
CH(CH3)2), 4.21 (dd, J(H,H) = 9.1 Hz, J(H,H) = 6.8 Hz, 1H, NCH), 5.73 (d, J(H,H) = 9.6 Hz, 
1H, OCH), 7.33 (br s, 5H, Ph-H), 7.43-7.47 (m, 2H, Ph-H), 7.45-7.54 (m, 1H, Ph-H), 8.01-
8.03 (m, 2H, Ph-H). 
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13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 19.9 (CH(CH3)2), 21.3 (CH(CH3)2), 29.8 
(CH(CH3)2), 77.3 (NCH), 84.8 (OCH), 127.8 (2C, Ph-H), 128.5 (Ph-H), 128.7 (2C, Ph-H), 
128.7 (Ph-C), 128.8 (2C, Ph-H), 128.9 (2C, Ph-H), 131.8 (Ph-H), 138.2 (Ph-C), 163.3 
(C=N). 
MS (FAB) m/z (rel int %): 266 (M + H, 75), 222 (10), 159 (17), 144 (13), 105 (100), 91 (11), 
77 (25). 
IR (KBr) : υ~  [cm-1] = 3451w, 3062w, 3033w, 2956m, 2868m, 1646s, 1575m, 1493m, 
1450m, 1358m, 1327s, 1301m, 1267m, 1209w, 1178w, 1059s, 1021m, 944s, 768m, 698s. 
EA % found (calcd): C: 81.35 (81.48), H: 7.26 (7.22), N: 5.17 (5.28). 
 
(4S,5R)-2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5-phenyl-4,5-dihydrooxazole (111) 
 
 
 
 
Product 111 was prepared according to general procedure V (page 149) from (4S,5R)-4-
isopropyl-2,5-diphenyl-4,5-dihydrooxazole (0.50 g, 1.88 mmol), sec-BuLi in cyclohexane 
(1.60 mL, 2.07 mmol), TMEDA (0.31 mL, 2.07 mmol), chlorodiortho-tolylphosphine (0.61 g, 
2.45 mmol) and pentane as a solvent (28.0 mL). After column chromatography (Hx : EtOAc  
15 : 1, Rf = 0.25) on silica compound 111 (635 mg, 71%) was isolated as a colorless solid. 
 
C32H32NOP (477.58). 
m.p. 52-54 °C.  
20][ Dα  = -158.6° (c = 0.590, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.58 (d, J(H,H) = 6.5 Hz, 3H, CH(CH3)2), 0.60 
(d, J(H,H) = 6.6 Hz, 3H, CH(CH3)2), 1.39 (ds, J(H,H) = 7.2 Hz, J(H,H) = 6.6 Hz, 1H, 
CH(CH3)2), 2.35 (br s, 6H, oTol-CH3), 4.06 (dd, J(H,H) = 9.7 Hz, J(H,H) = 7.9 Hz, 1H, 
NCH), 5.56 (d, J(H,H) = 9.8 Hz, 1H, OCH), 6.74-6.78 (m, 2H, Ar-H), 6.95 (dddd, J(H,H) = 
7.6 Hz, J(H,H) = 3.5 Hz, J(H,H) = 1.5 Hz, J(H,H) = 0.5 Hz, 1H, Ar-H), 7.05-7.08 (m, 2H, 
Ar-H), 7.18-7.26 (m, 6H, Ar-H), 7.27-7.31 (m, 3H, Ar-H), 7.33 (dt, J(H,H) = 7.6 Hz, J(H,H) 
= 1.4 Hz, 1H, Ar-H), 7.43 (dt, J(H,H) = 7.8 Hz, J(H,H) = 1.4 Hz, 1H, Ar-H), 7.99 (ddd, 
J(H,H) = 7.9 Hz, J(H,H) = 3.9 Hz, J(H,H) = 1.4 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 19.4 (d, J(C,P) = 1.0 Hz, CH(CH3)2), 21.1 
(CH(CH3)2), 21.4 (d, J(C,P) = 3.8 Hz, oTol-CH3), 21.6 (d, J(C,P) = 3.8 Hz, oTol-CH3), 29.7 
Experimental Part 
 170
O
HN
OH
Ph
(CH(CH3)2), 77.8 (NCH), 84.4 (OCH), 126.5 (Ar-H), 126.5 (Ar-H), 127.8 (Ar-H), 127.8 
(Ar-H), 128.3 (Ar-H), 128.5 (2C, Ar-H), 128.8 (Ar-H), 128.9 (Ar-H), 128.9 (Ar-H), 130.4 
(d, J(C,P)=3.3 Hz, Ar-H), 130.5 (d, J(C,P) = 4.8 Hz, Ar-H), 130.5 (d, J(C,P) = 4.8 Hz, Ar-
H), 131.5 (Ar-H), 133.5 (d, J(C,P) = 22.6 Hz, Ar-CN), 133.6 (Ar-H), 133.7 (Ar-H), 135.1 
(Ar-H), 137.3 (d, J(C,P) = 11.5 Hz, oTol-P), 137.3 (d, J(C,P) = 13.4 Hz, oTol-P), 138.0 (Ar-
CHO), 138.3 (d, J(C,P) = 24.5 Hz, Ar-P), 142.8 (d, J(C,P) = 27.8 Hz, oTol-CH3), 142.9 (d, 
J(C,P) = 27.9 Hz, oTol-CH3), 162.6 (d, J(C,P) = 2.4 Hz, C=N). 
31P{1H} NMR (162.0 MHz, CD2Cl2, 300 K): δ = -29.5. 
MS (FAB) m/z (rel int %): 478 (M + H, 25), 332 (100), 317 (14), 165 (5), 145 (6), 105 (12), 
91 (19), 57 (7), 55 (8), 43 (9), 41 (9). 
IR (KBr) : υ~  [cm-1] = 3432m, 3052m, 3003w, 2955s, 2870m, 1650s, 1586w, 1493w, 1451s, 
1376w, 1322m, 1302m, 1202w, 1162w, 1130m, 1086m, 1036s, 961m, 748s, 695s. 
EA % found (calcd): C: 80.41 (80.48), H: 7.00 (6.75), N: 2.73 (2.93). 
 
N-((1R, 2S)-1-hydroxy-3-methyl-1-phenylbutan-2-yl)benzamide 112 
 
 
 
 
A solution of benzoylchloride (0.50 mL, 4.60 mmol) in dioxane (5.10 mL) was added within 
40 min to a solution of (1R,2S)-2-amino-3-methyl-1-phenylbutan-1-ol hydrochloride (1.00 g, 
4.60 mmol) and triethylamine (2.15 mL, 15.5 mmol) in dioxane (7.70 mL) at 0 °C. The 
resulting suspension was stirred for 1.5 h at rt. The solvent was removed under reduced 
pressure, the residue was dissolved in ethyl acetate (13 mL) and filtered over silica gel, which 
was washed with ethyl acetate (64 mL). The solvent was removed under reduced pressure and 
the colorless solid (1.27, 97%) was used without further purification in the following step. 
 
C18H21NO2 (283.36). 
Rf = 0.28 (Hx : EtOAc  2 : 1). 
m.p. 121-123 °C. 
20][ Dα  = -127.4° (c = 0.510, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.96 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.11 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.83 (ds, J(H, H) = 6.8 Hz, J(H, H) = 6.8 Hz, 1H, 
CH(CH3)2), 3.56 (d, J(H,H) = 4.5 Hz, 1H, OH), 4.28-4.33 (m, 1H, NHCH), 5.01 (t, J(H,H) = 
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4.5 Hz, 1H, CHOH), 5.94 (d, J(H,H) = 8.8 Hz, 1H, NH), 7.25-7.44 (m, 7H, Ph-H), 7.49-7.53 
(m, 1H, Ph-H), 7.64-7.66 (m, 2H, Ph-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 18.9 (CH3), 21.4 (CH3), 29.1 (CH(CH3)2), 
61.2 (NHCH), 75.7 (CHOH), 127.3 (2C, Ph-H), 127.4 (2C, Ph-H), 128.2 (Ph-H), 128.7 (2C, 
Ph-H), 129.1 (2C, Ph-H), 132.1 (Ph-H), 135.1 (Ph-C), 141.7 (Ph-C), 169.0 (CO). 
MS (FAB) m/z (rel int %): 284 (M + H, 26), 266 (26), 176 (20), 105 (100), 77 (26), 51 (15), 
39 (16). 
IR (KBr) : υ~  [cm-1] = 3335s, 3062w, 3031w, 2962m, 1637s, 1579s, 1533s, 1490m, 1458m, 
1387w, 1320m, 1077m, 1044m, 1028m, 1013w, 915w, 838w, 800m, 756m, 696s. 
EA % found (calcd): C: 76.13 (76.30), H: 7.50 (7.47), N: 4.81 (4.94). 
 
(4S,5S)-4-Isopropyl-2,5-diphenyl-4,5-dihydrooxazole (113) 
 
 
 
 
Product 113 was prepared according to general procedure IV (page 142) from N-((1R,2S)-1-
hydroxy-3-methyl-1-phenylbutan-2-yl)benzamide (1.00 g, 3.50 mmol), methanesulfonic acid 
(0.70 mL, 10.9 mmol), CaH2 (4.50 g) and dichloromethane as a solvent (64.0 mL). After 
column chromatography (Hx : EtOAc 5 : 1, Rf = 0.50) on silica compound 113 (0.85 g, 91%) 
was isolated as a colorless solid with a de-value of 96%. By means of semipreperative HPLC 
(OD, Hep : IPA  95 : 5, 0.5 mL/min, 220 nm and 254 nm, 7.8 min and 13.8 min) the pure 
diastereomer 113 (0.65 g, 69%) could be isolated as a colorless solid. 
 
C18H19NO (265.35). 
m.p. 53-55 °C. 
20][ Dα  = +54.3° (c = 0.510, CHCl3). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 1.00 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.06 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.96 (ds, J(H,H) = 6.8 Hz, J(H,H) = 6.8 Hz, 1H, 
CH(CH3)2), 3.99 (dd, J(H,H) = 6.5 Hz, J(H,H) = 6.3 Hz, 1H, NCH), 5.29 (d, J(H,H) = 6.6 Hz, 
1H, OCH), 7.32-7.39 (m, 5H, Ph-H), 7.43-7.46 (m, 2H, Ph-H), 7.50-7.53 (m, 1H, Ph-H), 
8.00-8.02 (m, 2H, Ph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 18.8 (CH(CH3)2), 18.9 (CH(CH3)2), 33.6 
(CH(CH3)2), 82.0 (NCH), 84.0 (OCH), 126.3 (2C, Ph-H), 128.6 (Ph-H), 128.8 (2C, Ph-H), 
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128.9 (2C, Ph-H), 129.3 (2C, Ph-H), 131.8 (Ph-H), 142.6 (Ph-C), 162.6 (C=N). (One 
quaternary C-atom is not visible). 
MS (FAB) m/z (rel int %): 266 (M + H, 85), 222 (10), 159 (12), 105 (100), 91 (11), 77 (22). 
IR (KBr) : υ~  [cm-1] = 3060w, 3031w, 2954m, 2888m, 2868m, 1648s, 1578m, 1492m, 
1466m, 1450m, 1330m, 1278m, 1258m, 1175w, 1080m, 1066s,1024m, 974m, 754m, 693s. 
EA % found (calcd): C: 81.17 (81.48), H: 7.15 (7.22), N: 5.16 (5.28). 
 
(4S,5S)-2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5-phenyl-4,5-dihydrooxazole (114) 
 
 
 
 
Product 114 was prepared according to general procedure V (page 149) from (4S,5S)-4-
isopropyl-2,5-diphenyl-4,5-dihydrooxazole (0.50 g, 1.88 mmol), sec-BuLi in cyclohexane 
(1.60 mL, 2.07 mmol), TMEDA (0.31 mL, 2.07 mmol), chlorodiortho-tolylphosphine (0.61 g, 
2.45 mmol) and pentane as a solvent (28.0 mL). After column chromatography (Hx : EtOAc  
15 : 1, Rf = 0.25) on silica compound 114 (568 mg, 63%) was isolated as a slightly yellow 
solid. 
 
C32H32NOP (477.58). 
m.p. 153-156 °C. 
20][ Dα  = -3.8° (c = 0.580, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.81 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 0.83 
(d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 1.69 (ds, J(H,H) = 6.8 Hz, J(H,H) = 6.6 Hz, 1H, 
CH(CH3)2), 2.36 (br s, 6H, Ar-CH3), 3.85 (dd, J(H,H) = 6.8 Hz, J(H,H) = 6.6 Hz, 1H, NCH), 
5.07 (d, J(H,H) = 7.0 Hz, 1H, OCH), 6.74 (br s, 2H, Ar-H), 6.95 (ddd, J(H,H) = 7.6 Hz, 
J(H,H) = 3.6 Hz, J(H,H) = 1.3 Hz, 1H, Ar-H), 7.03-7.08 (m, 2H, Ar-H), 7.18-7.27 (m, 6H, 
Ar-H), 7.27-7.34 (m, 4H, Ar-H), 7.41 (ddd, J(H,H) = 7.5 Hz, J(H,H) = 7.6 Hz, J(H,H) = 1.3 
Hz, 1H, Ar-H), 7.97 (ddd, J(H,H) = 7.7 Hz, J(H,H) = 3.8 Hz, J(H,H) = 1.3 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 18.7 (CH(CH3)2), 19.0 (CH(CH3)2), 21.4 
(d, J(C,P) = 4.8 Hz, oTol-CH3), 21.6 (d, J(C,P) = 4.5 Hz, oTol-CH3), 33.4 (CH(CH3)2), 82.7 
(NCH), 83.9 (OCH), 126.5 (Ar-H), 126.6 (Ar-H), 126.6 (Ar-H), 128.5 (Ar-H), 128.7 (Ar-
H), 128.9 (Ar-H), 129.0 (Ar-H), 129.2 (Ar-H), 130.5 (d, J(C,P) = 4.5 Hz, Ar-H), 130.5(d, 
J(C,P) = 4.5 Hz, Ar-H), 130.5 (Ar-H), 131.0 (Ar-H), 133.2 (d, J(C,P) = 22.5 Hz, Ar-CN), 
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133.5 (Ar-H), 133.9 (Ar-H), 134.9 (Ar-H), 137.3 (d, J(C,P) = 12.8 Hz, oTol-P), 137.4 (d, 
J(C,P) = 12.8 Hz, oTol-P), 138.5 (d, J(C,P) = 25.5 Hz, Ar-P), 142.4 (Ar-CHO), 143.0 (d, 
J(C,P) = 27.9 Hz, oTol-CH3), 143.1 (d, J(C,P) = 27.8 Hz, oTol-CH3), 161.9 (d, J(C,P) = 2.4 
Hz, C=N). 
31P{1H} NMR (162.0 MHz, CD2Cl2, 300 K): δ = -30.0. 
MS (FAB) m/z (rel int %): 478 (M + H, 24), 332 (100), 317 (12), 165 (6), 145 (7), 131 (6), 
105 (9), 91 (18), 57 (8), 55 (9), 43 (9), 41 (9). 
IR (KBr) : υ~  [cm-1] = 3427m, 3048w, 2953m, 2865m, 1647s, 1586w, 1463s, 1379w, 1320s, 
1271w, 1202w, 1165w, 1131w, 1087m, 1036s, 955m, 754s, 701m. 
EA % found (calcd): C: 80.52 (80.48), H: 6.80 (6.75), N: 2.71 (2.93). 
 
 
13.4 [3+2] Cycloadditions 
 
13.4.1 Synthesis of Subatrates for [3+2] Cycloadditions 
 
(E)-4-(2-Formyl-phenoxy)-but-2-enoic acid methyl ester (158) 
 
 
 
 
General Procedure VII: 
Methyl 4-bromobut-2-enoate (1.64 mL, 12.4 mmol) was added to a mixture of 
2-hydroxybenzaldehyde (157) (1.10 mL, 11.5 mmol) and K2CO3 (2.10 g, 15.0 mmol) in DMF 
(15 mL) at rt. The reaction was closely monitored by TLC and worked up when all 
2-hydroxybenzaldehyde (157) was consumed (1 h). Toluene (25 mL) and water (25 mL) were 
added and the aqueous layer was extracted with toluene (3 x 10 mL). The combined extracts 
were washed with brine and dried over MgSO4. After removal of the solvent the residue was 
purified by column chromatography (Hx  :EtOAc  5 : 1, ; Rf = 0.15) to afford 158 as a white 
solid (1.70 g, 66 %). 
 
C12H12O4 (220.07). 
m.p. 62-64 °C. 
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1H NMR (400.1 MHz, CD2Cl2, 295 K): δ = 3.74 (s, 3H, CH3), 4.84 (app dd, J(H,H) = 4.0 Hz, 
J(H,H) = 2.0 Hz, 2H, OCH2), 6.23 (dt, J(H,H) = 15.9 Hz, J(H,H) = 2.0 Hz, 1H, CH2CH=CH), 
6.98 (d, J(H,H) = 8.3 Hz, 1H, Ph-H), 7.06-7.09 (m, 1H, Ph-H), 7.10 (dt, J(H,H) = 15.9 Hz, 
J(H,H) = 2.0 Hz, 1H, CH2CH=CH), 7.55-7.59 (m, 1H, Ph-H), 7.82 (dd, J(H,H) = 7.6 Hz, 
J(H,H) = 1.8 Hz, 1H, Ph-H), 10.53 (s, 1H, COH). 
13C{1H} NMR (100.6 MHz, CDCl3, 295 K): δ = 52.2 (CH3), 67.2 (CH2), 112.9 (Ph-H), 
121.8 (Ph-H), 122.4 (CH2CH=CH), 125.5 (Ph-C), 129.2 (Ph-H), 136.3 (Ph-H), 141.8 
(CH2CH=CH), 160.5 (Ph-CO), 166.6 (COOCH3), 189.6 (COH). 
MS (FAB) m/z (rel. Int. %): 221 (M+ + H, 100), 219 (14), 203 (10), 189 (15), 188 (14), 161 
(48), 99 (54), 98 (22), 71 (16). 
IR (KBr): υ~  [cm-1] = 2953w, 2871w, 1641s, 1719s, 1685s, 1662m, 1597s, 1485m, 1442m, 
1396m, 1307s, 1242s, 1193m, 1169s, 1079m, 1019w, 956m, 846m, 768m, 662w. 
EA % found (calcd): C: 65.37 (65.45), H: 5.42 (5.49). 
 
(E)-4-(1-Formylnaphtalen-2-yloxy)-but-2-enoic acid methyl ester (167) 
 
 
 
 
Product 167 was prepared according to general procedure VII (page 173) from 2-hydroxy-2-
naphthaldehyde (1.98 g, 11.5 mmol), methyl 4-bromobut-2-enoate (1.64 mL, 12.4 mmol), 
K2CO3 (2.10 mL, 15.0 mmol), and DMF as a solvent (15.0 mL). After column 
chromatography (Hx : EtOAc  1 : 1, Rf = 0.62) on silica compound 167 (2.80 g, 90%) was 
isolated as a slightly yellow solid. 
 
C16H14O4 (270.09). 
m.p. 96-99 °C. 
1H NMR (400.1 MHz, CDCl3, 295 K): δ = 3.78 (s, 3H, CH3), 4.98 (app dd, J(H,H) = 4.0 Hz, 
J(H,H) = 2.3 Hz, 2H, OCH2), 6.25 (dt, J(H,H) = 15.9 Hz, J(H,H) = 2.0 Hz, 1H, CH2CH=CH), 
7.15 (dt, J(H,H) = 15.9 Hz, J(H,H) = 4.0 Hz, 1H, CH2CH=CH), 7.22 (d, J(H,H) = 8.3 Hz, 1H, 
Naph-H), 7.43-7.47 (m, 1H, Naph-H), 7.62-7.65 (m, 1H, Naph-H), 7.79 (d, J(H,H) = 8.3 Hz, 
1H, Naph-H), 8.06 (d, J(H,H) = 9.1 Hz, 1H, Naph-H), 9.27 (d, J(H,H) = 8.8 Hz, 1H, Naph-
H), 11.00 (s, 1H, COH). 
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13C{1H} NMR (100.6 MHz, CDCl3, 295 K): δ = 52.2 (CH3), 68.1 (CH2), 113.5 (Naph-H), 
117.5 (Naph-C), 122.6 (CH2CH=CH), 125.3 (Naph-H), 125.5 (Naph-H), 128.6 (Naph-H), 
129.2 (Naph-C), 130.4 (Naph-H), 131.8 (Naph-C), 137.9 (Naph-H), 141.8 (CH2CH=CH), 
162.5 (Ph-CO), 166.5 (COOCH3), 191.8 (COH). 
MS (FAB) m/z (rel. Int. %): 271 (M+ + H, 100), 211 (38), 183 (27), 171 (28), 144 (11), 115 
(16), 100 (11), 71 (18), 57 (13), 43 (11), 41 (17). 
IR (KBr): υ~  [cm-1] = 2956w, 2874w, 1721s, 1665s, 1590m, 1466m, 1438m, 1345m, 1308s, 
1196s, 1159s, 1100m, 1063m, 1022m, 963m, 822m, 759m, 724w. 
 
Imine synthesis 
 
General Procedure VIII: 
Triethylamine (1.8 mmol) and anhydrous MgSO4 (6.4 mmol) were added to a solution of the 
amine hydrochloride (1.6 mmol) in dichloromethane (10 mL). After a stirring period of 1 h 
the aldehyde (1.5 mmol) was added (for the synthesis of the imines 159, 163 and 169 the 
reaction mixture had to be cooled to 0 °C before the aldehyde was added). The mixture was 
stirred for 24 h (in case of the imines 159, 163 and 169, 60 h at 0 °C) before the MgSO4 was 
removed by filtration. The organic layer was washed with H2O (3 x 5 mL), saturated 
NaHCO3-solution (3 x 5 mL) and brine (5 mL) and dried over MgSO4. The solvent was 
removed under reduced pressure and the residue was dried at 0.8 mbar/rt. The resulting crude 
product, which contained 1-10 mol% of aldehyde (1H NMR), was isolated in quantitative 
yield and used without further purification. 
 
(E)-methyl 2-(naphthalene-2-ylmethyleneamino)acetate (37) 
 
 
 
 
Compound 37 was prepared according to general procedure VIII (page 175) from 
2-naphthaldehyde (5.00 g, 32.0 mmol), glycine methylester hydrochloride (4.40 g, 
35.0 mmol), triethylamine (5.30 mL, 38.4 mmol), anhydrous MgSO4 (15.4 g, 128 mmol) and 
dichloromethane as a solvent (40.0 mL). The crude product was recrystallized from 
hexane/dichloromethane to give a slightly yellow solid. 
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m.p. 88-90 °C. 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 3.77 (s, 3H, CH3), 4.45 (d, J(H,H) = 1.3 Hz, 2H, 
CH2), 7.52-7.58 (m, 2H, Naph-H), 7.87-7.94 (m, 3H, Naph-H), 8.01 (dd, J(H,H) = 8.6 Hz, 
J(H,H) = 1.8 Hz, 1H, Naph-H), 8.10 (s, 1H, Naph-H), 8.44 (s, 1H, CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 52.5 (CH3), 62.4 (CH2), 124.1 (Naph-H), 
127.1 (Naph-H), 128.0 (Naph-H), 128.4 (Naph-H), 129.1 (Naph-H), 129.2 (Naph-H), 131.1 
(Naph-H), 133.6 (Naph-C), 134.0 (Naph-C), 135.5 (Naph-C), 165.6 (CH=N), 171.1 (CO). 
MS (FAB) m/z (rel. Int. %): 228 (100, [M+ + H]), 168 (20), 141 (16). 
IR (KBr): υ~  [cm-1] = 3056w, 3002w, 2952w, 2878w, 1721s, 1642m, 1424m, 1267s. 
 
(E)-methyl 2-(4-fluorobenzylideneamino)acetate (128) 
 
 
 
 
Compound 128 was prepared according to general procedure VIII (page 175) from 
4-fluorobenzaldehyde (2.00 mL, 18.9 mmol), glycine methylester hydrochloride (2.60 g, 
20.8 mmol), triethylamine (3.10 mL, 22.7 mmol), anhydrous MgSO4 (9.80 g, 81.4 mmol) and 
dichloromethane as a solvent (28.0 mL). The colorless oil was used without further 
purification. 
 
C10H10FNO2 (195.19). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 3.74 (s, 3H, CH3), 4.37 (d, J(H,H) = 1.2 Hz, 2H, 
CH2), 7.10-7.16 (m, 2H, Ph-H), 7.75-7.81 (m, 2H, Ph-H), 8.25 (s, 1H, CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 52.5 (CH3), 62.2 (CH2), 116.2 (2C, d, 
J(C,F) = 21.9 Hz, Ph-H), 130.9 (2C, d, J(C,F) = 8.8 Hz, Ph-H), 132.7 (d, J(C,F) = 3.1 Hz, 
Ph-C), 164.2 (CH=N), 165.1 (d, J(C,F) = 250.7 Hz, Ph-F), 171.0 (C=O). 
19F{1H} NMR (376.5 MHz, CD2Cl2, 300 K): δ = -109.8 (m). 
MS (FAB) m/z (rel int %): 196 (M +1, 100), 136 (32), 109 (21), 89 (10), 77 (12), 57 (11), 39 
(17). 
IR (NaCl) : υ~  [cm-1] = 3003w, 2954m, 2879m, 1746s, 1648s, 1600s, 1508s, 1435m, 1388m, 
1346m, 1271s, 1228s, 1063m, 1016m, 965w, 838s. 
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(E)-methyl 2-(4-bromobenzylideneamino)acetate (129) 
 
 
 
 
Compound 129 was prepared according to general procedure VIII (page 175) from 
4-bromobenzaldehyde (2.00 g, 11.0 mmol), glycine methylester hydrochloride (1.50 g, 
12.1 mmol), triethylamine (1.80 mL, 12.7 mmol), anhydrous MgSO4 (5.30 g, 44.0 mmol) and 
dichloromethane as a solvent (15.0 mL). The colorless solid was used without further 
purification. 
 
C10H10BrNO2 (256.10). 
m.p. 47-49 °C. 
1H NMR (CDCl3, 400 MHz, 300 K): δ = 3.78 (s, 3H, CH3), 4.40 (d, J(H,H) = 1.3, 2H, CH2), 
7.55 (d, J(H,H) = 8.4, 2H, Ph-H), 7.65 (d, J(H,H) = 8.6, 2H, Ph-H), 8.24 (s, 1H, CH=N). 
13C{1H} NMR (CDCl3, 80 MHz, 300 K): δ = 52.6 (CH3), 62.3 (CH2), 126.2 (Ph-Br), 130.3 
(2C, Ph-H), 132.3 (2C, Ph-H), 134.9 (Ph-C), 164.6 (CH=N), 170.7 (C=O). 
MS (FAB): m/z (rel int %): 256 (M+, 100), 196 (21), 171 (11), 89 (12), 77 (14), 55 (19), 41 
(17), 39 (14). 
IR (KBr) : υ~  [cm-1] = 3477w, 3056w, 2997w, 2948w, 2884w, 1752s, 1646m, 1588w, 1484w, 
1434w, 1406w, 1350w, 1197s, 1067m, 1009m, 960w, 848w, 820m, 694w. 
 
(E)-methyl 2-(4-methoxybenzylideneamino)acetate (130) 
 
 
 
 
Compound 130 was prepared according to general procedure VIII (page 175) from 
anisaldehyde (2.30 mL, 18.9 mmol), glycine methylester hydrochlorid (2.60 g, 20.8 mmol), 
triethylamine (3.10 mL, 22.7 mmol), anhydrous MgSO4 (9.80 g, 81.4 mmol) and 
dichloromethane as a solvent (28.0 mL). Hexane was added to the crude product whereupon 
the product precipitated as a colorless solid which was washed several times with hexane. 
 
C11H13NO3 (207.23). 
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m.p. 68-70 °C. 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 3.74 (s, 3H, CH3), 3.84 (s, 3H, CH3), 4.34 (d, 
J(H,H) = 1.3 Hz, 2H, CH2), 6.93-6.96 (m, 2H, Ph-H), 7.69-7.72 (m, 2H, Ph-H), 8.19 (s, 1H, 
CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 52.4 (CH3), 55.9 (CH3), 62.3 (CH2), 114.5 
(2C, Ph-H), 129.2 (Ph-C), 130.5 (2C, Ph-H), 162.7 (Ph-OMe), 164.8 (CH=N), 171.3 (C=O). 
MS (EI, 70 eV): m/z (rel int %): 207 (M +1, 19), 148 (93), 134 (19), 121 (100), 91 (11). 
IR (KBr) : υ~  [cm-1] = 3474w, 3012w, 2962w, 2875w, 1745s, 1646s, 1600s, 1506m, 1461m, 
1418w, 1353w, 1305m, 1255s, 1197s, 1156s, 1070m, 1021m, 960w, 832m. 
 
(E)-methyl 2-(benzo[d][1,3]dioxol-5-ylmethyleneamino)acetate (131) 
 
 
 
 
Compound 131 was prepared according to general procedure VIII (page 175) from 
piperonal (2.00 g, 13.3 mmol), glycine methylester hydrochloride (1.80 g, 14.7 mmol), 
triethylamine (2.10 mL, 15.3 mmol), anhydrous MgSO4 (6.90 g, 57.2 mmol) and 
dichloromethane as a solvent (20.0 mL). The crude product was recrystallized from 
hexane/dichloromethane to give colorless needles. 
 
C11H11NO4 (221.21). 
m.p. 84-85 °C. 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 3.73 (s, 3H, CH3), 4.33 (d, J(H,H) = 1.3 Hz, 2H, 
CH2), 6.02 (s, 2H, OCH2O), 6.85 (d, J(H,H) = 7.8 Hz, 1H, Ph-H), 7.15 (dd, J(H,H) = 7.8, 
J(H,H) = 1.7, 1H, Ph-H), 7.36 (d, J(H,H) = 1.5 Hz, 1H, Ph-H), 8.15 (s, 1H, CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 52.4 (CH3), 62.1 (NCH2), 102.3 (OCH2O), 
106.9 (Ph-H), 108.5 (Ph-H), 125.5 (Ph-H), 131.2 (Ph-C), 149.0 (Ph-C), 150.9 (Ph-C), 164.7 
(CH=N), 171.2 (C=O). 
MS (FAB) m/z (rel int %): 222 (M+1, 100), 162 (M-CO2CH3, 15), 135 (4), 104 (1). 
IR (KBr) : υ~  [cm-1] = 3056w, 3003w, 2959w, 2919w, 2867m, 1750s, 1693w, 1645s, 1603s, 
1501s, 1450s, 1417m, 1395m, 1364w, 1344w, 1263s, 1196s, 1178s, 1034s, 927s, 821m, 
796m, 704m. 
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2-(Benzylidene-amino)-3-methyl-butyric acid methyl ester (133) 
 
 
 
 
Compound 133 was prepared according to general procedure VIII (page 175) from 
benzaldehyde (1.2 mL, 11.4 mmol), L-valine methyl ester hydrochloride (2.00 g, 12.0 mmol), 
triethylamine (1.70 mL, 12.6 mmol), anhydrous MgSO4 (5.50 g, 45.7 mmol) and 
dichloromethane as a solvent (8.00 mL). The crude product was purified by bulb-to-bulb 
distillation (110 °C, 10-1 bar) to give a colorless oil. 
 
C13H17NO2 (219.29). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 0.94 (d, J(H,H) = 6.8 Hz, 3H, CH3), 0.97 (d, 
J(H,H) = 6.8 Hz, 3H, CH3), 2.38 (ds, J(H,H) = 7.0 Hz, J(H,H) = 6.9 Hz, 1H, CH(CH3)2), 3.67 
(d, J(H,H) = 7.4 Hz, 1H, NCH), 3.74 (s, 3H, OCH3), 8.25 (s, 1H, CH=N), 7.45-7.39 (m, 3H, 
Ph-H), 7.80-7.78 (m, 2H, Ph-H,). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 19.1 (CH(CH3)2), 19.9 (CH(CH3)2), 32.1 
(CH(CH3)2), 52.3 (OCH3), 80.8 (NCH), 128.9 (2C, Ph-H), 129.0 (2C, Ph-H), 131.4 (Ph-H), 
136.1 (Ph-C), 163.7 (CH=N), 172.8 (C=O). 
 
(E)-tert-butyl 2-(naphthalen-2-ylmethyleneamino)acetate (134) 
 
 
 
 
Compound 134 was prepared according to general procedure VIII (page 175) from 
2-naphthaldehyde (2.00 g, 12.6 mmol), glycine tert-butylester hydrochlorid (2.40 g, 
14.3 mmol), triethylamine (2.30 mL, 16.3 mmol), anhydrous MgSO4 (6.50 g, 54.0 mmol) and 
dichloromethane as a solvent (18.0 mL). The crude product was recrystallized from hexane to 
give a colorless solid. 
 
C17H19NO2 (269.34). 
m.p. 72-74 °C. 
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1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 1.50 (s, 9H, C(CH3)3), 4.34 (d, J(H,H) = 1.5 Hz, 
2H, CH2), 7.51-7.58 (m, 2H, Naph-H), 7.87-7.94 (m, 3H, Naph-H), 8.02 (dd, J(H,H) = 8.6, 
J(H,H) = 1.5, 1H, Naph-H), 8.09 (s, 1H, Naph-H), 8.41 (s, 1H, CHN). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 27.6 (3C, C(CH3)3), 62.5 (CH2), 80.9 
(C(CH3)3), 123.4 (Naph-H), 126.3 (Naph-H), 127.1 (Naph-H), 127.6 (Naph-H), 128.2 
(Naph-H), 128.4 (Naph-H), 130.1 (Naph-H), 132.8 (Naph-C), 133.4 (Naph-C), 134.6 
(Naph-C), 164.5 (CH=N), 169.0 (C=O). 
MS (FAB) m/z (rel int %): 270 (M + 1, 74), 214 (100), 212 (19), 168 (40), 141 (29), 77 (11), 
57 (51), 51 (12), 41 (18), 39 (16). 
IR (KBr) : υ~  [cm-1] = 3062w, 2978m, 2933m, 2878m, 2832m, 1734s, 1641s, 1458m, 1437m, 
1370s, 1347s, 1236s, 1160s, 1064m, 1003m, 972m, 895m, 865m, 828s, 790w, 754s. 
 
(E)-N-(naphthalen-2-ylmethylene)(pyridine-2-yl)methanamine (135) 
 
 
 
 
Compound 135 was prepared according to general procedure VIII (page 175) from 
2-naphthaldehyde (1.00 g, 6.40 mmol), 2-picolylamine (750 µL, 7.30 mmol), anhydrous 
MgSO4 (3.30 g, 27.5 mmol) and dichloromethane as a solvent (9.00 mL). The crude product 
was recrystallized from hexane/dichloromethane to give a colorless solid. 
 
C17H14N2 (246.31). 
m.p. 75-77 °C. 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 4.97 (d, J(H,H) = 1.0 Hz, 2H, CH2), 7.18-7.21 
(m, 1H, Ar-H), 7.47 (d, J(H,H) = 7.6 Hz, 1H, Ar-H), 7.52-7.59 (m, 2H, Ar-H), 7.71 (td, 
J(H,H) = 7.6, J(H,H) = 1.8, 1H, Ar-H), 7.89-7.96 (m, 3H, Ar-H), 8.06-8.08 (m, 1H, Ar-H), 
8.12 (s, 1H, Ar-H), 8.56-8.58 (m, 1H, Ar-H), 8.64 (s, 1H, CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 67.4 (CH2), 122.5 (Ar-H), 122.8 (Ar-H), 
124.3 (Ar-H), 124.3 (Ar-H), 127.1 (Ar-H), 127.8 (Ar-H), 128.4 (Ar-H), 129.0 (Ar-H), 130.8 
(Ar-H), 133.7 (Ar-C), 134.6 (Ar-C), 135.3 (Ar-C), 137.0 (Ar-H), 149.8 (Ar-H), 160.1 (Ar-
C), 163.3 (CH=N). 
MS (FAB) m/z (rel int %): 247 (M +1, 100), 141 (7), 93 (69), 77 (5), 65 (9), 51 (6), 39 (7). 
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IR (KBr) : υ~  [cm-1] = 3448w, 3047w, 3006w, 2886w, 2867m, 1641s, 1584s, 1566m, 1474m, 
1434s, 1417s, 1349m, 1324m, 1324s, 1121m, 1048s, 1002m, 901w, 864s, 828s, 747s. 
 
(E)-N-(benzo[d][1,3]dioxol-5-ylmethylene)(phenyl)methanamine (136) 
 
 
 
 
Compound 136 was prepared according to general procedure VIII (page 175) from 
piperonal (2.0 g, 13.3 mmol), benzylamine (1.7 mL, 15.2 mmol), anhydrous MgSO4 (6.9 g, 
57.2 mmol) and dichloromethane as a solvent (18 mL). The crude product was recrystallized 
from hexane/dichloromethane to give colorless needles. 
 
C15H13NO2 (239.27). 
m.p. 74-75 °C. 
1H NMR (400.1 MHz, CD2Cl2, 295 K): δ = 4.75 (d, J(H,H) = 1.0 Hz, 2H, CH2), 6.00 (s, 2H, 
OCH2O), 6.85 (d, J(H,H) = 7.8 Hz, 1H, Ar-H), 7.16 (dd, J(H,H) = 8.1 Hz, J(H,H) = 1.5 Hz, 
1H, Ar-H), 7.29-7.23 (m, 1H, Ar-H), 7.32-7.36 (m, 4H, Ar-H), 7.39 (d, J(H,H) = 1.5 Hz, 1H, 
Ar-H), 8.28 (s, 1H, CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 295 K): δ = 65.3 (CH2), 102.2 (OCH2O), 106.9 (Ar-H), 
108.5 (Ar-H), 125.0 (Ar-H), 127.4 (Ar-H), 128.5 (2C, Ar-H), 128.9 (2C, Ar-H), 131.8 (Ar-
C), 140.4 (Ar-C), 148.9 (Ar-C), 150.5 (Ar-C), 161.3 (CH=N). 
MS (FAB) m/z (rel int %): 240 (M+1, 100), 162 (3), 148 (3), 91 (80), 77 (5), 65 (3), 51 (4). 
IR (KBr) : υ~  [cm-1] = 3061w, 3027m, 2911w, 2859m, 2830m, 1641s, 1602m, 1501s, 1484s, 
1443s, 1385w, 1331w, 1257s, 1206w, 1121w, 1097s, 1045s, 1028s, 924s, 870m, 825m, 792w, 
747m, 695s. 
 
Methyl N-(diphenylmethylene)glycinate96 (132) 
 
 
 
 
Benzophenone (926 µL, 5.52 mmol) was added to a solution of glycine methyl ester 
hydrochloride (693 mg, 5.52 mmol) in CH2Cl2 (20.0 mL) and the resulting mixture was 
Experimental Part 
 182
N CO2Me
O CO2Me
stirred for 24 h. The reaction mixture was filtered and the solvent was removed under reduced 
pressure. The residue was diluted in diethyl ether (20 mL), washed with water (20 mL) and 
dried over MgSO4. The solvent was removed under reduced pressure and the crude product 
was recrystallized from diethyl ether/hexane (1:8) to afford colorless needles. 
 
C16H15NO2 (253.30). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 3.75 (s, 3H, CH3), 4.22 (s, 2H, CH2), 7.19-7.17 
(m, 2H, Ph-H), 7.36-7.32 (m, 2H, Ph-H), 7.43-7.38 (m, 1H, Ph-H), 7.49-7.44 (m, 3H, Ph-H), 
7.68-7.65 (m, 2H, Ph-H). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 52.4 (CH3), 56.0 (CH2), 128.1 (2C, Ph-H), 
128.5 (2C, Ph-H), 129.1 (2C, Ph-H), 129.2 (2C, Ph-H), 129.3 (Ph-H), 130.9 (Ph-C), 136.3 
(Ph-C), 139.6 (Ph-C), 171.5 (C=N), 172.4 (C=O). 
 
(E)-4-[2-(Methoxycarbonylmethylimino-methyl)-phenoxy]-but-2-enoic acid methyl ester 
(159) 
 
 
 
 
Compound 159 was prepared according to general procedure VIII (page 175) from 4-(2-
formyl-phenoxy)-but-2-enoic acid methyl ester (500 mg, 2.30 mmol), glycine methylester 
hydrochloride (314 mg, 2.50 mmol), triethylamine (314 µL, 2.70 mmol), anhydrous MgSO4 
(1.20 g, 9.80 mmol) and dichloromethane as a solvent (10.0 mL). The crude product appeared 
as a colorless oil and was used without further purification. 
 
C15H17NO5 (291.30). 
Rf = 0.65 (hexane : EtOAc  1:1). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 3.75 (s, 3H, CH3), 3.76 (s, 3H, CH3), 4.42 (d, 
J(H,H) = 1.2 Hz, 2H, NCH2), 4.79 (dd, J(H,H) = 4.3 Hz, J(H,H) = 2.0 Hz, 2H, OCH2), 6.19 
(td, J(H,H) = 15.7 Hz, J(H,H) = 2.0 Hz, 1H, CH2CH=CH), 6.92 (d, J(H,H) = 8.3 Hz, 1H, Ph-
H), 7.04 (t, J(H,H) = 7.6 Hz, 1H, Ph-H), 7.11 (td, J(H,H) = 15.8 Hz, J(H,H) = 4.3 Hz, 1H, 
CH2CH=CH), 7.71-7.45 (m, 1H, Ph-H), 8.00 (dd, J(H,H) = 7.8 Hz, J(H,H) = 1.8 Hz, 1H, Ph-
H), 8.77 (s, 1H, CH=N). 
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13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 52.1 (CH3), 52.4 (CH3), 62.8 (NCH2), 67.5 
(OCH2), 112.8 (Ph-H), 122.0 (Ph-H), 122.3 (CH=CHCO2Me), 125.0 (Ph-C), 128.1 (Ph-H), 
133.0 (Ph-H), 142.7 (CH=CHCO2Me), 158.0 (Ph-C), 161.0 (CH=N), 166.7 (C=O), 171.2 
(C=O). 
MS (FAB) m/z (rel. Int. %): 292 (100, [M+ + H]), 232 (17), 193 (13), 133 (16), 99 (17), 77 
(14), 69 (11), 57 (20). 
IR (NaCl): υ~  [cm-1] = 3485w, 3415w, 3004w, 2953w, 2867w, 1750s, 1720s, 1636m, 1603m, 
1493m, 1450m, 1309s, 1249s, 1197s, 1173s, 1116m, 1070m, 1021m, 754m. 
 
(E)-4-[2-(tert-Butoxycarbonylmethylimino-methyl)-phenoxy]-but-2-enoic acid methyl 
ester (163) 
 
 
 
 
Compound 163 was prepared according to general procedure VIII (page 175) from 4-(2-
formyl-phenoxy)-but-2-enoic acid methyl ester (400 mg, 1.48 mmol), glycine tert-butylester 
hydrochloride (273 mg, 1.63 mmol), triethylamine (248 µL, 1.78 mmol), anhydrous MgSO4 
(766 mg, 6.36 mmol) and dichloromethane as a solvent (10.0 mL). The crude product 
appeared as colorless oil and was used without further purification. 
 
C18H23NO5 (333.38). 
Rf = 0.41 (hexane : EtOAc  2:1). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 1.48 (s, 9H, C(CH3)3), 3.74 (s, 3H, OCH3), 4.29 
(s, 2H, NCH2), 4.78 (dd, J(H,H) = 4.0 Hz, J(H,H) = 2.0 Hz, 2H, OCH2), 6.18 (td, J(H,H) = 
15.9 Hz, J(H,H) = 2.0 Hz, 1H, CH2CH=CH), 6.91 (d, J(H,H) = 8.3 Hz, 1H, Ph-H), 7.02 (t, 
J(H,H) = 7.6 Hz, 1H, Ph-H), 7.10 (td, J(H,H) = 15.9 Hz, J(H,H) = 4.0 Hz, 1H, CH2CH=CH), 
7.38-7.43 (m, 1H, Ph-H), 7.99 (dd, J(H,H) = 7.8 Hz, J(H,H) = 1.5 Hz, 1H, Ph-H), 8.72 (s, 1H, 
CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 28.4 (3C, C(CH3)3), 52.1 (OCH3), 63.6 
(NCH2), 67.5 (OCH2), 81.5 (C(CH3)3), 112.8 (Ph-H), 121.9 (Ph-H), 122.3 (CH2CH=CH), 
125.3 (Ph-C), 128.1 (Ph-H), 132.8 (Ph-H), 142.8 (CH2CH=CH), 158.0 (PhO), 160.7 
(CH=N), 166.7 (C=O), 170.0 (C=O). 
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MS (FAB) m/z (rel. Int. %): 334 (85, [M+ + H]), 278 (75), 232 (16), 218 (17), 180 (18), 133 
(19), 99 (27), 77 (11), 57 (100). 
IR (NaCl): υ~  [cm-1] = 3415w, 3050w, 2978m, 2865w, 1726s, 1641m, 1600m, 1485m, 
1448m, 1372m, 1284s, 1245s, 1158s, 1020m, 757m. 
 
(E)-4-[2-((1-Methoxycarbonyl-ethylimino)-methyl)-phenoxy]-but-2-enoic acid methyl 
ester (164) 
 
 
 
 
Compound 164 was prepared according to general procedure VIII (page 175) from 4-(2-
formyl-phenoxy)-but-2-enoic acid methyl ester (500 mg, 2.30 mmol), L-alanine methyl ester 
hydrochloride (350 mg, 2.50 mmol), triethylamine (379 µL, 2.70 mmol), anhydrous MgSO4 
(1.20 g, 9.80 mmol) and dichloromethane as a solvent (20.0 mL). The crude product appeared 
as colorless oil and was used without further purification. 
 
C16H19NO5 (305.33). 
Rf = 0.65 (hexane : EtOAc  1:1). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 1.48 (d, J(H,H) = 6.8 Hz, 3H, CHCH3), 3.72 (s, 
3H, OCH3), 3.74 (s, 3H, OCH3), 4.17 (q, J(H,H) = 6.8 Hz, 1H, NCH), 4.78 (dd, J(H,H) = 4.0 
Hz, J(H,H) = 2.0 Hz, 2H, OCH2), 6.18 (td, J(H,H) = 15.9 Hz, J(H,H) = 2.0 Hz, 1H, 
CH2CH=CH), 6.90 (d, J(H,H) = 8.4 Hz, 1H, Ph-H), 7.02 (t, J(H,H) = 7.6 Hz, 1H, Ph-H), 7.10 
(td, J(H,H) = 15.9 Hz, J(H,H) = 4.0 Hz, 1H, CH2CH=CH), 7.38-7.43 (m, 1H, Ph-H), 7.97 
(dd, J(H,H) = 7.8 Hz, J(H,H) = 1.8 Hz, 1H, Ph-H), 8.77 (s, 1H, CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 19.9 (CHCH3), 52.1 (OCH3), 52.5 (OCH3), 
67.5 (CHCH3), 68.8 (OCH2), 112.8 (Ph-H), 121.9 (Ph-H), 121.9 (CH2CH=CH), 125.2 (Ph-
C), 128.2 (Ph-H), 132.9 (Ph-H), 142.8 (CH2CH=CH), 158.0 (PhO), 158.7 (CH=N), 166.7 
(C=O), 173.6 (C=O). 
MS (FAB) m/z (rel. Int. %): 306 (100, [M+ + H]), 246 (21), 207 (12), 148 (18), 132 (14), 99 
(14), 77 (18). 
IR (NaCl): υ~  [cm-1] = 3415w, 3050w, 2978m, 2865w, 1726s, 1641m, 1600m, 1485m, 
1448m, 1372m, 1284s, 1245s, 1158s, 1020m, 757m. 
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(E)-4-[2-((Pyridin-2-ylmethylimino)-methyl)-phenoxy]-but-2-enoic acid methyl ester 
(155) 
 
 
 
 
Compound 155 was prepared according to general procedure VIII (page 175) from 4-(2-
formyl-phenoxy)-but-2-enoic acid methyl ester (650 mg, 3.00 mmol), 2-picolylamin (332 µL, 
3.30 mmol), anhydrous MgSO4 (1.50 g, 12.7 mmol) and dichloromethane as a solvent 
(10.0 mL). The crude product appeared as slightly yellow oil and was used without further 
purification. 
 
C18H18N2O3 (310.35). 
Rf = 0.72 (Hx : EtOAc  1:1). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 3.74 (s, 3H, CH3), 4.78 (s, 2H, NCH2), 4.93 (s, 
2H, OCH2), 6.20 (dt, J(H,H) = 15.9 Hz, J(H,H) = 2.0 Hz, 1H, CH2CH=CH), 6.92 (d, J(H,H) 
= 8.3 Hz, 1H, Ar-H), 7.03 (t, J(H,H) = 7.5 Hz, 1H, Ar-H), 7.11 (dt, J(H,H) = 15.8 Hz, J(H,H) 
= 4.1 Hz, 1H, CH2CH=CH), 7.18 (dd, J(H,H) = 7.0 Hz, J(H,H) = 5.2 Hz, 1H, Ar-H), 7.40 
(dd, J(H,H) = 7.3 Hz, J(H,H) = 1.8 Hz, 2H, Ar-H), 7.68 (td, J(H,H) = 7.7 Hz, J(H,H) = 1.8 
Hz, 1H, Ar-H), 8.03 (d, J(H,H) = 4.6 Hz, 1H, Ar-H), 8.55 (d, J(H,H) = 4.6 Hz, 1H, Ar-H), 
8.93 (s, 1H, CH=N). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 52.1 (CH3), 67.5 (CH2), 67.7 (CH2), 112.8 
(Ar-H), 121.9 (Ar-H), 122.2 (CH2CH=CH), 122.4 (Ar-H), 122.7 (Ar-H), 125.5 (Ar-C), 
128.0 (Ar-H), 132.5 (Ar-H), 136.9 (Ar-H), 142.8 (CH2CH=CH), 149.7 (Ar-H), 157.9 (Ar-
C), 158.7 (CH=N), 160.2 (Ar-C), 166.7 (C=O). 
MS (FAB) m/z (rel. Int. %): 311 (100, [M+ + H]), 93 (41), 92 (11). 
IR (NaCl): υ~  [cm-1] = 3388m, 3008m, 2949m, 2893m, 1722s, 1636s, 1599s, 1487s, 1435s, 
1375s, 1307s, 1246s, 1173s, 1113s, 1045s, 1020s, 966m, 838w, 756s. 
 
(E)-Methyl 4-(1-((E)-(2-methoxy-2-oxoethylimino)methyl)naphthalene-2-yloxy)but-2-en-
oate (169) 
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Compound 169 was prepared according to general procedure VIII (page 175) from (E)-
methyl 4-(1-formylnaphthalen-2-yloxy)but-2-enoate (250 mg, 0.92 mmol), glycine 
methylester hydrochloride (126 mg, 1.00 mmol), triethylamine (154 µL, 1.11 mmol), 4Å 
molecular sieves (1.20 g) and dichloromethane as a solvent (10.0 mL). The crude product 
appeared as slightly yellow oil and was used without further purification. 
 
C19H19NO5 (341.36). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 3.75 (s, 3H, CH3), 3.81 (s, 3H, CH3), 4.55 (d, 
J(H,H) = 1.2 Hz, 2H, NCH2), 4.92 (dd, J(H,H) = 4.3 Hz, J(H,H) = 2.0 Hz, 2H, OCH2), 6.23 
(td, J(H,H) = 15.9 Hz, J(H,H) = 2.0 Hz, 1H, CH2CH=CH), 7.11-8.11 (m, 7H, Naph-H & 
CH2CH=CH), 8.77 (s, 1H, CH=N); 
 
Analytical datas of the dimer of 4-[2-(Methoxycarbonylmethylimino-methyl)-phenoxy]-
but-2-enoic acid methyl ester (160) 
 
 
 
 
 
 
C30H34N2O10 (582.22). 
Rf = 0.15 (hexane : EtOAc  5:1). 
m.p. 321-323 °C. 
1H NMR (500 MHz, CD2Cl2, 295 K): δ = 3.01 (m, 2H, CH2CH), 3.14 (s, 6H, OCH3), 3.58 
(dd, J(H,H) = 6.6 Hz, J(H,H) = 3.5 Hz, 2H, NHCH(Ph)CH), 3.83 (s, 6H, OCH3), 3.91 (d, 
J(H,H) = 7.3 Hz, 2H, NHCHCO2Me), 4.12 (dd, J(H,H) = 9.3 Hz, J(H,H) = 3.5 Hz, 2H, CH2), 
4.47 (dd, J(H,H) = 9.5 Hz, J(H,H) = 1.0 Hz, 2H, CH2), 5.06 (bd, J(H,H) = 6.4 Hz, 2H, 
NHCHPh), 6.94 (dd, J(H,H) = 8.2 Hz, J(H,H) = 0.9 Hz, 2H, Ph-H), 6.97 (td, J(H,H) = 7.5 
Hz, J(H,H) = 0.8 Hz, 2H, Ph-H), 7.18 (dd, J(H,H) = 7.6 Hz, J(H,H) = 1.4 Hz, 2H, Ph-H), 
7.28 (ddd, J(H,H) = 8.0 Hz, J(H,H) = 7.4 Hz, J(H,H) = 1.6 Hz, 2H, Ph-H).(NH not visible) 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 48.1 (2C, CH2CH), 51.7 (2C, OCH3), 52.7 
(2C, OCH3), 52.8 (2C, NHCH(Ph)CH), 61.3 (2C, NHCHPh), 63.7 (2C, NHCHCO2Me), 68.5 
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(2C, CH2), 111.0 (2C, Ph-H), 121.2 (2C, Ph-H), 125.7 (2C, Ph-H), 126.3 (2C, Ph-H), 129.1 
(2C, Ph-H), 156.1 (2C, Ph-H), 173.5 (2C, CO), 174.3 (2C, CO). 
MS (FAB) m/z (rel. Int. %): 583 (100, [M+ + H]), 581 (10), 198 (12), 172 (12),133 (10), 132 
(14), 99 (18), 77 (12), 59 (15). 
IR (KBr): υ~  [cm-1] = 3324w, 2952m, 2883w, 1735s, 1604m, 1499s, 1456s, 1436s, 1380m, 
1285s, 1246s, 1170s, 1124s, 1066m, 1015m, 958m, 912m, 753s, 678w. 
EA % found (calcd): C: 61.60 (61.85), H: 5.87 (5.88), N: 4.81 (4.81). 
 
6,6-Dimethoxy-hexanal (172) 
 
 
 
 
Ozone was bubbled through a solution of cyclohexene (7.60 mL, 75.0 mmol) in 
dichloromethane (250 mL) and methanol (50.0 mL) at -78 °C till the solution turned blue. 
Afterwards nitrogen was passed through the solution until the blue color was discharged. The 
cold bath was removed and p-toluenesulfonic acid (1.21 g, 6.4 mmol) was added. The 
solution was allowed to warm to rt as it stirred under an atmosphere of nitrogen for 90 min. 
Thereupon anhydrous sodium bicarbonate (2.15 g, 25.6 mmol) was added and the mixture 
was stirred for 15 min, before dimethyl sulfide (12.0 mL, 163 mmol) was added. After being 
stirred for 12 h, the heterogenous mixture was concentrated to approximately 50 mL under 
reduced pressure. Dichloromethane (100 mL) was added and the mixture was washed with 
water (75 mL). The aqueous layer was extracted with dichloromethane (2 x 100 mL), and the 
combined organic layers were washed with water (100 mL). After extracting the aqueous 
layer with dichloromethane (100 mL), the organic layers were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was 
purified by column chromatography (EtOAc : Hx 1 : 1, Rf = 0.38) to afford 172 (8.00 g, 66%) 
as a colorless oil. 
 
C8H16O3 (160.21). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 1.34-1.42 (m, 2H, CH2), 1.59-1.69 (m, 4H, CH2), 
2.21 (dt, J(H,H) = 7.3 Hz, J(H,H) = 1.5 Hz, 2H, CH2), 3.31 (s, 6H, OCH3), 4.35 (t, J(H,H)= 
5.8 Hz, 1H, CH), 9.76 (t, J(H,H) = 1.5 Hz, 1H, CHO). 
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13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 22.0 (CH2), 24.3 (CH2), 32.4 (CH2), 44.0 
(CH2), 52.9 (2C, OCH3), 104.4 (CH), 202.6 (CO). 
IR (NaCl): υ~  [cm-1] = 3428w, 2945s, 2830s, 2721s, 1725s, 1458s, 1387s, 1191s, 1166s, 
1128s, 1057s, 969s, 915m, 811w, 738w. 
 
(E)-8,8-Dimethoxy-oct-2-enoic acid methyl ester (173) 
 
 
 
 
6,6-dimethoxy-hexanal (1.66 g, 10.4 mmol) was added dropwise to a solution of 
(triphenylphosphoranyliden)-2-propanon (3.10 g, 9.40 mmol) in dichloromethane (35.0 mL). 
The resulting solution was stirred overnight before the solvent was removed under reduced 
pressure. The residue was diluted with diethyl ether and filtered to remove the precipitated 
triphenylphosphine oxide. The crude product was purified by column chromatography (Hx : 
EtOAc  5 : 1, Rf = 0.38) to give 173 as a colorless oil (1.50 g, 67%).  
 
C11H20O4 (216.27). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 1.34-1.40 (m, 2H, CH2), 1.44-1.52 (m, 2H, CH2), 
1.57-1.62 (m, 2H, CH2), 2.21 (qd, J(H,H) = 7.3 Hz, J(H,H) = 1.5 Hz, 2H, CH2), 3.31 (s, 6H, 
OCH3), 3.72 (s, 3H, CO2CH3), 4.34 (t, J(H,H)= 5.8 Hz, 1H, CH), 5.82 (td, J(H,H) = 15.6 Hz, 
J(H,H) = 1.5 Hz, 1H, CH2CH=CH), 6.95 (td, J(H,H) = 15.6 Hz, J(H,H) = 7.1 Hz, 1H, 
CH2CH=CH). 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K): δ = 24.3 (CH2), 28.0 (CH2), 32.3 (CH2), 32.4 
(CH2), 51.5 (CO2CH3), 52.8 (2C, OCH3), 104.5 (CH), 121.2 (CH2CH=CH), 149.5 
(CH2CH=CH), 167.3 (CO). 
IR (NaCl): υ~  [cm-1] = 3432w, 2945s, 2830s, 2676w, 1725s, 1656s, 1440s, 1272s, 1125s, 
957s, 844w, 716w. 
 
(E)-8-Oxo-oct-2-enoic acid methyl ester (174) 
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A 2M HCl-solution (7.00 mL) was added to a solution of (E)-8,8-dimethoxy-oct-2-enoic acid 
methyl ester (1.00 g, 4.60 mmol) in THF (10.0 mL). After stirring for 8 hours at rt, the 
reaction mixture was extracted with diethyl ether (3 x 25 mL). The organic phases were 
combined, washed with an aqueous NaHCO3-solution (3 x 5 mL), brine (2 x 3 mL) and dried 
over MgSO4. The solvent was removed under reduced pressure to give 174 as a colorless oil 
(682 mg, 87%).(Analytical data in accordance to that reported82). 
 
C9H14O3 (170.21). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 1.46-1.54 (m, 2H, CH2), 1.62-1.70 (m, 2H, CH2), 
2.23 (qd, J(H,H) = 7.1 Hz, J(H,H) = 1.5 Hz, 2H, CH2), 2.45 (dt, J(H,H) = 7.3 Hz, J(H,H) = 
1.5 Hz, 2H, CH2), 3.72 (s, 3H, CO2CH3), 5.83 (td, J(H,H) = 15.7 Hz, J(H,H) = 1.5 Hz, 1H, 
CH2CH=CH), 6.94 (td, J(H,H) = 15.7 Hz, J(H,H) = 6.8 Hz, 1H, CH2CH=CH), 9.76 (d, 
J(H,H) = 1.5, 1H, CHO). 
 
(E)-Methyl 8-((S)-1-Methoxy-1-oxopropan-2-ylimino)oct-2-enoat (175) 
 
 
 
 
A concentrated aqueous ammonia solution (1.5 mL) was added to a solution of L-alanine 
methyl ester hydrochloride (110 mg, 1.07 mmol) in anhydrous dichloromethane (10 mL). The 
mixture was shaken for 5 min before the organic layer was separated and dried over MgSO4. 
The solvent was removed under reduced pressure to isolate the free amine. 
A mixture of 8-oxo-oct-2-enoic acid methyl ester (200 mg, 1.18 mmol), the free amine and 
anhydrous MgSO4 (610 mg, 5.07 mmol) in anhydrous dichloromethane (5 mL) was stirred for 
48 h at rt. The reaction mixture was filtered and the solvent was removed under reduced 
pressure to afford 175 as a colorless solid which was used without further purification in the 
following step (8 mol% of aldehyde were detected by 1H NMR spectroscopy as the only 
impurity). 
 
C13H21NO4 (255.31). 
1H NMR (400.1 MHz, CDCl3, 300 K): δ = 1.34 (d, J(H,H) = 6.8 Hz, 3H, CHCH3), 1.48-1.58 
(m, 4H, CH2), 2.20-2.30 (m, 4H, CH2), 3.67 (s, 3H, CO2CH3), 3.68 (s, 3H, CO2CH3), 3.86 (q, 
J(H,H) = 6.8 Hz, 1H, CHCH3), 5.82 (td, J(H,H) = 15.6 Hz, J(H,H) = 1.5 Hz, 1H, 
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CH2CH=CH), 6.93 (td, J(H,H) = 15.7 Hz, J(H,H) = 6.8 Hz, 1H, CH2CH=CH), 7.67 (t, J(H,H) 
= 4.8, 1H, CH=N). 
 
13.4.2 Asymmetric Ag(I)-Catalyzed [3+2] Cycloadditions 
 
General Procedure IX: 
A suspension of AgOAc (3 mol%) and the ligand (3.3 mol%) in degassed toluene was stirred 
for 10 h. The resulting solution was cooled to 0 °C before the substrate(s) were added 
(concentration of the imine 0.05 M). After stirring for 5-12 h the solvent was removed under 
reduced pressure and the residue was purified by column chromatography on silica. 
 
(+)-Dimethyl 5-(naphthalen-2-yl)pyrrolidine-2,4-dicarboxylate (38a) 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C18H19NO4 (313.35). 
colorless oil. Rf = 0.26 (Et2O : pentane  3:1). 
20][ Dα  = +17.3° (c = 0.610, CHCl3. 62% ee). 
1H NMR (400.1 MHz, CD2Cl2, 295 K): δ = 2.37-2.49 (m, 2H, CH2), 2.85 (br s, 1H, NH), 
3.11 (s, 3H, OCH3), 3.39 (q, J(H,H) = 7.5 Hz, 1H, CHCO2CH3), 3.81 (s, 3H, OCH3), 4.01 (t, 
J(H,H) = 8.3 Hz, 1H, NHCHCO2CH3), 4.67 (d, J(H,H) = 7.8 Hz, 1H, NHCH), 7.41-7.50 (m, 
3H, Naph-H), 7.79-7.85 (m, 4H, Naph-H). 
13C{1H} NMR (100.8 MHz, CD2Cl2, 295 K): δ = 33.8 (CH2), 50.1 (CHCO2CH3), 51.6 
(OCH3), 52.6 (OCH3), 60.4 (NHCHCO2CH3), 66.3 (NHCH), 125.8 (Naph-H), 125.9 (Naph-
H), 126.4 (Naph-H), 126.6 (Naph-H), 128.1 (Naph-H), 128.1 (Naph-H), 128.4 (Naph-H), 
133.4 (Naph-C), 133.7 (Naph-C), 137.7 (Naph-C), 173.6 (CHCO2CH3), 174.3 
(NHCHCO2CH3). 
MS (FAB) m/z (rel. Int. %): 314 (100, [M+ + H]), 254 (19), 227 (16), 194 (15), 167 (13). 
IR (NaCl): υ~  [cm-1] = 3446w, 3053w, 2995w, 2951m, 2886w, 1736s, 1600w, 1508w, 1438s, 
1374m, 1207s, 1169s, 1126m, 1036w, 823m, 750m. 
EA % found (calcd): C: 68.80 (68.99), H: 6.10 (6.11), N: 4.47 (4.47). 
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HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (80 : 20), 
0.5 ml/min, 25 °C, tR = 41 min, 72 min, λlocal max 225 nm, 275 nm. 
 
Analytical data of 38b. 
C18H19NO4 (313.35). 
colorless oil. Rf = 0.26 (Et2O : pentane  3:1). 
1H NMR (400.1 MHz, CD2Cl2, 295 K): δ = 2.41 (ddd, J(H,H) = 13.1 Hz, J(H,H) = 8.7 Hz, 
J(H,H) = 5.7 Hz, 1H, CH2), 2.52 (ddd, J(H,H) = 13.1 Hz, J(H,H) = 8.7 Hz, J(H,H) = 8.3 Hz, 
1H, CH2), 3.00 (q, J(H,H) = 8.5 Hz, 1H, C(4)HCO2CH3), 3.61 (s, 3H, OCH3), 3.78 (s, 3H, 
OCH3), 4.08 (dd, J(H,H) = 8.8 Hz, J(H,H) = 5.8 Hz, 1H, C(2)HCO2CH3), 4.55 (d, J(H,H) = 
8.4 Hz, 1H, NHCH), 7.44-7.61 (m, 3H, Naph-H), 7.81-8.00 (m, 4H, Naph-H). (NH not 
visible). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (80 : 20), 
0.5 ml/min, 25 °C, tR = 27 min, 31 min, λlocal max 225 nm, 275 nm. 
 
Analytical data of 38c. 
C18H19NO4 (313.35). 
colorless oil. Rf = 0.26 (Et2O : pentane  3:1). 
1H NMR (400.1 MHz, CD2Cl2, 295 K): δ = 2.17 (ddd, J(H,H) = 12.6 Hz, J(H,H) = 10.2 Hz, 
J(H,H) = 9.5 Hz, 1H, CH2), 2.53 (ddd, J(H,H) = 12.6 Hz, J(H,H) = 7.9 Hz, J(H,H) = 6.3 Hz, 
1H, CH2), 2.85 (br s, 1H, NH), 3.43 (ddd, J(H,H) = 9.3 Hz, J(H,H) = 8.8 Hz, J(H,H) = 7.8 
Hz, 1H, C(3)HCO2CH3), 3.67 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 4.15 (t, J(H,H) = 8.8 Hz, 
1H, C(2)HCO2CH3), 4.36 (dd, J(H,H) = 10.2 Hz, J(H,H) = 6.3 Hz, 1H, NHCH), ~7.40-~8.00 
(7H, Naph-H). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (80 : 20), 
0.5 ml/min, 25 °C, tR = 43.2 min, 61.3 min, λmeasured 225 nm, 275 nm. 
 
(+)-4-tert-Butyl 2-methyl 5-(naphthalen-2-yl)pyrrolidine-2,4-dicarboxylate (149a) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
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C21H25NO4 (355.18). 
colorless solid. Rf = 0.24 (Et2O : pentane  3:1). 
m.p. 120–122 °C. 
20][ Dα  = +13.0° (c = 0.190, CHCl3. 43% ee). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 0.90 (s, 9H, C(CH3)3), 2.37-2.55 (m, 2H, CH2), 
3.36 (dt, J(H,H) = 7.5 Hz, J(H,H) = 5.6 Hz, 1H, CHCO2C(CH3)3), 3.84 (s, 3H, OCH3), 4.05 
(t, J(H,H) = 8.3 Hz, 1H, NHCHCO2CH3), 4.66 (d, J(H,H) = 7.6 Hz, 1H, NHCH), 7.44-7.48 
(m, 3H, Naph-H), 7.78-7.83 (m, 4H, Naph-H).(NH not visible). 
13C{1H} NMR (100.8 MHz, CD2Cl2, 300 K): δ = 27.8 (3C, C(CH3)3), 34.5 (CH2), 50.5 
(CHCO2CH3), 52.8 (OCH3), 60.3 (NHCHCO2CH3), 66.2 (NHCH), 81 2 (OC(CH3)3), 126.0 
(2C, Naph-H), 126.2 (Naph-H), 126.5 (Naph-H), 127.9 (Naph-H), 128.1 (Naph-H), 128.3 
(Naph-H), 133.2 (Naph-C), 133.6 (Naph-C), 136.7 (Naph-C), 172.2 (CHCO2CH3), 173.9 
(NHCHCO2CH3). 
MS (FAB) m/z (rel int): 356 (M + 1, 66), 300 (100), 240 (16), 227 (16), 222 (12), 194 (21), 
179 (12), 167 (23), 57 (73), 41 (30).  
IR (KBr) : υ~  [cm-1] = 3427w, 3275w, 3056w, 2976m, 2946m, 1742s, 1703s, 1436m, 1368m, 
1309w, 1208m, 1153s, 1110m, 1031w, 965w, 930w, 888w, 856w, 828w, 749m. 
EA % found (calcd): C: 70.57 (70.96), H: 7.11 (7.09), N: 3.94 (3.95). 
HPLC: Daicel Chiralcel AS (0.46 cm x 25 cm), n-Heptan : i-Propanol (90 : 10), 1.0 ml/min, 
20 °C, tR = 7.6 min, 13.1 min, λlocal max 220 nm, 254 nm. 
 
Analytical data of 149b. 
C21H25NO4 (355.18). 
1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 1.34 (s, 9H, C(CH3)3), 2.35 (ddd, J(H,H) = 12.9 
Hz, J(H,H) = 8.7 Hz, J(H,H) = 5.8 Hz, 1H, CH2), 2.49 (ddd, J(H,H) = 12.8 Hz, J(H,H) = 8.8 
Hz, J(H,H) = 8.6 Hz, 1H, CH2), 3.36 (app q, J(H,H) = 8.4 Hz, 1H, CHCO2C(CH3)3), 3.77 (s, 
3H, OCH3), 4.05 (t, J(H,H) = 8.4 Hz, 1H, NHCHCO2CH3), 4.48 (d, J(H,H) = 8.3 Hz, 1H, 
NHCH), 7.44-7.53 (m, 3H, Naph-H), 7.81-7.93 (m, 4H, Naph-H).(NH not visible). 
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(+)-Trimethyl 5-(naphthalen-2-yl)pyrrolidine-2,3,4-tricarboxylate (150a) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C20H21NO6 (371.39). 
colorless solid. Rf = 0.10 (Et2O : pentane  3:1). 
m.p. 123-126 °C. 
20][ Dα  = +25.8° (c = 0.610, CHCl3. 60% ee). 
1H NMR (CD2Cl2, 500.13 MHz, 295 K): δ = 3.13 (s, 3H, CO2CH3), 3.41 (br t, J(H,H) = 10.4 
Hz, 1H, NH), 3.64 (s, 3H, CO2CH3), 3.68 (dd, J(H,H) = 8.2 Hz, J(H,H) = 6.6 Hz, 1H, 
C(4)HCO2Me), 3.78 (s, 3H, CO2CH3), 3.79 (dd, J(H,H) = 9.2 Hz, J(H,H) = 8.2 Hz, 1H, 
C(3)HCO2Me), 4.18 (t, J(H,H) = 9.2 Hz, 1H, C(2)HCO2Me), 4.58 (dd, J(H,H) = 10.9 Hz, 
J(H,H) = 6.7 Hz, 1H, C(5)HCO2Me), 7.43 (dd, J(H,H)=8.6 Hz, J(H,H)=1.8 Hz, 1H, Naph-H), 
7.46-7.50 (m, 2H, Naph-H), 7.81-7.86 (m, 4H, Naph-H). 
13C{1H} NMR (CD2Cl2, 125.0 MHz, 295 K): δ = 51.7 (OCH3), 51.9 (C(3)), 52.5 (OCH3), 
52.7 (OCH3), 53.0 (C(4)), 62.4 (C(2)), 65.8 (C(5)), 125.4 (Naph-H), 125.9 (Naph-H), 126.5 
(Naph-H), 126.8 (Naph-H), 128.1 (Naph-H), 128.3 (Naph-H), 128.4 (Naph-H), 133.3 
(Naph-C), 133.7 (Naph-H), 135.6 (Naph-H), 171.2 (CO), 171.5 (CO), 171.7 (CO). 
MS (FAB) m/z (rel int): 372 (M + 1, 100), 312 (14), 252 (10), 227 (27), 167 (14), 59 (9).  
IR (KBr) : υ~  [cm-1] = 3451w, 3289w, 3053w, 2998w, 2951m, 1743s, 1436s, 1348m, 1301m, 
1207s, 1109m, 1051m, 956m, 860m, 826m, 742w. 
EA % found (calcd): C: 64.68 (64.68), H: 5.70 (5.70), N: 3.80 (3.77). 
HPLC: Daicel Chiralcel AS (0.46 cm x 25 cm), n-Heptan : i-Propanol (70 : 30), 0.5 ml/min, 
20 °C, tR = 22.9 min, 52.7 min, λlocal max 224 nm, 266 nm. 
 
Analytical data of 150b. 
C20H21NO6 (371.39). 
1H NMR (CD2Cl2, 500.13 MHz, 295 K): δ = 2.73 (br s, 1H, NH), 3.34 (dd, J(H,H) = 8.8 Hz, 
J(H,H) = 7.6 Hz, 1H, C(4)HCO2Me), 3.62 (s, 3H, CO2CH3), 3.64 (dd, J(H,H) = 9.1 Hz, 
J(H,H) = 6.1 Hz, 1H, C(3)HCO2Me), 3.70 (s, 3H, CO2CH3), 3.80 (s, 3H, CO2CH3), 4.39 (d, 
J(H,H) = 6.3 Hz, 1H, C(2)HCO2Me), 4.80 (d, J(H,H) = 7.8 Hz, 1H, C(5)HCO2Me), ), 7.46-
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7.49 (m, 2H, Naph-H),7.57 (dd, J(H,H) = 8.6 Hz, J(H,H) = 1.8 Hz, 1H, Naph-H), 7.82-7.91 
(m, 4H, Naph-H). 
 
(2S*,4S*,5R*)-Methyl 5-(naphthalen-2-yl)-4-(2-oxooxazolidine-3-carbonyl)pyrrolidine-
2-carboxylate (151b) 
 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C20H20N2O5 (368.39). 
colorless solid. Rf = 0.04 (EtOAc : Hx  1:2). 
m.p. 128-130 °C. 
1H NMR (500.1 MHz, CD2Cl2, 300 K): δ = 2.36-2.42 (m, 1H, CH2(py)), 2.54-2.60 (m, 1H, 
CH2(py)), 2.78 (br s, 1H, NH), 2.87-2.92 (m, 1H, CH2(ox)), 3.21 (q, J(H,H) = 8.5 Hz, 1H, 
CH2(ox)), 3.50-3.56 (m, 1H, CH2(ox)), 3.81 (s, 3H, OCH3), 3.89-3.93 (m, 1H, CH2(ox)), 4.00 (t, 
J(H,H) = 8.5 Hz, 1H, CHCO2Me), 4.73-4.78 (m, 1H, CHC(O)N), 4.81 (d, J(H,H) = 8.5 Hz, 
1H, Naph-CH), 7.41 (dd, J(H,H) = 8.5 Hz, J(H,H) = 2.0 Hz, 1H, Naph-H), 7.45-7.49 (m, 2H, 
Naph-H), 7.77-7.84 (m, 4H, Naph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 32.6 (CH2(Py)), 42.3 (CH2(Ox)), 47.9 
(CHC(O)N), 52.0 (OCH3), 59.9 (CHCO2Me), 61.7 (CH2 (Ox)), 65.6 (Naph-CH), 125.4 (Naph-
H), 125.6 (Naph-H), 126.0 (Naph-H), 126.3 (Naph-H), 127.5 (Naph-H), 127.5 (Naph-H), 
127.8 (Naph-H), 132.9 (Naph-C) 136.9 (2C, Naph-C), 153.1 (OC(O)N), 172.5 (CHC(O)N), 
173.6 (CO). 
MS (FAB) m/z (rel int %): 369 (M + H, 100), 309 (10), 282 (14), 227 (11), 194 (13), 167 
(10). 
IR (KBr) : υ~  [cm-1] = 3451w, 3056w, 2950w, 2911m, 1769s, 1745s, 1681m, 1477w, 1436w, 
1396m, 1272m, 1204s, 1103m, 1040m, 925w, 860w, 809m, 761m. 
EA % found (calcd): C: 65.10 (65.21), H: 5.47 (5.47), N: 7.54 (7.60). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : EtOH (85 : 15), 0.5 ml/min, 
25 °C, tR = 36.3 min, 82.4 min, λlocal max 225 nm, 275 nm. 
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(+)-Methyl 5-(4-fluorophenyl)-4-(phenylsulfonyl)pyrrolidine-2-carboxylate (153b) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C18H18FNO4S (363.40). 
colorless solid. Rf = 0.18 (EtOAc : Hx  1 : 2). 
m.p. 83-85 °C. 
20][ Dα  = +29.1° (c = 0.650, CHCl3, 88% ee). 
1H NMR (CD2Cl2, 500.1 MHz, 295 K): δ = 2.28-2.36 (m, 1H, CH2), 2.53 (br s, 1H, NH), 
2.63 (ddd, J(H,H) = 14.0, J(H,H) = 7.6, J(H,H) = 4.8, 1H, CH2), 3.58-3.62 (m, 1H, 
CHSO2Ph), 3.73 (s, 3H, OCH3), 4.10 (t, J(H;H) = 8.1 Hz, 1H, CHCO2Me), 4.66 (d, J(H,H) = 
5.8 Hz, 1H, pFPhCH), 6.90-6.94 (m, 2H, pFPh-H), 7.20-7.22 (m, 2H, pFPh-H), 7.49-7.53 (m, 
2H, Ph-H), 7.61-7.65 (m, 1H, Ph-H), 7.78-7.80 (m, 2H, Ph-H). 
13C{1H} NMR (CD2Cl2, 125.8 MHz, 295 K): δ = 31.5 (CH2), 52.7 (OCH3), 59.7 
(CHCO2Me), 62.5 (CHPhF), 70.5 (CHSO2Ph), 115.7 (d, J(C,F) = 21.6 Hz, 2C, pFPh-H), 
129.0 (2C, Ph-H), 129.3 (d, J(C,F) = 8.2 Hz, 2C, pFPh-H), 129.9 (2C, Ph-H), 134.5 (Ph-H), 
137.9 (d, J(C,F) = 3.4 Hz, pFPh(ipso)-C), 138.6 (Ph-S), 162.7 (d, J(C,F) = 245.3 Hz, Ph-F), 
173.6 (C=O). 
19F{1H} NMR (376.5 MHz, CD2Cl2, 300 K): δ = -117.5 (m). 
MS (FAB) m/z (rel int %): 364 (M + H, 100), 333 (12), 221 (25), 162 (92), 136 (42),120 (17), 
107 (32), 105 (13), 91 (31), 89 (46), 77 (58), 71 (11), 69 (16), 65 (31), 63 (29), 57 (45), 55 
(27), 51 (38), 43 (31), 41 (43), 39 (71). 
IR (KBr) : υ~  [cm-1] = 3350m, 3053w, 2961w, 2870w, 1744s, 1601w, 1507m, 1448m, 
1379m, 1297s, 1218s, 1144s, 1088m, 1018m, 846m, 741m, 686m, 597s. 
EA % found (calcd): C: 59.54 (59.49), H: 4.95 (4.99), N: 3.93 (3.85). 
HPLC: Daicel Chiralcel AS (0.46 cm x 25 cm), n-Heptan : iPrOH (60 : 40), 0.8 ml/min, 25 
°C, tR = 20.2 min, 29.1 min, λlocal max 208 nm, 265 nm. 
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(+)-Dimethyl 5-(4-fluorophenyl)pyrrolidine-2,4-dicarboxylate (137a) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C14H16FNO4 (281.23). 
colorless oil. Rf = 0.18 (EtOAc : Hx  1 : 2). 
20][ Dα  = +25.1° (c = 0.890, CHCl3, 65% ee). 
1H NMR (CD2Cl2, 500.1 MHz, 295 K): δ = 2.31-2.40 (m, 2H, CH2), 2.68 (br s, 1H, NH), 
3.22 (s, 3H, OCH3), 3.25-3.31 (m, 1H, CHCO2Me), 3.78 (s, 3H, OCH3), 3.94 (t, J(H,H) = 8.2, 
1H, NHCHCO2Me), 4.66 (d, J(H,H) = 8.1, 1H, FPhCH), 6.98-7.03 (m, 2H, Ph-H), 7.30-7.34 
(m, 2H, Ph-H). 
13C{1H} NMR (CD2Cl2, 125.8 MHz, 295 K): δ = 33.3 (CH2), 50.0 (CHCO2Me), 51.6 
(OCH3), 52.6 (OCH3), 60.2 (NHCHCO2Me), 65.2 (pFPhCH), 115.3 (d, J(C,F) = 21.1, 2C, 
pFPh-H), 129.2 (d, J(C,F) = 8.2, 2C, pFPh-H), 136.3 (d, J(C,F) = 3.4, pFPh(ipso)-C), 162.7 (d, 
J(C,F) = 244.8, Ph-F),173.3 (C=O), 174.3 (C=O). 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -118.0 (m). 
MS (FAB) m/z (rel int %): 282 (M + H, 100), 222 (32), 162 (12), 137 (20),107 (10), 91 (11), 
77 (18), 65 (12), 57 (21), 55(12), 51 (15), 43 (13), 41 (20), 39 (26). 
IR (NaCl) : υ~  [cm-1] = 3352m, 3055w, 2997m, 2954s, 2893w, 1737s, 1605m, 1511s, 1440s, 
1377s, 1214s, 1166s, 1116m, 1036m, 938m, 842s. 
EA % found (calcd): C: 59.41 (59.78), H: 5.73 (5.73), N: 5.38 (4.98). 
HPLC: Daicel Chiralcel OB-H (0.46 cm x 25 cm), n-Heptan : iPrOH (95 : 5), 0.5 ml/min, 25 
°C, tR = 57.0 min, 66.8 min, λlocal max 207 nm, 265 nm. 
 
(+)-Methyl 5-(4-methoxyphenyl)-4-(phenylsulfonyl)pyrrolidine-2-carboxylate (154b) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
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C19H21NO5S (375.44). 
colorless oil. Rf = 0.11 (EtOAc : Hx  1 : 2). 
20][ Dα  = +16.0° (c = 0.660, CHCl3, 81% ee). 
1H NMR (CD2Cl2, 500.1 MHz, 300 K): δ = 2.31 (ddd, J(H,H) = 13.9, J(H,H) = 9.3, J(H,H) = 
8.5, 1H, CH2), 2.47 (br s, 1H, NH), 2.64 (ddd, J(H,H) = 13.9, J(H,H) = 7.6, J(H,H) = 4.9, 1H, 
CH2), 3.60-3.65 (m, 1H, CHSO2Ph), 3.72 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 3.78 (s, 3H, 
OCH3), 4.05 (t, J(H,H) = 8.0, 1H, NHCHCO2Me), 4.59 (d, J(H,H) = 6.3, 1H, pMeOPhCH), 
6.73-6.76 (m, 2H, pMeOPh-H), 7.10-7.14 (m, 2H, pMeOPh-H), 7.47-7.52 (m, 2H, Ph-H), 
7.59-7.64 (m, 1H, Ph-H), 7.77-7.80 (m, 2H, Ph-H). 
13C{1H} NMR (CD2Cl2, 125.8 MHz, 300 K): δ = 31.9 (CH2), 52.7 (OCH3), 55.7 (OCH3), 
59.6 (CHCO2Me), 63.0 (CHPhOMe), 70.3 (CHSO2Ph), 114.3 (2C, pMeOPh-H), 128.7 (2C, 
pMeOPh-H), 130.0 (2C, Ph-H), 129.8 (2C, Ph-H), 133.6 (Ph-C), 134.4 (Ph-H), 138.7 (Ph-
C), 159.7 (Ph-C), 173.6 (C=O).  
MS (FAB) m/z (rel int %): 376 (M + H, 100), 333 (10), 233 (41), 207 (11), 174 (63), 147 
(37), 137 (28), 120 (11), 107 (17), 91 (17), 89 (19), 77 (25), 68 (14), 65 (18), 63 (12), 57 (10), 
51 (16), 43 (13), 41 (17), 39 (29). 
IR (NaCl) : υ~  [cm-1] = 3343w, 3062w, 3001w, 2953m, 2840w, 1737s, 1611m, 1586w, 1513s, 
1445s, 1374m, 1297s, 1246s, 1218s, 1144s, 1086s, 1029s, 832s, 758m, 723m, 691m, 597s. 
EA % found (calcd): C: 60.33 (60.78), H: 5.26 (5.64), N: 3.43 (3.73). 
HPLC: Daicel Chiralcel AS (0.46 cm x 25 cm), n-Heptan : iPrOH (60 : 40), 0.8 ml/min, 20 
°C, tR = 31.4 min, 39.9 min, λlocal max 218 nm, 267 nm. 
 
(2S*,4S*,5R*)-Dimethyl 5-(4-methoxyphenyl)pyrrolidine-2,4-dicarboxylate (139a) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C15H19NO5 (293.32). 
colorless oil. Rf = 0.08 (EtOAc : Hx  1 : 2). 
1H NMR (CD2Cl2, 500.1 MHz, 295 K): δ = 2.30-2.40 (m, 2H, CH2), 2.57 (br s, 1H, NH), 
3.22-3.28 (m, 1H, CHCO2CH3), 3.23 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 
3.92 (t, J(H,H) = 8.2 Hz, 1H, NHCHCO2CH3), 4.45 (d, J(H,H) = 7.8 Hz, 1H, pMeOPhCH), 
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6.82-6.85 (d, J(H,H) = 8.7 Hz, 2H, pMeOPh-H), 7.20-7.24 (d, J(H,H) = 8.7 Hz, 2H, 
pMeOPh-H). 
13C{1H} NMR (CD2Cl2, 125.8 MHz, 300 K): δ = 33.6 (CH2), 50.1 (CHCO2Me), 51.6 
(OCH3), 52.6 (OCH3), 55.7 (OCH3), 60.2 (NHCHCO2CH3), 65.6 (pMeOPhCH), 113.9 (2C, 
pMeOPh-H), 128.5 (2C, pMeOPh-H), 132.1 (pMeOPh(ipso)CH), 159.6 (pMeOPh), 173.6 
(C=O), 174.4 (C=O). 
MS (+EI) m/z (rel int %): 293 (M +, 5), 234 (26), 207 (83), 202 (17), 175 (29), 147 (100), 132 
(14). 
IR (NaCl) : υ~  [cm-1] = 3350w, 3054w, 2998w, 2952m, 2840w, 1737s, 1612m, 1513s, 1440s, 
1377m, 1248s, 1207s, 1175s, 1114m, 1034m, 937w, 836m. 
EA % found (calcd): C: 61.02 (61.42), H: 6.40 (6.53), N: 4.72 (4.78). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan : iPrOH (80 : 20), 0.5 ml/min, 
25 °C, tR = 28.6 min, 45.5 min, λlocal max 207 nm, 227 nm. 
 
(+)-Dimethyl 5-(4-bromophenyl)pyrrolidine-2,4-dicarboxylate (138a) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C14H16BrNO4 (342.19). 
colorless oil. Rf = 0.15 (Et2O : Pe  3 : 2). 
20][ Dα  = +22.6° (c = 0.660, CHCl3, 50% ee). 
1H NMR (CD2Cl2, 400.1 MHz, 300 K): δ = 2.30-2.42 (m, 2H, CH2), 2.77 (br s, 1H, NH), 
3.27 (s, 3H, OCH3), 3.31 (q, J(H,H) = 7.1, 1H, CHCO2Me), 3.82 (s, 3H, OCH3), 3.98 (t, 
J(H,H) = 8.1, 1H, NHCHCO2Me), 4.50 (d, J(H,H) = 7.8, 1H, pBrPh-CH), 7.21-7.25 (m, 2H, 
Ar-H), 7.42-7.46 (m, 2H, Ar-H). 
13C{1H} NMR (CD2Cl2, 125.8 MHz, 300 K): δ = 33.5 (CH2), 49.9 (CHCO2Me), 51.8 
(OCH3), 52.8 (OCH3), 60.2 (pBrPh-CH), 65.5 (NHCHCO2Me), 121.9 (pBrPh), 129.0 (2C, 
pBrPh-H), 131.7 (2C, pBrPh-H), 138.8 (pBrPh(ipso)-C), 173.1 (C=O), 174.1 (C=O). 
MS (FAB): m/z (rel int %) = 342 (M+, 100, 79Br), 282 (29, 79Br), 222 (10, 79Br), 88 (10). 
IR (NaCl) : υ~  [cm-1] = 3370w, 2994w, 2951w, 2889w, 2884w, 1738s, 1591w, 1487w, 
1438m, 1375w, 1207s, 1169s, 1076w, 1010m, 936w, 831w. 
Experimental Part 
 199
N
H
MeO2C
CO2t-Bu2-Naph
EA % found (calcd): C: 49.08 (49.14), H: 4.68 (4.71), N: 4.20 (4.09). 
HPLC: Daicel Chiralcel AS (0.46 cm x 25 cm), n-Heptan : iPrOH (50 : 50), 0.5 ml/min, 20 
°C, tR = 11.4 min, 18.9 min, λlocal max 222 nm, 260 nm. 
 
Analytical data of 138b. 
C14H16BrNO4 (342.19). 
1H NMR (CD2Cl2, 400.1 MHz, 300 K): δ = 1.99-2.07 (m, 1H, CH2), 2.38-2.48 (m, 1H, CH2), 
3.37 (app q, J(H,H) = 7.8 Hz, 1H, CHCO2Me), 3.65 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 4.10 
(d, J(H,H) = 8.5 Hz, 1H, pBrPh-CH), 4.18 (dd, J(H,H) = 10.1 Hz, J(H,H) = 6.3 Hz, 1H, 
NHCHCO2Me), 7.35 (d, J(H,H) = 8.6 Hz, 2H, Ar-H), 7.45-7.48 (m, 2H, Ar-H).(NH not 
visible) 
 
(+)-2-tert-Butyl 4-methyl 5-(naphthalen-2-yl)pyrrolidine-2,4-dicarboxylate (143a) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C21H25NO4 (355.43). 
colorless solid. Rf = 0.45 (Et2O : Pe  3 : 1). 
m.p. 75-77 °C. 
20][ Dα  = +4.5° (c = 0.670, CHCl3, 45% ee). 
1H NMR (500.13 MHz, CD2Cl2, 295 K): δ = 1.53 (s, 9H, C(CH3)3), 2.30-2.43 (m, 2H, CH2), 
2.82(br s, 1H, NH), 3.12 (s, 3H, OCH3), 3.38 (dt, J(H,H) = 7.8 Hz, J(H,H) = 6.4 Hz, 1H, 
CHCO2Me), 3.88 (t, J(H,H) = 8.3 Hz, 1H, NHCHCO2Me), 4.64 (d, J(H,H) = 7.8 Hz, 1H, 
CHNaph), 7.42 (dd, J(H,H) = 8.4 Hz, J(H,H) = 6.6 Hz 1H, Naph-H), 7.44-7.49 (m, 2H, 
Naph-H), 7.78-7.84 (m, 4H, Naph-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 295 K): δ = 28.4 (3C, C(CH3)3), 34.1 (CH2), 50.3 
(CHCO2Me), 51.5 (OCH3), 61.3 (CHCO2tBu), 66.4 (CHNaph), 81.8 (C(CH3)3), 125.9 
(Naph-H), 125.9 (Naph-H), 126.4 (Naph-H), 126.6 (Naph-H), 128.1 (Naph-H), 128.1 
(Naph-H), 128.4 (Naph-H), 133.4 (Naph-C), 133.7 (Naph-C), 138.0 (Naph-C), 173.0 (CO), 
173.2 (CO). 
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MS (FAB) m/z (rel int): 356 (M + 1, 76), 300 (100), 254 (71), 222 (13), 194 (21), 167 (12), 
57 (55), 41 (23).  
IR (KBr) : υ~  [cm-1] = 3431w, 3281w, 3053w, 2975m, 2853m, 1728s, 1441m, 1369m, 
1296m, 1210s, 1160s, 1105m, 1040m, 945m, 893w, 856m, 825m, 742m. 
EA % found (calcd): C: 71.04 (70.96), H: 7.01 (7.09), N: 4.04 (3.94). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : iPrOH (80 : 20), 0.5 ml/min, 
20 °C, tR = 34.4 min, 47.6 min, λlocal max 224 nm, 275 nm. 
 
Analytical data of 143b. 
C21H25NO4 (355.43). 
1H NMR (500.13 MHz, CD2Cl2, 295 K): δ = 1.51 (s, 9H, C(CH3)3), 2.32-2.39 (m, 1H, CH2), 
2.45-2.53 (m, 1H, CH2), 2.51 (br s, 1H, NH), 2.97 (app q, J(H,H) = 8.8 Hz, 1H, CHCO2Me), 
3.61 (s, 3H, OCH3), 3.88 (dd, J(H,H) = 8.8 Hz, J(H,H) = 5.3 Hz, 1H, NHCHCO2Me), 4.51 (d, 
J(H,H) = 8.6 Hz, 1H, CHNaph), 7.46-7.49 (m, 2H, Naph-H), 7.59 (dd, J(H,H) = 8.6 Hz, 
J(H,H) = 1.8 Hz 1H, Naph-H),7.82-7.88 (m, 4H, Naph-H). 
 
Methyl 2-(naphthalen-2-yl)-5-(pyridin-2-yl)pyrrolidine-3-carboxylate (144a, 144b) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C21H20N2O2 (332.40). 
colorless oil. Rf = 0.13 (Hx : EtOAc  2 : 1, 8% Et3N). 
144a: 
1H NMR (500.1 MHz, CD2Cl2, 300 K): δ = 2.31-2.37 (m, 1H, CH2), 2.50-2.55 (m, 1H, CH2), 
3.04 (s, 3H, OCH3), 3.51-3.56 (m, 1H, CHCO2Me), 4.48 (dd, J(H,H) = 9.6 Hz, J(H,H)= 7.5 
Hz, 1H, CHPy), 4.84 (d, J(H,H) = 8.9 Hz, 1H, CHNaph), 7.23 (ddd, J(H,H) = 7.4 Hz, J(H,H) 
= 4.8 Hz, J(H,H) = 1.3 Hz, 1H, Py-H), 7.44-7.49 (m, 2H, Naph-H), 7.55 (dd, J(H,H) = 8.5 
Hz, J(H,H) = 1.8 Hz, 1H, Naph-H), 7.69 (dt, J(H,H) = 7.8 Hz, J(H,H) = 1.0 Hz, 1H, Py-H), 
7.75 (dt, J(H,H) = 7.8 Hz, J(H,H)= 1.8 Hz, 1H, Py-H), 7.80 (d, J(H,H) = 8.6 Hz, 1H, Naph-
H), 7.82-7.85 (m, 2H, Naph-H), 7.92 (s, 1H, Naph-H), 8.58 (ddd, J(H,H) = 4.8 Hz, J(H,H) = 
1.8 Hz, J(H,H) = 0.9 Hz, 1H, Py-H). 
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13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 36.6 (CH2), 50.0 (CHCO2Me), 50.8 
(OCH3), 63.5 (CHPy), 65.3 (CHNaph), 121.3 (Py-H), 122.2 (Py-H), 125.6 (Naph-H), 125.8 
(Naph-H), 125.8 (Naph-H), 125.9 (Naph-H), 127.3 (Naph-H), 127.5 (Naph-H), 127.8 
(Naph-H), 132.8 (Naph-C), 133.1 (Naph-C), 136.5 (Py-H), 138.4 (Naph-C), 148.9 (Py-H), 
162.2 (Py-C), 173.4 (CO). 
MS (FAB) m/z (rel int): 333 (M + 1, 100), 246 (22), 230 (11), 178 (5), 141 (5), 118 (6), 108 
(12), 80 (6). 
IR (NaCl) : υ~  [cm-1] = 3328w, 3265w, 3054w, 3011w, 2948m, 2848m, 1951w, 1731s, 
1633w, 1592s, 1507w, 1435m, 1368m, 1314m, 1296m, 1168s, 1086m, 1041m, 945m, 893w, 
858m, 819m, 753m. 
144b: 
1H NMR (500.1 MHz, CD2Cl2, 300 K): δ = 2.31-2.38 (m, 1H, CH2), 2.48-2.55 (m, 1H, CH2), 
3.22 (s, 3H, OCH3), 3.52-3.59 (m, 1H, CHCO2Me), 4.48 (dd, J(H,H) = 10.0 Hz, J(H,H)= 6.8 
Hz, 1H, CHPy), 4.77 (d, J(H,H) = 9.1 Hz, 1H, CHNaph), 7.18 (ddd, J(H,H) = 7.5 Hz, J(H,H) 
= 4.8 Hz, J(H,H) = 1.3 Hz, 1H, Py-H), 7.45-7.55 (m, 3H, Naph-H), 7.69 (dt, J(H,H) = 7.8 Hz, 
J(H,H) = 1.8 Hz, 1H, Py-H), 7.76 (dd, J(H,H) = 8.3 Hz, J(H,H)= 1.5 Hz, 1H, Py-H), 7.84-
7.89 (m, 3H, Naph-H), 7.92 (s, 1H, Naph-H), 7.89 (br s, 1H, Naph-H), 8.51-8.53 (m, 1H, Py-
H). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan : iPrOH (92 : 8), 0.5 ml/min, 
30 °C, endo (144a) tR = 51.7 min, 76.6 min/ exo (144b) tR = 42.1 min, 69.7 min, λlocal max 225 
nm, 265 nm. 
 
(+)-Dimethyl 5-(benzo[d][1,3]dioxol-5-yl)pyrrolidine-2,4-dicarboxylate (140a) 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C15H17NO6 (307.30). 
colorless solid. Rf = 0.21 (Hx : EtOAc  1 : 1). 
m.p. 65-68 °C. 
20][ Dα  = +16.1° (c = 0.670, CHCl3, 47% ee). 
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1H NMR (400.1 MHz, CD2Cl2, 300 K): δ = 2.33 (m, 2H, CH2), 2.60 (br s, 1H, NH), 3.24 (q, 
J(H,H) = 7.5 Hz, 1H, CHCO2Me), 3.29 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.91 (t, J(H,H) = 
8.3 Hz, 1H, NHCHCO2Me), 4.43 (d, J(H,H) = 8.0 Hz, 1H, CHPh), 5.93 (s, 2H, OCH2O), 
6.73 (d, J(H,H) = 8.0 Hz, 1H, Ph-H), 6.77 (dd, J(H,H) = 8.0 Hz, J(H,H) = 2.0 Hz, 1H, Ph-H), 
6.84 (d, J(H,H) = 1.5 Hz, 1H, Ph-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 300 K): δ = 32.8 (CH2), 49.5 (CHCO2Me), 51.1 
(OCH3), 52.0 (OCH3), 59.6 (NHCHCO2Me), 65.1 (CHPh), 101.2 (OCH2O), 107.4 (Ph-H), 
107.6 (Ph-H), 120.1 (Ph-H), 133.8 (Ph-C), 146.8 (Ph-C), 147.5 (Ph-C), 172.8 (CO), 173.8 
(CO). 
MS (FAB) m/z (rel int): 308 (M + 1, 100), 248 (17), 221 (31), 216 (10), 188 (10), 161 (14).  
IR (KBr) : υ~  [cm-1] = 3435w, 3282w, 3050w, 2956m, 2891m, 1733s, 1612m, 1493s, 1439s, 
1359m, 1289m, 1240s, 1206s, 1172s, 1106m, 1032m, 926m, 880w, 814m. 
EA % found (calcd): C: 58.74 (58.63), H: 5.50 (5.58), N: 4.61 (4.56). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : iPrOH (80 : 20), 0.5 ml/min, 
25 °C, tR = 37.2 min, 49.9 min, λlocal max 206 nm, 286 nm. 
 
(2S,3R,3aR,9bR)-1,2,3,3a,4,9b-Hexahydro-5-oxa-1-aza-cyclopenta[a]naphthalene-2,3-
dicarboxylic acid dimethyl ester (161) 
 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C15H17NO5 (291.30). 
white solid. Rf = 0.29 (Hx : EtOAc  1 : 1). 
m.p. 132-134 °C. 
20][ Dα  = +19.5° (c = 0.930, CHCl3, 96% ee). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 2.34 (qd, J(H,H) = 11.5 Hz, J(H,H) = 4.3 Hz, 1H, 
H-3a), 2.55 (br s, 1H, H-1), 3.08 (dd, J(H,H) = 11.9 Hz, J(H,H) = 10.0 Hz, 1H, H-3), 3.67 (s, 
3H, C(3)CO2CH3), 3.69 (s, 3H, C(2)CO2CH3), 3.77 (d, J(H,H) = 11.2 Hz, 1H, H-9b), 4.18 
(dd, J(H,H) = 11.5 Hz, J(H,H) = 10.1 Hz, 1H, H-4), 4.38 (d, J(H,H) = 10.1 Hz, 1H, H-2), 
4.57 (dd, J(H,H) = 10.1 Hz, J(H,H) = 4.3 Hz, 1H, H-4), 6.81 (dd, J(H,H) = 7.1 Hz, J(H,H) = 
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1.0 Hz, J(H,H) = 1.4 Hz, 1H, H-6), 6.89 (td, J(H,H) = 6.3 Hz, J(H,H) = 1.1 Hz, 1H, H-8), 
7.13–7.17 (m, 1H, H-7), 7.25 (dd, J(H,H) = 4.7 Hz, J(H,H) = 1.5 Hz, 1H, H-9). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 47.0 (C-3a), 50.3 (C-3), 52.7 
(C(3)CO2CH3), 52.9 (C(2)CO2CH3), 60.6 (C-9b), 64.6 (C-2), 69.8 (C-4), 116.4 (C-6), 120.7 
(C-8), 125.1 (C-9), 125.3 (C-9a), 129.1 (C-7), 153.7 (C-5a), 172.3 (C(3)CO), 172.3 
(C(2)CO). 
MS (FAB) m/z (rel. Int. %): 292 (100, [M+ + H]), 290 (28), 232 (32). 
IR (KBr): υ~  [cm-1] = 3301m, 2988w, 2946m, 1732s, 1622m, 1599m, 1512m, 1471m, 1433m, 
1386m, 1370m, 1270s, 1226s, 1208s, 1171m, 1132s, 1109m, 1038m, 1024m, 973m, 902m, 
880m,828m, 785m, 754m, 645w, 517w, 443w. 
EA % found (calcd): C: 61.92 (61.85), H: 5.83 (5.88), N: 4.71 (4.81). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (90 : 10), 0.5 
ml/min, 25 °C, tR = 35 min, 48 min, λlocal max 205 nm, 277 nm. 
 
(2S,3R,3aR,9bR)-Hexahydro-5-oxa-1-aza-cyclopenta[a]naphthalene-2,3-dicarboxylic 
acid 2-tert-butyl ester 3-methyl ester (165) 
 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C18H23NO5 (333.38). 
white solid. Rf = 0.52 (Hx : EtOAc  4 : 1). 
m.p. 98-100 °C. 
20][ Dα  = +18.1° (c = 0.800, CHCl3, 99% ee). 
1H NMR (500.0 MHz, CD2Cl2, 295 K): δ = 1.43 (s, 9H, C(CH3)3), 2.33 (qd, J(H,H) = 11.6 
Hz, J(H,H) = 4.3 Hz, 1H, H-3a), 2.49 (bs, 1H, H-1), 3.02 (dd, J(H,H) = 11.6 Hz, J(H,H) = 
10.4 Hz, 1H, H-3), 3.70 (s, 3H, OCH3), 3.71-3.75 (m, 1H, H-9b), 4.15 (dd, J(H,H) = 11.6 Hz, 
J(H,H) = 10.4 Hz, 1H, H-4), 4.24 (d, J(H,H) = 9.1 Hz, 1H, H-2), 4.55 (dd, J(H,H) = 10.1 Hz, 
J(H,H) = 4.3 Hz, 1H, H-4), 6.80 (d, J(H,H) = 8.1 Hz, 1H, H-6), 6.88 (t, J(H,H) = 7.6 Hz, 1H, 
H-8), 7.15 (t, J(H,H) = 7.6 Hz, 1H, H-7), 7.26 (d, J(H,H) = 7.3 Hz, 1H, H-9). 
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13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 28.2 (3C, C(CH3)3), 47.3 (C-3a), 50.4 (C-
3), 52.5 (OCH3), 60.4 (C-9b), 64.8 (C-2), 69.9 (C-4), 82.8 (C(CH3)3), 116.4 (C-6), 120.6 (C-
8), 125.1 (C-9), 125.5 (C-9a), 129.0 (C-7), 153.7 (C-5a), 170.8 (C(2)CO), 172.4 (C(3)CO). 
MS (FAB) m/z (rel. Int. %): 334 (60, [M+ + H]), 278 (100), 232 (64), 172 (12), 131 (9), 57 
(62), 41 (22). 
IR (KBr): υ~  [cm-1] = 3378w, 3259w, 2970w, 1735s, 1648w, 1577w, 1486w, 1451m, 1382m, 
1314m, 1288m, 1212s, 1172m, 1095w, 1059w, 913w, 842w,822w, 763m. 
EA % found (calcd): C: 64.86 (64.85), H: 6.92 (6.95), N: 4.22 (4.20). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (90 : 10), 0.5 
ml/min, 20 °C, tR = 33 min, 52 min, λmax 205 nm, 276 nm. 
 
(2S,3R,3aR,9bR)-9b-Methyl-1,2,3,3a,4,9b-hexahydro-5-oxa-1-aza-cyclopenta[a]naph-
thalene-2,3-dicarboxylic acid dimethyl ester (166) 
 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C16H19NO5 (305.33). 
white solid. Rf = 0.38 (Hx : EtOAc  5 : 1). 
m.p. 137-139 °C. 
20][ Dα  = +12.0° (c = 0.980, CHCl3, 96% ee). 
1H NMR (500.0 MHz, CD2Cl2, 295 K): δ = 1.66 (s, 3H, C(2)CH3), 2.48 (dq, J(H,H) = 11.6 
Hz, J(H,H) = 4.3 Hz, 1H, H-3a), 2.65 (d, J(H,H) = 12.1 Hz, 1H, H-3), 2.77 (s, 1H, H-1), 3.65 
(s, 3H, C(2)CO2CH3), 3.67 (s, 3H, C(3)CO2CH3), 3.90 (d, J(H,H) = 11.1 Hz, 1H, H-9b), 4.14 
(dd, J(H,H) = 11.4 Hz, J(H,H) = 10.1 Hz, 1H, H-4), 4.55 (dd, J(H,H) = 10.1 Hz, J(H,H) = 4.3 
Hz, 1H, H-4), 6.80 (d, J(H,H) = 8.1 Hz, 1H, H-6), 6.87 (t, J(H,H) = 6.8 Hz, 1H, H-8), 7.12-
7.20 (m, 2H, H-7, H-9). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 27.4 (C(2)CH3), 47.0 (C-3a), 52.6 
(C(3)CO2CH3), 53.1 (C(2)CO2CH3), 58.5 (C-3), 58.9 (C-9b), 69.9 (C-4), 70.6 (C-2), 116.4 
(C-6), 120.6 (C-8), 125.1 (C-9), 125.6 (C-9a), 128.9 (C-7), 153.8 (C-5a), 172.1 (C(3)CO), 
174.3 (C(2)CO). 
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MS (FAB) m/z (rel. Int. %): 306 (100, [M+ + H]), 246 (62), 214 (6), 186 (8), 173 (6), 131 (8), 
102 (27), 42 (7). 
IR (KBr): υ~  [cm-1] = 3445s, 3326w, 2986w, 2889w, 1727s, 1608w, 1576w, 1488m, 1439m, 
1375w, 1326w, 1212s, 1170m, 1097w, 1037w, 989m, 916w, 869w,831w, 770m. 
EA % found (calcd): C: 63.05 (62.94), H: 6.21 (6.27), N: 4.64 (4.59). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (90 : 10), 0.5 
ml/min, 25 °C, tR = 27 min, 58 min, λlocal max 205 nm, 275 nm. 
 
(2R,3S,3aS,9bS)-2-Pyridin-2-yl-1,2,3,3a,4,9b-hexahydro-5-oxa-1-aza-cyclopenta[a]naph-
thalene-3-carboxylic acid methyl ester (156) 
 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C18H18N2O3 (310.35). 
white solid. Rf = 0.10 (Hx : EtOAc  1 : 1). 
m.p. 92-94 °C. 
20][ Dα  = -30.1° (c = 0.560, CHCl3, 83% ee). 
1H NMR (500.0 MHz, CD2Cl2, 295 K): δ = 2.60 (dqd, J(H,H) = 11.7 Hz, J(H,H) = 4.4 Hz, 
J(H,H) = 0.3 Hz, 1H, H-3a), 3.17 (dd, J(H,H) = 11.8 Hz, J(H,H) = 10.2 Hz, 1H, H-3), 3.21 (s, 
3H, C(3)CO2CH3), 3.90 (dt, J(H,H) = 11.2 Hz, J(H,H) = 1.1 Hz, 1H, H-9b), 4.17 (dd, J(H,H) 
= 11.7 Hz, J(H,H) = 9.9 Hz, 1H, H-4), 4.54 (dd, J(H,H) = 9.9 Hz, J(H,H) = 4.3 Hz, 1H, H-4), 
4.99 (d, J(H,H) = 10.1 Hz, 1H, H-2), 6.83 (dd, J(H,H) = 8.2 Hz, J(H,H) = 1.1 Hz, 1H, H-6), 
6.90 (td, J(H,H) = 7.4 Hz, J(H,H) = 1.2 Hz, 1H, H-8), 7.16 (dddd, J(H,H) = 8.3 Hz, J(H,H) = 
7.5 Hz, J(H,H) = 1.8 Hz, J (H,H) = 0.8 Hz, 1H, H-7), 7.17 (ddd, J(H,H) = 7.5 Hz, J(H,H) = 
4.8 Hz, J(H,H) = 1.2 Hz, 1H, Py(5)), 7.32 (dddd, J(H,H) = 7.5 Hz, J(H,H) = 1.7 Hz, J(H,H) = 
1.2 Hz, J (H,H) = 0.5 Hz, 1H, H-9), 7.33 (dt, J(H,H) = 7.8 Hz, J(H,H) = 1.1 Hz, 1H, Py(3)), 
7.65 (td, J(H,H) = 7.6 Hz, J(H,H) = 1.8 Hz, 1H, Py(4)), 8.46 (ddd, J(H,H) = 4.8 Hz, J(H,H) = 
1.7 Hz, J(H,H) = 1.0 Hz, 1H, Py(6)) (NH not visible). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 45.3 (C-3a), 51.5 (C(3)CO2CH3), 52.5 (C-
3), 60.3 (C-9b), 66.8 (C-2), 70.1 (C-4), 116.2 (C-6), 120.3 (C-8), 123.0 (Py(5)), 123.8 
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(Py(3)), 125.1 (C-9), 126.0 (C-9a), 128.7 (C-7), 136.5 (Py(4)), 149.2 (Py(6)), 153.8 (C-5a), 
159.0 (Py(2)), 171.6 (C(3)CO). 
MS (FAB) m/z (rel. Int. %): 311 (100, [M+ + H]), 310 (22), 309 (25), 290 (28), 232 (32), 131 
(13), 108 (36), 107 (42), 89 (11), 78 (11), 77 (19), 73 (12), 57 (12), 55 (12), 51 (13), 43 (14), 
41 (14), 39 (15). 
IR (KBr): υ~  [cm-1] = 3433w, 2947m, 2925m, 2868m, 2400w, 1723s, 1594m, 1571m, 1484m, 
1455s, 1426s, 1374m, 1314m, 1254m, 1201s, 1171s, 1135m, 1082m, 1032m, 982s, 931m, 
881m, 812m, 750s, 677w, 632w. 
EA % found (calcd): C: 69.68 (69.66), H: 5.91 (5.85), N: 8.97 (9.03). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (90 : 10), 0.5 
ml/min, 25 °C, tR = 49 min, 99 min, λlocal max 205 nm, 263 nm. 
 
(2S,3R,3aR,9bR)-1-(Toluene-4-sulfonyl)-1,2,3,3a,4,9b-hexahydro-5-oxa-1-aza-cyclopent-
[a]naphthalene-2,3-dicarboxylic acid dimethyl ester (162) 
 
 
 
 
 
 
Triethylamine (115 µL, 0.83 mmol) was added to a solution of p-toluenesufonyl chloride (159 
mg, 0.83 mmol) and 1,2,3,3a,4,9b-hexahydro-5-oxa-1-aza-cyclopenta[a]naphthalene-2,3-
dicarboxylic acid dimethyl ester (157 mg, 0.54 mmol) in dichloromethane (20.0 mL). The 
reaction mixture was heated to reflux for 20 h. The solvent was removed under reduced 
pressure and the crude product was purified by column chromatography (EtOAc : Hx  1 : 1, 
Rf = 0.35) on silica to give a colorless solid (200 mg, 83%). Crystals suitable for X-ray 
analysis were obtained from ethyl acetate/pentane. 
 
C22H23NO7S (445.49). 
Colorless solid. 
m.p. 178-180 °C. 
20][ Dα  = +107.3° (c =0.780, CHCl3, 97% ee). 
1H NMR (400.1 MHz, CD2Cl2, 295 K): δ = 2.43 (dd, J(H,H) = 12.6 Hz, J(H,H)= 7.8 Hz, 1H, 
H-3), 2.47 (s, 3H, CH3), 3.01 (dq, J(H,H) = 12.0 Hz, J(H,H) = 5.2 Hz 1H, H-3a), 3.60 (s, 3H, 
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C(2)CO2CH3), 3.63 (s, 3H, C(3)CO2CH3), 4.05 (dd, J(H,H) = 12.0 Hz, J(H,H) = 9.7 Hz, 1H, 
H-4), 4.32 (d, J(H,H) = 11.0 Hz, 1H, H-9b), 4.56 (dd, J(H,H) = 9.6 Hz, J(H,H) = 5.2 Hz, 1H, 
H-4), 4.75 (d, J(H,H) = 7.9 Hz, 1H, H-2), 6.82 (dd, J(H,H) = 8.1 Hz, J(H,H) = 1.1 Hz, 1H, H-
6), 6.95 (dt, J(H,H) = 7.5 Hz, J(H,H) = 1.0 Hz, 1H, H-8), 7.17-7.21 (m, 1H, H-7), 7.43 (d, 
J(H,H) = 8.0 Hz, 2H, Ph(Tos)-H), 7.69 (dt, J(H,H) = 7.7 Hz, J(H,H) = 1.3 Hz, 1H, H-9), 7.82 
(d, J(H,H) = 8.3 Hz, 2H, Ph(Tos)-H). 
13C{1H} NMR (100.6 MHz, CD2Cl2, 295 K): δ = 22.0 (CH3), 43.5 (C-3a), 47.3 (C-3), 52.9 
(C(3)CO2CH3), 53.2 (C(2)CO2CH3), 63.1 (C-9b), 65.6 (C-2), 70.1 (C-4), 116.5 (C-6), 120.8 
(C-8), 125.7 (C-9), 126.9 (C-9a), 128.9 (2C, Ph(Tos)-H), 129.2 (C-7), 130.8 (2C, Ph(Tos)-H), 
133.1 (Ph(q)(Tos)), 145.9 (Ph(q)(Tos)), 153.8 (C-5a), 169.1 (C(3)CO), 169.9 (C(2)CO). 
MS (FAB) m/z (rel int %): 446 (M + H, 100), 386 (51), 290 (60), 230 (63), 172 (13), 132 
(11), 91 (70), 77 (23), 63 (16), 57 (15), 51 (23), 41 (19). 
IR (KBr) : υ~  [cm-1] = 3449m, 3057w, 2956m, 1743s, 1607w, 1484m, 1454m, 1359s, 1326m, 
1213s, 1167s, 1032m, 823m, 759m, 667s, 591w, 547w. 
EA % found (calcd): C: 59.55 (59.32), H: 5.22 (5.20), N: 3.14 (3.14). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (90 : 10), 
0.5 mL/min., 25 °C, tR = 43 min, 47 min, λlocal max 204 nm, 224 nm. 
 
(2S*,3R*,3aR*,11cR*)-1,2,3,3a,4,11c-hexahydro-5-oxa-1-aza-cyclopenta[c]phenan-
threne-2,3-dicarboxylic acid dimethyl ester (170a) 
 
 
 
 
 
The synthesis was performed according to general procedure IX (page 190). 
 
C19H19NO5 (341.13). 
colorless solid. Rf = 0.15 (Hx : EtOAc  2 : 1). 
1H NMR (500.1 MHz, CD2Cl2, 300 K): δ = 2.55 (dq, J(H,H) = 11.7 Hz, J(H,H) = 3.8 Hz, 1H, 
H-3a), 2.59 (bd, J(H,H) ≈ 11 Hz, 1H, H-1), 3.12 (dd, J(H,H) = 11.7 Hz, J(H,H) = 10.8 Hz, 
1H, H-3), 3.70 (s, 3H, C(3)CO2CH3), 3.71 (s, 3H, C(2)CO2CH3), 4.08 (bt, J(H,H) = 11.5 Hz, 
1H, H-11c), 4.22 (dd, J(H,H) = 11.7 Hz, J(H,H) = 10.2 Hz, 1H, H-4), 4.45 (bt, J(H,H) = 9.5 
Hz, 1H, H-2), 4.57 (dd, J(H,H) = 10.2 Hz, J(H,H) = 3.7 Hz, 1H, H-4), 7.04 (d, J(H,H) = 9.1 
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Hz, 1H, H-6), 7.32 (m, 1H, H-9), 7.44 (m, 1H, H-10), 7.67 (bd, J(H,H) = 8.8 Hz, 1H, H-7), 
7.74 (bd, J(H,H) = 8.1 Hz, 1H, H-8), 8.75 (bd, J(H,H) = 8.8 Hz, 1H, H-11). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 300 K): δ = 49.0 (C-3a), 49.2 (C-3), 52.5 
(C(3)CO2CH3), 52.8 (C(2)CO2CH3), 60.2 (C-11c), 64.0 (C-3a), 68.5 (C-4), 115.9 (C-11b), 
118.7 (C-6), 123.7 (C-9), 126.1 (C-11), 126.4 (C-10), 128.3 (C-8), 129.3 (C-7a), 129.7 (C-7), 
132.8 (C-11a), 152.3 (C-5a), 172.4 (C(3)CO2CH3), 172.5 (C(2)CO2CH3). 
HPLC: Daicel Chiralcel AD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (90 : 10), 
0.5 ml/min, 25 °C, tR = 41 min, 49 min, λlocal max 231 nm, 276 nm. 
 
(2R*,3R*,3aR*,11cS*)-1,2,3,3a,4,11c-hexahydro-5-oxa-1-aza-cyclopenta[c]phenan-
threne-2,3-dicarboxylic acid dimethyl ester (170b) 
 
 
 
 
 
C19H19NO5 (341.13). 
m.p. 80–83 °C. 
Rf = 0.17 (Hx : EtOAc  5:1). 
1H NMR (500.0 MHz, CD2Cl2, 295 K): δ = 2.60 (br s, 1H, H-1), 2.84 (dddd, J(H,H) = 11.2 
Hz, J(H,H) = 6.1 Hz, J(H,H) = 4.9 Hz, J(H,H) = 3.5 Hz, 1H, H-3a), 2.86 (dd, J(H,H) = 6.6 
Hz, J(H,H) = 3.5 Hz, 1H, H-3), 3.67 (s, 3H, C(3)CO2CH3), 3.79 (t, J(H,H) = 10.7 Hz, 1H, H-
4), 3.79 (s, 3H, C(2)CO2CH3), 4.20-4.25 (m, 1H, H-3), 4.28 (d, J(H,H) = 6.4 Hz, 1H, H-2), 
4.63 (d, J(H,H) = 5.8 Hz, 1H, H-11c), 7.07 (d, J(H,H) = 8.9 Hz, 1H, H-6), 7.37 (ddd, J(H,H) 
= 8.1 Hz, J(H,H) = 6.9 Hz, J(H,H) = 1.2 Hz, 1H, H-9), 7.53 (ddd, J(H,H) = 8.5 Hz, J(H,H) = 
6.9 Hz, J(H,H) = 1.4 Hz, 1H, H-10), 7.70 (dq, J(H,H) = 8.9 Hz, J(H,H) = 0.5 Hz, 1H, H-7), 
7.77 (ddt, J(H,H) = 8.1 Hz, J(H,H) = 1.4 Hz, J(H,H) = 0.7 Hz, 1H, H-8), 8.20 (dq, J(H,H) = 
8.5 Hz, J(H,H) = 0.9 Hz, 1H, H-11). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 42.0 (C-3a), 50.9 (C-3), 52.7 
(C(3)CO2CH3), 52.8 (C(2)CO2CH3), 54.3 (C-11c), 62.8 (C-2), 65.2 (C-4), 114.6 (C-11b), 
118.8 (C-6), 123.9 (C-11), 124.1 (C-9), 127.1 (C-10), 128.5 (C-8), 129.7 (C-7a), 129.8 (C-7), 
133.8 (C-11a), 152.8 (C-5a), 173.2 (C(3)CO2CH3), 173.5 (C(2)CO2CH3); 
MS (FAB) m/z (rel. Int. %): 342 (M+1,100), 341 (22), 340 (10), 282 (30), 182 (27), 181 (12). 
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13.5 Asymmetric Hydrogenation of Olefines and Imines 
 
13.5.1 Preparation of Ir(I)-PHOX Complexes 
 
(4S,5R)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5-phenyl-
4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate (196) 
 
 
 
 
 
 
General Procedure X: 
A solution of the (4S,5R)-2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5-phenyl-4,5-
dihydrooxazole (70.0 mg, 0.15 mmol) in dichloromethane (3.00 mL) was added to a solution 
of [Ir(COD)Cl]2 (49.0 mg, 0.07 mmol) in dichloromethane (3.00 mL). The reaction mixture 
was heated to reflux for 2 h before NaB(ArF)4 (203 mg, 0.23 mmol) was added at rt followed 
by H2O (6.00 mL). The resulting two-phase mixture was stirred vigorously for 10 min. The 
layers were separated and the aqueous layer was extracted with dichloromethane (2 x 6 mL). 
The combined organic extracts were washed with H2O (6 mL), dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude product was purified by column 
chromatography (Diethyl ether : DCM  4 : 1) on silica to afford the pure complex 196 as a red 
solid (200 mg, 81%). 
 
C72H56NOPF24BIr (1641.18). 
m.p. 86-89 °C. 
20][ Dα  = -161.5° (c = 0.390, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = 0.06 (d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 0.25 
(d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 1.12 (br s, 1H, CH2(COD)), 1.27 (br s, 1H, CH2(COD)), 
1.60 (br s, 1H, CH(CH3)2), 1.66-1.75 (m, 2H, CH2(COD)), 1.88-1.98 (m, 2H, CH2(COD)), 2.04-
2.17 (m, 2H, CH2(COD)), 2.15 (s, 3H, oTol-CH3), 2.40 (br s, 3H, oTol-CH3), 2.66 (br s, 1H, 
CH(COD)), 3.15 (br s, 1H, CH(COD)), 3.98 (dd, J(H,H) = 8.9 Hz, J(H,H) = 2.7 Hz, 1H, NCH), 
4.42-4.48 (m, 1H, CH(COD)), 4.66 (br s, 1H, CH(COD)), 5.36 (d, J(H,H) = 8.9 Hz, 1H, OCH), 
6.61 (dd, J(H,P) = 12.0 Hz, J(H,H) = 7.9 Hz, 1H, Ar-H), 6.81-6.86 (m, 2H, Ar-H), 6.92-6.98 
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(m, 5H, Ar-H), 7.00-7.04 (m, 2H, Ar-H), 7.06-7.12 (m, 5H, Ar-H), 7.13-7.17 (m, 1H, Ar-H), 
7.64 (br s, 4H, B(ArF)4-H), 7.95 (ddd, J(H,P) = 8.1 Hz, J(H,H) = 4.3 Hz, J(H,H) = 1.3 Hz, 
1H, Ar-H), 8.19 (br s, 8H, B(ArF)4-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 17.3 (CH(CH3)2), 17.5 (CH(CH3)2), 24.2 
(d, J(C,P) = 6.2 Hz, oTol-CH3), 25.1 (d, J(C,P) = 6.1 Hz, oTol-CH3), 26.0 (d, J(C,P) = 1.9 
Hz, CH2(COD)), 28.4 (CH2(COD)), 31.8 (CH(CH3)2), 32.9 (CH2(COD)), 35.6 (d, J(C,P) = 4.8 Hz, 
CH2(COD)), 67.3 (CH(COD)), 67.6 (CH(COD)), 74.0 (NCH), 86.5 (OCH), 90.2 (d, J(C,P) = 13.9 
Hz, CH(COD)), 94.8 (d, J(C,P) = 10.6 Hz, CH(COD)), 118.1 (sept, J(C,F) = 3.8 Hz, 4C, B(ArF)4-
H), 120.5 (d, J(C,P) = 53.2 Hz, oTol(ipso)-P), 125.5 (q, J(C,F)= 272.6 Hz, 8C, CF3), 126.3 (2C, 
Ar-H), 127.3 (d, J(C,P)= 11.0 Hz, Ar-H), 127.4 (d, J(C,P)= 10.1 Hz, Ar-H), 129.6 (2C, Ar-
H), 130.2 (d, J(C,P) = 48.5 Hz, oTol(ipso)-P), 130.2 (qq, J(C,F) = 31.7 Hz, J(C,B) = 2.9 Hz, 
8C, Ar-CF3), 131.6 (Ar-H), 132.5 (d, J(C,P) = 1.9 Hz, Ar-H), 132.8 (d, J(C,P) = 2.3 Hz, Ar-
H), 132.9 (Ar-H), 133.0 (Ar-H), 133.1 (d, J(C,P) = 1.4 Hz, Ar-H), 133.3 (d, J(C,P) = 8.1 Hz, 
Ar-H), 133.6 (d, J(C,P) = 6.7 Hz, Ar-H), 134.0 (d, J(C,P) = 9.6 Hz, Ar-H), 134.3 (d, J(C,P) = 
8.2 Hz, Ar-H), 135.8 (Ar-H), 135.8 (br s, 8C, B(ArF)4-H), 141.8 (d, J(C,P) = 9.6 Hz, 
oTol(ortho)-CH3), 143.7 (d, J(C,P) = 9.6 Hz, oTol(ortho)-CH3), 162.9 (q, J(C,B) = 49.9 Hz, 4C, 
C-B), 164.5 (d, J(C,P) = 6.2 Hz, C=N). (Three quaternary C-atoms are not visible). 
31P{1H} NMR (202.5 MHz, toluene-d8, 300 K): δ = 12.7. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.4 (m). 
+ESIMS, CH2Cl2, m/e: 778 ([M - B(ArF)4]+, 100%). 
IR (KBr) : υ~  [cm-1] = 3449w, 3066w, 2966m, 2926m, 2889w, 1607m, 1456w, 1356s, 1279s, 
1127s, 965w, 890m, 839w, 805w, 750w, 713m, 676m. 
EA % found (calcd): C: 52.84 (52.69), H: 3.41 (3.44), N: 1.07 (0.85). 
 
(4S,5S)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5-phenyl-
4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate (195) 
 
 
 
 
 
Complex 195 was prepared according to general procedure X (page 209) from (4S,5R)-2-(2-
(Dio-tolylphosphino)phenyl)-4-isopropyl-5-phenyl-4,5-dihydrooxazole (100 mg, 0.21 mmol), 
[Ir(COD)Cl]2 (70.0 mg, 0.10 mmol), NaB(ArF)4 (327 mg, 0.33 mmol) and dichloromethane as 
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a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  4 : 1) on silica 
complex 195 (290 mg, 84%) was isolated as a red solid. 
 
C72H56NOPF24BIr (1641.18). 
m.p. 80–83 °C. 
20][ Dα  = -151.8° (c = 0.400, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = -0.01 (d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 
0.68 (d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 0.97-1.05 (m, 1H, CH2(COD)), 1.06-1.14 (m, 1H, 
CH2(COD)), 1.56-1.63 (m, 2H, CH2(COD)), 1.77-1.87 (m, 2H, CH2(COD)), 1.95-2.06 (m, 3H, 
CH2(COD) & CH(CH3)2)), 2.12 (s, 3H, oTol-CH3), 2.37 (br s, 3H, oTol-CH3), 2.58 (br s, 1H, 
CH(COD)), 3.10 (br s, 1H, CH(COD)), 3.75 (app t, J(H,H) = 3.2 1H, NCH), 4.19-4.25 (m, 1H, 
CH(COD)), 4.32 (br s, 1H, CH(COD)), 5.04 (d, J(H,H) = 3.8 Hz, 1H, OCH), 6.61 (dd, J(H,P) = 
12.8 Hz, J(H,H) = 7.9 Hz, 1H, Ar-H), 6.83-6.86 (m, 1H, Ar-H), 6.87-6.93 (m, 3H, Ar-H), 
6.95-7.02 (m, 4H, Ar-H), 7.05-7.19 (m, 7H, Ar-H), 7.65 (br s, 4H, B(ArF)4-H), 7.93 (dd, 
J(H,P) = 7.9 Hz, J(H,H) = 7.9 Hz, 1H, Ar-H), 8.19 (br s, 8H, B(ArF)4-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 13.7 (CH(CH3)2), 18.2 (CH(CH3)2), 24.3 
(d, J(C,P) = 6.2 Hz, oTol-CH3), 25.0 (d, J(C,P) = 6.1 Hz, oTol-CH3), 26.0 (d, J(C,P) = 1.9 
Hz, CH2(COD)), 28.3 (d, J(C,P) = 3.8 Hz, CH2(COD)), 32.9 (d, J(C,P)= 1.0 Hz, CH2(COD)), 33.0 
(CH(CH3)2), 35.6 (d, J(C,P) = 5.2 Hz, CH2(COD)), 67.3 (2C, CH(COD)), 79.3 (NCH), 81.6 
(OCH), 89.2 (d, J(C,P) = 13.9 Hz, CH(COD)), 95.1 (d, J(C,P) = 10.0 Hz, CH(COD)), 118.1 (sept, 
J(C,F) = 3.8 Hz, 4C, B(ArF)4-H), 120.4 (d, J(C,P) = 59.0 Hz, oTol(ipso)-P), 124.7 (2C, Ar-H), 
125.5 (q, J(C,F) = 272.6 Hz, 8C, CF3), 127.3 (d, J(C,P) = 11.5 Hz, Ar-H), 127.4 (d, J(C,P) = 
10.0 Hz, Ar-H), 129.7 (d, J(C,P) = 65.0 Hz, oTol(ipso)-P), 130.1 (2C, Ar-H), 130.2 (qq, J(C,F) 
= 31.1 Hz, J(C,B) = 2.8 Hz, 8C, Ar-CF3), 130.3 (Ar-H), 132.5 (d, J(C,P) = 1.9 Hz, Ar-H), 
132.8 (Ar-H), 132.9 (Ar-H), 132.9 (Ar-H), 133.2 (d, J(C,P) = 1.9 Hz, Ar-H), 133.3 (d, J(C,P) 
= 8.6 Hz, Ar-H), 133.4 (d, J(C,P) = 6.7 Hz, Ar-H), 133.8 (d, J(C,P) = 7.6 Hz, Ar-H), 134.0 
(d, J(C,P) = 10.0 Hz, Ar-H), 135.6 (Ar-H), 135.8 (br s, 8C, B(ArF)4-H), 138.4 (OCH-Ph(ipso), 
141.8 (d, J(C,P) = 9.1 Hz, oTol(ortho)-CH3), 143.8 (d, J(C,P) = 9.1 Hz, oTol(ortho)-CH3), 162.9 
(q, J(C,B) =49.9 Hz, 4C, C-B), 163.8 (d, J(C,P) = 6.7 Hz, C=N).(two quaternary C-atoms are 
not visible). 
31P{1H} NMR (202.5 MHz, toluene-d8, 300 K): δ = 13.4. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.5 (m). 
+ESIMS, CH2Cl2, m/e: 778 ([M - B(ArF)4]+, 100%). 
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IR (KBr) : υ~  [cm-1] = 3448w, 3066w, 2966m, 2926m, 1607m, 1457w, 1355s, 1279s, 1127s, 
965w, 890m, 839w, 805w, 749w, 714m, 677m. 
EA % found (calcd): C: 52.71 (52.69), H: 3.59 (3.44), N: 0.95 (0.85). 
 
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Diphenylphosphino)phenyl)-4-isopropyl-5,5-diphenyl-
4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate (193) 
 
 
 
 
 
Complex 193 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Diphenylphosphino)phenyl)-4-isopropyl-5,5-diphenyl-4,5-dihydrooxazole (100 mg, 
0.19 mmol), [Ir(COD)Cl]2 (64.0 mg, 0.10 mmol), NaB(ArF)4 (263 mg, 0.30 mmol) and 
dichloromethane as a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  
4 : 1) on silica complex 193 (230 mg, 72%) was isolated as a red solid. 
 
C76H56NOPF24BIr (1689.22). 
m.p. 85–88 °C. 
20][ Dα  = -104.0° (c = 0.170, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = -0.09 (d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 0.94 
(d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 1.34-1.42 (m, 1H, CH2(COD)), 1.62-1.70 (m, 1H, 
CH2(COD)), 1.84-1.90 (m, 1H, CH2(COD)), 2.01 (ds, J(H,P) = 6.9 Hz, J(H,H) = 2.1 Hz, 1H, 
CH(CH3)2)), 2.03-2.13 (m, 2H, CH2(COD)), 2.22 (dd, J(H,P) = 15.6 Hz, J(H,H) = 8.4 Hz, 1H, 
CH2(COD)), 2.47 (dd, J(H,P) = 15.6 Hz, J(H,H) = 7.4 Hz, 1H, CH2(COD)), 2.57-2.65 (m, 1H, 
CH2(COD)), 2.89-2.94 (m, 1H, CH(COD)), 3.44-3.47 (m, 1H, CH(COD)), 4.36 (br s, 1H, CH(COD)), 
4.89 (d, J(H,H) = 2.2 Hz, 1H, NCH), 5.04-5.09 (m, 1H, CH(COD)), 7.06-7.10 (m, 2H, Ph-H), 
7.26-7.27 (m, 1H, Ph-H), 7.31-7.35 (m, 2H, Ph-H), 7.37-7.41 (m, 1H, Ph-H), 7.42-7.63 (m, 
15H, Ph-H), 7.56 (br s, 4H, B(ArF)4-H), 7.72 (br s, 8H, B(ArF)4-H), 7.72 (tt, J(H,P) = 7.6 Hz, 
J(H,H)=1.1 Hz, 1H, Ph-H), 7.90 (tt, J(H,P) = 7.8 Hz, J(H,H) = 1.4 Hz, 1H, Ph-H), 8.72 (ddd, 
J(H,P) = 8.1 Hz, J(H,H) = 4.1 Hz, J(H,H) = 1.1 Hz, 1H, Ph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 15.0 (CH(CH3)2), 20.2 (CH(CH3)2), 26.5 
(d, J(C,P) = 1.9 Hz, CH2(COD)), 27.7 (d, J(C,P) = 1.9 Hz, CH2(COD)), 31.1 (CH(CH3)2), 32.9 (d, 
J(C,P) = 1.4 Hz, CH2(COD)), 37.1 (d, J(C,P) = 4.8 Hz, CH2(COD)), 63.9 (CH(COD)), 64.3 
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(CH(COD)), 78.9 (NCH), 94.3 (d, J(C,P) = 13.4 Hz, CH(COD)), 94.5 (OC), 99.1 (d, J(C,P) = 
10.6 Hz, CH(COD)), 118.0 (sept, J(C,F) = 3.8 Hz, 4C, B(ArF)4-H), 123.4 (d, J(C,P) = 57.6 Hz, 
Ph(ipso)-P), 124.3 (2C, Ph-H), 125.4 (q, J(C,F) = 272.2 Hz, 8C, CF3), 126.2 (2C, Ph-H), 128.9 
(Ph-H), 129.2 (2C, Ph-H), 129.3 (Ph-H), 129.4 (Ph-H), 129.4 (d, J(C,P) = 47.0 Hz, Ph(ortho)-
P), 129.4 (qq, J(C,F) = 31.7 Hz, J(C,B) = 2.9 Hz, 8C, Ar-CF3), 129.7 (d, J(C,P) = 13.0 Hz, 
Ph(ipso)-CN), 129.8 (Ph-H), 129.9 (2C, Ph-H), 130.1 (d, J(C,P) = 52.3 Hz, Ph(ipso)-P), 130.2 
(Ph-H), 130.3 (Ph-H), 132.5 (d, J(C,P) = 2.4 Hz, Ph-H), 133.2 (d, J(C,P) = 2.4 Hz, Ph-H), 
133.3 (d, J(C,P) = 1.9 Hz, Ph-H), 133.8 (Ph-H), 133.9 (Ph-H), 134.6 (d, J(C,P) = 8.2 Hz, Ph-
H), 135.0 (d, J(C,P) = 7.2 Hz, Ph-H), 135.3 (br s, 8C, B(ArF)4-H), 135.3 (Ph-H), 135.5 (d, 
J(C,P)= 1.4 Hz, Ph-H), 136.0 (d, J(C,P) = 1.4 Hz, Ph-H), 137.0 (C(Ph(ipso))2), 143.6 
(C(Ph(ipso))2), 162.3 (q, J(C,B) = 49.9 Hz, 4C, C-B), 163.0 (d, J(C,P) = 6.7 Hz, C=N). 
31P{1H} NMR (202.5 MHz, CD2Cl2, 295 K): δ = 16.1. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.5 (m). 
MS (FAB) m/z (rel int %): 826 ([M – B(ArF)4]+, 100), 542 (10), 453 (14), 375 (22), 305 (30), 
300 (16), 178 (12), 165 (28), 105 (46), 91 (38), 79 (14), 65 (22). 
IR (KBr) : υ~  [cm-1] = 3066w, 2966m, 1610m, 1567m, 1483m, 1450w, 1438m, 1355s, 1278s, 
1127s, 1000m, 980w, 929w, 886m, 839w, 745w, 712m, 698m. 
EA % found (calcd): C: 54.13 (54.04), H: 3.51 (3.34), N: 1.00 (0.83). 
 
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-diphenyl-
4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate (194) 
 
 
 
 
 
Complex 194 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-diphenyl-4,5-dihydrooxazole (300 mg, 
0.57 mmol), [Ir(COD)Cl]2 (195 mg, 0.29 mmol), NaB(ArF)4 (789 mg, 0.89 mmol) and 
dichloromethane as a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  
4 : 1) on silica complex 194 (730 mg, 75%) was isolated as a red solid. 
 
C78H60NOPF24BIr (1717.28). 
m.p. 82–84 °C. 
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20][ Dα  = -181.5° (c = 0.830, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = -0.11 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 
0.64 (d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 0.96-1.01 (m, 1H, CH2(COD)), 1.19-1.23 (m, 1H, 
CH2(COD)), 1.48-1.52 (m, 1H, CH2(COD)), 1.68-1.76 (m, 3H, CH2(COD)), 1.82-1.90 (m, 2H, 
CH2(COD) & CH(CH3)2)), 1.99 (br s, 3H, oTol-CH3), 2.05-2.12 (m, 1H, CH2(COD)), 2.46 (br s, 
3H, oTol-CH3), 2.56 (br s, 1H, CH(COD)), 3.18 (br s, 1H, CH(COD)), 4.13 (br s, 1H, CH(COD)), 
4.54 (br s, 1H, CH(COD)), 4.64 (d, J(H,H) = 2.1 Hz, 1H, NCH), 6.63 (ddd, J(H,P) = 12.5 Hz, 
J(H,H) =7.9 Hz, J(H,H) = 1.0 Hz, 1H, Ar-H), 6.77-6.80 (m, 1H, Ph-H), 6.81-6.84 (m ,1H, Ar-
H), 6.92-7.14 (m, 15H, Ar-H), 7.18-7.21 (m, 1H, Ar-H), 7.25-7.27 (m, 2H, Ar-H), 7.65 (br s, 
4H, B(ArF)4-H), 8.23 (br s, 8H, B(ArF)4-H), 8.26 (ddd, J(H,P) = 7.9 Hz, J(H,H) = 7.9 Hz, 
J(H,H) = 1.0 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 15.4 (CH(CH3)2), 19.3 (CH(CH3)2), 24.3 
(d, J(C,P) = 6.1 Hz, oTol-CH3), 25.1 (d, J(C,P) = 6.1 Hz, oTol-CH3), 25.7 (d, J(C,P) = 2.3 
Hz, CH2(COD)), 28.1 (CH2(COD)), 31.2 (CH(CH3)2), 32.8 (CH2(COD)), 35.7 (d, J(C,P) = 5.2 Hz, 
CH2(COD)), 67.5 (CH(COD)), 67.5 (CH(COD)), 78.9 (NCH), 89.6 (d, J(C,P) = 14.6 Hz, CH(COD)), 
94.7 (OC), 95.9 (d, J(C,P) = 9.9 Hz, CH(COD)), 118.1 (sept, J(C,F)= 3.9 Hz, 4C, B(ArF)4-H), 
120.2 (d, J(C,P) = 54.0 Hz, oTol(ipso)-P), 124.1 (2C, Ar-H), 125.4 (q, J(C,F)= 273.0 Hz, 8C, 
CF3), 125.5 (Ar-H), 126.1 (2C, Ar-H), 127.3 (d, J(C,P) = 5.0 Hz, Ar-H), 127.4 (d, J(C,P) = 
5.0 Hz, Ar-H), 128.3 (Ar-H), 128.4 (d, J(C,P) = 12.8 Hz, Ar(ipso)-CN), 128.8 (Ar-H), 128.9 
(Ar-H), 129.3 (Ar-H), 129.6 (Ar-H), 129.6 (d, J(C,P) = 37.0 Hz, Ar(ortho)-P), 130.1 (qq, 
J(C,F) = 31.2 Hz, J(C,B) = 2.9 Hz, 8C, Ar-CF3), 130.2 (d, J(C,P) = 48.0 Hz, oTol(ipso)-P), 
132.6 (d, J(C,P) = 1.9 Hz, Ar-H), 132.7 (d, J(C,P) = 1.9 Hz, Ar-H), 132.8 (Ar-H), 132.9 (Ar-
H), 132.9 (Ar-H), 133.2 (d, J(C,P) = 8.2 Hz, Ar-H), 133.7 (d, J(C,P) = 6.2 Hz, Ar-H), 133.9 
(d, J(C,P) = 4.8 Hz, Ar-H), 133.9 (d, J(C,P) = 2.4 Hz, Ar-H), 135.7 (br s, 8C, B(ArF)4-H), 
135.9 (Ar-H), 136.8 (C(Ph(ipso))2), 141.7 (d, J(C,P) = 9.3 Hz, oTol(ortho)-CH3), 143.4 
(C(Ph(ipso))2), 143.5 (d, J(C,P) = 10.0 Hz, oTol(ortho)-CH3), 162.7 (d, J(C,P) = 5.8 Hz, C=N), 
162.8 (q, J(C,B) = 50.0 Hz, 4C, C-B). 
31P{1H} NMR (202.5 MHz, toluene-d8, 300 K): δ = 13.0. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = - 64.6 (m). 
MS (FAB) m/z (rel int %): 854 ([M – B(ArF)4]+, 100), 745 (11), 479 (14), 401 (20), 387 (17), 
313 (22), 178 (15), 165 (20), 105 (30), 91 (25), 77 (33), 63 (13), 55 (17), 51 (19), 43 (19), 41 
(25), 39 (28). 
IR (KBr) : υ~  [cm-1] = 3449s, 3066w, 2966m, 2931m, 1655m, 1612m, 1458w, 1356s, 1279s, 
1128s, 889m, 751w, 709w, 676w. 
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EA % found (calcd): C: 54.47 (54.55), H: 3.48 (3.52), N: 0.90 (0.82). 
 
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-diphenyl-
4,5-dihydrooxazole}iridium(I)]-hexafluorophosphate (219) 
 
 
 
 
 
 
Complex 219 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-diphenyl-4,5-dihydrooxazole (300 mg, 
0.57 mmol), [Ir(COD)Cl]2 (195 mg, 0.29 mmol) and dichloromethane as a solvent (6.00 mL). 
Anion exchange was achieved by washing the reaction solution twice with an aqueous 
solution of NH4PF6 (0.4M, two 11 mL portions). The organic layer was washed with water 
and dried over Na2SO4. Crystals suitable for X-ray analysis were obtained from diethyl 
ether/pentane. 
 
C46H48NOP2F6Ir (999.27). 
m.p. 275 °C (decomposition). 
20][ Dα  = -402.5° (c = 0.400, CHCl3). 
1H NMR (500.1 MHz, CD3CN, 300 K): δ = -0.25 (br s, 3H, CH(CH3)2), 0.99 (d, J(H,H) = 7.1 
Hz, 3H, CH(CH3)2), 1.39 (br s, 1H, CH2(COD)), 1.59 (br s, 1H, CH2(COD)), 1.89-1.94 (m, 2H, 
CH2(COD)), 2.06 (m, 3H, 2 x CH2(COD) & CH(CH3)2)), 2.31 (s, 3H, oTol-CH3), 2.34 (br s, 1H, 
CH2(COD)), 2.43 (br s, 1H, CH2(COD)), 2.74 (br s, 3H, oTol-CH3), 3.06 (br s, 1H, CH(COD)), 3.37 
(br s, 1H, CH(COD)), 4.10 (br s, 1H, CH(COD)), 4.95 (br s, 1H, CH(COD)), 5.04 (br s, 1H, NCH), 
6.81 (ddd, J(H,P) = 12.8 Hz, J(H,H) =7.9 Hz, J(H,H) = 1.2 Hz, 1H, Ar-H), 7.19-7.29 (m, 3H, 
Ar-H), 7.33-7.38 (m, 4H, Ar-H), 7.41-7.50 (m, 7H, Ar-H), 7.54-7.56 (m, 2H, Ar-H), 7.74-
7.80 (m, 3H, Ar-H), 7.92-7.95 (m, 1H, Ar-H), 8.85 (br s, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, CD3CN, 300 K): δ = 14.6 (CH(CH3)2), 20.1 (CH(CH3)2), 25.0 
(oTol-CH3), 26.0 (oTol-CH3), 26.0 (CH2(COD)), 28.3 (CH2(COD)), 31.0 (CH(CH3)2), 33.6 
(CH2(COD)), 36.4 (CH2(COD)), 67.8 (CH(COD)), 67.8 (CH(COD)), 79.2 (NCH), 89.6 (d, J(C,P) = 
14.9 Hz, CH(COD)), 94.9 (OC), 97.1 (d, J(C,P) = 10.1 Hz, CH(COD)), 125.1 (2C, Ar-H), 126.7 
(2C, Ar-H), 127.9 (d, J(C,P) = 10.0 Hz, Ar-H), 128.0 (d, J(C,P) = 10.0 Hz, Ar-H), 128.6 
(Ar(q)), 129.0 (Ar-H), 129.5 (2C, Ar-H), 129.9 (Ar-H), 130.2 (2C, Ar-H), 132.9 (Ar-H), 
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133.3-133.7 (5C, Ar-H), 134.7 (Ar-H), 134.7 (Ar-H), 135.3 (Ar-H), 135.4 (Ar-H), 136.9 (br 
s, Ar(q)), 138.3 (Ar(q)), 142.8 (br s, Ar(q)), 144.5 (Ar(q)), 144.6 (Ar(q)), 144.9 (Ar(q)), 163.3 (d, 
J(C,P) = 6.2 Hz, C=N). (One quaternary C-atom is not visible). 
31P{1H} NMR (202.5 MHz, CD3CN, 300 K): δ = 5.8 (s), -147.6 (sept, J(P,F) = 705 Hz). 
19F{1H} NMR (376.5 MHz, CD3CN, 300 K): δ = -74.0 (d, J(F,P) = 707 Hz). 
+ESIMS, CH2Cl2, m/e: 854 ([M – PF6]+, 100%). 
IR (KBr) : υ~  [cm-1] = 3448m, 3058w, 2963m, 2941m, 2916m, 2883m, 2840m, 1600s, 
1582m, 1566m, 1477m, 1450s, 1358s, 1283m, 1256m, 1235m, 1126s, 985m, 839m, 761s, 
710s, 679w. 
  
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-di(naph-
thalen-2-yl)-4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]-
borate (197) 
 
 
 
 
 
Complex 197 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-di(naphthalen-2-yl)-4,5-dihydrooxazole (143 
mg, 0.22 mmol), [Ir(COD)Cl]2 (73.0 mg, 0.11 mmol), NaB(ArF)4 (302 mg, 0.34 mmol) and 
dichloromethane as a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  
4 : 1) on silica complex 197 (340 mg, 85%) was isolated as a red solid. 
 
C86H64NOPF24BIr (1817.29). 
m.p. 110-114 °C. 
20][ Dα  = -220.0° (c = 0.460, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = 0.02 (d, J(H,H) = 6.9 Hz, 3H, CH(CH3)2), 0.72 
(d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 0.92-1.00 (m, 1H, CH2(COD)), 1.27 (br s, 1H, CH2(COD)), 
1.39-1.47 (m, 1H, CH2(COD)), 1.48-1.54 (m, 1H, CH2(COD)), 1.55-1.62 (m, 1H, CH2(COD)), 1.78-
1.84 (m, 1H, CH2(COD)), 1.85-1.90 (m, 1H, CH2(COD)), 1.98 (br s, 3H, oTol-CH3), 2.00 (ds, 
J(H,H) = 7.1 Hz, J(H,H) = 2.1 Hz, 1H, CH(CH3)2), 2.05-2.12 (m, 1H, CH2(COD)), 2.45 (br s, 
3H, oTol-CH3), 2.56 (br s, 1H, CH(COD)), 3.26 (br s, 1H, CH(COD)), 4.45 (br s, 1H, CH(COD)), 
4.76 (quint, J(H,H) = J(H,P) = 7.1 Hz, 1H, CH(COD)), 5.06 (d, J(H,H) = 2.1 Hz, 1H, NCH), 
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6.64 (dd, J(H,P) = 12.5 Hz, J(H,H) = 7.9 Hz, 1H, Ar-H), 6.82-6.85 (m, 2H, Ar-H), 6.94-7.00 
(m, 3H, Ar-H), 7.00-7.05 (m, 2H, Ar-H), 7.13-7.29 (m, 8H, Ar-H), 7.47-7.54 (m, 5H, Ar-H), 
7.58-7.59 (m, 1H, Ar-H), 7.62-7.64 (m, 1H, Ar-H),7.64 (br s, 4H, B(ArF)4-H), 7.94 (d, J(H,H) 
= 1.6 Hz, 1H, Ar-H), 7.96 (d, J(H,H) = 1.6 Hz, 1H, Ar-H), 8.21 (br s, 8H, B(ArF)4-H), 8.45 
(dd, J(H,H) = 7.9 Hz, J(H,P) = 4.1 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 15.9 (CH(CH3)2), 19.5 (CH(CH3)2), 24.4 
(d, J(C,P) = 6.2 Hz, oTol-CH3), 25.1 (d, J(C,P) = 5.8 Hz, oTol-CH3), 25.1 (d, J(C,P) = 2.4 
Hz, CH2(COD)), 28.2 (CH2(COD)), 31.7 (CH(CH3)2), 32.7 (CH2(COD)), 35.7 (d, J(C,P) = 5.3 Hz, 
CH2(COD)), 67.8 (2C, CH(COD)), 78.4 (NCH), 89.4 (d, J(C,P) = 14.9 Hz, CH(COD)), 95.5 (OC), 
95.8 (d, J(C,P) = 9.6 Hz, CH(COD)), 118.1 (sept, J(C,F) = 3.8 Hz, 4C, B(ArF)4-H), 120.4 (d, 
J(C,P) = 53.8 Hz, oTol(ipso)-P), 122.5 (Ar-H), 123.4 (Ar-H), 123.9 (Ar-H), 125.5 (Ar-H), 
125.5 (q, J(C,F) = 272.6 Hz, 8C, CF3), 127.4 (Ar-H), 127.5 (Ar-H), 127.7 (Ar-H), 127.8 (Ar-
H), 128.1 (Ar-H), 128.1 (Ar-H), 128.2 (Ar-H), 128.3 (Ar-H), 128.3 (Ar-H), 128.5 (Ar-H), 
129.1 (Ar-H), 129.9 (d, J(C,P) = 50.9 Hz, Ar(ortho)-P), 130.2 (qq, J(C,F) = 31.7 Hz, J(C,B) = 
2.9 Hz, 8C, Ar-CF3), 130.2 (d, J(C,P) = 47.5 Hz, oTol(ipso)-P), 130.4 (Ar-H), 132.7 (d, J(C,P) 
= 1.9 Hz, Ar-H), 132.8 (d, J(C,P) = 1.9 Hz, Ar-H), 132.9 (Ar-H), 132.9 (Ar-H), 133.1 (d, 
J(C,P) = 1.9 Hz, Ar-H), 133.4 (d, J(C,P) = 8.6 Hz, Ar-H), 133.5 (2C, Naph-C), 133.8 (d, 
J(C,P) = 6.7 Hz, Ar-H), 134.0 (d, J(C,P) = 8.2 Hz, Ar-H), 134.0 (2C, Naph-C), 134.1 (d, 
J(C,P) = 10.1 Hz, Ar-H), 135.8 (br s, 8C, B(ArF)4-H), 136.1 (Ar-H), 137.4 (C(Naph(ipso))2), 
140.1 (C(Naph(ipso))2), 141.8 (d, J(C,P) = 9.6 Hz, oTol(ortho)-CH3), 143.6 (d, J(C,P) = 10.0 Hz, 
oTol(ortho)-CH3), 163.0 (q, J(C,B) = 49.9 Hz, 4C, C-B), 163.1 (d, J(C,P) = 5.8 Hz, C=N). (One 
quaternary C-atom is not visible). 
31P{1H} NMR (202.5 MHz, toluene-d8, 300 K): δ = 13.3. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.3 (m). 
+ESIMS, CH2Cl2, m/e: 954 ([M - B(ArF)4]+, 100%). 
IR (KBr) : υ~  [cm-1] = 3448w, 3062w, 2966m, 2926m, 2888w, 1606m, 1454w, 1355s, 1278s, 
1127s, 965w, 890m, 838w, 813w, 748w, 712m, 676m. 
EA % found (calcd): C: 56.90 (56.84), H: 3.58 (3.55), N: 0.86 (0.77). 
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(oTol)2P N
O
Ir
B(ArF)4
oTol
oTol
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-dio-tolyl-
4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate (198) 
 
 
 
 
 
Complex 198 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Dio-tolylphosphino)phenyl)-4-isopropyl-5,5-dio-tolyl-4,5-dihydrooxazole (150 mg, 
0.26 mmol), [Ir(COD)Cl]2 (87.0 mg, 0.10 mmol), NaB(ArF)4 (356 mg, 0.40 mmol) and 
dichloromethane as a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  
4 : 1) on silica complex 198 (350 mg, 77%) was isolated as a red solid. 
 
C80H64NOPF24BIr (1745.33). 
m.p. 94–96 °C. 
20][ Dα  = -274.3° (c = 0.740, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = -0.13 (d, J(H,H) = 6.8 Hz, 3H, CH(CH3)2), 
0.92 (d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 1.02-1.09 (m, 1H, CH2(COD)), 1.29 (br s, 1H, 
CH2(COD)), 1.55-1.61 (m, 2H, CH2(COD) & CH(CH3)2), 1.59 (s, 3H, oTol-CH3), 1.75-1.88 (m, 
3H, CH2(COD)), 1.90-1.98 (m, 1H, CH2(COD)), 2.05 (br s, 3H, oTol-CH3), 2.08 (s, 3H, oTol-
CH3), 2.11-2.18 (m, 1H, CH2(COD)), 2.32 (br s, 3H, oTol-CH3), 2.52 (br s, 1H, CH(COD)), 3.53 
(br s, 1H, CH(COD)), 4.73 (br s, 1H, CH(COD)), 5.34 (br s, 2H, CH(COD) & NCH), 6.60 (ddd, 
J(H,P) = 12.1 Hz, J(H,H) = 7.9 Hz, J(H,H) = 1.3 Hz, 1H, Ar-H), 6.72 (br d, J(H,H) = 1.7 Hz, 
1H, Ar-H), 6.81-7.09 (m, 15H, Ar-H), 7.39-7.47 (m, 1H, Ar-H), 7.48 (br d, J(H,H) = 1.9 Hz, 
1H, Ar-H), 7.64 (br s, 4H, B(ArF)4-H), 7.92 (ddd, J(H,P) = 7.9 Hz, J(H,H) = 4.1 Hz, J(H,H) = 
1.5 Hz, 1H, Ar-H), 8.22 (br s, 8H, B(ArF)4-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 15.0 (CH(CH3)2), 21.4 (CH(CH3)2), 21.8 
(oTol-CH3), 22.2 (oTol-CH3), 24.3 (d, J(C,P) = 6.2 Hz, oTol-CH3), 24.8 (d, J(C,P) = 6.2 Hz, 
oTol-CH3), 25.5 (d, J(C,P) = 2.4 Hz, CH2(COD)), 28.0 (CH2(COD)), 31.3 (CH(CH3)2), 33.6 
(CH2(COD)), 36.0 (CH2(COD)), 67.9 (CH(COD)), 68.5 (CH(COD)), 74.9 (NCH), 86.7 (d, J(C,P) = 
15.8 Hz, CH(COD)), 94.9 (d, J(C,P) = 9.1 Hz, CH(COD)), 97.1 (OC), 118.3 (sept, J(C,F) = 3.8 
Hz, 4C, B(ArF)4-H), 120.6 (d, J(C,P) = 53.8 Hz, oTol(ipso)-P), 125.1 (Ar-H), 125.3 (Ar-H), 
125.4 (q, J(C,F) = 272.6 Hz, 8C, CF3), 125.7 (Ar-H), 127.4 (d, J(C,P) = 5.8 Hz, Ar-H), 127.5 
(d, J(C,P) = 5.8 Hz, Ar-H), 128.3 (Ar-H), 128.5 (Ar-H), 129.3 (Ar-H), 129.6 (Ar-H), 130.1 
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Cy
(qq, J(C,F) = 31.2 Hz, J(C,B) =2.9 Hz, 8C, Ar-CF3), 130.5 (Ar-H), 132.3 (d, J(C,P) = 1.9 Hz, 
Ar-H), 132.7 (Ar-H), 132.7 (Ar-H), 132.8 (Ar-H), 133.0 (Ar-H), 133.3 (d, J(C,P) = 7.2 Hz, 
Ar-H), 133.3 (d, J(C,P) = 7.2 Hz, Ar-H), 133.9 (d, J(C,P) = 10.0 Hz, Ar-H), 133.9 (d, J(C,P) 
= 8.1 Hz, Ar-H), 134.9 (oTol(ortho)-CH3), 134.9 (oTol(ortho)-CH3), 135.1 (Ar-H), 135.7 (br s, 
8C, B(ArF)4-H), 138.9 (2C, C(oTol(ipso))2), 142.1 (d, J(C,P) = 9.1 Hz, oTol(ortho)-CH3), 143.4 
(d, J(C,P) = 9.6 Hz, oTol(ortho)-CH3), 162.5 (d, J(C,P) = 5.8 Hz, C=N), 162.8 (q, J(C,B)=50.0 
Hz, 4C, C-B). (Three quaternary C-atoms are not visible). 
31P{1H} NMR (202.5 MHz, toluene-d8, 340 K): δ = 13.1. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.4 (m). 
MS (FAB) m/z (rel int %): 882 ([M – B(ArF)4]+, 100), 772 (16), 401 (23), 387 (19), 313 (27), 
165 (21), 105 (30), 91 (31), 77 (36), 63 (20), 57 (14), 51 (27), 39 (36). 
IR (KBr) : υ~  [cm-1] = 3450m, 3067w, 2966m, 2932m, 1610m, 1459w, 1355s, 1278s, 1128s, 
891m, 753m, 713m, 676m. 
EA % found (calcd): C: 54.95 (55.05), H: 3.71 (3.70), N: 1.00 (0.80). 
 
(S)-[(η4-1,5-cyclooctadien)-{5,5-dicyclohexyl-2-(2-(dio-tolylphosphino)phenyl)-4-iso-
propyl-4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate 
(192) 
 
 
 
 
 
Complex 192 was prepared according to general procedure X (page 209) from (S)-5,5-
dicyclohexyl-2-(2-(dio-tolylphosphino)phenyl)-4-isopropyl-4,5-dihydrooxazole (55.0 mg, 
0.10 mmol), [Ir(COD)Cl]2 (34.0 mg, 0.05 mmol), NaB(ArF)4 (141 mg, 0.16 mmol) and 
dichloromethane as a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  
4 : 1) on silica complex 192 (140 mg, 81%) was isolated as a red solid. 
 
C78H72NOPF24BIr (1729.38). 
m.p. 76-79 °C. 
20][ Dα  = -166.8° (c = 0.320, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = 0.40 (d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 0.86 
(d, J(H,H) = 6.9 Hz, 3H, CH(CH3)2), 0.92-0.99 (m, 1H, CH2(COD)), 0.99-1.72 (m, 10H, 
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CH2(cy)), 1.19-1.26 (m, 1H, CH2(COD)), 1.38-1.41 (m, 1H, CH2(cy)), 1.48-1.50 (m, 1H, CH2(cy)), 
1.50-1.76 (m, 13H, 8 x CH2(cy) & 2 x CH(cy) &CH(CH3)2 & 2 x CH2(COD)), 1.79-1.89 (m, 2H, 
CH2(COD)), 2.07-2.15 (m, 2H, CH2(COD)), 2.13 (s, 3H, oTol-CH3), 2.39 (s, 3H, oTol-CH3), 2.69 
(br s, 1H, CH(COD)), 3.45 (br s, 1H, CH(COD)), 3.98 (d, J(H,H) = 3.3 Hz, 1H, NCH), 4.39-4.45 
(m, 1H, CH(COD)), 4.97 (br s, 1H, CH(COD)), 6.67 (ddd, J(H,H) = 12.5 Hz, J(H,H) = 7.9 Hz, 
J(H,H) = 1.1 Hz, 1H, Ar-H), 6.78-6.81 (m, 1H, Ar-H), 6.84-6.87 (m, 1H, Ar-H), 6.91 (tt, 
J(H,H) = 7.8 Hz, J(H,H)= 1.1 Hz, 1H, Ar-H), 6.96-7.09 (m, 7H, Ar-H), 7.66 (br s, 4H, 
B(ArF)4-H), 7.94 (ddd, J(H,H) = 8.1 Hz, J(H,H) = 4.3 Hz, J(H,H) = 1.3 Hz, 1H, Ar-H), 8.19 
(br s, 8H, B(ArF)4-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 17.9 (CH(CH3)2), 20.8 (CH(CH3)2), 23.6 
(d, J(C,P) = 6.2 Hz, oTol-CH3), 24.2 (d, J(C,P) = 6.7 Hz, oTol-CH3), 24.9 (d, J(C,P) = 2.9 
Hz, CH2(COD)), 26.0 (CH2(Cy)), 26.1 (CH2(Cy)), 26.6 (3C, CH2(Cy)), 27.0 (CH2(Cy)), 27.5 (d, 
J(C,P) = 1.5 Hz, CH2(COD)), 28.3 (CH2(Cy)), 28.9 (CH2(Cy)), 29.1 (CH(CH3)2), 29.1 (CH2(Cy)), 
30.0 (CH2(Cy)), 32.9 (CH2(COD)), 35.3 (d, J(C,P) = 5.3 Hz, CH2(COD)), 42.6 (CH(Cy)), 45.8 
(CH(Cy)), 66.8 (CH(COD)), 67.6 (CH(COD)), 75.1 (NCH), 85.9 (CH(COD)), 92.9 (d, J(C,P) = 9.6 
Hz, CH(COD)), 96.5 (OC), 117.4 (sept, J(C,F)= 3.8 Hz, 4C, B(ArF)4-H), 119.9 (d, J(C,P) = 52.8 
Hz, oTol(ipso)-P), 124.8 (q, J(C,F) = 272.6 Hz, 8C, CF3), 126.7 (d, J(C,P) = 10.1 Hz, Ar-H), 
126.7 (d, J(C,P) = 10.1 Hz, Ar-H), 128.7 (Ar(ipso)-CN), 129.3 (d, J(C,P) = 49.0 Hz, Ar(ortho)-
P), 129.5 (qq, J(C,F) = 31.7 Hz, J(C,B) = 2.9 Hz, 8C Ar-CF3), 129.6 (d, J(C,P) = 48.0 Hz, 
oTol(ipso)-P), 131.8 (d, J(C,P) = 1.9 Hz, Ar-H), 132.0 (d, J(C,P) = 2.4 Hz, Ar-H), 132.2 (Ar-
H), 132.2 (Ar-H), 132.3 (Ar-H), 132.5 (Ar-H), 132.6 (Ar-H), 132.8 (d, J(C,P) = 8.2 Hz, Ar-
H), 133.4 (d, J(C,P) = 9.6 Hz, Ar-H), 134.9 (Ar-H), 135.1 (br s, 8C, B(ArF)4-H), 141.4 (d, 
J(C,P) = 9.1 Hz, oTol(ortho)-CH3), 142.7 (d, J(C,P) = 10.6 Hz, oTol(ortho)-CH3), 162.3 (q, 
J(C,B) = 49.9 Hz, 4C, Ar-B), 162.3 (d, J(C,P) = 5.8 Hz, C=N). 
31P{1H} NMR (202.5 MHz, toluene-d8, 340 K): δ = 13.7. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.6 (m). 
+ESIMS, CH2Cl2, m/e: 886 ([M - B(ArF)4]+, 100%). 
IR (KBr) : υ~  [cm-1] = 3447w, 3066w, 2933m, 2855m, 1609m, 1453w, 1356s, 1279s, 1127s, 
978w, 888m, 838w, 750w, 713m, 676m. 
EA % found (calcd): C: 54.25 (54.17), H: 4.21 (4.20), N: 0.84 (0.81). 
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B(ArF)4
3,5-dimethylphenyl
3,5-dimethylphenyl
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-5,5-bis(3,5-dimethyl-
phenyl)-4-isopropyl-4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-
phenyl]borate (199) 
 
 
 
 
 
Complex 199 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Dio-tolylphosphino)phenyl)-5,5-bis(3,5-dimethylphenyl)-4-isopropyl-4,5-dihydrooxazole 
(210 mg, 0.33 mmol), [Ir(COD)Cl]2 (110 mg, 0.16 mmol), NaB(ArF)4 (453 mg, 0.51 mmol) 
and dichloromethane as a solvent (6 mL). After column chromatography (Diethyl ether : 
DCM  4 : 1) on silica complex 199 (450 mg, 77%) was isolated as a red solid. 
 
C82H68NOPF24BIr (1773.39). 
m.p. 90-93 °C. 
20][ Dα  = -181.1° (c = 0.500, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = 0.04 (d, J(H,H) = 6.9 Hz, 3H, CH(CH3)2), 0.70 
(d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 1.01-1.07 (m, 1H, CH2(COD)), 1.23-1.32 (m, 1H, 
CH2(COD)), 1.51-1.58 (m, 1H, CH2(COD)), 1.74-1.82 (m, 3H, CH2(COD)), 1.86-1.91 (m, 1H, 
CH2(COD)), 1.96-2.02 (m, 1H, CH(CH3)2), 2.00 (s, 3H, oTol-CH3), 2.03 (s, 6H, 3,5-
dimethylphenyl-CH3), 2.06 (s, 6H, 3,5-dimethylphenyl-CH3), 2.11-2.16 (m, 1H, CH2(COD)), 
2.43 (s, 3H, oTol-CH3), 2.58 (br s, 1H, CH(COD)), 3.22 (br s, 1H, CH(COD)), 4.50 (br s, 1H, 
CH(COD)), 4.68-4.74 (br s, 1H, CH(COD)), 4.85 (d, J(H,H) = 2.2 Hz, 1H, NCH), 6.61-6.65 (m, 
2H, Ar-H), 6.71 (br s, 1H, Ar-H), 6.81-6.95 (m, 2H, Ar-H), 6.95-6.98 (m, 5H, Ar-H), 7.00-
7.05 (m, 2H, Ar-H), 7.06-7.07 (m, 1H, Ar-H), 7.10-7.13 (m, 3H, Ar-H), 7.17-7.21 (m, 1H, 
Ar-H), 7.66 (br s, 4H, B(ArF)4-H), 8.20 (br s, 8H, B(ArF)4-H), 8.40 (d, J(H,H) = 8.0 Hz, 
J(H,H) = 4.1 Hz, J(H,H) = 1.1 Hz, 1H, Ar-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 15.9 (CH(CH3)2), 19.4 (CH(CH3)2), 21.2 
(2C, 3,5-dimethylphenyl-CH3), 21.2 (2C, 3,5-dimethylphenyl-CH3), 24.5 (d, J(C,P) = 6.2 Hz, 
oTol-CH3), 25.2 (d, J(C,P) = 6.7 Hz, oTol-CH3), 26.0 (d, J(C,P) = 2.4 Hz, CH2(COD)), 28.5 
(CH2(COD)), 31.6 (CH(CH3)2), 33.0 (CH2(COD)), 35.9 (d, J(C,P) = 5.0 Hz, CH2(COD)), 67.5 
(CH(COD)), 67.6 (CH(COD)), 78.7 (NCH), 89.9 (d, J(C,P) = 14.9 Hz, CH(COD)), 95.6 (OC), 95.9 
(d, J(C,P) = 9.6 Hz, CH(COD)), 118.3 (sept, J(C,F) = 4.0 Hz, 4C, B(ArF)4-H), 120.6 (d, J(C,P) 
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B(ArF)4
= 53.0 Hz, oTol(ipso)-P), 122.6 (2C, 3,5-dimethylphenyl-H), 124.6 (2C, 3,5-dimethylphenyl-
H), 125.7 (q, J(C,F) = 273 Hz, 8C, CF3), 127.5 (Ar-H), 127.6 (Ar-H), 129.0 (Ar(ipso)-CN), 
130.0 (d, J(C,P) = 54.7 Hz, Ar-P), 130.4 (qq, J(C,F) = 31.7 Hz, J(C,B) = 2.9 Hz, 8C Ar-CF3), 
130.8 (Ar-H), 131.5 (Ar-H), 132.8 - 134.2 (9C, Ar-H), 135.9 (br s, 8C, B(ArF)4-H), 136.2 
(Ar-H), 139.0 (2C, 3,5-dimethylphenyl(meta)-CH3), 139.8 (2C, 3,5-dimethylphenyl(meta)-
CH3), 142.0 (d, J(C,P) = 9.6 Hz, oTol(ortho)-CH3), 143.8 (d, J(C,P) = 10.1 Hz, oTol(ortho)-CH3), 
143.8 (2C, C(3,5-dimethylphenyl(ipso))2), 163.1 (q, J(C,B) = 50.0 Hz, 4C, Ar-B), 163.3 (d, 
J(C,P) = 5.8 Hz, C=N). (One quaternary C-atom is not visible). 
31P{1H} NMR (202.5 MHz, toluene-d8, 340 K): δ = 13.2. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.2 (m). 
+ESIMS, CH2Cl2, m/e: 910 ([M - B(ArF)4]+, 100%). 
IR (KBr) : υ~  [cm-1] = 3452w, 3056w, 2963m, 2927m, 1603m, 1459w, 1356s, 1278s, 1128s, 
889m, 840w, 805w, 749w, 712m, 677m. 
EA % found (calcd): C: 55.56 (55.54), H: 3.71 (3.86), N: 1.00 (0.79). 
 
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Diphenylphosphino)phenyl)-5,5-diethyl-4-isopropyl-
4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate (190) 
 
 
 
 
 
Complex 190 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Diphenylphosphino)phenyl)-5,5-diethyl-4-isopropyl-4,5-dihydrooxazole (100 mg, 
0.23 mmol), [Ir(COD)Cl]2 (78.0 mg, 0.12 mmol), NaB(ArF)4 (322 mg, 0.36 mmol) and 
dichloromethane as a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  
4 : 1) on silica complex 190 (250 mg, 68%) was isolated as a red solid. 
 
C68H56NOPF24BIr (1593.13). 
m.p. 60-64 °C. 
20][ Dα  = -110.0° (c = 0.230, CHCl3). 
1H NMR (500.1 MHz, CD2Cl2, 295 K): δ = 0.31 (br s, 3H, CH(CH3)2), 0.83 (br s, 3H, 
CH(CH3)2), 0.97 (t, J(H,H) = 7.6 Hz, 3H, CH2CH3), 1.03 (t, J(H,H) = 7.4 Hz, 3H, CH2CH3), 
1.43-1.51 (m, 1H, CH2(COD)), 1.62 (dq, J(H,H) = 14.8 Hz, J(H,H) = 7.6 Hz, 1H, CH2CH3), 
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(oTol)2P N
O
Ir
B(ArF)4
1.66-1.73 (m, 1H, CH2(COD)), 1.82 (dq, J(H,H) = 14.7 Hz, J(H,H) = 7.4 Hz, 1H, CH2CH3), 
1.92-2.04 (m, 4H, CH2(COD) & 2 x CH2CH3 & CH(CH3)2), 2.07-2.13 (m, 1H, CH2(COD)), 2.44-
2.67 (m, 4H, CH2(COD)), 2.96-3.01 (m, 1H, CH(COD)), 3.40-3.42 (m, 1H, CH(COD)), 3.76 (d, 
J(H,H) = 1.8 Hz, 1H, NCH), 4.92 (br s, 1H, CH(COD)), 4.99-5.04 (m, 1H, CH(COD)), 7.08-7.12 
(m, 2H, Ph-H), 7.38-7.42 (m, 1H, Ph-H), 7.43-7.46 (m, 2H, Ph-H), 7.49-7.65 (m, 7H, Ph-H), 
7.56 (br s, 4H, B(ArF)4-H), 7.69-7.74 (m, 1H, Ph-H), 7.73 (br s, 8H, B(ArF)4-H), 8.27 (dddd, 
J(H,H) = 8.0 Hz, J(H,H) = 4.3 Hz, J(H,H) = 1.5 Hz, J(H,H) = 0.5 Hz, 1H, Ph-H). 
13C{1H} NMR (125.8 MHz, CD2Cl2, 295 K): δ = 7.9 (CH2CH3), 9.1 (CH2CH3), 16.8 
(CH(CH3)2), 19.7 (CH(CH3)2), 22.3 (CH2CH3), 26.9 (d, J(C,P) = 1.4 Hz, CH2(COD)), 28.7 
(CH2CH3), 28.9 (d, J(C,P) = 1.4 Hz, CH2(COD)), 31.3 (CH(CH3)2), 33.3 (d, J(C,P) = 1.4 Hz, 
CH2(COD)), 37.1 (d, J(C,P) = 5.2 Hz, CH2(COD)), 63.6 (CH(COD)), 63.9 (CH(COD)), 75.8 (NCH), 
94.5 (d, J(C,P) = 13.4 Hz, CH(COD)), 94.5 (OC), 98.1 (d, J(C,P) = 11.0 Hz, CH(COD)), 118.0 
(sept, J(C,F) = 3.8 Hz, 4C, B(ArF)4-H), 123.6 (d, J(C,P) = 58.1 Hz, Ph(ipso)-P), 125.2 (q, 
J(C,F) = 272.2 Hz, 8C, CF3), 128.8 (d, J(C,P) = 48.0 Hz, Ph(ortho)-P), 129.2 (Ph-H), 129.3 
(Ph-H), 129.4 (qq, J(C,F) = 31.2 Hz, J(C,B) = 2.9 Hz, 8C Ar-CF3), 130.2 (Ar-CN), 130.3 (d, 
J(C,P) = 52.8 Hz, Ph(ipso)-P), 130.3 (Ph-H), 130.3 (Ph-H), 132.4 (d, J(C,P) = 2.4 Hz, Ph-H), 
132.9 (d, J(C,P) = 1.9 Hz, Ph-H), 133.2 (d, J(C,P) = 2.4 Hz, Ph-H), 133.9 (Ph-H), 133.9 (Ph-
H), 134.4 (Ph-H), 134.5 (d, J(C,P) = 1.9 Hz, Ph-H), 135.4 (br s, 8C, B(ArF)4-H), 135.5 (Ph-
H), 135.5 (Ph-H), 135.6 (d, J(C,P) = 1.9 Hz, Ph-H), 162.3 (q, J(C,B) = 49.9 Hz, 4C, C-B), 
163.6 (d, J(C,P) = 6.7 Hz, C=N). 
31P{1H} NMR (202.5 MHz, CD2Cl2, 295 K): δ = 15.6. 
19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.3 (m). 
+ESIMS, CH2Cl2, m/e: 730 ([M - B(ArF)4]+, 100%). 
IR (KBr) : υ~  [cm-1] = 3448w, 3067w, 2974w, 2890w, 1607w, 1565w, 1463w, 1437w, 1356s, 
1279s, 1127s, 891m, 839w, 744w, 710m, 677m. 
EA % found (calcd): C: 51.09 (51.27), H: 3.64 (3.54), N: 0.89 (0.88). 
 
(S)-[(η4-1,5-cyclooctadien)-{2-(2-(Dio-tolylphosphino)phenyl)-5,5-diethyl-4-isopropyl-
4,5-dihydrooxazole}iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)-phenyl]borate (191) 
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Complex 191 was prepared according to general procedure X (page 209) from (S)-2-(2-
(Dio-tolylphosphino)phenyl)-5,5-diethyl-4-isopropyl-4,5-dihydrooxazole (100 mg, 
0.22 mmol), [Ir(COD)Cl]2 (73.0 mg, 0.11 mmol), NaB(ArF)4 (302 mg, 0.34 mmol) and 
dichloromethane as a solvent (6.00 mL). After column chromatography (Diethyl ether : DCM  
4 : 1) on silica complex 191 (270 mg, 76%) was isolated as a red solid. 
 
C70H60NOPF24BIr (1621.19). 
m.p. 70-74 °C. 
20][ Dα  = -140.0° (c = 0.180, CHCl3). 
1H NMR (500.1 MHz, toluene-d8, 340 K): δ = 0.21 (d, J(H,H) = 7.0 Hz, 3H, CH(CH3)2), 0.55 
(d, J(H,H) = 7.1 Hz, 3H, CH(CH3)2), 0.60 (t, J(H,H) = 7.6 Hz, 3H, CH2CH3), 0.73 (t, J(H,H) 
= 7.4 Hz, 3H, CH2CH3), 1.01-1.09 (m, 1H, CH2(COD)), 1.17-1.25 (m, 2H, CH2(COD) & 
CH2CH3), 1.41 (dq, J(H,H) = 14.7 Hz, J(H,H) = 7.3 Hz, 1H, CH2CH3), 1.54-1.71 (m, 5H, 2 x 
CH2(COD) & 2 x CH2CH3 & CH(CH3)2), 1.84-1.94 (m, 2H, CH2(COD)), 2.04-2.12 (m, 2H, 
CH2(COD)), 2.10 (br s, 3H, oTol-CH3), 2.39 (br s, 3H, oTol-CH3), 2.57 (br s, 1H, CH(COD)), 
3.15 (br s, 1H, CH(COD)), 3.45 (d, J(H,H) = 2.2 Hz, 1H, NCH), 4.39-4.45 (m, 1H, CH(COD)), 
4.61 (br s, 1H, CH(COD)), 6.60 (dd, J(H,H) = 12.7 Hz, J(H,H) = 7.8 Hz, 1H, Ar-H), 6.81-6.84 
(m, 2H, Ar-H), 6.86-6.89 (m, 1H, Ar-H), 6.97-7.08 (m, 7H, Ar-H), 7.66 (br s, 4H, B(ArF)4-
H), 7.86 (dddd, J(H,H) = 8.0 Hz, J(H,H) = 4.1 Hz, J(H,H) = 1.3 Hz, J(H,H) = 0.3 Hz, 1H, Ar-
H), 8.21 (br s, 8H, B(ArF)4-H). 
13C{1H} NMR (125.8 MHz, toluene-d8, 340 K): δ = 6.9 (CH2CH3), 8.2 (CH2CH3), 16.8 
(CH(CH3)2), 18.7 (CH(CH3)2), 22.2 (CH2CH3), 24.2 (d, J(C,P) = 6.2 Hz, oTol(ortho)-CH3), 
25.0 (br s, oTol(ortho)-CH3), 25.8 (d, J(C,P) = 2.4 Hz, CH2(COD)), 28.1 (CH2(COD)), 28.8 
(CH2CH3), 31.1 (CH(CH3)2), 33.0 (CH2(COD)), 35.6 (CH2(COD)), 67.0 (CH(COD)), 67.1 
(CH(COD)), 75.8 (NCH), 89.7 (d, J(C,P) = 13.9 Hz, CH(COD)), 94.2 (OC), 94.7 (d, J(C,P) = 
10.1 Hz, CH(COD)), 118.1 (sept, J(C,F) = 3.8 Hz, 4C, B(ArF)4-H), 120.5 (d, J(C,P) = 53.8 Hz, 
oTol(ipso)-P), 125.4 (q, J(C,F) = 272.6 Hz, 8C, CF3), 127.3 (d, J(C,P) = 9.6 Hz, Ar-H), 127.3 
(d, J(C,P) = 9.7 Hz, Ar-H), 130.1 (d, J(C,P) = 47.5 Hz, Ar-P), 130.1 (qq, J(C,F) = 31.7 Hz, 
J(C,B) = 2.9 Hz, 8C Ar-CF3), 132.3 (d, J(C,P) = 1.9 Hz, Ar-H), 132.6 (d, J(C,P) = 1.9 Hz, 
Ar-H), 132.8 (Ar-H), 132.8 (Ar-H), 132.9 (Ar-H), 133.1-133.2 (3C, Ar-H), 133.9-134.0 (2C, 
Ar-H), 135.7 (br s, 8C, B(ArF)4-H), 141.8 (d, J(C,P) = 9.6 Hz, oTol(ipso)-CH3), 143.5 (d, 
J(C,P) = 9.6 Hz, oTol(ipso)-CH3), 162.8 (q, J(C,B) = 49.9 Hz, 4C, C-B), 163.3 (d, J(C,P) = 6.2 
Hz, C=N). (Two quaternary C-atoms are not visible). 
31P{1H} NMR (202.4 MHz, CD2Cl2, 340 K): δ = 12.6. 
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19F{1H} NMR (376.5 MHz, CDCl3, 300 K): δ = -64.2 (m). 
+ESIMS, CH2Cl2, m/e: 758 ([M - B(ArF)4]+, 100%). 
IR (KBr) : υ~  [cm-1] = 3449w, 3064w, 2975w, 2889w, 1604w, 1565w, 1459w, 1356s, 1279s, 
1128s, 891m, 839w, 750w, 713m, 676m. 
EA % found (calcd): C: 51.80 (51.86), H: 3.81 (3.73), N: 0.90 (0.86). 
 
 
13.5.2 Asymmetric Hydrogenations 
 
General Procedure XI: 
Catalytic Hydrogenation at Elevated Pressure: 
In a glove box, substrate, iridium complex and dichloromethane were added into little vials 
(1.5 mL) equipped with a magnetic stir bar. Four vials were added to a 60 mL autoclave 
(premex AG, Lengnau, Switzerland). The autoclave was pressurized with H2 (Carbagas, 
Switzerland, 99.995%) according to the stated reactions conditions. After reaction, the 
pressure was released and the solvent was evaporated. The residue was dispersed in diethyl 
ether/pentane (1:1) and filtered over a short plug of silica gel eluting with diethyl ether and 
pentane (1:1). The filtrate was analyzed by GC, chiral GC, and chiral HPLC to determine the 
conversion and enantioselectivity. HPLC samples were prepared in heptane and iso-propanol. 
The analytical procedures were used as previously described.97 
 
Hydrogenation products (GC and HPLC data) 
 
The conversion of all hydrogenation reactions was determined by GC analysis using a Restek 
Rtx-1701 (30 m × 0.25 mm × 0.25 µm) column, helium as a carrier gas and the following 
temperature program: 100 °C, 2 min isotherm, 7 °C/min, 250 °C, 5 min isotherm. 
The enantiomeric excess of the isolated products was determined by chiral HPLC using the 
columns and conditions described for each product. The enantiomeric excess of the 
hydrogenation products of the tetrasubstituted olefin 212 was determined by chiral GC using 
a β-cyclodextrine (30 m × 0.25 mm × 0.25 µm) column, hydrogen as a carrier gas and the 
following temperature program: 80 °C, 1 °C/min, 120 °C, 10 °C/min, 180 °C, 2 min isotherm. 
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Ph
Ph
MeO MeO
OH*
CO2Et
(R)-1,2-Diphenylpropane (206) 
 
 
 
GC:  tR = 13.5 min (product), 16.6 (starting material). 
HPLC: Daicel Chiralcel OJ (0.46 cm x 25 cm), n-Heptan : i-Propanol (99:1), 
0.5 ml/min, 20 °C, tR = 13.8 min (R), 23.0 min (S), λ 254 nm. 
 
(R)-2-(4-Methoxyphenyl)butane (207), (S)-2-(4-Methoxyphenyl)butane (208) 
 
 
 
 
GC:  tR = 7.6 min (product), 11.8 min (Z), 14.2 min (E). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan (100), 0.5 ml/min, 20 °C, 
tR = 15.1 min (S), 17.0 min (R), λ 254 nm. 
 
2-Methyl-3-phenylpropanol (210) 
 
 
 
 
GC:  tR = 14.1 min (product), 15.7 min (starting material). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (95:5), 
0.5 ml/min, 40 °C, tR = 15.3 min, 17.3 min, λ 254 nm. 
 
(R)-3-Phenyl-butyric acid ethyl ester (211) 
 
 
 
 
GC:  tR = 15.0 min (product), 17.7 min (starting material). 
HPLC: Daicel Chiralcel OB-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (99.5:0.5), 
0.5 ml/min, 20 °C, tR = 16.4 min (R), 19.5 min, λ 254 nm. 
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(S)-6-Methoxy-1-methyl-1,2,3,4-tetrahydronaphthaline (209) 
 
 
 
 
GC:  tR = 17.0 min (product), 18.0 min (starting material). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan (100), 0.5 ml/min, 20 °C, 
tR = 29.2 min (S), 37.0 min (R), λ 254 nm. 
 
(−)-2-(4-Methoxyphenyl)-3-methyl-2-butane (213) 
 
 
 
 
GC:  tR = 13.5 min (product), 14.1 min (starting material). 
GC: tR = 19.5 min, 20.6 min. 
 
(R)-N-Phenyl-1-phenylethylamine 
 
 
 
 
GC:  tR = 34.4 min (product), 18.0 min (starting material). 
HPLC: Daicel Chiralcel OD-H (0.46 cm x 25 cm), n-Heptan : i-Propanol (99:1), 
0.5 ml/min, 20 °C, tR = 24.5 min (S), 34.2 min (R), λ 254 nm. 
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14 Appendix 
 
14.1 X-Ray Crystal Structures 
 
Single crystals were obtained by the conditions stated. The crystals were mounted with 
paraffin on a glass fibre goniometer head. This was attached to the KappaCCD diffractometer. 
Measurement were recorded at 173 K. The space group was determined by the systematic 
extinction by means of the “Collect” data collection software (Nonius BV, 2002). Collect can 
use either the HKL software (denzo/scalepack/xdisp) for integration98, or the 
dirax/view/EvalCCD programs from Utrecht University.99 The structure was solved with 
either SIR92100 or SIR97101 and refined in Crystals.102 The absolute configuration and 
enantiopurity could be determined by refinement of the flack parameter.103 The refined 
structures were checked with checkcif.104 
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Table 30. 
Compound 170b 170a 
Molecular Formula C19H19N1O5 C22H23N1O7S1 
Formula Weight 341.36 445.49 
Shape Plate block 
Colour Yellow colourless 
Temperature (K) 173 173 
Crystal size (mm3) 0.04 x 0.20 x 0.20 0.22 x 0.25 x 0.28 
Crystal system Triclinic Orthorhombic 
Space group P 1 P 21 21 21 
a (Å) 7.5458(4) 10.5141(15) 
b (Å) 9.4723(6) 13.1759(13) 
c (Å) 12.0209(6) 15.0878(4) 
α (Å) 96.477(4) 90 
β (Å) 104.091(5) 90 
γ (Å) 95.300(5) 90 
Volume (Å3) 821.61(8) 2090.2(4) 
Z 2 4 
Density (calc.)(Mg m-3) 1.380 1.416 
Absorption coeff. (mm-1) 0.100 0.200 
Radiation type (λ [Å])  MoKα (0.71073) MoKα (0.71073) 
F (000) 360 936 
Θ range of data collection (°)  3.333-32.499 3.092-27.515 
Completeness to Θmax (%) 0.999 0.997 
Limiting indices (measured) -11≤h≤10 
-14≤k≤14 
0≤l≤18 
-13≤h≤13 
0≤k≤17 
0≤l≤19 
Reflections measured 68118 70275 
Reflections independent 5956 (Rint = 0.08) 4802 (Rint = 0.247) 
Reflection used 2955 3299 
Number of parameters 227 281 
R (observed data) 0.0453 (I > 3 σ(I)) 0.0437 (I > 3 σ(I)) 
wR (all data) 0.1273 0.0439 
Goodness of fit on F 1.5045  1.0175 
Residual density (e Å-3) -0.21/0.28 -0.63/0.53 
Flack-parameter         - -0.01(6) 
CCDC deposition code         -       - 
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Table 31. 
Compound 216 160 
Molecular Formula C40H39Ag1N1O3P1 (1.44 C7H8) C30H34N2O10 
Formula Weight 853.63 582.61 
Shape Plate block 
Colour colourless colourless 
Temperature (K) 173 173 
Crystal size (mm3) 0.08 x 0.16 x 0.19 0.16 x 0.20 x 0.21 
Crystal system Orthorhombic Triclinic 
Space group P 2 21 21 P 1 
a (Å) 10.4799(6) 9.83130(10) 
b (Å) 20.3716(14) 11.35580(10) 
c (Å) 20.5745(13) 13.4160(2) 
α (Å) 90 94.4348(5) 
β (Å) 90 108.2460(5) 
γ (Å) 90 97.9535(5) 
Volume (Å3) 4392.5(5) 1397.16(3) 
Z 4 2 
Density (calc.)(Mg m-3) 1.291 1.385 
Absoption coeff. (mm-1) 0.537 0.105 
Radiation type (λ [Å])  MoKα (0.71073) MoKα (0.71073) 
F (000) 1776.750 616 
Θ range of data collection (°) 
X to X 
1.943-27.470 3.022-31.929 
Completeness to Θmax (%) 0.938 0.996 
Limiting indices (measured) -13≤h≤13 
0≤k≤26 
0≤l≤26 
-14≤h≤13 
-16≤k≤16 
0≤l≤19 
Reflections measured 17867 19142 
Reflections independent 8816 (Rint = 0.047) 9601 (Rint = 0.019) 
Reflection used 5661 5731 
Number of parameters 611 380 
R (observed data) 0.0390 (I > 2 σ(I)) 0.0400 (I > 3 σ(I)) 
wR (all data) 0.0436 0.0794 
Goodness of fit on F 1.0373 1.0707 
Residual density (e Å-3) -0.60/0.69 -0.24/0.28 
Flack-parameter -0.01(2)        - 
CCDC deposition code       - 264392 
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Compound 219 
Molecular Formula C46H48F6IrN1O1P2 
Formula Weight 999.05 
Shape Plate 
Colour red 
Temperature (K) 173 
Crystal size (mm3) 0.08 x 0.16 x 0.19 
Crystal system Orthorhombic 
Space group P 21 21 21 
a (Å) 14.6150(2) 
b (Å) 15.2066(2) 
c (Å) 18.8443(2) 
α (Å) 90 
β (Å) 90 
γ (Å) 90 
Volume (Å3) 4188.04(9) 
Z 4 
Density (calc.)(Mg m-3) 1.584 
Absorption coeff. (mm-1) 3.328 
Radiation type (λ [Å])  MoKα (0.71073) 
F (000) 2000 
Θ range of data collection (°)  1.721-27.821 
Completeness to Θmax (%) 1.000 
Limiting indices (measured) -19≤h≤19 
0≤k≤19 
0≤l≤24 
Reflections measured 33996 
Reflections independent 9934 (Rint = 0.050) 
Reflection used 9872 
Number of parameters 569 
R (observed data) 0.0236 (I > 2.0 σ(I)) 
wR (all data) 0.0569 
Goodness of fit on F 0.8418  
Residual density (e Å-3) -0.98/1.50 
Flack-parameter 0.006(5) 
CCDC deposition code         - 
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